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I have now personally known, supervised, mentored, and worked with Dr. Kumbhari for more 
than six years, since beginning his training as an advanced therapeutic fellow in 2013. I have 
been his Auxiliary Supervisor during his study as a PhD student since March 2013. During his 
fellowship, he demonstrated research and clinical interests in the field of endoluminal bariatric 
therapies. Upon completion of his fellowship, we recruited him as an Assistant Professor of 
Medicine and full-time faculty in 2015. Dr. Kumbhari is an outstanding member of the John 
Hopkins Division of Gastroenterology. He has demonstrated excellence in all aspects of the 
tripartite mission of Johns Hopkins and has attained national and international recognition for 
his basic, translational and clinical research in endoluminal bariatric therapies. 
 
Dr. Kumbhari has dedicated his clinical expertise as well as research efforts and contributions 
towards advancing the field of minimally invasive endoluminal therapies to treat patients with 
obesity and metabolic disease. He has been an early adopter of several novel endoscopic 
techniques and devices. He has a passion for objectively assessing outcomes, resulting in a 
multitude of publications focusing on endobariatric therapies. He has also identified a potential 
new target for obesity therapy that he has performed rigorous scientific assessment in 
preclinical models. 
 
Dr. Kumbhari hypothesized that the gastric mucosa is a critical regulator of satiation, glucose 
and lipid metabolism and has led to research resulting in several original publications.  Based on 
this work, he successfully published a methods patent, protecting the concept of gastric 
mucosal ablation/resection/exclusion for weight loss. This patent was subsequently licensed 
[US 2017/0367723 A1] and has already resulted in new device developments. Furthermore, he 
has commenced clinical trials investigating gastric mucosal devitalization, a potential 
revolutionary method for weight loss. 
 
I have had the opportunity to supervise mentor many outstanding faculty during my tenure as 
Division Chief of Gastroenterology and Hepatology at Johns Hopkins. In my experience, it can 
be difficult to be independently recognized in the first five years of joining as faculty due to the 
world-renowned members that reside within the division. Dr Kumbhari stands with the best, 
and it was clear from the time he commenced his therapeutic endoscopy fellowship that he had 
the ambition, motivation and dedicated work ethic to be a national and international leader in 
the field of endoluminal bariatric therapies. Therefore, in an attempt to accelerate his 
recognition, I strongly advised and continued to reiterate that he should assign himself as the 
senior and corresponding author of his published works, despite writing the manuscript and 
being the primary researcher. I counselled him that if he assigned himself as first author and 
allotted the senior/corresponding authorship to another, or myself he would run the risk of 
having his efforts and successes attributed to the senior/corresponding author as opposed to 
himself. 
 
Dr Kumbhari diligently adhered to my advice and this has resulted in him being 
senior/corresponding author in the great majority of the manuscripts submitted as part of his 
thesis. I can attest to the fact that in the position of senior/corresponding author, where 
relevant, he was the principal contributor towards the; study concept and design; acquisition of 
grant funding; acquisition and optimization of data; analysis and interpretation of the data; 
drafting of the manuscript and critical revision of the manuscript for important intellectual 
content. Furthermore, he gave the final approval for all manuscripts. 
 
Because of adopting this strategy, Dr. Kumbhari has already been invited on more than fifty 
occasions to lecture on topics in the field of bariatric endoscopy both nationally and 
internationally. Furthermore, he has co-directed international symposia, performed live cases 
and moderated/chaired sessions both nationally and internationally. Additionally, Dr. Kumbhari 
has been appointed to several national and international committees. Dr. Kumbhari’s clinical 
and research efforts have earned him the role as a Board Member in the Association of 
Bariatric Endoscopy, a division of the American Society of Gastrointestinal Endoscopy and the 
premier bariatric endoscopy society that guides the future and direction of bariatric endoscopy. 
His knowledge and contribution to bariatric endoscopy has also resulted in him being appointed 
to organize and direct the endoscopic bariatric postgraduate course at the International 
Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) annual meeting (2018), an 
honor traditionally reserved for surgeons. 
 
Further reinforcing the benefit of assigning himself to the senior/corresponding author 
position, as opposed to first author, is his rapid promotion to Associate Professor of Medicine. 
He earnt this promotion within four years of joining as faculty, with the mean time to 
promotion in the Department of Medicine being seven years. This remarkable achievement is 
based on his research productivity and him being a recognized leader in endoluminal bariatric 
therapies both nationally and internationally.  
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The Moses and Helen Golden Paulson Professor of Gastroenterology  
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Abstract 
 
Background 
The majority of obese patients remain untreated, creating the need for an effective, well-tolerated, 
safe and appealing therapeutic approach. Endoluminal therapies have the potential to fulfil this 
unmet clinical need, though traditionally, these approaches mimic the restrictive elements of 
bariatric surgery but ignore the complex physiologic and neurohormonal mechanisms responsible 
for bariatric surgeries’ weight-independent reduction in metabolic comorbidities. 
Hypothesis 
The overarching hypothesis of this thesis was that although endoluminal gastric space occupying 
and restrictive interventions result in weight loss, weight-independent improvements in obesity 
related comorbidities require eradication of the gastric mucosa. 
Aims 
The aims of this thesis were to assess the efficacy and safety of the intragastric balloon (IGB) and 
endoscopic sleeve gastroplasty (ESG), and to evaluate whether gastric mucosal devitalization 
(GMD) is a potential therapeutic approach to treat patients with obesity. 
Methods 
Gastric space occupation and gastric volume reduction were modelled using IGB and ESG, 
respectively. To evaluate the effects of GMD (without alteration in gastric volume), high fat diet 
rats were compared to GMD, laparoscopic sleeve gastrectomy (LSG), and sham rats. To determine 
the translatability of GMD, the feasibility, efficacy and safety of GMD was compared to LSG and 
sham in a porcine model.  
Results 
The clinical research demonstrated that IGBs and ESG result in clinically meaningful weight loss 
with an acceptable safety profile. However, neither produced improvements in metabolic 
parameters that were disproportionate to the weight loss observed. GMD resulted in a reduction in 
body weight and visceral adiposity, improved serum lipid and glucose profiles, and reduced liver 
lipid content. GMD also resulted in a significant reduction in blood pressure, plasma renin activity 
and cardiac as well as aortic lipid droplet deposition. In a porcine model, GMD reduced visceral 
adiposity, with outcomes greater than what would be expected from weight loss alone. 
Conclusions 
Weight-independent metabolic improvements can be achieved by selecting the gastric mucosa as 
a therapeutic target; therefore, endoscopic GMD is a new potential approach for the management 
of obesity. 
Introduction 
 
 
Obesity has escalated from a seemingly innocuous public health concern to a worldwide 
insidious epidemic that has ravaged the health care system of many countries.1 Obesity is 
associated with decreased quality of life, life expectancy, and increased morbidity.2-8 These grim 
associations are the consequence of the metabolic comorbidities associated with obesity, which 
include, but are not limited to: type 2 diabetes mellitus, non-alcoholic steatohepatitis, hypertension, 
and cardiovascular disease. Weight loss has long been proven to decrease the metabolic 
comorbidities associated with obesity, however, significant long-term weight loss is rarely 
sustained through diet and exercise alone.9, 10 This has resulted in an increasing demand for 
treatment options that extend beyond the clinical guidelines of lifestyle modification. 
 
 There is an emerging population of adults who, in their efforts to lose weight, find 
themselves caught between intensive lifestyle modification therapy and bariatric surgery. Patients 
favour less invasive options, yet are often disgruntled with lifestyle modification therapy due to 
suboptimal outcomes.11 Obesity pharmacotherapy has been the only bridge thus far, but its use is 
limited due to cost, intolerable side effects and modest weight loss that is poorly sustained over 
time. Bariatric surgery is the most successful treatment for weight loss with documented 
improvement in metabolic outcomes; however, many patients avoid surgery due to its invasive 
nature and their fear of complications.12, 13 
 
Endoluminal weight loss and metabolic therapies have emerged as an innovative 
alternative for obese patients who have failed intensive diet and lifestyle therapy and 
pharmacotherapy yet feel that bariatric surgery is too invasive. Endoluminal therapies often require 
flexible endoscopy. These therapies include intragastric balloons (IGBs), endoscopic sleeve 
gastroplasty (ESG), aspiration therapy and intragastric Botox injection.14, 15 Major 
gastroenterology societies now recognise obesity as a chronic disease and recommend a 
multidisciplinary approach to management in order to facilitate improved outcomes as well as 
patient experience.16 
 
The field of endoluminal weight loss and metabolic therapies is still in its infancy. A recent 
and detailed overview of the indications, efficacy, and safety of endoluminal weight loss and 
metabolic therapies is provided in CHAPTER 1.17 As of October 2019, there were seven Food and 
Drug Administration (FDA) approved endoluminal therapies for clinical use in the United States.  
Only three of these have been commercially available for clinical use for three or more years: two 
fluid-filled IGBs (the single balloon [Orbera (Apollo Endosurgery, Austin, Texas USA)], and the 
dual balloon [ReShape (ReShape Lifesciences, San Clemente, CA, USA)]), and a full thickness 
suturing system that enables ESG (OverStitch [Apollo Endosurgery, Austin, Texas, USA]).17 
 
The overarching hypothesis of this thesis was that although endoluminal gastric space 
occupying and restrictive interventions result in weight loss, weight-independent improvements in 
obesity related comorbidities require eradication of the gastric mucosa. Current FDA-approved 
endoluminal therapies have all targeted the stomach using approaches that limit the quantity of 
ingested contents to induce weight loss. Based on their commercial availability for study, fluid-
filled IGBs (gastric space occupation) and ESG (gastric volume reduction) were the clinical 
interventions used to test the overarching hypothesis of this thesis. Remarkably, these approaches 
mimic the restrictive elements of bariatric surgery, but potentially evade the complex physiologic 
and neurohormonal mechanisms that are responsible for bariatric surgeries’ reduction in metabolic 
comorbidities.18, 19 
 
 I hypothesised that endoluminal gastric space occupation would result in weight loss 
without weight-independent metabolic improvements. Therefore, Aim 1 of this thesis was to assess 
the efficacy, safety and mechanical alterations induced by gastric space occupation in patients with 
obesity treated with the IGB. Fluid-filled IGBs were selected as a model because their mechanism 
of action is almost exclusively space occupation, though a component of their effect may be due 
to mechanical obstruction causing delayed gastric emptying. Other proposed mechanisms include 
alterations in gastric hormones, but the data supporting this are contradictory.20, 21  
 
The Orbera and Reshape IGBs have been subjected to randomized controlled trials (RCT) 
in the United States. These multicentre trials were limited to patients with class 1 and 2 obesity 
(BMI 30–40 kg/m2). In the Orbera pivotal United States multicentre clinical trial (n=255), patients 
were randomized to Orbera in addition to lifestyle counselling (n=125), or lifestyle counselling 
alone (n=130). Based on a modified intention-to-treat analysis, the weight loss at 12-months with 
Orbera was 7.6% compared to 3.1% in the lifestyle counselling group.22 In the ReShape pivotal 
United States multicentre clinical trial (n=326), patients were randomized to ReShape in addition 
to lifestyle counselling (n=187), or sham endoscopy and lifestyle counselling (n=139). Based on 
per protocol analysis (completed cases only), the weight loss at 12-months with ReShape was 7.6% 
compared to 3.6% in the control group.23 
 
The results of these two aforementioned prospective RCTs were notable for three main 
reasons. First, the weight loss outcomes with these fluid-filled IGBs were inferior to what had been 
previously reported outside of the United States.24, 25 Second, IGBs were poorly tolerated with an 
observed early removal rate of almost 20%. These observations may be explained by a relative 
lack of subject commitment in the clinical trial setting, where those enrolled participated at no 
charge, compared with self-pay patients who invest between 7,000 to 10,000 USD. The third 
observation was that there was barely any statistically significant (and no clinically significant) 
reduction in metabolic comorbidities in the IGB treated cohorts. This may have been the result of 
the relatively mediocre weight loss observed in these trials. Therefore the motivation for 
CHAPTER 226 was to investigate the efficacy and safety of the largest sized fluid-filled IGB in a 
real-world clinical practice setting. This study was a retrospective review of data collected on 202 
patients that underwent therapy with Reshape. The mean TBWL was 11.4% at 6-months and 
14.7% at 12-months - outcomes substantially superior to its respective RCT. Additionally, I co-
authored a multicentre study investigating the safety and efficacy of Orbera in the real-world 
setting.27 This study was a retrospective review of prospectively collected data on 321 patients that 
underwent therapy with Orbera.  The mean TBWL was 11.8% at 6-months and 13.3% at 9-months 
- outcomes also markedly greater to those seen in its respective RCT. Furthermore, the rates of 
early IGB removal were less than their respective RCTs. The superior efficacy and reduced early 
removal rates could be attributed to improved patient engagement as a result of the financial 
commitment required in the real-world clinical practice setting. 
 
 In view of the observed mean weight loss at 6-months being >10% TBWL in the two 
previously referenced real-world studies, one would expect to have observed a statistically 
significant and clinically meaningful reduction in obesity related metabolic comorbidities. Though 
the patient cohorts contained only a limited number of patients who were metabolically disturbed, 
the improvements in measured metabolic parameters were unimpressive. Furthermore, IGBs did 
not produce an improvement in metabolic parameters that was disproportionate to weight loss. It 
did appear that IGBs simply mimicked the restrictive effects of bariatric surgery without emulating 
its weight-independent metabolic effects.  
 
The poor adoption of bariatric surgery revolves around its lack of appeal to patients, which 
is based on concerns regarding its tolerability and safety. CHAPTER 2 revealed that ReShape had 
an acceptable safety profile with few severe adverse events and no mortality.26 However, patients 
undergoing ReShape were observed to have high rates of nausea, vomiting, and abdominal pain. 
Furthermore, although not elicited in this study (due to poor correlation between presence of 
symptoms and objective physiologic testing), gastroesophageal reflux disease (GERD) can also 
occur post-fluid-filled IGB insertion. GERD symptoms can manifest immediately and can be 
unremitting during the dwell of the IGB. Together, these side effects contributed to the almost 1 
in 15 patients that had their IGB removed early due to intolerability.26  
 
To improve the patient tolerability of IGBs, it would be valuable to elucidate the 
mechanical alterations caused by fluid-filled IGBs. The focus of CHAPTER 328 was to objectively 
measure the effect of the Orbera on gastric emptying and DeMeester score. The study confirmed 
that when compared to pre-IGB implantation, gastric emptying of solids was significantly delayed 
at 2- to 3-months post-IGB insertion.  The increased gastric emptying time did not correlate with 
the degree of weight loss. This suggests that other mechanisms are at play or that the IGB causes 
partial or intermittent mechanical obstruction, as opposed to the IGB precipitating a reduction in 
gastric muscular propulsion. The DeMeester score and lower oesophageal sphincter pressure were 
not statistically significantly altered as compared to baseline at 2- to 3-months post-IGB 
implantation.28 These findings were surprising considering the symptoms patients describe post-
IGB insertion. Further investigation into the mechanical alterations induced by IGB are necessary 
to improve patient selection and better control post-IGB tolerability.  
 
For endoluminal therapies to fulfil the unmet clinical need of the large number of obese 
patients who are currently without adequate or desirable treatment, there remains a requirement 
for not only an effective and safe therapy, but also one that is well-tolerated and appealing to 
patients and clinicians. An approach that has greater durability and avoids the placement and 
removal of a large foreign body may confer improved efficacy, safety and tolerability over IGBs. 
A potential solution was developed, called endoscopic sleeve gastroplasty (ESG).29 ESG is an 
endoluminal procedure that utilizes a FDA-approved full-thickness endoscopic suturing system 
(OverStitch; Apollo Endosurgery, Austin, Texas, USA) to reduce gastric volume through greater 
curvature plication.  In this procedure, sutures are placed in two rows along the greater curvature 
of the stomach. The result is a gastric cavity that forms a tubular sleeve along the lesser curvature, 
with the greater curvature closed off by plications from the gastroesophageal junction to the 
antrum. I described the technique in a teaching video manuscript.30 On completion of the 
procedure, the volume of the gastric lumen is reduced by approximately 70%, similarly to that of 
a stomach post-laparoscopic sleeve gastrectomy.30 ESG is an outpatient procedure and patients 
generally return to near full functionality by day 3 post-procedure.31 
 
 I hypothesised that endoluminal gastric volume reduction would be an effective and safe 
procedure, with outcomes superior to established non-surgical weight loss therapies, but inferior 
to laparoscopic sleeve gastrectomy. Thus, Aim 2 was to assess the technical feasibility, safety, 
reproducibility, efficacy and comparative effectiveness of gastric volume reduction using 
endoscopic sleeve gastroplasty in patients with obesity. ESG was the preferred model for gastric 
volume reduction as the technique results in a reduction in gastric volume, whilst maintaining the 
anatomic structure of the gastric wall layers, innervation and blood supply. 
 
A major criticism of ESG has been that it is technically demanding, with a significant 
amount of training and high level of skill required to perform the procedure. Clearly, if the 
technique was only suitable to be performed by a limited number of skilled endoscopists, then it 
would do little to fulfil the large unmet clinical need. Therefore, there was a need to decipher not 
only the efficacy and safety, but also the learning curve and reproducibility of ESG. In light of the 
substantial repetition that occurs during the ESG procedure, I hypothesised that the learning curve 
would be brisk. This was the focus of CHAPTER 4.32 The study identified that an endoscopist 
proficient in use of the endoscopic suturing system could expect to acquire efficiency after 
performing 7  ESG procedures. This supports the assumption that the learning curve was brisk, 
and that widespread dissemination of the technique was possible. 
 
Remarkably, four years after the first published series of ESG, there were only three centres 
worldwide that had published their data on the procedure. Therefore, it was unclear whether the 
efficacy and safety outcomes observed at these pioneering centres could be reproduced by those 
who were interested in adopting the procedure. This was the rationale behind CHAPTER 5.33 This 
study demonstrated that in three centres across two continents, the technical success rate was 100% 
with all procedures completed as outpatient. The observed mean TBWL was 14.9% at 6-months 
post-procedure and the procedure was performed safely with a low severe adverse event rate of 
2.7%. These results were similar to that of the pioneering centres.34 Therefore, it appeared that the 
technical feasibility, efficacy, and safety outcomes of ESG in its current form were reproducible, 
and hence the procedure was ready for widespread clinical adoption. 
 
By January 2019, there was sufficient published literature to perform a systematic review 
and meta-analysis to attain additional efficacy and safety data on ESG. CHAPTER 635 
encompassed data from seven original studies published online from 2016 to 2018 which included 
a total of 1579 patients.35 At 12-months, mean TBWL was 17.0% with a pooled severe adverse 
event rate of 2.3%. There were no reported deaths. These results surpass the efficacy and safety 
benchmarks set by the American Society of Gastrointestinal Endoscopy.36 Notably, the majority 
of studies did not evaluate nor report on obesity related metabolic comorbidities.35 Regardless, it 
appears that ESG is a technically feasible, effective, safe, and reproducible weight loss approach. 
 
Sharaiha et al. reported weight loss and metabolic outcomes at 6-, 12- and 24-months post-
ESG in a United States cohort.37 At 6-months, patients had a mean of 14.4% TBWL, at 12-months 
the TBWL was 17.6%, and at 24-months the TBWL further increased to 20.9%.37 At 12-months 
post-ESG, metabolic profiles were assessed and compared to baseline levels, which showed a 
statistically significant reduction in markers of diabetes, hypertension and hypertriglyceridemia. 
In those with diabetes or prediabetes at baseline, HbA1c levels were reduced from 6.6% to 5.6% 
(p=0.02). Statistically significant reduction was also seen in systolic blood pressure, from 
129.0mm Hg at baseline to 122.2mm Hg at 12-months (p=0.02), as well as in serum triglycerides, 
from 131.84 mmol/dL to 92.36 mmol/dL  (p=0.02).37 It must be noted, that though these results 
were statistically significant, they were not clinically meaningful improvements in metabolic 
parameters. Additionally, the improvement in metabolic parameters observed in patients that 
underwent ESG were proportionate to the observed weight loss.  
 
As ESG continued to gain traction world-wide, a comprehensive understanding of its 
outcomes and its position among other non-surgical weight loss therapies became essential. The 
US Preventative Service Task Force recommends that clinicians offer adults with a BMI >30 kg/m2 
intensive, multifaceted behavioural interventions.38 Remarkably, however, there was no published 
data comparing ESG to the first-line treatment of obesity: intensive lifestyle modification therapy. 
This provoked CHAPTER 7.39  In this case-matched study, high-intensity diet and lifestyle therapy 
(HIDLT) patients were matched by age, sex and BMI to ESG patients who underwent low-
intensity diet and lifestyle therapy (LIDLT) following their procedure. HIDLT patients were seen 
biweekly for some months before transitioning to monthly visits. Weight outcomes were evaluated 
to a maximum of 12-months from commencement of the intervention. The results revealed that 
the mean TBWL in those who had undergone ESG was statistically significantly higher at 12-
months compared to those who had undergone HIDLT (20.6% vs 14.3%, p<0.001).39 This was 
despite weight loss in the HIDLT cohort being extraordinarily high, with the literature generally 
reporting TBWL at 12-months of approximately 8%.40 ESG patients with BMI <40 kg/m2 
demonstrated statistically significantly greater TBWL at all follow-up time points. Conversely, 
subgroup analysis revealed no statistically significant difference in mean TBWL at 12-months in 
patients with BMI >40 kg/m2.39 Therefore, ESG is a superior weight loss approach for patients 
with BMI <40 kg/m2 and may be a valuable alternative for patients with BMI >40 kg/m2 who have 
difficulty adhering to HIDLT.  
 
Both ESG and IGB procedures have demonstrated efficacy and safety. However, there was 
no comparative data to guide the clinician in recommending one procedure over another. The main 
obstacle to performing such a comparative study across multiple centres was the impact of the 
variability in post-procedure dietary instructions and follow-up protocols. To compare outcomes 
between the two procedures, the pre- and post-procedural care and the 12-month ancillary weight 
management program would need to be identical following both interventions. Patients who 
underwent ESG or IGB at Johns Hopkins were subjected to one standardized care program, with 
all procedures being performed by one endoscopist. This was the motivation for CHAPTER 8.41 
The study revealed that IGB resulted in a significantly inferior TBWL compared to ESG at 6-
months (15% vs 19.5%; p=0.01) and 12-months (13.9% vs 21.3%; p=0.005). With regards to the 
ESG cohort in this single centre and single operator study, the observed weight loss trajectory was 
linear for the initial 6 months, with a decrease in the rate of weight loss between 6- and 12-months. 
In contrast, there was weight recidivism in the IGB cohort between 6- and 12-months, a finding 
not unique to this study.42-44 With respect to safety, IGB was associated with unplanned hospital 
readmissions at a significantly higher rate compared to ESG (17% vs 5.2%; p=0.048). Therefore, 
endoluminal gastric volume reduction with ESG is an effective and safe procedure, with outcomes 
superior to established non-surgical weight loss therapies. 
 
Laparoscopic sleeve gastrectomy (LSG) is the most frequently performed weight loss 
procedure worldwide. In the United States alone, approximately 150,000 LSGs were performed in 
2017, an order of magnitude greater than the total number of endoluminal weight loss and 
metabolic procedures performed in the United States in the same year.45 However, ESG began 
gaining momentum in 2017 as a promising technique that mimicked the physical gastric alterations 
of LSG. In clinical practice, a frequent question pertained to comparative outcomes between these 
two procedures. A paucity of data existed to guide the clinician, with only one non-matched cohort 
study which demonstrated LSG achieving superior TBWL compared to ESG at 6-months (23.48% 
vs 14.37%; p<0.001) and 12-months (29.28% vs 17.57%; p<0.001).46 The significant difference 
in baseline BMI between the ESG and LSG cohorts in this study was a major limitation as it is 
well known that baseline BMI is a predictor of the magnitude of weight loss.47 
 
CHAPTER 948 was the first study to compare LSG with its apparent endoluminal alternate 
(ESG) in a case-matched cohort. Outcomes were intentionally limited to six months due to this 
being the observed period of linear weight loss in the ESG cohort.41 The aetiology of the prompt 
rate of weight loss being limited to six months is multi-factorial. The most probable reason is that 
the volume reduction to a size similar to that of LSG was limited to this period. The TBWL at 6-
months post procedure was statistically and clinically significantly inferior in those undergoing  
ESG as compared to LSG (17.1% vs 23.6%; p<0.01). However, ESG was associated with a 
statistically and clinically significantly lower rate of adverse events compared with LSG (5.2% vs 
16.9%; p<0.05).  
 
The explanation for the aforementioned variance in TBWL between ESG and LSG was not 
clear. The mandatory 6-month diet and lifestyle counselling prior to LSG (required for approval 
by payers) may have biased the outcomes in favour of LSG. However, ESG being self-pay, 
potentially selected more highly motivated patients which likely negated the abovementioned bias. 
Notably, the metabolic improvements observed with endoluminal gastric volume reduction (ESG) 
appear to be proportional to the weight loss encountered. This is in contrast to the weight-
independent improvements in metabolic profile that are seen after patients undergo LSG. It 
appeared that the endoscopic bariatric community has predominantly focused innovative efforts 
on developing techniques to reduce the volume of the stomach, despite sufficient evidence 
demonstrating that the diminished gastric volume observed after bariatric surgery does not appear 
to be the basis behind its efficacy.19 I highlighted this concern in response to a publication 
describing the outcomes of a new gastric stapling device.49 
 
Studies comparing the efficacy of laparoscopic gastric plication to LSG may provide 
insight into the variance between the two procedures that occur despite similar luminal gastric 
configurations and volumes. Indeed, in two recent systematic reviews and meta-analysis, TBWL 
was significantly superior with LSG compared to laparoscopic gastric plication.50, 51 If gastric 
restriction was not the main mechanism behind the benefits of bariatric surgery, particularly LSG, 
then what was the mechanism? After review of the literature, it became apparent that the gastric 
mucosa is a hormonally active organ and may in fact be the critical component behind the weight 
loss efficacy and metabolic improvements seen after LSG. I published this hypothesis in response 
to a study comparing the outcomes of laparoscopic greater curvature plication to LSG.52  
 
I hypothesised that excision of the gastric mucosa is a key contributor to the improvement 
in obesity related comorbidities seen after LSG. If this is proven, then a method to remove or resect 
the mucosa may provide a conceivable strategy for the treatment of obese patients. Aim 3 was to 
evaluate whether gastric mucosal devitalization (GMD) could be a potential therapeutic approach 
to treat patients with obesity and its associated comorbidities. 
 
The gastric mucosa secretes orexigenic (ghrelin) and anorexigenic (leptin, obestatin, and 
nesfatin-1), making it a complex regulator of food intake as well as glucose and lipid 
metabolism.53-55 To test the hypothesis that the gastric mucosa was a critical metabolic regulator, 
experiments were performed in an obese rat model. It was necessary to determine effects of GMD 
(without alteration in gastric volume) on tissue adiposity, lipid and glucose metabolism and 
cardiovascular related diseases. The aim of CHAPTER 1056 was to ascertain the independent 
effects of the gastric mucosa on obesity and its associated comorbidities.56 In this study, it was 
observed that devitalization of the gastric mucosa, without alteration in gastric volume, resulted in 
a similar metabolic profile to sleeve gastrectomy. Argon plasma coagulation (APC) was used as 
the method to perform GMD for two reasons. First, widespread clinical experience with the 
technology existed, allowing its reproducible application. Second, there was familiarity with 
interpretation of the excised specimens. GMD resulted in a reduction in body weight, reduction in 
visceral adiposity, improved serum lipid and glucose profiles and reduced liver lipid content – all 
fundamental facets of any metabolic therapy.  
 
Bariatric surgery is the most effective treatment for obesity and its associated 
cardiovascular comorbidities; such as hypertension, cerebrovascular disease, congestive heart 
failure and myocardial infarction.57, 58 To date, no endoluminal therapy has demonstrated clinically 
meaningful reductions in the aforementioned comorbidities.17 A therapy that results in a significant 
reduction in blood pressure, renin and lipid deposition in the heart and aorta would likely reduce 
the aforementioned deadly comorbidities. Initially presented in abstract form in 2015 at the 
American Heart Association annual meeting, CHAPTER 1159 was designed to provide further data 
to elucidate the influence of the gastric mucosa on the cardiovascular comorbidities associated 
with obesity.59, 60 In this study, high-fat diet rats undergoing GMD were observed to have a 
significant reduction in blood pressure, plasma renin activity and cardiac as well as aortic lipid 
droplet deposition.  
 
Hypertension is the leading cause of death worldwide, and a strong direct correlation exists 
between blood pressure and the risk of comorbidities and death.61-63 Therefore, a therapy that 
results in a reduction in systolic and diastolic blood pressure has the potential to improve mortality. 
Furthermore, a reduction in renin has cardiovascular benefits that span beyond its lowered blood 
pressure. In detail, a reduction in renin would be expected to delay the onset of type 2 diabetes and 
reduce the frequency of stroke.64-66 Additionally, a reduction in the accumulation of lipid in the 
cardiovascular system would reduce atherosclerosis and cardiac lipotoxicity, thus improving 
cardiac function and helping to prevent heart failure and myocardial infarction.67, 68  
 
These collective metabolic and cardiovascular benefits of GMD in a high-fat diet-induced 
obese rat model were adequate enough to warrant contemplation of GMD as a therapeutic approach 
to treat obesity in the clinical setting. However, important developments needed to occur before a 
clinical trial commenced. The next step was to establish the translatability of GMD using 
commercially available endoscopic equipment for the treatment of obesity and its related 
comorbidities. The initial goal was to translate the technique into a large animal model to assess 
the technical feasibility, efficacy and safety of GMD using standard, commercially available 
endoscopic equipment. The porcine model was chosen as it has similar gastrointestinal anatomy 
to humans and has been traditionally used to investigate novel endoscopic bariatric therapies prior 
to clinical studies. CHAPTER 1269  documents an RCT comparing the effects of GMD to sham 
and a LSG cohort in a porcine model. GMD was performed using a combination of submucosal 
injection followed by ablation with APC. The purpose of the submucosal fluid cushion was to 
facilitate selective mucosal ablation without thermal injury to the deeper tissue layers. GMD was 
technically feasible and safe when performed in a human-sized porcine model. Furthermore, it was 
significantly more effective than sham in terms of relative reduction in body weight and visceral 
adiposity (as measured by MRI). Additionally, when GMD was compared to the LSG cohort, 
although relative weight loss was similar at 4 weeks and significantly less at 8 weeks, there were 
similar reductions in visceral adiposity at 8 weeks. This suggests that the benefits of GMD are of 
greater proportion to what would be expected from weight loss alone.69 
 
In view of the potential for translation to humans, a provisional patent [Endoscopic Gastric 
Mucosal Ablation/Resection/Exclusion (A/R/E) as a Minimally Invasive Weight Loss Approach] 
was submitted on December 8th, 2015. The US Patent Application Serial No. 15/533,8310 was 
subsequently published as US 2017/0367723 on December 28th, 2017. This patent has been 
licensed to ERBE Elektromedzin GmbH with an effective date of November 15th, 2017. As the 
method was now protected, a human pilot study titled “Endoscopic Gastric Mucosal Devitalization 
(GMD) as a primary obesity therapy” received ethics approval on January 30th, 2018 
(IRB00089675). This study is divided into three steps, with the last step being a 24-patient 
prospective single arm study with 12-month follow-up. The APPENDIX contains the published 
utility patent, evidence of the license obtained, and the institutional review board (IRB) approval 
letter. 
 
Following the success of GMD in rat and porcine models, it was timely to translate the 
method to humans. The first step was to determine optimal dosing parameters that would 
correspond with selective GMD, without injury to the deep submucosa or muscularis propria, in 
human stomachs ex-vivo. APC is an operator dependent technology with the dose administered 
dependent on application energy and time. Therefore, predetermined specific dosing parameters 
would likely not consistently translate to homogenous mucosal devitalization. However, APC 
application triggers colour change from white to golden to brown to eventually black. The 
importance of CHAPTER 1370 was to determine the optimal tissue colour that would likely 
correspond to selective GMD without damage to the deep submucosa or muscularis propria.70 The 
study was performed in fresh specimens removed at LSG. These specimens were ideal not only 
because of their ease of acquisition, but also because this was the precise tissue that would be 
ablated in-vivo.  
 
Importantly, from the perspective of ongoing translatability, GMD using a submucosal 
fluid cushion followed by APC was achieved without damage to the muscularis propria. 
Confirming common clinical experience, the experiment identified an association between tissue 
colour and depth of mucosal and submucosal thermal injury. Tissue colour was found to be a 
reliable indicator of depth of devitalization, with a “golden” colour deemed as the most appropriate 
colour indicator for in-vivo experiments as it represents achieving sufficient mucosal injury with 
a tolerable amount of submucosal injury. These findings provided essential data to proceed to the 
in-vivo human study (NCT03638843). 
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Obesity is a public health epidemic associated with a number of comorbidities, most notably type 2 diabetes and
hypertension, as well as elevated all-cause mortality. The treatment for obesity and its associated comorbidities has
most recently expanded into the field of bariatric endoscopy. This field bridges a gap between lifestyle counseling
with or without pharmaceutical treatment and the most effective treatment of obesity, bariatric surgery. Because
of its minimally invasive nature, bariatric endoscopic therapy has the potential to appeal to the large sector of the
obese population that resists surgery, as well as those early in the onset of obesity. To date, five endoscopic devices
have been approved by the U.S. Food and Drug Administration for the treatment of obesity, and many more are in
development, undergoing clinical trials, or being used around the world. Here, we present the current state of the
field, highlight recent developments, and describe the clinical outcomes of these minimally invasive procedures in
terms of weight loss, improvement in metabolic profile, and reduction in comorbidities.
Keywords: intragastric balloon; transoral gastroplasty; aspiration therapy; gastrointestinal bypass sleeve; endoscopic
sleeve gastroplasty; primary obesity surgery endoluminal
Background
Obesity is a public health epidemic currently
affecting 37.7% of adults and 17% of children and
adolescents in the United States.1,2 Globally, the
number of obese individuals continues to rise.3 This
is particularly problematic because of the comor-
bidities associated with obesity, which include type
2 diabetes mellitus, hypertension, cardiovascular
disease, stroke, gallbladder disease, metabolic syn-
drome, and several types of cancer. Furthermore,
depression is more common in obese individuals
than in the general population, and obesity is asso-
ciated with higher all-cause mortality, morbidity,
and lower quality of life.4–10
The growing prevalence of this health problem
has put a significant burden on our healthcare sys-
tem. Recent estimates have reported that $147–
210 billion is spent annually to treat obesity and its
attributed comorbidities in the United States alone,
therefore comprising about 21% of our healthcare
spending.11,12
Weight loss has long been shown to decrease the
comorbidities associated with obesity.13 However,
significant long-term weight loss is not often sus-
tained through diet and exercise alone.14 There-
fore, the rapid increase in the prevalence of obesity
has resulted in an increasing demand for treatment
options that extend beyond the clinical guidelines
of diet and exercise.
Bariatric surgery has been shown to be the most
effective treatment, with themost significant weight
loss and decrease in comorbidities, such as type 2
diabetes mellititus.15,16 A number of bariatric surg-
eries are currently offered, many of which func-
tion by altering gastric and intestinal anatomy to
reduce the capacity for food and the absorption of
nutrients. Some of these surgeries, including Roux-
en-Y gastric bypass (RYGB), have also been found
to induce physiological changes that support weight
loss, such as reduction in levels of the hunger-
stimulating hormone ghrelin and increases in pep-
tide YY (PYY) and glucagon-like peptide 1 (GLP-1),
both of which induce satiety.17
doi: 10.1111/nyas.13441
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Despite the clinical success, less than 2% of those
who qualify for bariatric surgery will undergo an
operation, primarily because of issues concern-
ing associated risks, morbidity, cost, accessibility,
and patient preference.18 Furthermore, a signifi-
cant fraction of obese individuals do not qualify
for surgery. The least invasive medical treatment
for obesity is pharmaceutical treatment. However,
pharmaceutical approaches are far less efficacious
than surgery, with 30% of patients prescribed the
highest dose failing to achieve clinically significant
weight loss.19 Therefore, bariatric endoscopy may
bridge a critical gap in the treatment of obesity.
Because endoscopic technology ismuch less inva-
sive than surgery, advancements in the field of
bariatric endoscopy allow physicians to treat a
greater portion of those struggling with obesity.
Specifically, endoscopic procedures are able to reach
patients earlier in the onset of obesity, including
pediatric patients and those with body mass indices
(BMIs) between 30 and 35 kg/m2. In addition to
increased applicability, endoscopic techniques have
lower cost and lower risk than surgery and main-
tain the structural integrity of the stomach. Fur-
thermore, because endoscopic procedures can be
repeated throughout one’s life, they are well suited
to manage the chronic nature of obesity.
The field of bariatric endoscopy is much younger
than the field of bariatric surgery; however, there
are currently five bariatric endoscopic procedures
approvedby theU.S. FoodandDrugAdministration
(FDA) for clinical use in the United States, and a
number of others in various stages of development,
testing, anduse in other countries.Here,wedescribe
the current state of bariatric endoscopic procedures
and examine their effects not only on weight loss
but also on metabolic profile.
Space-occupying devices
Space-occupying devices are traditionally inserted
endoscopically to reduce available gastric volume;
however, recent research indicates that intragastric
balloons (IGBs), the most commonly utilized
space-occupying devices, also function to delay
gastric emptying.20 Three IGBs were recently
approved for 6-month clinical use in the United
States, and additional balloons are undergoing
clinical trials. The primary limitation of treatment
with a space-occupying device is that obesity is
a chronic problem, and these devices can only
Figure 1. Endoscopic view of inflated Orbera intragastric bal-
loon.
remain in situ temporarily. However, it is important
to consider that these procedures can be repeated
throughout one’s life as needed, and for many
patients are a more attractive option than surgery.
Of note, the safety and effectiveness of successive
use has not been specifically examined by the FDA;
however, it has been used in clinical practice.21
Intragastric balloons
Orbera. The most commonly used IGB, which
was approved for clinical use in the United States
in 2015, is the Orbera IGB (Apollo Endosurgery,
Austin, TX), previously known as the BioEn-
terics Intragastric Balloon (Allergan, Irvine, CA)
(Fig. 1).22 As it had been used commercially since
1991 outside of the United States, there is a large
body of evidence supporting the use of the Orbera
IGB.
Importantly, therapy with the Orbera IGB has
been reported to result in significantly reduced
metabolic disease, diabetesmellitus, hyperuricemia,
hypertriglyceridemia, and hypercholesterolemia—
all of which remained reduced at 1-year follow-up
in an Italian study.23 More recently, in a multicenter
European study, Genco et al. found the rates of
comorbidities at 3 years after Orbera therapy to also
be significantly reduced. Specifically, in those who
had diabetes at baseline (n = 78), 31% experienced
complete resolution at 3-year follow-up. Moreover,
complete resolution occurred in 44% of those
with hypertension (n = 150), 34% of those with
hypercholesterolemia (n = 168), 45% of those
with dyslipidemia (n = 102), 47% of those with
osteoarthropathy (n = 132), and 100% of those
37Ann. N.Y. Acad. Sci. 1411 (2018) 36–52 C© 2017 New York Academy of Sciences.
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with respiratory disorders (n = 6).24 Furthermore,
an Italian center linked treatment with the Orbera
IGB to positive outcomes in obese womenwhowere
previously infertile.25 These lasting improvements
in comorbidities and indications of metabolic
syndrome are particularly noteworthy because the
primary concern regarding treatment with IGBs is
the tendency for partial weight regain after balloon
removal.
A current systematic review of 26 studies (n =
6101) found the percent excess bodyweight loss
(%EWL) at the time of removal (6 months) to be
36.2 ± 6.3%.26 Most recently, results of a U.S. mul-
ticenter randomized clinical trial (n= 255) through
12 months have shown mean total bodyweight loss
(%TBWL) in the Orbera group (n = 125) at 6,
9, and 12 months postinsertion to be 10.2%, 9.1%,
and 7.6%, respectively, compared with 3.3%, 3.4%,
and3.1% in the lifestyle counseling group (n= 130).
Notably, thismulticenter trialwas limited topatients
with class 1 and 2 obesity (BMI 30–40 kg/m2).27 A
recent meta-regression analysis demonstrated that
there is no significant difference in the %TBWL fol-
lowing treatment with the Orbera IGB over a wide
range of BMIs, thus indicating that this treatment
option is suitable for patients with varying degrees
of obesity.28 However, the FDA has only approved
Orbera for use in adults with a BMI between 30 and
40 kg/m2.
It has been noted that the bulk of weight loss
occurs in the first 3 months of therapy.29 This is
consistent with the results of a recent meta-analysis
(n = 1683), which reported a %EWL at 12 months
after balloon insertion (6 months postremoval)
of 25.44% and a pooled %TBWL at 3, 6, and
12 months postimplantation of 12.3%, 13.16%,
and 11.27%, respectively.28 To examine the dura-
bility of the weight loss, Dastis et al. assessed out-
comes at 2.5 years after balloon insertion. Success-
ful weight loss was defined as 10% TBWL, both
at 6 and 30 months follow-up. Of the 100 patients
who underwent IGB therapy, 63 achieved successful
weight loss at 6months—atwhich point the balloon
was removed—and24maintained thisweight loss at
2.5 years follow-up.Notably, therewasno structured
weight maintenance program offered to patients in
this study, which took place in Switzerland.30
To combat weight regain, IGBs are often used
repeatedly throughout a patient’s life. Peker et al.
compared back-to-back IGB treatment to that
of laparoscopic adjustable gastric band surgery
(LAGB) in a Turkish cohort and found that the
weight loss at 12 months was more significant in
those treated with the IGBs (n = 16) than in those
treated with LAGB (n = 16).31 However, Dumon-
ceau et al., who studied patients in Geneva, Switzer-
land, andBrussels, Belgium, reported that, at 5 years
follow-up, patients who had undergone either sin-
gle (n = 119) or repeated (n = 19) IGB placement
were equally likely to have achieved10%TBWL.21
Rates of adverse events were assessed in a man-
ual review of 68 studies. Early removal of the IGB
occurred in 7% of patients. The most common
adverse events, occurring in 33.7% of patients, were
pain and nausea. Serious adverse events were rare
and includedmigration in 1.4% of patients and gas-
tric perforation in 0.1%. Of the eight documented
gastric perforations that occurred, four occurred
in patients who had previously undergone gastric
surgery. Four Orbera-associated deaths have been
reported owing to gastric perforation or an aspi-
ration event.32 Recently, the FDA issued a notice
regarding the risk of acute pancreatitis and overin-
flation in fluid-filled balloons.
Mechanistically, theOrbera IGB is a single, spher-
ical balloon composed of silicone. During inser-
tion, the IGB is preloaded onto a catheter, deployed
into the gastric fundus, and then inflated with 450–
700 mL saline solution. In clinical practice, methy-
lene blue is often mixed with the saline to serve
as a potential in-urine indicator were the balloon
to rupture; however, the safety and effectiveness of
this practice have not been examined by the FDA.
The procedure is performed under light sedation
on an outpatient basis, and patients should be able
to return to work in a few days, although transi-
tioning to solid foods may take up to 2 weeks. After
6 months, the balloon must be removed endoscopi-
cally. Balloon removal is generally performed under
general anesthesia and requires first puncturing the
balloon with a needle and emptying the saline with
a catheter and then using grasping forceps or a
polypectomy snare to remove the deflated balloon.
As with the other FDA-approved balloons, the
Orbera IGB will likely be more commonly used in
the United States over the course of the next few
years.
ReShape. The ReShape IGB, which was approved
by the FDA in July 2015, is a dual-balloon device
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designed for increased satiety and resistance against
migration.Changes inmetabolic profile and comor-
bidities as a result of this therapy have yet to be
examined directly; however, significant weight loss
has been documented.
In a pivotal U.S. multicenter clinical trial
(n = 326), patients were randomized to ReShape
IGB treatment in addition to lifestyle counseling
(n = 187) or sham endoscopy and lifestyle counsel-
ing (n = 139) for 6 months. Weight loss with the
ReShape IGB was more than twice that of the con-
trol group,with 27.9%EWL in completers (n= 167)
compared with 12.3% EWL in control group com-
pleters (n = 126).
The adverse event profile was low. Balloon defla-
tion occurred in 6% of patients; however, nomigra-
tions occurred as a result of deflation. Initially,
gastric ulcers occurred in 39.6% of patients; how-
ever, the device was then modified, and consequen-
tially the rate of ulceration decreased to 10.3%,
and the size of subsequent ulcers decreased sig-
nificantly. Only one ulcer was clinically significant,
as it resulted in a hemorrhage that required blood
transfusion. Three serious adverse events occurred
during retrieval: one esophageal mucosal tear that
required hemoclip treatment, one cervical esoph-
agus perforation that was managed conservatively
with antibiotics, and one postretrieval aspiration
pneumonitis.33 A smaller, single-arm Spanish study
(n = 60) had similar outcomes.34 As previously
mentioned, the FDA recently issued a notice regard-
ing the risk of acute pancreatitis and overinflation
in fluid-filled balloons.
The ReShape IGB is distinct from other IGBs, as
it is composed of two silicone balloons connected
by a flexible tether (Fig. 2). The device is inserted
endoscopically and then inflated with up to 450 mL
salinemethylene blue in each balloon, up to 900mL
total. Notably, each of the two balloons has inde-
pendent channels so that unintended deflation in
one balloon will not deflate the other balloon, but
rather the inflated balloonwill keep the deflated bal-
loon frommigrating. Like the Orbera IGB, this IGB
is indicated for 6 months of treatment, but can be
repeated. Of note, the FDA has only approved the
ReShape IGB for treatment of adults with a BMI
between 30 and 40 kg/m2.
Obalon. Most recently approved by the FDA in
September 2016, the Obalon IGB (Obalon Thera-
Figure 2. Endoscopic view of the ReShape Duo intragastric
balloon during the deflation process.
peutics Inc., Carlsbad, CA) is unique in that it is
inserted via ingestion rather than endoscopy. The
multicenter U.S. pivotal trial (n = 387) compared
the outcomes of patients who underwent treat-
ment with the Obalon IGB and lifestyle counsel-
ing (n = 185) to a control group of sham capsules
and lifestyle counseling (n = 181). At 24 weeks,
significant improvements in systolic blood pres-
sure, fasting glucose, low-density lipoprotein (LDL)
cholesterol, and triglycerideswerenoted in the treat-
ment group but not in the control group. The
%TBWL was 6.81 ± 5.1% in the treatment group
and 3.59 ± 5.0% in the control group. One seri-
ous adverse event occurred, which was a gastric
ulcer that was managed conservatively. Nonseri-
ous adverse events occurred in 89.9% of subjects—
99.7% of which were rated mild or moderate. The
most common of these events were nausea and
abdominal cramping.35
The Obalon IGB has also been studied for use
specifically in the treatment of pediatric obesity
in Italy, with positive outcomes. Specifically, at
3 months postinsertion, Nobili et al. reported sig-
nificant improvement in alanine aminotransferase
(51.44± 19.04 to 27.00± 13.38, P= 0.01), total and
LDL cholesterol (179.8 ± 14.91 to 144.78 ± 14.36,
P = 0.001 and 99.62 ± 24.09 to 93.11 ± 17.14,
P = 0.001), insulin (27.40 ± 5.68 to 18.13 ± 7.67,
P = 0.01), HOMA-IR (5.85 ± 1.53 to 3.84 ± 2.09,
P= 0.03), and uric acid (7.32± 0.28 to 5.08± 1.23,
P = 0.001).36,37
In order for this IGB to be inserted via inges-
tion rather than endoscopy, it is packaged inside
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of a gelatin capsule with an attached valve and
catheter and is inflated with gas rather than saline
solution. The catheter extends through the mouth
to the stomach, allowing for inflation. The gelatin
subsequently dissolves within the stomach, and the
balloon is inflated using fluoroscopic imaging. Up
to three balloons can be inserted in this fashion,
either at the same time or progressively throughout
treatment. The IGB can remain in situ for up to
24 weeks (6 months), and device retrieval must
be performed endoscopically. As with other FDA-
approved IGBs, the Obalon device has only been
approved by the FDA for use in adults with a BMI
between 30 and 40 kg/m2.
Spatz. The Spatz adjustable balloon system (Spatz
Medical, Great Neck, NY) is unique in that it allows
for in situ volume adjustment, which can be used
to increase patient tolerance (deflation) or enhance
efficacy (inflation), and it has been approved for
12-month therapy outside of the United States.
Currently, a pivotal U.S. multicenter clinical trial
is underway; the results of small observational tri-
als have indicated significant weight loss despite a
potentially concerning adverse event profile.
A small pilot study (n = 18) conducted in the
Czech Republic found %EWL at 6 and 12 months
to be 26.4% and 38.8%, respectively. This study
showed the adjustment feature to be useful for toler-
ability and weight loss following plateaus; however,
39%of the IGBs were removed prematurely because
of various adverse events, including gastritis (1),
deflation (1), Mallory–Weiss tear (1), perforating
ulcer (1), and catheter shear (2).38
Similarly, Brooks et al. reported results in 73
patients in the United Kingdom. In those with suc-
cessful insertion (n = 70), the rate of early removal
was 30%, owing to reported premature satisfaction
(14), intolerance refusing adjustment (4), and defla-
tion (3)—although notably without migration. At
12 months (in 49 patients and <12 months in 21
patients owing to premature removal), the %EWL
was 45.7%. Two asymptomatic ulcers were discov-
ered upon retrieval, and three catheter impactions
required surgical extraction.39
When compared specifically to the Orbera IGB in
an Italian cohort, the Spatz IGB showed comparable
weight loss with a higher rate of complications.40
The Spatz IGB is similar to the Orbera IGB in that
it is a single IGB that is placed endoscopically and
filled with 400–800 mL saline solution. However,
a potential source of the increased rate of adverse
events with this IGB may be the attached catheter,
which is a unique component of this IGB designed
to prevent migration.
Because this IGB has been approved for 12-
month treatment outside of the United States, it
may serve as a more durable treatment option if the
adverse event profile can be improved. Upon the
conclusion of the U.S. pivotal trial that is currently
underway, the potential of this device will be better
understood.
Elipse. The Elipse balloon (Allurion Technolo-
gies,Wellesley,MA) is unique in that it is completely
“endoscopy-less,” meaning that it is designed for
passive excretion from the gastrointestinal tract, in
addition to placement via ingestion.
In a small pilot study (n = 8) conducted in the
Czech Republic, patients swallowed one Elipse cap-
sule intended to remain in situ for 6 weeks. The bal-
loon remained full through 6 weeks, self-emptied,
and passed as intended in six of eight patients. At
6 weeks, the mean %EWL was 12.4%. One patient
had the balloon endoscopically punctured owing to
partial collapse, and one patient elected to have the
balloon endoscopically removed; however, no seri-
ous adverse events occurred.41
Since this pilot study, Chuttani et al. reported
further success with the Elipse balloon in a multi-
center study of 34 patients through 6 months, and
improvements in HbA1c, triglycerides, and LDL
were noted. In this study, the balloon was set to
empty at 4months, at which point themean%EWL
was 37.2%, and 93% of the weight loss was main-
tained at 6months. Adverse events included nausea,
vomiting, and abdominal cramps, all of which were
either self-limiting or resolved with medication, as
to be expected with balloon therapy.42
Similar to the Obalon IGB, the Elipse balloon is
packaged inside of a capsule and is attached to a
catheter, which is used to inflate the balloon with
up to 550mL of distilled water. At around 4months
in situ, a valve on the IGB spontaneously opens,
the balloon empties, and the deflated IGB passes
through the intestines to the rectum.
The design of the Elipse IGB is particularly attrac-
tive, as it would conceivably require no hospital time
and therefore be less expensive and appeal to an even
larger segment of the obese population. The results
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of these initial trials are promising, and plans for a
U.S.multicenter clinical trialmay be on the horizon.
Nonballoon space-occupying devices
Transpyloric Shuttle. The Transpyloric Shuttle
(TPS, BAROnova Inc., Goleta, CA) was examined
in a small Australian trial (n = 20). Marinos et al.
reported promising results, with %EWL of 25.1 ±
14.0% at 3 months and 41.0 ± 21.1% at 6 months
postinsertion. The most common adverse event
was gastric ulceration, which resulted in premature
removal of the device in 10% of patients.43
The device is composed of two silicone bulbs con-
nected via a flexible catheter. The larger of the two
bulbs is spherical and is designed to prevent migra-
tion, while the smaller of the two is cylindrical with
the purpose of advancing into the duodenum via
peristalsis. This mechanism produces an intermit-
tent obstruction because of the larger bulb against
the pylorus, which hypothetically will cause a delay
in gastric emptying, thereby inducing early and pro-
longed satiety. The device is inserted via endoscopy
and functions without an anchor.
A pivotal multicenter, randomized clinical trial
designed to test the safety and effectiveness of this
device has recently completed its cohort enrollment.
The results of this study will likely elucidate this
device’s potential for widespread clinical use and
potential metabolic improvement.
Gastric restrictive methods
Gastric restrictive methods function to restrict
stomach volume, and some mechanisms also use
techniques hypothesized to delay gastric empty-
ing. Transoral gastroplasty is the predominant sub-
category within gastric restrictive procedures. This
mechanism involves the use of suturing, stapling, or
tissue anchor placement to alter the morphology of
the stomach.
Transoral gastroplasty
Endoscopic sleeve gastroplasty. Endoscopic
sleeve gastroplasty (ESG) is a transoral gastroplasty
procedure that utilizes an FDA-approved full-
thickness endoscopic suturing system (OverStitch;
Apollo Endosurgery, Austin, TX) to reduce gastric
volume by approximately 70%. Of note, ESG is not
an FDA-approved procedure, and the OverStitch
device has not been specifically approved for the
treatment of obesity. Rather, the OverStitch device
has been approved for a general tool claim of
endoscopic placement of sutures.
Sharaiha et al. recently reported weight loss and
metabolic outcomes at 6, 12, and 24 months post-
ESG in a U.S. cohort. At 12-month post-ESG,
metabolic profiles were assessed and compared to
baseline levels, which showed a significant reduction
in markers of diabetes, hypertension, and hyper-
triglyceridemia. HbA1c levels were decreased in the
entire cohort, from 6.1% ± 1.1% at baseline to
5.5% ± 0.48% at 12 months postprocedure
(P = 0.05). In those with diabetes or prediabetes
at baseline, HbA1c levels were reduced from 6.6%
± 1.2% to 5.6% ± 0.51% (P = 0.02). Furthermore,
of the 13 patients taking medication for diabetes at
baseline, five patients had stopped insulin and two
had stopped allmedications at 12-month follow-up.
Significant reduction was also seen in systolic blood
pressure, from 129.0 ± 13.4 mmHg at baseline to
122.2 ± 11.69 mmHg at 12 months (P = 0.02),
as well as in serum triglycerides, from 131.84 ±
83.19 mmol/dL to 92.36 ± 39.43 mmol/dL
(P = 0.02), and alanine aminotransferase, from
42.4 to 22 inmen (P= 0.05), and 28 to 20 in women
(P = 0.01).44
At 6 months, patients had a mean of 14.4%
TBWL (80% follow-up rate); at 12 months, the
%TBWL was 17.6% (76% follow-up rate); and at
24 months, the %TBWL further increased to 20.9%
(66% follow-up rate).44 The most recent trials con-
ducted at individual centers in theUnited States and
Spain have reported %EWL over 50% at 6 months
and 1 year postprocedure.45–47 A multicenter study
(n = 242) spanning the United States and Spain
reported weight loss through 18 months in 30 sub-
jects who were available for follow-up at that time.
The %TBWL at 18 months was 19.8 ± 11.6%.48
This study was therefore expanded to a 24-month
follow-up, with 92 patients returning to participate.
In this cohort, the TBWL was 18.6% (95% CI 15.7–
21.5), without differing significantly between the
three centers (P = 0.7). Further, 84% and 56% of
the cohort achieved 10% and 15% TBWL at
24 months on per protocol analysis.49
ESG appears to decrease caloric intake through
increased satiation. However, Abu Dayyeh et al.
recently studied the induction of physiological
changes that promote weight loss post-ESG in a
U.S. cohort. These changes parallel those seen after
bariatric metabolic surgery and include a decrease
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Figure 3. Endoscopic view of endoscopic sleeve gastroplasty at two time points. (A) Argon plasma coagulation marking in
preparation for suture placement via the OverStitch device. (B) Postprocedural lumen along the lesser curvature of the gastric
cavity.
in the appetite-stimulating hormone ghrelin, an
increase in insulin sensitivity, and a delay in gas-
tric emptying.45
The rate of adverse events post-ESG is minimal,
with a number of series reporting zero events.46,50 In
the largermulticenter study, adverse events occurred
in 2% of patients, comprising two cases of peri-
gastric inflammatory fluid collection, one case of
hemorrhage, one case of pulmonary embolism, and
one case of pneumoperitoneum and pneumothorax
that required chest tube placement. All five patients
recovered fully, with no further need for surgery.48,49
One clinical trial reported an incidence of a perigas-
tric leak, which was managed nonoperatively.44
The gastric remodeling that occurs in this pro-
cedure mimics that of laparoscopic sleeve gastrec-
tomy surgery; however, no incisions are made. In
this procedure, sutures are placed in two rows along
the greater curvature of the stomach, in a triangular
pattern from the anterior wall to the greater cur-
vature to the posterior wall. The result is a gastric
cavity that forms a tubular sleeve along the lesser
curvature, with the greater curvature closed off by
plications from the gastroesophageal junction to the
prepyloric antrum (Fig. 3).47,51,52
ESG is an outpatient procedure, and patients gen-
erally return to full functionality within 1–3 days
post-ESG.45 However, patients are instructed to fol-
low a liquid diet for 3 days postprocedure before
transitioning to smooth, pureed foods and then to
soft and then solid foods in 2-week intervals.
ESG is unique among endoscopic techniques in
that, although it can be reversed, it can also serve
as a durable alteration to gastric volume. Further, if
plications were found to break down over time, ESG
can be repeated as needed, as was recently reported
with positive outcomes.46,47,53
Primary obesity surgery endoluminal. Primary
obesity surgery endoluminal (POSE) is another
transoral gastroplasty procedure; however, POSE
depends on an Incisionless Operating Platform
(IOP) (USGI Medical, San Clemente, CA) to place
full-thickness tissue-anchor plications and is cur-
rently being examined by the FDA for safety and
efficacy.
To date, the results of four studies assessing the
safety andefficacyofPOSEhavebeenpublished, and
one study has examined the physiological effects of
the procedure. Lopez-Nava et al. assessed the out-
come of POSE treatment in a prospective single-
arm trial (n = 147) in Spain and found that, in the
116 patients available for follow-up at 1 year, the
mean %EWL was 44.9 ± 24.4 (15.1 ± 7.8 %TWL).
Further, patients tolerated the procedure well, with
no serious short-termor long-termadverse events.54
Similarly, Espinos et al. assessed these outcomes at
6 months (n = 45) in a Spanish cohort and found
%EWL of 49.4% (15.5% TBWL). Adverse events
that required additional hospitalization included
one case of low-grade fever and one case of chest
pain. Common side effects included nausea, gastric
pain, and chest pain.Notably, Espinos et al. included
patients with type 3 obesity, whereas other studies
of POSE were limited to type 1 and 2 obesity.55
Miller et al. assessed the outcomes of POSE
treatment in a controlled, multicenter European
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clinical trial comparing 12-month weight loss
results in patients who underwent POSE in addi-
tion to lifestyle counseling (n = 30) to those who
had lifestyle counseling alone (n= 9). They reported
a mean of 45.0% EWL (13.0% TBWL) in the POSE
group compared with 18.1% EWL (5.3% TBWL) in
the control group. The mean procedure time in this
study was 51.8 ± 14.5 minutes.56 A pivotal multi-
center U.S. clinical trial assessed these outcomes in a
similar fashion in a larger sample, comparing treat-
ment with POSE in addition to lifestyle intervention
(n = 221) to lifestyle intervention alone (n = 111).
In this trial, the %TBWL at 12 months in the POSE
group was 4.94 ± 7% compared with 1.38 ± 5.6%
in the control group. The rate of serious adverse
events in this trial was 4.7%, which consisted pri-
marily of postprocedural nausea, vomiting, and/or
pain requiring a prolonged hospital stay. Notably,
the mean procedure time in this study was 39.7 ±
12.9 minutes.57
Recently, Espinos et al. conducted the first study
assessing the physiological changes that occur as
a result of the POSE procedure (n = 18). At
2 and 6 months postprocedure, intake capacity
was decreased significantly from baseline levels
(P < 0.001). Gastric emptying was also delayed
at 2 months but returned to baseline levels at
6 months postprocedure. Further, patients expe-
rienced improved glucose homeostasis as well
as satiation peptide responses. Specifically, the
glucose/insulin ratio improved (P < 0.05), and
postprandial decrease in ghrelin was enhanced
(P = 0.03), as was postprandial increase in PYY
(P = 0.001). The procedure resulted in significant
sustained weight loss at 15 months, with %EWL
of 63.7± 25.1% (19.1± 6.6% TWL), which may be
mediated through these changes in gastrointestinal
neuroendocrine physiology.58
The specificmechanismreduces the accommoda-
tion of the gastric fundus via 8–10 plications placed
in a dual-ridge fashion to bring the fundic apex
to the level of the gastroesophageal junction, thus
inhibiting full gastric expansion. Three to four addi-
tional plications are placed in a single ridge in the
distal gastric body (across from the insura) to delay
gastric emptying.
The IOP has four channels, accommodating a
slim endoscope and three procedure-specific instru-
ments: the g-Prox EZ Endoscopic Grasper (USGI
Medical, San Clemente, CA), a shaft capable of
360° rotation equipped with stainless steel jaws to
create full thickness tissue folds; the g-Lix Tissue
Grasper (USGI Medical), a helical probe that gasps
tissue and feeds it to the g-Prox; and the g-Cath EZ
Suture Anchor Delivery Catheter (USGIMedical), a
catheter system that penetrates the target tissue and
deploys suture anchors. Generally, the procedure
and associated recovery time requires that patients
spend <24 h in the hospital. Following the proce-
dure, patients advance from a clear liquid diet to a
soft pureed diet during the first month and then to
solid food by 6 weeks.
If approved by the FDA, this procedure will likely
garner more widespread use.
Transoral gastroplasty device. The transoral gas-
troplasty device (TOGA, Satiety Inc., Palo Alto, CA)
is an endoscopic stapler capable of full-thickness
tissue apposition that has been used in transoral
gastroplasty in a number of trials.
Deviere et al. first conducted a multicenter study
on this technique in 2008 (n = 21) and found
24.4% EWL at 6 months. All patients had persis-
tent full or partial stapled sleeves, although 62% of
patients had a gap in the staple line.59 Since then,
the technique has been improved by the addition of
an adjustable septum, allowing closer apposition of
the staple lines. In a pilot study conducted in Bel-
gium using the second-generation device (n = 11),
Moreno et al. reported 46.0% EWL at 6 months and
no serious adverse events.60
Familiari et al. conducted a multicenter Euro-
pean single-arm clinical trial (n = 67) and reported
improvements in metabolic profile at 12 months.
Specifically, HbA1c levels decreased (P = 0.1),
triglyceride levels decreased (P< 0.0001), and high-
density lipoprotein levels increased (P < 0.0001).
The %EWL was 38.1 ± 17.1% in the subjects who
were available at follow-up (79%). Two complica-
tions occurred: a case of respiratory insufficiency
and an asymptomatic pneumoperitoneum, both
treated conservatively. The most common adverse
effects were nausea, vomiting, and pain.61
Recently, Nanni et al. compared the outcomes of
this procedure (n = 29) with laparoscopic gastric
bypass (LRYGB) (n= 20) and biliopancreatic diver-
sion (BPD) (n = 30) in morbidly obese patients in
Italy at 2 years postprocedure. This study concluded
that, although the weight loss resulting from tran-
soral gastroplasty with TOGA is less than that of
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LRYGB and BPD (32.45 ± 22.35% EWL at 2 years
follow-up), the lack of adverse events in combina-
tion with the adequate weight loss both immedi-
ately postoperatively and sustained through 2-year
follow-up demonstrated that TOGA is an effec-
tive alternative option for those who resist surgical
intervention.62
Using this device in transoral gastroplasty allows
endoscopists to create a restrictive pouch along the
lesser curvature of the stomach. The procedure takes
approximately 1–2hand is performedunder general
anesthesia. The TOGA stapler is introduced over a
guide wire to the proximal stomach, and a gastro-
scope is advanced through for visualization. Tissue
is gathered in the stapler via suction, and the stapler
is fired, inserting three rows of 11 titanium staples. If
necessary, this can be repeated to narrow the lumen
further; however, the stapler must be removed for
reloading. Thismechanismwas developed to induce
satiety by limiting the capability for gastric expan-
sion and by slowing the movement of food through
stomach.
Regrettably, the manufacturer of the TOGA
device, Satiety Inc., has closed, leaving the future
of this technique uncertain.
Articulating circular endoscopic device. The
articulating circular endoscopic device (ACE,
Boston Scientific Corporation, Natick, MA) is
another endoscopic stapling device that has recently
begun being clinically studied for use in gastric vol-
ume reduction.
Results of the first human application of the tech-
nique, a prospective phase I clinical study (n = 17)
conducted in the Netherlands, demonstrated that
the procedure is technically feasible and safe and
resulted in bothweight loss and reduction in comor-
bidities. At 12 months, resolution of dyslipidemia
had occurred in three of four patients and improved
in one. Of the four patients with hypertension, two
were in remission. Of the four patients with sleep
apnea, two were in remission, and all patients with
type 2 diabetes had either ceased (1) or reduced
(1) insulin use. The median %EWL was 34.9%
(IQR 17.8–46.6), and endoscopy revealed 6–9 intact
plications, as well as durability of gastric volume
reduction, in all participants available for follow-up
(65%). Adverse events included gastric pain (n = 7,
range 1–3 days), sore throat (n = 4, 2–3 days),
diarrhea (n = 4, 2–15 days), nausea (n = 3,
2–4 days), constipation (n = 4, 3–14 days), and
vomiting (n = 3, 1–4 days). No serious adverse
events occurred, and the median procedure time
was 123 min (IQR 95–129).63
Since this first trial, Biertho et al. studied the out-
comes of the procedure in 69 patients in amulticen-
ter study. In the 45 patients available for follow-up at
2 years, themean%EWLwas21.0±30.4%.Further-
more, eating habits as assessed through the Three-
factor Eating Questionnaire R18 were significantly
improved at both 1 and 2 years postprocedure.64
Mechanistically, this device is capable of 360°
rotation, which allows the endoscopist to place
staples where necessary. With this technique, tis-
sue is suctioned into the stapler, and, upon firing,
eight titanium staples are inserted, forming a full-
thickness, transmural plication. The device is then
removed, reloaded, and the procedure is repeated,
creating up to eight plications in the fundus and two
in the antrum of the stomach. These final two pli-
cations are hypothesized to delay gastric emptying
in addition to further decreasing gastric volume.
The results of the initial trials are encouraging,
and the potential of this device will likely be exam-
ined in further clinical trials.
Endomina device. The Endomina (EndoTool SA
(STT), Gosselies, Belgium) is a triangulation plat-
form being examined for use in transoral gastro-
plasty. Huberty et al. first studied this technique
in 11 subjects in Belgium. At 6 months, the mean
%EWL was 41 ± 33% in the patients who were
available for follow-up (91%). No severe adverse
events were noted, and the researchers concluded
that device appears to be safe and effective in the
short and middle term. The median length of pro-
cedure was 2 h (range 1.15–3.15 h); however, there
is reason to believe that there is a learning curve for
the operation.65
This device functions by creating anterior-to-
posterior plications along the greater curvature of
the stomach with the purpose of reducing gastric
volume. The Endomina is an over-the-scope device
that adds a bendable and nonbendable channel to
an endoscope. It is used in conjunction with a
Transmural Antero-Posterior Endoscopic Stitcher
(TAPES) to deliver an interrupted suture that is
anchored by two T-tags. This technique involves
tightening pairs of plications to one another and is
repeated four to six times per procedure.
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The results of this small studyarepromising; how-
ever, larger studies will need to be performed before
this technique can be fully understood.
Other gastric restrictive mechanisms
Transoral endoscopic restrictive implant system.
The transoral endoscopic restrictive implant system
(TERIS, BaroSense Inc., RedwoodCity, CA) is novel
in that the procedure involves insertion of a restric-
tor at the gastric cardia that is designed to remain
in situ permanently (however, it can be removed
if necessary). This mechanism creates a restric-
tive pouch and a 10-mm channel for food to pass
through. Interestingly, this procedure is under clin-
ical investigation for the treatment of both obesity
and gastroesophageal reflux disease (GERD).66
De Jong et al. first studied this procedure in
humans (n = 13) in the Netherlands and reported
a mean of 28% EWL at 3 months postproce-
dure. Severe adverse events developed in 23% of
patients, including one case of gastric perforation
requiring laproscopic treatment and two cases of
pneumoperitoneum.67 More recently, Legner et al.
studied the safety and effectiveness of this tech-
nique in a U.S.-led multicenter pilot study (n = 7)
for the treatment of both GERD (three patients)
and obesity (four patients). The procedure was not
completed in the first two GERD patients owing to
instrumentmalfunction. In the four patients treated
for obesity, the mean %EWL was 30.3% at 2 years
postprocedure. One patient vomited multiple times
postoperatively, loosening the gastroplasty sutures,
and another had an 8-mm outlet at the end of the
procedure, which was corrected.66
The safety of this procedure remains a concern;
however, because of the permanent nature of the
device, if technical improvements and further clin-
ical studies demonstrate this technique to be safe
and effective, TERIS could potentially constitute a
long-term treatment option.
Delaying gastric emptying
As previously discussed,methods of delaying gastric
emptyinghave been a secondary target of a variety of
otherbariatric endoscopicprocedures. Investigation
into mechanisms of regulating gastric emptying as
a primary treatment has also been underway.
Botulinum toxin A injection
Botulinum toxin A (BTA), commonly known as
Botox, is a neurotoxin that inhibits acetylcholine
release at the neuromuscular junction.68 By endo-
scopically injecting BTA into the gastric wall, the
hypothesized result would be a delay in gastric emp-
tying and inhibited ghrelin secretion, both of which
function to induce weight loss. Initial human stud-
ies conducted in Italy andMexicodemonstrated that
the treatment is safe; however, the efficacy was not
impressive, with some studies reporting no signifi-
cant change in body weight, hunger, gastric empty-
ing, or levels of plasma ghrelin or serum leptin.69–71
Since then, Foschi et al. studied the mechanism
using both antral and fundal injections rather
than solely antral injections. This controlled,
double-blind study conducted in Italy resulted in
significantly more weight loss and satiety and less
gastric capacity in the treatment group compared
with controls.72 Furthermore, Li et al., who studied
the technique in China, reported significant weight
loss accompanied by delayed gastric emptying and
a decrease in fasting ghrelin levels. However, results
also indicated a decrease in PYY levels, which is
undesirable, as PYY is associated with satiety.73
A recent meta-analysis of this mechanism con-
cluded that intragastric injection of BTA is effective
for the treatment of obesity when operationalized
in certain ways. Specifically, only wide-area injec-
tions including the gastric fundus or body (rather
than solely the antrum) are associated with weight
loss. Further, multiple (>10) injections are associ-
ated with weight loss; however, a large dose (500
IU) is not associated with weight loss.74 A separate
review emphasized that, despite the effects of BTA
treatment being short term (3–6 months), because
BTA is accessible and not associated with adverse
events, it is an attractive option for the treatment of
obesity.75
Aspiration therapy
Aspiration therapy (AT) refers to the aspiration of a
portion of ingested food contents through an intra-
gastric tube to an out-of-body reservoir.
AspireAssist
In June 2016, the FDA approved AspireAssist
(Aspire Bariatrics, King of Prussia, PA) for the
treatment of obesity. In the multicenter U.S. piv-
otal trial, which included 111 patients who under-
went treatment with the AspireAssist in addition to
lifestyle counseling and 60 patients who underwent
lifestyle counseling alone, patients in the treatment
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group saw significant improvements in indicators
of metabolic syndrome and diabetes in addition
to significant weight loss. HbA1c levels decreased
an average of 0.36% relative to 5.7% at base-
line (P < 0.0001). Triglycerides decreased by 9.9%
(P= 0.02), and high-density lipoprotein cholesterol
increased by 8.1% (P= 0.0001). Furthermore,mod-
est improvement was seen in systolic blood pressure
(–1.2%, P= 0.38), diastolic blood pressure (−2.6%,
P = 0.06), LDL cholesterol (−4.2%, P = 0.06), and
total cholesterol (−2.5%, P = 0.07). However, it is
important to note that these improvements were
not significantly different from those seen in the
lifestyle-counseling group,with the exceptionof gly-
cated hemoglobin. Themean%EWL at 52weeks for
completers in the AspireAssist group (n = 82) was
37.2 ± 27.5% (14.2 ± 9.8% TBWL) compared with
13.0 ± 17.6% (4.9 ± 7.0% TBWL) in the lifestyle-
counseling group (n = 31).76
Small pilot studies have seen more impressive
weight loss. At 1 year, Nore´n and Forssell reported
mean %EWL of 54.4 ± 28.8% in a Swedish cohort,
while Sullivan et al. reported mean %EWL of
49.0±7.7%inaU.S. cohort.77,78 Furthermore, Fors-
sel and Nore´n, who studied outcomes in a Swedish
cohort, reported a mean %EWL at 6 months of
40.8 ± 19.8%.79
The most common adverse events were peris-
tomal pain, stoma granulation tissue formation,
irritation, and infection.76 A concernwith the use of
AT is the potential for the promotion of eating dis-
orders. Therefore, it is important to note that there
has been no evidence of increased food intake or the
induction of adverse eating behaviors in patients
using the AspireAssist.77
This treatment modality consists of the endo-
scopic insertion of a silicone percutaneous gastros-
tomy tube, called the A-tube, which is coupled with
a SkinPort and an accessory tube for aspiration
(Fig. 4). The endoscopic procedure is completed
on an outpatient basis in approximately 15 min-
utes. There is no clearly defined recovery period,
but patients may experience pain following inser-
tion. Twoweeks after insertion, the endoscopist cuts
the proximal end of theA-Tube towithin 1 cmof the
abdominal wall and attaches it to the SkinPort.76–78
Once the device is installed, patients are
instructed to aspire 20 min after each meal, which
takes 5–15 min and removes approximately 30%
of ingested calories. Use of the AspireAssist must
Figure 4. Endoscopic view of AspireAssist A-tube.
be coupled with regular medical supervision and
lifestyle counseling. Interestingly, the device is
designed to self-regulate. The connector, which
allows for aspiration, contains a counter, which after
115 aspirations will lock the connector, blocking
access to the SkinPort. This is a safety measure
that protects against long-term use without clini-
cal supervision.76 AspireAssist is only approved by
the FDA for use in patients who are 21 years or older,
with a BMI between 35 and 55 kg/m2. Patients with
a history of disordered eating are not eligible for AT.
The device is removable, but has also been approved
for long-term use.
There is no indication that AT results in phys-
iological changes that induce weight loss, as with
RYGB; however, it has been suggested that the fis-
tula formed between the stomach and abdominal
wall owing to the A-Tube may inhibit gastric dis-
tention and thus result in earlier satiation. Further
discussion of this treatment has highlighted that the
behavior changes necessary for proper use of the
device align with behavioral suggestions for general
weight management, such as increased chewing of
food and consumption of water to facilitate aspi-
ration, limiting between-meal snacks to avoid the
need for additional aspirations, and developing a
meal schedule to accommodate aspiration while on
the go.76,77
Malabsorptive techniques
Malabsorptive endoscopic procedures function
through a similar mechanism to RYGB surgery in
that they prevent ingested nutrients from having
contact with the duodenum and proximal jejunum,
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which function in nutrient absorption. Thismecha-
nismprevents thedigestive actionofbiliary andpan-
creatic secretions, thus exposing the distal jejunum
to undigested nutrients, which further reduces
absorption. Moreover, this actionmay alter incretin
pathways, resulting in improved insulin sensitivity
in addition to weight loss.22
Gastrointestinal bypass sleeves
EndoBarrier. The duodenojejunal bypass sleeve
(DJBS) is the first endoluminal implant to induce
weight loss through malabsoprtion.80 The Endo-
Barrier (GI Dynamics, Lexington, MA) is a Teflon-
covered DJBS that is impermeable to nutrients.
Although it has not yet been approved for use in
the United States, a number of clinical trials have
been conducted to assess the safety and efficacy of
the EndoBarrier device. A recent meta-analysis of
the published literature from these clinical trials
determined that treatment with the EndoBarrier
DJBS had an impact on diabetic control, as
evidenced by improvements in HbA1c at 24 weeks
(P < 0.001) and after 52 weeks in situ (P < 0.001),
which was statistically significant when compared
with controls (P = 0.001).28 Notably, the potential
use of the EndoBarrier in reversing type II diabetes
mellitus independently of weight loss is under
investigation.28,81
The meta-analysis also found that, on average,
patients experienced 35.3% EWL at 12 months
(n = 105). Four of the trials compared 12–24 weeks
of treatment with the EndoBarrier DJBS (n = 90)
with a sham or control arm (n= 84). Themean dif-
ference in %EWL compared with a control group
was significant at 9.4%.28
A pivotal multicenter U.S. trial was terminated
before completion because the incidence of hepatic
abscess formation reached 3.5%. With enroll-
ment of 325/500 patients, analyses revealed that
subjects who received the DJBS lost significantly
more weight compared with the sham group at
12 months (%TBWL 7.7± 9.6% versus 2.1± 5.4%,
P< 0.0001) and hadmore significant improvement
in HgA1c (–1.1 ± 1.5% versus –0.3 ± 1.6%).
Early device retrieval owing to adverse events was
necessary in 10.9% of patients.81
This mechanism works by anchoring the proxi-
mal end of the sleeve to the duodenal bulb using a
nitinol implant that functions as a self-expanding
stent, while the distal end of the sleeve extends into
the jejunum. The sleeve extends 65 cm into the
small bowel and can remain in situ for 3–12months.
The device functions by preventing contact between
ingested food and the lining of the duodenum and
proximal jejunumwhile allowing pancreaticobiliary
secretions to travel along the outside of the device
to the jejunum, which results in food reaching the
mid-jejunum earlier.
The device is placed under general anesthesia
using endoscopic and fluoroscopic guidance. A cap-
sule containing the sleeve and anchor is advanced
over a guide wire, and the sleeve is deployed in the
proximal jejunum. When it is fully extended, the
anchoring crown is deployed in the duodenal bulb.
Device removal requires the use of a foreign body–
retrieval hood and a procedure-specific grasping
device that collapses the anchor.
Gastroduodenojejunal bypass sleeve. Modified
DJBSs are currently undergoing clinical trials,
including the gastroduodenojejunal bypass sleeve
(ValenTx Inc, Carpinteria, CA). This device oper-
ates in a similar mechanism as the EndoBarrier,
with a major exception: it is longer, at 120 cm,
and is secured at the gastroesophageal junction
rather than theduodenal bulb,using endoscopic and
laproscopic techniques. This modification causes
the sleeve to bypass the stomach in addition to the
duodenum and proximal jejunum, further mimick-
ing the effects of RYGB and reducing the capacity
for intake.32
In a small clinical trial (n=12) conducted inMex-
ico, twopatients required early removal of the device
owing to intolerance. The remaining 10 patients
kept the device in for 12 months. Each of the
measured comorbidities, which included diabetes
mellitus, hypertension, hyperlipidemia, and the use
of antihyperglycemics, improved during the trial.
Specifically, there was a mean improvement in fast-
ing glucose of 28% among the entire cohort and
a mean improvement of 38% among those with
preexisting diabetes mellitus. Furthermore, three
of the four patients with preexisting diabetes had
over a percentage point drop in their HbA1c val-
ues, and the fourth patient also improved to the
point of stopping diabetes medication. All patients
with hypertension saw improvement, and 71% had
blood pressure values in the normal range and were
therefore able to stop all antihypertensive medi-
cations. The mean change in blood pressure for
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the entire cohort was –15%. The one patient with
hypercholesterolemia experienced complete reso-
lution and stopped medication, and, of the five
patients with hypertriglyceridemia, four (80%) had
measurements within the normal range and were
off all medications at follow-up. The mean decrease
in triglyceride levels in the entire cohort was 26%.82
Upon removal, the device was fully attached and
functional in six patients. In these patients, themean
%EWL at 12 months was 54%; however, weight loss
was less significant in patients whose device was not
fully attached at 12 months.82 In a 12-week U.S.
trial (n = 22), 77% of patients completed the trial
period. The four patients who had elevated HbA1c
levels preoperatively showed improvement by the
endof the trial, and therewas ameanof 39.7%EWL.
The primary reason for premature removal of the
devicewas early postoperative dysphagia.83 Notably,
these two studies were limited to morbidly obese
patients who met the criteria for bariatric surgery.
This is a key distinction between the gastroduode-
nojejunal bypass sleeve and many other endoscopic
techniques.
SatiSphere. The SatiSphere device (EndoSphere
Inc., Columbus, CA) is another malabsorptive
method designed to be endoscopically implanted
into the duodenum and gastric antrum to delay the
transit time of nutrients. This mechanism is pro-
posed to function by decreasing glucose uptake and
thus insulin secretion. Sauer et al. reported success
in these outcomes, as well as altered GLP-1 lev-
els and significant weight loss (%EWL of 12.2% at
3 months); however, the study (n = 21), which was
conducted in Germany, had to be stopped prema-
turely owing to migration in 48% of patients.84
Since then, a second-generation SatiSphere
device with antimigration properties was tested
in a small study (n = 10) in the Czech Republic.
No migrations were reported; however, all devices
were prematurely removed within 5 weeks owing to
ulcer-like symptoms. Before removal, four patients
experienced 5–7% TBWL, thereby demonstrating
the efficacy of the technique. Further device
modifications are now underway in an effort to
enhance patient comfort and reduce the tendency
for tissue injury.85
Other small bowel endoscopic bariatric
therapies
Revita duodenal mucosal resurfacing. The
Revita duodenal mucosal resurfacing procedure
(Fractyl Laboratories, Cambridge, MA) was not
designed specifically for weight loss but rather to
treat one of the most common comorbidities of
obesity, type 2diabetes. By thermally ablating super-
ficial mucosa in the duodenum, the procedure is
intended to reset duodenal endocrine cells and thus
improve insulin signaling.
Rajagopalan et al. conducted a pilot study
(n = 39) in Chile in patients with type 2 diabetes
on one or more antidiabetic agents with HbA1c
7.5% (58 mmol/mol). Twenty-eight patients had
a long duodenal segment (LS) ablated (9.3 cm,
mean 9.3 cm), and 11 patients had a short seg-
ment (SS) ablated (<6 cm, mean 3.4 cm). At 3 and
6 months follow-up, HbA1c was improved in all
patients. More significant effects were seen in the
LS group, which experienced a 2.5% mean reduc-
tion in HbA1c at 3 months (1.4% reduction at
6 months) compared with a 1.2% mean reduction
in the SS group at 3 months (0.7% reduction at
6months). Notably, this difference remained signif-
icant despite medication reduction in the LS group
over the course of the 6-month follow-up.
The procedure was well tolerated, and there were
no procedural complications. The most common
adverse event was transient abdominal pain. Duo-
denal stenosis developed in 8% of patients, all of
whom were successfully treated with balloon dila-
tion. Notably, root cause analysis of these events
resulted in the adaption of procedural changes and
device improvements.86
This procedure involves a specifically designed
catheter to deliver hot water into the duodenum
for circumferential mucosal lift. This is followed by
inflation of a 2.0-cm balloon with heated water for
ablation of duodenal mucosa. This two-step proce-
dure is repeated successively until the desired length
of mucosal ablation is achieved.
The results reported here are promising, and fur-
ther testing will likely occur in the coming year,
which may shed light on longer-term outcomes.
Incision-less anastomosis system. The incision-
less anastomosis system (IAS, GIWindows, Boston,
MA) is a system of self-assembling magnets that
functions to create a dual-path enteral bypass,
thereby allowing a portion of ingested nutrients to
bypass the small bowel.
The IAS system was recently tested in a first
human trial (n = 10) in the Czech Republic. The
dual-path bypass was successfully and safely created
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Table 1. Summary of FDA approval of described treatment offerings
Mechanism of action Therapy type Name FDA approval
Space occupying Intragastric balloon Orbera Approved
ReShape Duo Approved
Obalon Approved
Spatz Pending
Ellipse Potential for trial
Nonballoon
space-occupying
device
Transpyloric shuttle Pending
Gastric restriction Transoral gastroplasty
procedure
Endoscopic sleeve gastroplasty The OverStitch suturing system is
approved for the general use of
tissue apposition
Primary obesity surgery
endoluminal
Not approved
Transoral gastroplasty device Manufacturer declared insolvency
Articulating circular endoscopic
device
Potential for trial
Endomina Potential for trial
Implant Transoral endoscopic restrictive
implant system
Potential for trial
Delaying gastric
emptying
Injection BTA Approved for human use in a
number of cases; not
specifically in GI tract
Aspiration Aspiration AspireAssist Approved
Malabsorptive Gastrointestinal
bypass sleeve
EndoBarrier Not approved; trial terminated
prematurely, undergoing
revision
Gastroduodenojejunal bypass
sleeve
Potential for trial
SatiSphere Device modifications underway
Other small bowel
endoscopic
bariatric treatments
Revita duodenal mucosal
resurfacing
Potential for trial
Incision-less anastomosis system Potential for trial
in 100%of patients, and, at 6months follow-up, sig-
nificant improvements in HbA1c and fasting blood
glucose levels were noted. All of the patients who
were originally prediabetic normalized (n = 3), and
all diabetic patients (type 2 only) either reduced
or ceased medication (n = 4). The mean %EWL
was 28.3% (10.6% TBWL). No serious adverse
events occurred, and the most common adverse
events—nausea and diarrhea—resolved acutely in
most patients and with diet and standard treatment
in a minority of patients.
The IAS is deployed endoscopically under general
anesthesia (with both endoscopic and fluoroscopic
visualization) to form magnetic octagons in both
the jejunum and ileum that mate. An anastomosis
forms through necrosis in the tissues undergoing
magnetic compression.
The results are very encouraging, and further clin-
ical study will likely occur in the near future.87
Conclusions
Advancements in the field of bariatric endoscopy
have occurred in the past year and will likely con-
tinue to make up a growing sector of obesity treat-
ment in the coming decade (Table 1). This field
bridges an important gap between lifestyle counsel-
ing and pharmaceutical treatment of obesity and
surgical intervention and is unique in the abil-
ity to be repeated throughout life for continued
management of this chronic disease. The true
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strength of these bariatric interventions lies not only
in weight loss but also in the reduction of comor-
bidities associated with obesity.
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Abbreviations used in this pap
weight loss; FDA, Food and Dru
MAC, monitored anesthesia caReshape Duo is a saline-ﬁlled dual, integrated intragastric balloon (IGB) approved by the Food
and Drug Administration for weight loss in patients with obesity. In a prospective, randomized
trial, obese patients who received the balloon had signiﬁcantly greater percent excess weight
loss (%EWL) compared with patients treated with diet and exercise alone. However, there are
limited data on the real-world efﬁcacy of the Reshape balloon.METHODS: We performed a retrospective study of data collected from 2 academic centers and 5 private
practices in which all patients paid for the IGB and follow-up visits out of pocket. The IGB
was removed after 6 months. We collected data (demographic, medical, and laboratory)
from 202 adults (mean age 47.8 – 10.8 years; 83% female) with a baseline mean body mass
index of 36.8 D 8.4 kg/m2 who had IGB insertion for weight loss therapy, along with coun-
selling on lifestyle modiﬁcations focused on diet and exercise. Primary outcomes were
percent total body weight loss (%TBWL) and %EWL at 1, 3, 6, 9, and 12 months after the
procedure.RESULTS: Mean %TBWL at 1, 3, 6, 9 and 12 months was 4.8 – 2.4%, 8.8 – 4.3%, 11.4 – 6.7%, 13.3 –
7.8%, and 14.7 – 11.8%, respectively. Data were available from 101 patients at 6 months and
12 patients at 12 months; 60.4% of patients achieved more than 10% TBWL and 55.4% had
more than 25% EWL. Seventeen patients (8.4%) had esophageal tears during balloon
insertion, with no intervention required. Thirteen patients (6.4%) had their IGB removed
before the end of the 6-month treatment period. Nausea, vomiting, and abdominal pain were
the most common adverse effects, occurring in 149 (73.8%), 99 (49%), and 51 (25.2%)
patients. In one patient, the IGB migrated distally leading to small intestinal obstruction
requiring surgical removal.CONCLUSION: In a retrospective analysis of real-world patients who received the Reshape Duo IGB, we found
it to be a safe and efﬁcacious endoscopic method for producing weight loss, with most patients
achieving greater than 10% TBWL at 6 months.Keywords: BMI; Overweight; Endoscopy; Satiety; Food Intake.hip.
er: BMI, body mass index; EWL, excess
g Administration; IGB, intragastric balloon;
re; TBWL, total body weight loss.
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besity has become a major epidemic, contributingOto increased prevalence of comorbid conditions
including type 2 diabetes, cardiovascular disease, osteo-
arthritis, hypertension, obstructive sleep apnea, and
obesity-related cancers.1 In the United States today,
37.9% of adults are obese, and 70.7% of adults are over-
weight or obese.2 Furthermore, treating obesity-related
medical conditions costs the United States an estimated
147 to 210 billion dollars annually.3 Endoscopic bariatric
therapies have the potential to fulﬁll the unmet need of
patients who would beneﬁt from a weight loss interven-
tion, although they are not receiving one. Studies have
shown that even a weight loss of 10% at 12 months
can signiﬁcantly reduce risk factors for cardiovascular
disease and diabetes.4
Endoscopic weight loss therapies range from space
occupying devices (intragastric balloons [IGBs]), gastric
restrictive procedures (endoscopic sleeve gastroplasty),
aspiration therapy, andmalabsorptive techniques.5 Studies
have shown impressiveweight losswith IGBs, with percent
excess weight loss (%EWL) exceeding 40%.6–8 The
ReShape Duo Integrated Dual Balloon System (ReShape
Lifesciences, San Clemente, CA) is a dual balloon implant
approved by the Food and Drug Administration (FDA) for
use in patients with a body mass index (BMI) between
30 and 40 kg/m2 and 1 or more obesity-related comorbid
conditions.9 The REDUCE Pivotal Trial was a prospective,
randomized trial designed to evaluate the safety and
effectiveness of 6 months of treatment with the ReShape
dual balloon plus a supervised diet and exercise regimen
compared with diet and exercise alone.10 Patients who
received the balloon had signiﬁcantly greater %EWL at
24 weeks (25.1%) compared with diet and exercise alone
(11.3%) (P < .001). However, there are limited real-world
data on the Reshape balloon in the United States. This
study reports the outcomes of the Reshape IGB outside of
a clinical trial setting; patients received no incentives for
participation, and they paid for the cost of the procedure
and follow-up visits out of pocket.
Methods
This study is a retrospective review of a prospectively
maintained database of the Reshape Duo IGB. This is a
multicenter investigator-initiated studywith7participating
centers (2 academic and5private practices). All procedures
were performed by experienced gastroenterologists. Insti-
tutional ReviewBoard approval or equivalentwas obtained
at each institution, and written informed consent was
obtained from all study participants. Study data were
collected and managed by using REDCap electronic data
capture tools hosted at Johns Hopkins University.11
The study included adults with BMI >30 kg/m2 who
had Reshape Duo IGB inserted for weight loss therapy.
All patients received counselling, and follow-up with anutritionist was offered. All patients were instructed to
follow lifestyle modiﬁcations focusing on diet and
exercise. The cost for the IGB, insertion, and removal
procedures, and subsequent follow-up was paid by the
patient and was not covered by insurance. The Reshape
Duo balloon was endoscopically delivered over a guide-
wire into the stomach (Figure 1A and B; Supplementary
Video). Each balloon was ﬁlled with 375 mL normal sa-
line for patients with height <64.5 inches or 450 mL
normal saline for all other patients. The balloon was
removed endoscopically 6 months after insertion
(Figure 1C and D). The balloon was removed sooner in
patients who experienced intolerable side effects. The
procedures were performed under monitored anesthesia
care (MAC) or general anesthesia. MAC was administered
by an anesthesiologist or nurse anesthetist and did not
include endotracheal intubation. General anesthesia
included endotracheal intubation for airway protection.
Data were collected on demographic information,
including pre-IGB weight, height, BMI, waist circumfer-
ence, age, gender, ethnicity, obesity-related comorbid-
ities, as well as relevant laboratory parameters. For
both balloon insertion and removal, we collected data
on complications (bleeding, perforations, superﬁcial
tears, hyperinﬂation, pancreatitis, spontaneous deﬂa-
tion), nausea/vomiting/pain and their severity/duration,
anesthesia type, balloon ﬁlling volume, and medications
given after procedure. We gathered data on subjects who
had the balloon removed in 6 months or fewer than
6 months (and reasons for early removal). Another
category of data collected was lifestyle interventions,
including number of nutrition, psychology, and physician
follow-up visits, percent no-show rate, and type of visit.
For outcome measurements, we collected data on weight
at 1, 3, 6, 9, and 12 months (after IGB insertion) and
blood pressure at 6 and 12 months, and the baseline
laboratory parameters were repeated at 6 months.
The primary study outcomes were percent total
body weight loss (%TBWL) and %EWL at 1, 3, 6, 9, and
12 months after balloon insertion. Excess weight was
calculated as Excess weight (EW) ¼ Baseline weight –
Ideal weight. Ideal weight was calculated by using
Lemmens formula, Ideal weight (kg) ¼ 22  (height in
meters)
ˇ
2.12 Procedural characteristics including compli-
cations with insertion and post-insertion along with time
of removal were studied. Severity of procedural adverse
events was deﬁned according to the American Society for
Gastrointestinal Endoscopy Lexicon by Cotton et al.13
Statistical Analysis
Data were exported to Microsoft Excel (Redmond,
WA) from REDCap database. Results are reported as
mean  standard deviation and as frequency counts and
percentages for categorical variables. Paired t test and
Wilcoxon paired signed rank test were used to compare
the means of the dependent variables before and after
procedure, and weight loss, BMI, %TBWL, %TBWL
Figure 1. (A) Deﬂated balloon being inserted. (B) Dual balloons after ﬁlling with saline and methylene blue. (C) Balloon being
aspirated at time of removal. (D) Snare being used to grasp balloon at time of removal. (E) Superﬁcial esophageal tear at time of
balloon insertion. (F) Esophagitis at time of balloon removal.
Table 1. Baseline Demographics and Comorbidities
Variable n ¼ 202 (%)
Age, y (mean  SD) 47.8  10.8
Gender
Male 34 (16.8)
Female 168 (83.2)
Ethnicity
White 140 (69.3)
Black 18 (8.9)
Hispanic 4 (2.0)
Other 40 (19.8)
Height, cm (mean  SD) 166  9.7
Weight, kg (mean  SD) 101.3  19.0
BMI, kg/m2 (mean  SD) 36.7  6.6
Excess weight, kg (mean  SD) 40.5  15.7
Hypertension 55 (27.2)
Hyperlipidemia 50 (24.8)
Type 2 diabetes 17 (8.4)
On insulin 7 (3.4)
On oral meds only 10 (5)
Obstructive sleep apnea 20 (9.9)
Depression 40 (19.8)
On SSRI or SNRI 17 (8.4)
SD, standard deviation; SNRI, selective serotonin-norepinephrine reuptake
inhibitor; SSRI, selective serotonin reuptake inhibitor.
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uted and non-normally distributed data, respectively.
Univariable and multivariable linear and logistic regres-
sion analyses were performed to identify predictors of
absolute weight loss and >10% TBWL at 6 months,
respectively. All the variables that were signiﬁcant on
univariable analysis and the variable that could have
been confounders were included in multivariable anal-
ysis. Statistical signiﬁcance was based on two-sided
design-based tests evaluated at a ¼ 0.05. Statistical
analysis was performed with IBM SPSS Statistics, version
23 (IBM Corporation, Armonk, NY).
Results
Patient Characteristics
A total of 202 consecutive patients from 7 centers
received the Reshape IGB (mean age, 47.8  10.8 years;
168 women (83.0%) (Table 1). One hundred forty
patients (69.0%) were white. Mean BMI at time of
insertion was 36.8  8.4 kg/m2. Most common comor-
bidities at presentation were hypertension in 27%,
hyperlipidemia in 24%, type 2 diabetes in 8.4%, and
depression in 19.8% (Table 1).
Balloon Insertion
Two hundred two patients underwent balloon
insertion. In 169 cases (83.7%), MAC was used for
sedation, whereas 33 cases (16.3%) were performedunder general anesthesia. Esophagogastroduodenoscopy
at insertion was notable for hiatal hernia in 19 cases
(9.4%) (Table 2). Methylene blue was used in the injec-
ted ﬂuid to ﬁll the balloons in 199 cases (98.5%).
During insertion, there were 17 patients (8.4%) who
developed an esophageal or gastric superﬁcial tear, with
Table 2. Balloon Insertion and Removal Endoscopy Findings
and Adverse Events
During balloon
insertion,
n ¼ 202 (%)
During balloon
removal,
n ¼ 109 (%)
Hiatal hernia 19 (9.4) —
Esophagitis 6 (3) 3 (2.8)
Erosions 2 (1) 15 (13.8)
Ulcer 2 (1) 1 (0.9)
Aspiration 0 0
Esophageal or gastric
perforation
0 0
Esophageal superﬁcial tear 17 (8.4) 5 (4.6)
Bleeding 4 (2) 1 (0.9)
Balloon malfunction 0 0
Respiratory or
hemodynamic instability
1 (0.5) 0
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(Table 2) (Figure 1E). Of those 17 patients, 16 had their
procedures performed under MAC and 1 under general
anesthesia. In 15 cases, the procedure was performed at
an academic center and in a private setting in the
remaining 2 cases. There were no reported perforations.
None of the patients required an intensive care unit
admission. There were no aspiration events or balloon
malfunctions at the time of insertion. One patient
developed transient hypoxia after anesthesia and
required supplementary oxygen through nasal cannula.
Post Balloon Insertion
Post balloon insertion, 187 patients (92.6%) were
placed on a proton pump inhibitor, and 166 (82.2%)
were prescribed ondansetron for management of nausea
and vomiting. Other commonly prescribed medications
were hyoscyamine in 131 cases (64.9%) and aprepitant
in 81 cases (40%) for nausea.
The most common adverse event immediately after
balloon insertion was nausea, which was seen in 149
patients (73.8%) (Supplementary Table 1). Of those,
nausea persisted for less than 1 week in 129 patients
(86.6%), between 1 and 4 weeks in 15 patients (10%),
and longer than 4 weeks in 5 patients (3.4%). Vomiting
was seen in 99 patients (49%). Of those patients, 89
(90%) had vomiting that resolved by the end of ﬁrst
week. Fifty-one patients (25.2%) complained of post-
procedural pain. Of those patients, pain did not last
beyond the ﬁrst week in 46 patients (90.2%).
In patientswho completed 6months of follow-up, mean
number of nutritionist encounters was 8.3  6.1, of which
mean number of in-person nutritionist visits was 6  4.7.
Balloon Removal
There were a total 109 balloon removals. The balloon
was removed in 13 patients (6.4%) before completion of6 months dwell. In 10 of those 13 cases, removal was in
the setting of nausea, vomiting, or abdominal pain. Of the
remaining 3 cases of early removal, 2 were in the setting
of spontaneous balloon deﬂation. Two deﬂations were of
a single balloon with no distal migration. They occurred
at 8 and 110 days after placement, respectively, and
balloons were endoscopically removed without any
complications. In 1 patient, the balloon migrated distally,
causing small bowel obstruction requiring surgical
intervention. In 1 case during routine removal at
6 months, 1 balloon was found to be deﬂated, most likely
a result of recent blunt abdominal trauma from a motor
vehicle accident. Thus, there were 4 total cases (2%) of
deﬂation out of 202 balloon insertions. There were no
balloon hyperinﬂations, pancreatitis, gastroesophageal
perforations, or deaths reported during the duration of
follow-up. The balloon was successfully removed endo-
scopically in all other patients. Sixty-three cases (57.8%)
of removal were under MAC, and 46 (42.2%) were per-
formed under general anesthesia. During the time of
removal of the balloon, there were 5 cases of superﬁcial
esophageal tears, with 1 patient developing bleeding
from the tear site that did not require further interven-
tion and was managed conservatively.
Weight Loss
Mean absolute weight loss at the end of 1, 3, 6, 9, and
12 months was 4.9  2.6 kg, 8.9  4.8 kg, 11.7  7.3 kg,
13.3  7.8 kg, and 15.8  14 kg, respectively (Table 3).
One hundred one patients (50%) had weights docu-
mented at 6 months, and 12 patients (6%) had data at
12 months. The absolute weight loss at 6 months was
signiﬁcantly higher than that at 3 months (P < .001)
(Figure 2). The mean absolute weight loss in ﬁrst
3 months (8.9  4.8 kg) was signiﬁcantly greater than in
months 3 to 6 (3.3  3.8 kg) (P < .001).
BMI decreased signiﬁcantly at 6 months from base-
line (32.8  6.7 kg/m2 vs 36.8  8.4 kg/m2, respectively)
(P < .001). The %TBWL was 8.8  4.3 at 3 months and
11.4  6.7 at 6 months (P < .001). There were 82.6%
and 82.2% of patients who lost more than 5% TBW at
3 and 6 months, respectively (P ¼ .94). However, there
were 60.4% patients who had lost more than 10% TBW
at 6 months, which was signiﬁcantly higher compared
with 33.3% at 3 months (P ¼ .001). At 6 months, patients
lost a mean of 29.9%  18.2% excess body weight.
Compared with 6 months, there was no signiﬁcant
difference in %TBWL, %EWL, and mean BMI at
12 months (Table 3). Table 4 summarizes changes in
metabolic variables at baseline and 6 months. Systolic
and diastolic blood pressure, hemoglobin A1c, fasting
blood sugar, and total cholesterol were signiﬁcantly
improved at 6 months compared with baseline (Table 4).
On multivariable analysis, pre-balloon body weight
signiﬁcantly predicted absolute weight loss (beta ¼ 0.38,
P ¼ .003) (Supplementary Table 2). There were no var-
iables identiﬁed predictive of %TBWL at 6 months
Table 3.Outcomes of Weight, %TBWL, and %EWL at 1, 3, 6, 9, and 12 Months After Balloon Insertion
Outcome
1 month
(n ¼ 151)
3 months
(n ¼ 99)
6 months
(n ¼ 101)
9 months
(n ¼ 32)
12 months
(n ¼ 12)
P valuea
(comparing baseline
and 6 months)
P valueb
(comparing 6
and 12 months)
Mean absolute weight loss (kg) 4.9  2.6 8.9  4.8 11.7  7.3 13.8  9 15.8  14 <.001 .59
Mean %TBWL 4.8  2.4 8.8  4.3 11.4  6.7 13.3  7.8 14.7  11.8 <.001 .67
% Patients with >10% TBWL 2 33.3 60.4 62.5 58.3 — —
Mean %EWL 13.2  7.2 23.8  11.8 29.9  18.2 34.7  21.4 36.4  28.1 <.001 .90
% Patients with >25% EWL 6.6 42.4 55.4 59.4 58.3 — —
% Patients with >40% EWL 0 7.1 28.7 34.3 50 — —
EWL, excess weight loss; TBWL, total body weight loss.
aUsing 1-sample t test.
bUsing paired t test.
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ﬁll volume, reduced balloon ﬁlling volume was not asso-
ciated with reduced weight loss (odds ratio, 0.8; P ¼ .53).
Furthermore, reduced balloon ﬁll volume was not asso-
ciatedwith reduced abdominal pain (odds ratio, 2;P¼ .12)
or nausea/vomiting (odds ratio, 0.63; P ¼ .42).Discussion
Because obesity and related comorbidities are a
public health crisis, there is a large unmet need for
effective weight loss therapies.2 Standard lifestyle
measures only achieve 3%–5% TBWL, and addition of
pharmacologic therapies increase mean %TBWL by mereFigure 2. Graphical representation of mean absolute weight los1%–5%.14,15 Bariatric surgery provides durable and
signiﬁcant long-term weight loss; however, of the
patients who qualify, <1% undergo bariatric surgery for
weight loss.16 Thus, minimally invasive endoscopic pro-
cedures are poised well to ﬁll the void, including IGBs.
This study demonstrates improved weight loss
outcomes since FDA approval of the Reshape Duo IGB
compared with the pre-approval pivotal REDUCE trial.10
Mean %EWL of 29.9% compares favorably with 25.1%
mean %EWL seen in the initial trial. In addition, 55.4% of
patients had >25% EWL compared with 48.8% in the
trial. It is difﬁcult to compare the 2 results head-to-head
because of the differences between a clinical trial and
real-world effectiveness; however, the outcomes seem
comparable or better. In a single center prospectives (A), mean BMI (B), mean %EWL (C), and mean %TBWL (D).
Table 4. Comparison of Metabolic Risk Factors Before and After Balloon Removal
Variable At baseline (n) At balloon removal (n) P value
Blood pressure
Systolic (mm Hg) 131.3  18.6 (128) 125  15.7 (66) .002
Diastolic (mm Hg) 83.5  13.2 (128) 77.6  10.2 (66) <.001
Hemoglobin A1c (%) 5.7  0.9 (60) 5.5  0.4 (24) .04
Fasting blood sugar (mg/dL) 108.7  39.0 (66) 97.9  15.9 (30) .03
High-density lipoprotein (mg/dL) 57.4  19 (64) 64.9  39.9 (27) .64
Low-density lipoprotein (mg/dL) 118.0  30.2 (64) 110.3  30.7 (27) .08
Triglyceride (mg/dL) 151.9  104.5 (66) 128.0  60.0 (29) .07
Total cholesterol (mg/dL) 203.1  35.3 (67) 191.0  34.3 (29) <.001
Aspartate aminotransferase (U/L) 24.7  12.8 (60) 22.0  8.1 (25) .17
Alanine aminotransferase (U/L) 28.8  18.0 (60) 23.7  16.8 (25) .23
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placement, Lopez-Nava et al7 reported a mean %EWL of
47.1%, which they attributed to close monitoring of
patients by a multidisciplinary team. It is possible that
because of greater emphasis on counseling and nutritional
support, their outcomes were superior. An additional
reason for better outcomes in the real-world datamay lie in
the difference in early balloon removal: 6.4% in the current
sample versus 9.1% in the pivotal trial. In our study, we
included results on weight for all patients, including early
removals. This is similar to the pivotal trial where the
results on weight loss were reported in an intent-to-treat
analysis and included patients with early removals.
Outside of theUnitedStates, early balloon removal has been
observed in approximately 7.5% of the patients.17
In the real world, the balloon insertion procedure is not
covered by insurance, whereas in the pivotal trial, the pa-
tients did not bear any cost. Paying out of pocket may make
the patients have a higher threshold to tolerate the accom-
modative side effects and thus lead to fewer early removals.
Free participation in weight loss studies has been shown to
have higher dropout rates.18 Wing and Hill19 deﬁned suc-
cessful weight loss as “individuals who have intentionally
lost at least 10% of their body weight and kept it off at least
one year.” Ten percent TBWL has been shown to have sig-
niﬁcant improvements in obesity-related comorbidities.20
This study demonstrated 60.4% people with greater than
10% TBWL at 6 months, with a mean 11.4% TBWL. The
REDUCE trial reported 25.1% EWL at 24 weeks and 18.8%
EWL at 48 weeks.10 Another pivotal trial involving the
Orbera (Apollo Endosurgery, SanDiego, CA) singleﬁlled IGB
demonstrated mean %TBWL at 6 months of 10.2% and
7.6% at 12 months.21 Although most studies have shown
signiﬁcant weight loss at 12 months, there is invariably
some regain thereafter. Our study did not demonstrate
signiﬁcant weight regain at 12 months. This may be due to
superior lifestyle modiﬁcation techniques and underscores
the importance of continued health provider contact in the
months after balloon removal. Furthermore, because pa-
tients in our study made a ﬁnancial investment when un-
dertaking IGB therapy, it is likely that they had superior
motivation to lose weight and keep it off compared with
patients recruited in funded clinical trials.We also noted that patients lost the majority of their
weight in the ﬁrst 3 months (8.9  4.8 kg compared with
3.3  3.8 kg in months 3 to 6; P < .001). In fact, of those
who lost more than 5% TBW, almost all had done so
within the ﬁrst 3 months. To maximize weight loss, it is
imperative to have close follow-up in the ﬁrst 3 months
so that those failing to lose at least 8% TBW in ﬁrst
3 months can be offered intensive lifestyle coaching and/
or consider anti-obesity medications.
Bautista-Castano et al22 reported younger age and
female gender as predictors of poorerweight losswith diet
and exercise. However,we did notﬁnd any effect of gender
or age on %TBWL or absolute weight loss. Our study was
not adequately powered to study the effects of the IGB on
obesity-related metabolic comorbidities. One reason it
was difﬁcult to study these factors is that their prevalence
was not high at baseline (Table 1). We did observe a sta-
tistically signiﬁcant improvement in systolic and diastolic
blood pressure, glycated hemoglobin, fasting blood sugar,
and total cholesterol. However, it is difﬁcult to ascertain
that these statistically signiﬁcant improvements translate
into meaningful clinical outcomes.
Our study found that a large number of patients
suffered from nausea, vomiting, and abdominal pain after
balloon insertion. This is likely due to accommodative
stress on gastric wall after balloon placement.10,23
Majority of those symptoms resolved within 1 week of
balloon placement. Thus, one should have close follow-
up with patients in the immediate post-insertion period
because they may need to be treated for severe nausea,
vomiting, and dehydration. With the initial balloon
design, Ponce et al10 had noted 35% incidence of gastric
ulceration. With subsequent design changes, it was
reduced to 10%. We found only 1 reported gastric
ulceration at time of balloon removal, but there were a
number of patients with gastric superﬁcial erosions
(13.8%). Although this may be clinically inconsequential,
it highlights the importance of being on proton pump
inhibitor therapy throughout the time of balloon dwell.
There were 8.4% and 4.6% of patients who suffered
a superﬁcial esophageal tear at the time of insertion
and removal, respectively. This has not been reported
in previous studies and is likely related to the long
July 2018 Dual Intragastric Balloon for Weight Loss 1087balloon-based delivery system with a central bridge con-
necting the 2 balloons, causing bowing during passage.
During the insertion process, having sufﬁcient guidewire in
the small bowel such that adequate tension can be applied
to allow the balloon catheter to traverse smoothly through
the upper and lower esophageal sphincters is essential.
The balloon deﬂated in 3 patients, warranting early
removal. In 1 case the balloon was found to be deﬂated
at the time of removal; thus, the total incidence of
spontaneous deﬂation was approximately 2%. This is
less than the 6% reported previously and consistent with
the 0.9%–4.5% incidence seen with other IGBs.24 With
the dual IGB, even if one balloon deﬂates, the other ﬁlled
balloon should be able to prevent distal migration.
However, there was 1 case where the balloon migrated
distally, leading to small bowel obstruction that required
surgical intervention. Until now, this incident has not
been reported with the Reshape balloon, but it has been
reported with other balloons.25,26 Most deﬂated balloons
usually pass through the rectum, with less than 1%
causing bowel obstruction.27 There were no mortalities
or esophageal or gastric perforations reported in our
study. Perforations have been reported in 0.19%–1.6%
cases with gastric balloons in general.24 Thus, it is
important to have the support of surgical expertise in
anticipation of such an adverse event. FDA has recently
issued 2 alerts on the potential risks of spontaneous
balloon hyperinﬂation, acute pancreatitis and 5 reports
of unanticipated deaths that occurred in patients with
IGBs.28–30 The deaths are still being investigated. A meta-
analysis of IGBs in 2015 reported a mortality rate of
0.08%, which is less than that of bariatric surgery.16,17
A limitation of this study includes its retrospective
design. There were also limited data on 9-month and
12-month weight outcomes. Furthermore, we did not
have adequate data on metabolic variables. Prospective
studies with large sample size are needed to better
identify predictors of weight loss and balloon intolerance
associated with IGBs. The ability to identify factors pre-
dicting early balloon removal and suboptimal weight loss
may allow for better patient selection and improved
clinical outcomes.
In conclusion, the outcomes after use of the Reshape IGB
in the realworld are promising,with themajority of patients
achieving and maintaining 10% TBWL, with an acceptable
tolerability and adverse event proﬁle. Reshape IGB, in con-
cert with diet and exercise, has the potential to meet an
unmet need in managing obesity in patients with BMI
between 30 and 40 kg/m2. Further studies are required to
assess the balloons’ impact on metabolic parameters.
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Supplementary Table 1. Characteristics of Nausea,
Vomiting, and Abdominal Pain After
Balloon Placement (N ¼ 202)
Nausea Vomiting
Abdominal
pain
Absent 53 (26.2%) 103 (51%) 151 (74.8%)
Present 149 (73.8%) 99 (49%) 51 (25.2%)
Duration
3 days 83 (41.9%) 74 (36.6%) 31 (15.3%)
>3 to 7 days 46 (22.8%) 15 (7.4%) 15 (7.4%)
>1 and 4 weeks 15 (7.4%) 7 (3.5%) 1 (0.5%)
>4 weeks 2 (1%) 1 (0.5%) 1 (0.5%)
Throughout balloon
dwell
3 (1.5%) 2 (1%) 3 (1.5%)
Supplementary Table 2. Predictors of Absolute Weight Loss
at 6 Months
Variable
Beta (P value)
Univariable Multivariablea
Age 0.1 (.2) 0.09 (.32)
Gender (female) –0.19 (.06) –0.06 (.57)
Pre-balloon weight 0.4 (.001) 0.38 (.003)
Binge eating before balloon –0.07 (.51) –0.06 (.5)
Balloon ﬁlling volume 0.19 (.06) 0.12 (.96)
Depression –0.51 (.61) –0.04 (.71)
SSRI medication –0.06 (.49) –0.06 (.62)
Total no. of nutritionist follow-ups 0.19 (.07) 0.18 (.08)
Being on anti-obesity medications –0.15 (.15) –0.14 (.17)
Type 2 diabetes mellitus 0.07 (.48) 0.07 (.5)
SSRI, selective serotonin reuptake inhibitor.
aAdjusted for age, gender, pre-balloon weight, balloon ﬁlling, and total number
of nutritionist follow-ups.
Supplementary Table 3. Predicators of Percent Total Body
Weight Loss at 6 Months
Variable
Odds ratio (P value)
Univariable Multivariablea
Age 1.01 (.39) 1.00 (.45)
Gender (female) 1.21 (.75) 1.02 (.97)
Pre-balloon weight 1.01 (.23) 1.03 (.11)
Binge eating before balloon 0.67 (.58) 3.15 (.16)
Balloon ﬁll volume 1.0 (.75) 1.00 (.93)
Depression comorbidity 0.83 (.72) 1.98 (.31)
SSRI medication 1.60 (.43) 0.29 (.15)
Total no. of nutritionist follow-ups 1.02 (.57) 1.03 (.50)
Being on anti-obesity medications 1.59 (.33) 2.07 (.18)
Type 2 diabetes mellitus 0.85 (.81) 0.65 (.62)
SSRI, selective serotonin reuptake inhibitor.
aAdjusted for age, gender, pre-balloon weight, and balloon ﬁlling.
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Abstract
Background and Aims The mechanism of weight loss with the intra-gastric balloon (IGB) is thought to be a decrease in gastric
emptying (GE); however the evidence is conflicting. Nausea, abdominal pain, and gastroesophageal reflux disease (GERD) can
cause intolerance resulting in early removal. This is demoralizing for the patient and costly for the healthcare system. The ability
to predict which patients will have superior weight loss and tolerance is invaluable. We sought to investigate if the IGB induced
weight loss by reducing GE and the effect of the IGB on the DeMeester score.
Methods We retrospectively reviewed prospectively collected data for patients undergoing IGB placement at a single hospital.
Manometry and pH studies were performed before and with the IGB in place. Weight was measured at baseline, at removal, and
6 months later. Adverse events leading to early removal were recorded.
Results Twenty-four patients were evaluated. There was a statistically significant decrease in GE for solids with the IGB (117.92
± 150.23 vs 281.48 ± 206.49 min; p = 0.0048), but not for liquids (54.44 ± 17.97 vs 56.08 ± 43.96 min; p = 0.7228). The lower
esophageal sphincter (LES) pressure did not change significantly with placement of the IGB (17.76 ± 7.39 vs 14.74 ±
7.24 mmHg; p = 0.09). On multivariate analysis, increase in DeMeester score was associated with total body weight loss (p =
0.0125) and change in GE (p = 0.038) independently.
Conclusion The IGB delays GE for solids, but not for liquids, and increases the DeMeester score by a mechanism other than a
loss of LES pressure.
Keywords Intra-gastric balloon . Endoscopic bariatric therapy . DeMeester score . Gastric emptying
Abbreviations
IGB Intra-gastric balloon
GE Gastric emptying
GERD Gastroesophageal reflux disease
Introduction
Obesity is a global epidemic with dire economic and health
consequences. The World Health Organization defines over-
weight and obesity as a body mass index (BMI) of 25–29.9 kg/
m2 and greater than 30 kg/m2, respectively. In 2015 the USA and
China had the highest number of obese adults [1] with approxi-
mately 69% of American adults being overweight or obese [2].
In the USA, the intra-gastric balloon (IGB) is approved for
weight loss in patients with a body mass index (BMI) of 30–
40 kg/m2. It is critical that weight loss is addressed in this cate-
gory of patients as globally 39% of deaths and 37% of disability-
adjusted life years occurred in overweight individuals [1].
Remarkably, weight loss of as little as 5–10% of initial
bodyweight is sufficient to promote clinically significant meta-
bolic outcomes in nonalcoholic fatty liver disease (NAFLD) and
gastroesophageal reflux disease GERD.
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Since its debut in the 1980s, the IGB has had tacit approval
worldwide, albeit its mechanism has remained poorly under-
stood. The primary mechanism is presumed to be a decrease in
gastric emptying (GE) and gastric reservoir or activation of
stretch-responsive gastric mechanoreceptors in the fundus,
thus decreasing ghrelin secretion and inducing satiety; how-
ever the data is conflicting [3, 4].
It is important to decipher the mechanism of action of the
IGB as it may shed light on the characteristics of patients that
have superior weight loss and the attributes of patients with
poor tolerance necessitating early removal. Knowledge, pru-
dence, and foresight are essential when treating patients for
obesity. However, neither experience nor refinement has aided
with predicting which subjects will be intolerant to the IGB.
Thus, there is a compelling clinical need to glean this infor-
mation as it may help select patients more judiciously and
cost-effectively. Early removal is costly for the system, frus-
trating for the endoscopist, and disheartening for the patient
who has struggled with the swinging pendulum of weight gain
and loss. The most common symptoms experienced in those
requiring early removal are epigastric abdominal pain de-
scribed as cramping, GERD with or without esophagitis, and
nausea/vomiting [5–7].
GERD is a known adverse health consequence of obesity
[8–10], and amelioration of symptoms is often witnessed with
weight loss [9, 10]. The effect of an IGB onGERD and esoph-
agitis is conflicting. Some studies have demonstrated GERD
and erosive esophagitis in obese patients after IGB insertion
[11, 12]. However, others reveal no GERD despite chronic
gastric distension by an IGB [13, 14].
Methods
We analyzed prospectively collected data from 24 patients
who underwent IGB placement. We assessed the effects of
IGB on esophageal and stomach motility, upper and lower
esophageal sphincter pressures, and DeMeester score.
Patient Selection
Patients that did not meet BMI criteria for bariatric surgery seen
in an outpatient bariatric surgery practice in Hospital Estadual
Mario Covas, located in Santo André, São Paulo, Brazil, over a
6-month period were invited to participate in the study. Inclusion
criteria were age above 18, a BMI between 30 and 40 kg/m2, and
prior failed attempts at weight loss with intense diet and lifestyle
modification. Contraindications to IGB placement were a large
hiatal hernia more than 5 cm, use of anti-coagulant medications,
peptic ulcer disease, severe gastroesophageal reflux disease on
acid-reducing medications, known motility disorders, diabetes
mellitus, and prior gastric or intestinal surgery. The ethics com-
mittee at the Hospital Estadual Mario Covas approved the IRB
for the study. There was no incentive to perform manometry and
pH testing. All studies were performed at Hospital Estadual
Mario Covas which is a government institution.
IGB Placement and Removal
We inserted a single IGB under IV sedation at Hospital
Estadual Mario Covas. The Corporea intra-gastric balloon,
(Medicone Corporea, Cachoeirinha, RS, Brazil) is a silicone
single intra-gastric balloon, very similar to the Orbera intra-
gastric balloon (Apollo Endosurgery, Austin, TX, USA). The
Corporea intra-gastric balloon is not FDA approved or avail-
able in the USA. Under endoscopic guidance, the balloon-
preloaded catheter was advanced transorally into the stomach.
After optimal positioning was confirmed, it was inflated with
600mL of normal saline andmethylene blue. The catheter and
endoscope were subsequently removed. All patients were
instructed to follow a structured diet plan and return in
6 months for IGB removal. The initial week consisted of a
clear liquid diet that was gradually advanced to full liquids and
then a regular diet over 2 weeks based on the patient’s toler-
ance of the IGB. All patients received a prescription for anti-
emetics and anti-spasmodics for 5 days to be taken as needed
and a proton pump inhibitor for 6 months.
The IGB remained in the stomach for approximately
6 months. Removal of the balloon was performed under gen-
eral anesthesia. The balloon was perforated using the Orbera
needle instrument (Apollo Endosurgery, Austin, TX, USA)
introduced through the working channel of the endoscope
and advanced into the balloon. The needle was withdrawn
and the fluid suctioned out until the IGB was completely de-
flated. The IGB was then removed using a raptor-grasping
device (US Endoscopy, Mentor, Ohio) and extracted through
the mouth.
We measured body weight prior to insertion, at the time of
IGB removal 6 months later, and 6 months after removal. The
baseline height was measured in meters using a wall-mounted
stadiometer, and weight was measured in kilograms with a
calibrated scale. Patients wore indoor clothing and no shoes
for all measurements. BMI was calculated as weight in kilo-
grams divided by the square of height inmeters. The change in
body weight and percentage loss of initial body weight
(%TBWL) were calculated.
Gastric Emptying, Manometry, and pH Studies
GE, manometry, and pH studies were performed before IGB
placement and 8–12 weeks after IGB insertion. GE was mea-
sured with a 2-h liquid and solid study using scintigraphy with
technetium (99Tc). Manometry was performed using the
Multiplex II manometry catheter, and pH studies were per-
formed using the AL-3 esophageal pHmetry catheter (Alacer
Biomédica, Brazil). A standard swallow protocol consisting of
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a baseline phase and a series of 10 wet swallows in the supine
position was utilized. The pH catheter was placed once ma-
nometry was completed and remained in place for 24 h. We
held proton-pump inhibitor therapy for 1 week prior to ma-
nometry and pH testing. Medications such as narcotics, anti-
cholinergic drugs, and prokinetic agents that could alter gas-
tric emptying were discontinued prior to testing.
Statistical Analysis
Wilcoxon paired t test was used to compare the median BMI
prior to and after IGB insertion, after IGB insertion, and
6 months after removal. Wilcoxon paired t test was also used
to assess statistically significant differences in the change in
liquid and solid GE, the change in DeMeester score, and the
change in upper and lower esophageal sphincter pressure be-
fore IGB insertion and with the balloon in place. We used
Pearson’s correlations (r2) to assess the linear association be-
tween weight loss and change in liquid and solid gastric emp-
tying. To determine the independent effect of weight loss,
change in gastric emptying, and lower esophageal sphincter
pressure, on DeMeester score, a multiple linear regression was
performed. Analyses involved use of R software (online at
http://www.R-project.org, the R Foundation for Statistical
Computing, Vienna, Austria). A 2-tailed p < 0.05 was consid-
ered statistically significant. Data is presented as median ± SD
or median (IQR).
Results
Twenty-four patients that had the IGB inserted at Hospital
EstadualMario Covas in SantoAndré, São Paulo, Brazil, were
included in the study. Table 1 depicts the baseline characteris-
tics of participants prior to IGB insertion. The average age at
the time of insertion was 35 years (35.46 ± 6.85 years), and 23
patients (95.8%) were female. Of the 24 patients enrolled, 22
retained the IGB for the 6-month period and completed the
study. One patient had persistent nausea and vomiting requir-
ing early removal at 2 months. This patient had delayed gastric
emptying for solids prior to IGB placement, with further delay
in GE with the IGB in place. There was no significant change
in GE for liquids before and after IGB placement. A second
patient presented with abdominal pain and distension, and was
found to have spontaneous hyperinflation requiring removal
of the IGB at 5 months.
Table 2 illustrates the weight in kilograms and BMI before
IGB insertion, at the time of IGB removal, and 6 months after
removal. The mean weight of patients was 97.09 ± 12 kg prior
to insertion.Meanweight at 8–12weeks was 89.39 ± 11.02 kg
and 80 ± 11.01 kg at the time of removal. The weight
remained stable at 6-month follow-up (81.37 ± 11.04 kg).
Mean BMI prior to IGB insertion was 35.58 ± 2.79 kg/m2.
There was a statistically significant decrease in BMI at 6 and
12 months, 29.31 ± 2.83 kg/m2 and 29.85 ± 2.84 kg/m2, re-
spectively (p < 0.001) (Fig. 1).
Table 3 depicts the mean DeMeester score and upper and
lower esophageal sphincter pressure before and with the IGB
in place. There was an increase in the mean DeMeester score
with the IGB in place compared with pre-implantation (13.62
± 12.53 mmHg versus 23.61 ± 17.92 mmHg; p = 0.1743),
without reaching statistical significance (Fig. 2). As expected
the upper and lower esophageal sphincter pressure did not
change significantly with the IGB in place, 39.32 ±
19.05 mmHg versus 41.45 ± 18.93 mmHg (p = 0.59) and
14.74 ± 7.24 mmHg versus 17.76 ± 7.39 mmHg (p = 0.09),
respectively.
Multivariate linear regression found that magnitude of
weight loss and change in gastric emptying were predictors
of the change in DeMeester score independently. DeMeester
score increases as weight loss (p = 0.0125) and gastric empty-
ing time increase (p = 0.385). Change in lower esophageal
sphincter pressure was not associated with the change in
DeMeester score.
Manometry at baseline was abnormal in two patients and
remained abnormal with the IGB in place. One patient had
ineffective motility (IEM) and the other had a jackhammer
esophagus. As expected, the patient with ineffective motility
had an abnormal DeMeester score. Both patients tolerated the
IGB without significant side effects.
Table 4 depicts the liquid and solid gastric emptying before
and after IGB implantation. There was a statistically signifi-
cant decrease in gastric emptying for solids with the IGB in
place (117.92 ± 150.23 min vs 281.48 ± 206.49 min, p =
0.0048), but not for liquids (54.44 ± 17.97 min vs 56.08 ±
43.96 min, p = 0.7228). However, there was no statistically
significant correlation between weight loss and gastric empty-
ing for solids or liquids (Fig. 3).
Discussion
The IGB is an effective option for significant and sustained
weight loss in patients with a BMI of 30–40 kg/m2 who do not
qualify for bariatric surgery or do not desire it due to fear of
going under the knife. Regrettably, intolerance leading to early
Table 1 Baseline characteristics of participants
Overall (N = 24)
Age (years) (mean (SD)) 35.46 (6.85)
Female, n (%) 23 (95.8)
Height (m) (mean (SD)) 1.65 (0.08)
Weight (kg) (mean (SD)) 97.09 (12)
BMI (kg/m2) (mean (SD)) 35.58 (2.79)
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removal is discouraging for the endoscopist and disheartening
for the patient. Our study demonstrated a statistically signifi-
cant decrease in weight and BMI 6 and 12 months after IGB
insertion. The IGB induces a significant decrease in GE for
solids; however, this did not correlate with the degree of
weight loss suggesting that there are other mechanisms that
interplay to produce weight loss. It is also possible that the
mechanism of weight loss and degree of intolerance differ
based on the location of the IGB, antrum versus fundus, and
that a select group of patients has a better response to the IGB.
Deciphering which patients are likely to lose more weight and
have less intolerance would be invaluable in better selecting
patients for weight loss with the IGB.
Similar to our study, Gómez et al. in their prospective
study of 29 patients demonstrated a delay in GE with the
IGB. Slower emptying was associated with greater
%TBWL and GE returned to normal after removal of
the IGB [3]. Contrarily, Mion et al. demonstrated lower
GE and ghrelin levels with the IGB, but only variations
in ghrelin were related to IGB-induced weight loss [4].
Yet, other studies have shown that the presence of an
IGB did not alter fasting or meal-suppressed ghrelin con-
centrations despite a 10–15% weight loss. However, ghrel-
in concentration was suppressed more with balloons locat-
ed in the fundus [15]. Papavramidis et al. in their study
showed that antral placement of the IGB led to higher
weight loss and side effects including GERD [16]. Thus,
it is plausible that the mechanism of the IGB is related to
activation of stretch-responsive gastric mechanoreceptors
in the fundus [16] that decrease ghrelin and induce satiety
if the IGB is positioned in the fundus. If on the other hand
the IGB migrates into the antrum, it induces a delay in
gastric emptying by acting as a barricade in front of the
antrum.
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Table 2 BMI and weight (before,
during, and 6 months after
removal of IGB)
Pre-
implantation
At removal p value 6 months after removal
of IGB
p value
BMI (kg/m2) (mean (SD)) 35.58 (2.79) 29.31 (2.83) < 0.001 29.85 (2.84) < 0.001
Weight (kg) (mean (SD)) 97.09 (12.00) 80.00 (11.01) < 0.001 81.37 (11.04) < 0.001
%TBWL (mean (SD)) 17.09 (5.42) 9.33 (5.43)
Decrease in BMI (mean
(SD))
12.50 (7.07) 12.50 (7.07)
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Similar to previous studies, our study demonstrated an IGB
induced delay in GE for solids but not liquids. This finding
raises several questions: Does an IGB cause a mechanical
obstruction preferentially to solids or does it interfere with
the grinding of food into smaller particles and disruption of
normal peristalsis? Is the disturbance mechanical, physiolog-
ic, or perhaps a combination of both and should the IGB fill
volume be calculated based on the diameter of the stomach for
optimal positioning? Would patients be more tolerant to a
liquid diet as the IGB does not delay liquid GE, or does this
reduce the potential for maximal weight loss, as patients are
able to consume more liquid calories? We are unaware of the
patient phenotype that presents with intolerance nor the anat-
omy and physiology of patients that have exceptional out-
comes with greater weight loss. Further randomized control
studies are imperative to substantiate the need for a graduated
diet and affirm optimal placement of the IGB and the ideal fill
volume based on the size and shape of the stomach to eluci-
date the mechanism of action and explanation for intolerance.
Monitoring of pH is the gold standard for diagnosis of
GERD. It provides a direct measurement of gastric and esoph-
ageal pH. The DeMeester score is a composite score of the acid
exposure during prolonged ambulatory pH monitoring and
used to quantify gastroesophageal reflux using 6
parameters—percent total time pH < 4, percent upright time
pH < 4, percent supine time pH < 4, number of reflux episodes,
number of reflux episodes ≥ 5 min, and longest reflux episode
in minutes. A reflux episode is defined as a drop in esophageal
pH below 4. A DeMeester score > 14.72 indicates gastroesoph-
ageal reflux.
As previously inferred, our study demonstrated that the
IGB does indeed increase GERD as demonstrated by an in-
crease in the DeMeester score. Our study found that weight
loss was correlated with an increase in DeMeester score. It is
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Table 3 DeMeester score and
HRM pressures pre-implantation
and with the IGB in place
Pre-implantation IGB in place p value
DeMeester score (mean (SD)) 13.62 (12.53) 23.61 (17.92) 0.1743
Upper esophageal sphincter pressure (mmHg) (mean (SD)) 39.32 (19.05) 41.45 (18.93) 0.59
Lower esophageal sphincter pressure (mmHg) (mean (SD)) 14.74 (7.24) 17.76 (7.39) 0.09
Paired Wilcoxon test
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intriguing that regression analysis showed that this effect was
independent of change in lower esophageal sphincter pressure
and gastric emptying for solids. GERD is a known adverse
health consequence of obesity, with compelling improvement
following weight loss. A higher prevalence of esophageal mo-
tor disorders [17], increased frequency of transient lower
esophageal sphincter relaxations (TLESR) [18, 19], develop-
ment of a hiatal hernia [20], disorders of gastric accommoda-
tion [21], and increased intra-gastric pressure [22] have been
implicated as a genesis of GERD in obese subjects.We saw no
significant change in esophageal motility or upper and lower
esophageal sphincter pressure before and after IGB place-
ment. Hence, the increase in the DeMeester score is not pro-
voked by a change in the LES tone. We hypothesize that the
presence of a large object within the stomach with repetitive
distention would not only alter the physiology of the stomach
but also cause the LES to become transiently defective and
reduce the threshold for the occurrence of TLESRs and induce
regurgitation resulting in GERD [10, 19, 21]. It is thus
conceivable that the location of the IGB, antral versus fundal,
induces two different mechanisms of weight loss, tolerability
and side effects such as GERD [10]. Further studies are re-
quired to confirm this provocative finding. Until then the IGB
should plausibly be eschewed in those with significant GERD
or a history of esophagitis and esophageal ulcers.
The small sample size is a limitation of our study. However,
the unique results of GE, manometry, and pH studies in the same
group of patients before and during IGB placement are unique. A
4-h study was not performed as we were not looking for disease,
but simply comparing the change in GE before and after IGB
placement. The overall outcome may be different with a longer
study. However, we believe that to detect a change in GE before
and after IGB placement, the 2-h study was in fact sufficient. In
our study, manometry was performed in an erect position; how-
ever supine manometry may shed light on the role of transient
lower esophageal sphincter relaxation (TLESR) and esophageal
clearance as a mechanism for increased reflux. Patients self-
reported adverse outcomes and the severity was not quantified.
Table 4 Solid and liquid
scintigraphy pre-implantation and
with the IGB in place
Pre-implantation IGB in place p value
Liquid scintigraphy (min) (mean (SD)) 54.44 (17.97) 56.08 (43.96) 0.7228
Solid scintigraphy (min) (mean (SD)) 117.92 (150.23) 281.48 (206.49) 0.0048
Paired Wilcoxon test
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Further studies comparing the DeMeester score and GE with a
severity score for each adverse outcome will likely elucidate
which patients will be poor candidates for the IGB.
Our study could not predict which patients would be intol-
erant to the IGB based on baseline GE and DeMeester score. It
would be highly relevant to determine the mechanism of
weight loss and which factors increase intolerance resulting
in early removal. In the era of personalized medicine, with the
development of novel space-occupying devices, the ability to
prognosticate which patients will have a superior response of
weight loss with less intolerance would be invaluable for bet-
ter selection of patients. Further prospective studies are imper-
ative to delineate the exact mechanism of weight loss with the
IGB, so that individualized therapy can be recommended for
superlative weight loss with minor intolerance.
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Introduction
Endoscopic sleeve gastroplasty (ESG) has recently emerged as a
safe and effective minimally invasive procedure for treatment
of obesity [1–5]. ESG has been associated with weight loss
comparable to laparoscopic adjustable band surgery, with indi-
vidual centers reporting excess weight loss (EWL) over 50% at 1
year post-procedure [1, 5, 6]. Significant weight loss coupled
with a relative lack of adverse events, short recovery period,
and cost-effectiveness makes ESG ideal for treatment of obesi-
ty in patients that do not qualify for, or object to, bariatric sur-
gery [1, 2, 4].
ESG reduces stomach volume using a full-thickness endo-
scopic suturing system, in a mechanism that mimics that of la-
proscopic sleeve gastrectomy. This results in the gastric cavity
forming a tubular structure along the lesser curvature, with the
greater curvature closed off by plications from the gastroeso-
phogeal junction to the prepyloric antrum [3, 4, 7]. Weight loss
has been found to be durable at 1-year follow up [5]. Further,
the anatomy has the potential to be reversed [3].
Endoscopic sleeve gastroplasty: the learning curve
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ABSTRACT
Background and study aims Endoscopic sleeve gastro-
plasty (ESG) is gaining traction as a minimally invasive bar-
iatric treatment. Concern that the learning curve may be
slow, even among those proficient in endoscopic suturing,
is a barrier to widespread implementation of the procedure.
Therefore, we aimed to define the learning curve for ESG in
a single endoscopist experienced in endoscopic suturing
who participated in a 1-day ESG training program.
Patients and methods Consecutive patients who under-
went ESG between February 2016 and November 2016
were included. The performing endoscopist, who is profi-
cient in endoscopic suturing for non-ESG procedures, parti-
cipated in a 1-day ESG training session before offering ESG
to patients. The outcome measurements were length of
procedure (LOP) and number of plications per procedure.
Nonlinear regression was used to determine the learning
plateau and calculate the learning rate.
Results Twenty-one consecutive patients (8 males), with
mean age 47.7 ±11.2 years and mean body mass index
41.8 ±8.5 kg/m2 underwent ESG. LOP decreased significant-
ly across consecutive procedures, with a learning plateau at
101.5 minutes and a learning rate of 7 cases (P=0.04). The
number of plications per procedure also decreased signifi-
cantly across consecutive procedures, with a plateau at 8
sutures and a learning rate of 9 cases (P<0.001). Further,
the average time per plication decreased significantly with
consecutive procedures, reaching a plateau at 9 procedures
(P <0.001).
Conclusions Endoscopists experienced in endoscopic su-
turing are expected to achieve a reduction in LOP and num-
ber of plications per procedure in successive cases, with
progress plateauing at 7 and 9 cases, respectively.
Original article
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For widespread use of any endoscopic therapy, the proce-
dure must be effective, safe, and able to be performed by a
large number of providers. Currently, many endoscopists resist
performing ESG because of the belief that it requires time-con-
suming training and has a slow learning curve. However, the
learning curve for ESG has yet to be defined. Therefore, we
aimed to define the learning curve for ESG, specifically, follow-
ing a 1-day training program undertaken by an endoscopist ex-
perienced in suturing.
Patients and methods
This retrospective study was approved by our Institutional Re-
view Board for Human Research and complied with Health In-
surance Portability and Accountability Act (HIPAA) regulations.
The performing endoscopist achieved proficiency in endo-
scopic suturing for non-ESG procedures prior to ESG training.
Examples of these procedures include but are not limited to su-
turing for covered stent fixation, closure of endoscopic submu-
cosal dissection sites, and transoral gastric outlet reduction.
The endoscopist performed >20 of these procedures before be-
ginning ESG training. ESG training was limited to 1 day, and
consisted of a half-day didactic lecture followed by 1 proctored
ESG procedure in a porcine explant stomach. The session was
led by a group of physicians who had been performing ESG for
more than 1 year. Proctoring for the explant ESG was 1-on-1,
while the didactic portion of the training was not. The lecture
was classroom-style, but incorporated the ability to ask ques-
tions. The specific topics covered in the lecture included evolu-
tion of the procedure, demonstration of optimal suturing pat-
terns, technical pearls, and troubleshooting tips for commonly
encountered problems. Notably, a complete ESG procedure
was not shown from start to finish in the training or in other
available resources. Outside of this formal training, the endos-
copist read articles about ESG and watched videos of portions
of the procedure, but did not have the ability to see the entire
procedure before performing it.
Upon completion of the 1-day training session, the endos-
copist began offering ESG to patients. The first ESG procedure
performed on a patient occurred 1 week after the training ses-
sion. All consecutive patients who underwent ESG by the single
endoscopist (V. K.) between the commencement of the pro-
gram, in February 2016, and the completion of the study, in No-
vember 2016, were included in the learning curve analysis. All
ESG procedures took place at the Johns Hopkins Medical Insti-
tutions (Baltimore, Maryland, United State). Further, the anes-
thesia and nursing teams were consistent throughout each pro-
cedure. Members of the nursing team were familiar with the
OverStitch device but they were naïve to ESG prior to com-
mencement of the program.
Prior to ESG, all patients were counseled on the spectrum of
therapies available to treat obesity, including diet and lifestyle,
pharmaceutical treatment, endoscopic bariatric therapies, and
bariatric surgery. The decision to perform ESG was made only
after a patient demonstrated an understanding of all available
treatment options. Unless contraindications appeared to be
likely based on clinical history and physical examination, no
endoscopic assessment was performed prior to ESG. Contrain-
dications for ESG include prior gastric surgery, gastric ulcera-
tion, acute gastritis, anticoagulation, pregnancy, and psychia-
tric disorders that pose a substantial risk of interfering with
the patient’s ability to follow post-procedural instructions or
make the recommended lifestyle adjustments post-ESG [1, 4,
5]. Patients were given an electronic prescription 2 weeks prior
to the procedure, which included omeprazole 40mg qD to be
taken 1 week pre-ESG and for 6 weeks post-ESG, emend (apre-
pitant) 125mg to be taken 3 hours prior to ESG, emend (Apre-
pitant) 80mg qD to be taken the day after the procedure, hyos-
cyamine (Levsin) 0.125mg 1 tab q 6h as needed for cramping
post-ESG, and ondansetron (Zofran) 4mg sublingual tab 1 tab q
6h as needed for nausea post-ESG. On the day preceding the
procedure, a liquid diet was prescribed with no intake permit-
ted after midnight.
ESG was completed as a day case, with no overnight hospi-
talization required. The patient was positioned in the left lateral
position. General anesthesia was administered via inhalation
gas throughout the procedure. Fentanyl 100 mcg, ondansetron
8mg and dexamethasone 8mg were delivered intravenously
(IV) within a predicted 30 minutes from completion of the pro-
cedure. During the pre-procedure, intra-procedure and post-
procedural time, 2 L of IV fluids were administered.
All ESG procedures were performed as described by Lopez-
Nava et al. [4, 5, 8] and Sharaiha et al. [2]. The suture line was
first marked with argon plasma coagulation (APC) along the
anterior wall, greater curvature, and posterior wall. Using a
full-thickness endoscopic suturing system (OverStitch; Apollo
Endosurgery, Austin, Texas, USA) the sutures were placed dis-
tally to proximally (from the incisura angularis to the fundus)
in a triangular pattern from the anterior wall to the greater cur-
vature to the posterior wall. For the second row of plications,
the process was repeated in the opposite direction using the ar-
gon marks to guide the endoscopist’s orientation within the
stomach. Importantly, full-thickness bites were taken between
the guidelines on the anterior wall and the greater curvature,
and between the posterior wall and the greater curvature, in
order to avoid the formation of two long gastric pockets. Gen-
erally, 6 to 9 bites per suture were performed. On completion of
the suture pattern, the T tag was released and the stitches were
then brought together to form a plication using a cinching
device [9]. The suture line was brought proximally until within
1 cm of the gastroesophageal junction on the lesser curvature
aspect. The fundus (towards the proximal body aspect) was su-
tured until the endoscope began to retroflex. Therefore, a small
fundal pouch (approximately 15mL in capacity) remained at
each procedure as desired. On completion of the final plication,
a quick endoscopy without the OverStitch attachment was per-
formed to ensure ESG had an optimal appearance and absence
of bleeding (▶Fig. 1).
Post-procedure, patients were instructed to follow a liquid
diet for 3 days before transitioning to smooth, pureed foods as
tolerated. Successive transitions from pureed foods to soft
foods and then to solid foods occurred in 2-week intervals.
Medications were also prescribed to ease post-procedural
symptoms of nausea, heartburn, cramping and pain. The most
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common post-placement symptoms were nausea and pain,
making dehydration a post-procedural concern.
All patients were enrolled in a comprehensive ancillary pro-
gram, focused on helping them make positive dietary and life-
style changes for a minimum of 12 months post-ESG. This pro-
gram consists of routine treatment from a multidisciplinary
weight loss team, composed of a gastroenterologist with ex-
pertise in weight management, a registered dietician, an exer-
cise physiologist, and a behavioral psychologist (The Johns
Hopkins Weight Management Center, Baltimore, MD).
Statistical analysis
Results are reported as mean ± standard deviation (SD) for con-
tinuous data and as frequencies and proportions for categorical
data. Continuous variables, namely pre-procedure and post-
procedure body mass index (BMI) and excess body weight,
were compared with paired t tests. To define the “learning
curve,” nonlinear regression was used to fit an inverse curve,
with case number as the independent variable and procedure
time as the dependent variable. This statistical method yields
an estimate of a (asymptote) and b (slope), as described by
Feldman et al. [10]. The “learning plateau” is then defined as
the procedure time at the asymptote of the learning curve
(i. e., the theoretical best score that a subject could achieve
with infinite practice). The “learning rate” is defined as the
number of trials required to reach 90% of potential (i. e., the
speed at which the subject acclimates to the task). When pro-
cedure time=a+0.1 × (slowest individual procedure time − a),
then learning rate case number =10×b/(slowest time − a). The
outcome measurements were length of procedure (LOP), num-
ber of plications per procedure and average time per plication
per procedure. The LOP was defined as time from initial endo-
scope entry into the mouth to final endoscope withdrawal.
Data sets were compiled using Microsoft Excel, and all statisti-
cal analyses were performed using SPSS version 21 (SPSS Inc,
Chicago, IL, USA).
Results
Twenty-one consecutive patients (8 males) underwent ESG by
the single endoscopist (V. K.) between the commencement of
the program, in February of 2016, and the end of the study
period, in November 2016. The mean age was 47.7±11.2 years
(range 29–73), and the mean initial BMI was 41.8 ±8.5 kg/m2
(range 33–69).
ESG was performed with technical success in all (100%) pa-
tients. All patients had general anesthesia successfully. Bleed-
ing was encountered on occasion with bites, but in all cases,
bleeding ceased once the plication was complete.
Median LOP was 105 minutes (range 63–220). Total proce-
dure time decreased significantly over the course of consecu-
tive ESG procedures, with a learning plateau at 101.5 minutes
and a learning rate of 7 cases (P=0.04) (▶Fig. 2). The total
number of plications performed per ESG procedure also de-
creased significantly across the consecutive procedures. The
median number of plications performed per ESG procedure
was 9 (range 6–4). The learning plateau was reached at 8 su-
tures and the learning rate was 9 cases (P<0.001) (▶Fig. 3).
Further, the average time per plication decreased significantly
with consecutive procedures. The median average time per pli-
cation was 13.125 minutes (range 8.1–24.4) (▶Fig. 4). The
average time per plication reached a plateau at a rate of 9 pro-
cedures (P<0.001).
One patient (4.8%) was lost to follow-up. Thirty-day post-
procedure follow-up data on the remaining 20 patients showed
a mean reduction in BMI of 3.2 ±1.4 kg/m2 (P<0.001) and a
mean weight loss of 23.6 ±8.9 lb (P<0.001). The immediate
▶ Fig. 1 Endoscopic view demonstrating gastric sleeve upon com-
pletion of the procedure.
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▶ Fig. 2 Total procedure time significantly decreased over the
course of consecutive endoscopic sleeve gastroplasty procedures,
with a learning plateau at 101.5 minutes and a learning rate of
7 cases (P=0.04).
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readmission rate was 0%, and the 30-day readmission rate was
4.8%. No immediate post-procedural complications occurred.
No symptoms of gastroesophageal reflux disease (GERD) were
present at 30-day follow up. One patient experienced an AE of
mild severity, as classified according to the ASGE Lexicon by
Cotton et al. [11]. That patient recovered well post-procedure,
before presenting with abdominal pain and vomiting 12 days
after ESG. The patient was diagnosed with perigastric fluid col-
lection, which was responsive to antibiotics. Treatment requir-
ed readmission, with a length of stay of 1 day. This event is dis-
cussed further by Barola et al. [7] No patients underwent a re-
peat procedure.
Discussion
Results of this analysis indicate that the LOP, number of plica-
tions per procedure, and average time spent per plication per
procedure decreased significantly with the number of proce-
dures performed. The decrease in time spent per plication and
the decrease in total LOP are straightforward indicators of effi-
ciency, however, the decrease in the number of plications used
per procedure appears to be due to a distinct component of
mastery. The endoscopist found that with experience came
the ability to reduce the number of plications per procedure by
increasing the distance between bites, without compromising
the appearance of the endoscopic sleeve. This is notable be-
cause using less plications not only decreases the time neces-
sary to complete the sleeve, but also decreases the cost.
Notably, only 7 procedures were required before the endos-
copist reached 90% potential efficiency, following a 1-day train-
ing session. This finding begins to fill a gap in our knowledge of
ESG, and is an important factor to consider when deciding
whether to incorporate ESG into one’s treatment offerings. To
effectively determine whether or not the investment in a proce-
dure is worth the outcome, it is important to consider the
learning curve in conjunction with the potential impact.
Weight loss reported post-ESG has been impressive, with
multiple centers reporting over 50% EWL at 1 year post-proce-
dure [1, 5]. Despite the suturing mechanism of ESG, the rate of
AEs is minimal with a number of series reporting 0 events [2, 5].
The recovery period is also short, with patients generally re-
turning to full functionality within 1 to 3 days post-ESG [1]. To-
gether, these factors contribute to the appeal and effectiveness
of ESG, and therefore indicate the potential impact of the elec-
tive treatment. Given the results of this study, we hypothesize
that the widespread implementation of this procedure will in-
crease.
When interpreting the results of this learning curve analysis,
it is essential to bear in mind the specific qualifications and ex-
perience of the performing endoscopist. The single-endos-
copist modeled in this analysis is an expert in bariatric endos-
copy who had experience in endoscopic suturing prior to train-
ing for ESG. It is also worth considering that all procedures in
this analysis were performed with the assistance of nursing
and endoscopy teams that were experienced in assisting endo-
scopic suturing, and which were held constant throughout the
series. This factor likely has an effect on procedural times, but is
not quantifiable. To perform ESG, the performing endoscopist
must be able to place full-thickness bites using the OverStitch
device, however, no specific duration of experience is required.
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▶ Fig. 3 Number of plications per procedure significantly de-
creased over the course of consecutive endoscopic sleeve gastro-
plasty procedures, with a learning plateau at 8 sutures and a learn-
ing rate of 9 cases (P<0.001).
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▶ Fig. 4 Total procedure time per number of plications decreased
significantly over time, reaching a plateau at a rate of 9 procedures
(P<0.001).
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The ESG procedure is repetitive in nature, which likely contri-
butes to the speed of the learning curve.
Because the analysis was restricted to the learning curve of
only 1 endoscopist, the results will likely vary when applied to
a variety of endoscopists. This point is further evidenced in the
variation of median and mean procedure times in the current
literature, which ranges from 75 to 157 minutes, in series of
20 and 10 patients, respectively [2, 4, 5]. Currently, it is not pos-
sible to compare other reports of an ESG learning curve to this
one, as there are no published reports to date. However, Abu
Dayyeh et al. has previously indicated the presence of a learning
curve in his series of cases. First, in a 4-case series, procedure
time decreased significantly from 245 minutes in the initial pa-
tient to 172 minutes in the fourth, despite 3 additional sutures,
therefore indicating a learning curve [3]. In a later study, Abu
Dayyeh et al. determined that procedure times significantly de-
creased in a series of 25 cases, from 217±17 minutes (average
of first 5 procedures) to 98±4 minutes (average of last five pro-
cedures) (P< .01) [1].
It is worth noting that sample size is not a limitation of the
study, as the plateau for all 3 variables was reached. Increasing
the sample size is not predicted to alter the value at which each
variable reached a plateau. Details of weight outcomes, as well
as long-term outcomes, are not reported here so as to not dou-
ble publish data. A more detailed analysis of the weight out-
comes is reported in a separate, larger study. Data on suture
stability at follow-up is not reported, because ESG is a self-pay
procedure and we could not justify a second-look endoscopy or
upper gastrointestinal endoscopy to assess suture strength at
follow-up.When considering undergoing ESG training, it is im-
portant to consider the length of time between the training
session and clinical ESG procedure. We recommend a short in-
terval of time between the two. In this case, there was a 1-week
interval between training and procedure. Whether the interval
between training and procedure would significantly affect the
learning curve is uncertain, but it is a factor worth considering.
Conclusion
We conclude that an endoscopist proficient in endoscopic su-
turing can expect to acquire efficiency in performing ESG after
approximately 7 cases. Further, the number of necessary plica-
tions can be expected to decrease, with an expected 8 sutures
per patient once proficiency has been reached. Therefore, the
learning curve for ESG in endoscopists familiar with the Over-
Stitch suturing device is relatively short and should encourage
interested endoscopists to perform this procedure to help
stem the obesity epidemic.
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Abstract
Objective Endoscopic sleeve gastroplasty (ESG), an incisionless endoscopic bariatric procedure, has shown impressive results in
case series. This study examines the reproducibility, efficacy, and safety in three centers across two countries, and identifies key
determinants for procedural success.
Design Patients who underwent ESG between February 2016 and May 2017 at one of three centers (Australia and USA) were
retrospectively analyzed. All procedures were performed on an outpatient basis using the Apollo OverStitch device (Apollo
Endosurgery, Austin, TX). Primary outcomes included absolute weight loss (ΔWeight, kg), change in body mass index (ΔBMI,
in kg/m2), total body weight loss (TBWL, %), excess weight loss (EWL, in %), and immediate and delayed adverse events.
Results In total, 112 consecutive patients (male 31%, age 45.1 ± 11.7 years, baseline BMI 37.9 ± 6.7 kg/m2) underwent ESG. At
1, 3, and 6 months, Δweight was 9.0 ± 4.6 kg (TBWL 8.4 ± 4.1%), 12.9 ± 6.4 kg (TBWL 11.9 ± 4.5%), and 16.4 ± 10.7 kg
(TBWL 14.9 ± 6.1%), respectively. The proportion of patients who attained greater than 10% TBWL and 25% EWL was 62.2
and 78.0% at 3 months post-ESG and 81.0 and 86.5% at 6 months post-ESG. Weight loss was similar between the three centers.
Multivariable analysis showed that male sex, greater baseline body weight, and lack of prior endoscopic bariatric therapy were
predictors of greater Δweight at 6 months. Three (2.7%) severe adverse events were observed.
Conclusions ESG is an effective, reproducible, and safe weight loss therapy that is suitable for widespread clinical adoption.
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Introduction
The accelerating global obesity epidemic portends substantial
increases in morbidity and mortality [1]. This has critical eco-
nomic implications, most obviously for future healthcare
spending, but also in terms of economic productivity, disabil-
ity, and potential increased reliance on social safety nets.
Current surgical interventions for obesity are effective, but
are limited in their application and reach by poor patient ac-
ceptance and relatively high requirements for healthcare re-
sources [2, 3]. In this context, endoluminal techniques are
emerging as effective therapies in the management of over-
weight and obesity [4–7]. The two most widely utilized endo-
scopic technologies to date are intragastric balloons and the
duodenojejunal liner [2, 4, 8–10]. Although used in Europe
and South America, widespread dissemination has been hin-
dered by their tolerability and safety [4]. Both techniques uti-
lize an implanted device that remains in situ for no more than
12 months [7, 11]. These therapies, therefore, introduce the
risk of device-related complications such as migration, gastro-
intestinal ulceration, and infection [4, 10]. Moreover, the lim-
ited duration of device implantation allows for potential
weight recidivism following device retrieval, unless long-
term behavioral and lifestyle changes are adopted and main-
tained [4]. Thus, endoscopic sleeve gastroplasty (ESG), a re-
portedly safe and efficacious endoscopic therapy that does not
require an implanted device, has generated much interest and
potentially represents a major advance in obesity therapy [7,
12–14].
Endoscopic sleeve gastroplasty is an incisionless transoral
endoscopic procedure whereby a restrictive gastric luminal
sleeve is fashioned within the corpus of the stomach by the
application of a series of transmural sutures (Fig. 1). Using a
suturing platform mounted on the endoscope (OverStitch,
Apollo Endosurgery, Austin, Texas, USA), running sutures
are applied along the greater curvature of the stomach,
resulting in a reduction in functional volume by approximate-
ly 70%. In addition to imbrication of the greater curvature, the
stomach is shortened by approximately 30% [14, 15].
Contemporary approaches spare the fundus, leaving a very
small fundal pouch [16].
The Mayo Clinic in the USA first published the clinical fea-
sibility of this technique in 2013 [13]. Two other centers (Weill
CornellMedicine, NewYork, NY,USA andMadrid Sanchinarro
University Hospital, Madrid, Spain) adopted the procedure early
in its development. The published results of their single-center
series have demonstrated admirable efficacy and safety outcomes
[17, 18]. Recently, the three centers combined their data of 242
patients and found a 15.2% total body weight loss (%TBWL) at
6 months post-procedure and 18.6% at 24 months [19].
However, there remains a paucity of data outside of these three
centers, limiting the generalizability of the results.
Thus, we present this multicentered study as the first to
report efficacy and safety of ESG for the treatment of obesity,
outside the core facilities where the technique was developed,
to demonstrate the generalizability of the procedure and to
assess reproducibility of the results. In addition, we investi-
gated the key determinants for weight loss outcomes.
Materials and Methods
Patients
Data from 112 consecutive patients who underwent ESG be-
tween February 2016 and May 2017 across three Western
centers (Center AUS; Center US1; Center US2) were retro-
spectively analyzed. All patients were overweight/obese
adults with no known contraindications to ESG as stated in the
literature [20]. Prior to ESG, all patients were counseled on the
Fig. 1 Illustration of gastrointestinal tract post completed ESGprocedure,
with dotted lines indicating pre-ESG form. Note the small fundus that
remains
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spectrum of therapies available to treat obesity, including diet
and lifestyle, pharmacologic treatment, endoscopic bariatric
therapies (EBTs), and bariatric surgery. Informed consent
was obtained from all patients. Inclusion criteria included
body mass index (BMI) greater than 27 kg/m2, and individ-
uals with multiple unsuccessful diet and lifestyle weight man-
agement attempts. Exclusion criteria included personal or
family history of gastric malignancy, active gastric ulceration,
the presence of any gastric condition which required endo-
scopic surveillance (e.g., known gastric intestinal metaplasia),
known vascular abnormalities, decompensated organ failure,
obligate therapeutic anticoagulation, and pregnancy/lactation.
Procedural Technique
All ESGswere performed as described by Lopez-Nava et al. [15,
20], Sharaiha et al. [17], and Kumbhari et al. [21, 22]. All pro-
cedures were performed using general anesthesia and CO2 insuf-
flation and all patients were administered prophylactic antibiotics
and DVT prophylaxis in line with local protocols. The patient
was placed in either the left-lateral or the supine position. A
diagnostic EGDwas performed to confirm the absence of exclu-
sion criteria (Fig. 2a). An esophageal overtube (Apollo
Endosurgery, Austin, Texas, USA) was inserted to safeguard
the esophagus and prevent decompression of the insufflated
stomach. A double-channel therapeutic gastroscope (GIF-
2TH180, OLYMPUS, Tokyo, Japan) was then inserted. In most
instances, themedial boundaries of the proposed suture line were
first marked with argon plasma coagulation (APC, Forced coag-
ulation, Effect 2, 50W) (VIO 300D/APC2-HF-generator; ERBE
Elektromedizin, Tubingen, Germany) along the anterior and pos-
terior walls (Fig. 2b). Using the OverStitch system, a 2/0 poly-
propylene suture was applied, beginning at the anterior wall at
the level of the incisura angularis, with further bites taken on the
greater curvature and then the posterior wall, at all times remain-
ing lateral to the APC demarcations (Fig. 2c). The suture linewas
then continued in a retrograde fashion within 1 cm proximal to
the initial row, from posterior wall to anterior wall, via the greater
curvature (Fig. 2d). Importantly, full-thickness bites of the prox-
imal row were staggered in relation to the distal row so as to
avoid the formation of longitudinal gastric pockets (Fig. 2e).
Generally, six to nine bites per suture were performed. On com-
pletion of the suture pattern, the needle was released, anchoring
the leading end of the suture. Using the proprietary cinching
device, the suture was pulled tight so as to bring the tissue to-
gether, and the trailing end of the suture was anchored by
deploying the cinch. The suture was contemporaneously
trimmed [9] (Fig. 2f).
Sutures were placed serially using this approach until within
1 cm of the gastroesophageal junction, as measured along the
lesser curvature. The fundus was sutured until the endoscope
began to retroflex and crossing of the suture during the stitching
process occurred frequently. Therefore, only a small fundal
pouch remained at the end of each procedure. Typically, a total
of 6–9 sutures were used per patient. On completion of the final
suture line, a check endoscopywithout theOverStitch attachment
was performed to ensure optimal appearance and absence of
bleeding. The luminal diameter on completion of the procedure
was 13–16 mm. The estimated volume of the stomach on com-
pletion of the procedure was approximately 100 mL.
Key technical elements common to all centers included
using the tissue helix (Apollo Endosurgery, Austin, Texas,
USA) for every bite, attaining a Bpink out^ with each bite to
ensure a transmural bite, doubling back with each suture
(using each suture to form two-rows) to ensure foreshortening
of the stomach and leaving a small residual fundal pouch. The
decision to perform a reinforcing inner row of sutures
(Breinforcing layer^) was left to the discretion of the
endoscopist during the individual case.
In all three centers, patients were discharged on the same
day and given daily proton pump inhibitors as well as a reg-
imen of antiemetics, analgesics, and antispasmodics. All pa-
tients commenced a low-calorie liquid diet for at least 3 weeks,
progressing through puree to a solid diet by 5 weeks post-
procedure. All three centers provided patients with a compre-
hensive ancillary program involving intensive consultation
and follow-up visits with the endoscopists and allied health
professionals (dietitians, behavioral psychologists, and exer-
cise physiologists). The programs, lasting a minimum of
12 months post-ESG, aimed to help patients establish positive
dietary and lifestyle changes.
Outcomes
Patient information, including age, sex, medical history of
obesity-related chronic diseases/conditions (ORCD), previous
bariatric procedures, and baseline height, weight, and body
mass index (BMI), was collected retrospectively from review
of the electronic medical record. Patients’ excess weight (EW)
was calculated as the difference between their baseline weight
and healthy weight (weight if their BMI was 24.9 kg/m2)
using baseline height. Primary outcomes included absolute
weight loss (Δ weight, in kg), change of body mass index
(ΔBMI, in kg/m2), total body weight loss (TBWL, in %),
excess weight loss (EWL, in %), and immediate and delayed
adverse events and complications at 24 h, 1 week, and 1, 3,
and 6 months post-procedure. The proportion of patients
achieving ≥ 10% TBWL, ≥ 15% TBWL, and 25% EWL was
also assessed at all time points as this has previously been
recognized as a predictor of long-term weight loss mainte-
nance and bariatric procedure efficacy thresholds [4, 19].
Data Analysis
All analyses were performed on a per protocol basis and in-
clude those subjects who reached the specified follow up time
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points. Results are expressed as mean ± standard deviation for
continuous variables and proportion (%) for categorical vari-
ables. Statistical analysis was done by means of ANOVA test
for numerical variables and Chi-square analysis or Fisher’s
exact test for categorical variables. Multivariable regression
analysis was done to compare the difference between patients
of different centers, adjusting for significantly different base-
line measurements. Repeat-measurement analysis was per-
formed to track the change of weight loss outcomes. In all
figures, boxplot was used to display median, minimum-max-
imum-range, inter-quartile-range, and outliers. Statistical anal-
yses were performed using SPSS for Windows 22.0 software
(SPSS Inc., Chicago, IL, USA). For all tests, a P value of <
0.05 was considered statistically significant.
Results
Patients
Consecutive patients (N = 112), who underwent ESG and
reached at least 3 months follow-up, were eligible for the
study. Patients’ baseline BMI ranged from 28.5 to 69.0 kg/
m2. Patients undergoing ESG with Centre US1 had higher
baseline BMIs and were more likely to be male in comparison
to the other centers (Table 1). Ten out of 51 patients with
Centre AUS had previous experience with intragastric
balloon/s for weight loss, which was absent in the two US
centers. Importantly, all patients experienced with intragastric
balloons had either failed to respond adequately to this therapy
or had suffered complete weight recidivism prior to ESG.
Efficacy
On average, total weight loss was 12.9 kg at 3 months (TBWL
11.9%; EWL 39.9%; ΔBMI 4.5 kg/m2) and 16.4 kg at
6 months procedure (TBWL 14.9%; EWL 50.3%; ΔBMI
5.6 kg/m2). Findings (Table 2) were similar between the three
centers after adjusting for age, sex, baseline BMI, and obesity-
related chronic diseases/conditions. By 3 months post-ESG,
62.2% and 35.4% of patients had TBWL greater than 10 and
15% respectively increasing to 81% and 53.8% by 6 months.
The proportion of patients who attained greater than 25%
EWL was 78.0% at 3 months post-ESG and 86.5% at
6 months. More than half of patients’ weight loss during the
follow up period was lost within the first month post-ESG
(Fig. 3). However, there was no apparent weight loss plateau
Fig. 2 Images of the gastric
cavity throughout progressive
stages of the ESG procedure. a
Endoscopic view of the gastric
cavity prior to ESG. b Markings
made with APC. c First bite is
taken. d Illustration of the U-
shape suture pattern progressing
proximally. e The gastric cavity in
the body region immediately
following completion of suturing.
f Gastric cavity as seen from the
gastroesophageal junction
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observed, as all parameters continued to improve to 6 months
post-ESG.
Predictors
Wide distributions of weight loss outcomes were observed.
Covariates, including the treatment center, age, sex, baseline
BMI, previous obesity-related chronic diseases/conditions,
previous bariatric procedure history, and number of sutures
used at ESG, were assessed using multi-variable linear models
against weight change outcomes, adjusting for each other.
Details can be found in Supplementary Table 1.
Being male was a consistent determinant of greater abso-
lute weight loss and change of BMI at all time points, but not
%TBWL or EWL. Higher baseline BMI was positively asso-
ciatedwith absolute weight loss but negatively associatedwith
EWL. Absence of previous experience with an intragastric
balloonwas a positive predictor for all weight loss parameters.
Figure 4 shows the weight loss distributions at 1, 3, and
6 months post-ESG in patients in each baseline weight cate-
gory. Detailed weight loss distributions in patients of differing
sex and intragastric balloon history categories can be found in
Supplementary Figures 1 & 2 and Supplementary Table 2.
Safety
All patients were discharged on the day of the procedure. No
intraprocedural complications were encountered, across all
sites. Mild adverse events such as nausea, vomiting, and ab-
dominal pain occurred in a large proportion of patients and
were anticipated. However, most notably, two severe adverse
events occurred within the first week post-procedure, both of
which were upper gastrointestinal bleeding. One instance was
in a patient with anti-thrombin IIIa deficiency, and the decision
was made to recommence low molecular weight heparin med-
ication (LMWH) and warfarin on day 1 post-procedure. On
day 4, while still on LMWH, she was found to have an INR of
2. She had hematemesis and melena with an emergent EGD
demonstrating linear ulcerations in the proximal body at the
suture line. The second patient had hematemesis and melena
3 days post-procedure without any inciting agents. She was
admitted, managed conservatively, and discharged after 24 h.
One patient had a 3 cm perigastric fluid collection diag-
nosed 12 days post-procedure. Detailed explanation was de-
scribed elsewhere [23]. The patient was treated with oral an-
tibiotics and progressed well without need for drainage. No
patients required conversion to surgery for the management of
these complications.
Table 1 Characteristics of
patients Characteristics
a Total
(N = 112)
AUS
(N = 51)
US1 (N = 42) US2 (N = 19) P valueb
Age (year) 45.1 ± 11.7 43 ± 11.9 49.2 ± 11.4 41.9 ± 9.6 ns
BMI (kg/m2) 37.9 ± 6.7 36.7 ± 4.9 41.2 ± 8.0* 33.6 ± 4.0 < 0.001
Excess weight (kg) 36.7 ± 21.1 33.3 ± 14.9 46.5 ± 26.2* 23.9 ± 12.9 0.001
BMI category (range) < 0.001
< 34.9 38.5 41.2 17.1 82.4c
35–39.9 27.5 35.3 26.8 5.9
40+ 33.9 23.5 56.1c 11.8
Sex (male) 31.3 29.4 40.5c 15.8 0.001
ORCD (yes) 53.6 60.8 50.0 42.1 ns
Diabetes (yes) 12.5 19.6 7.1 5.3 ns
Hypertension (yes) 23.2 17.6 28.6 26.3 ns
GERD (yes) 30.4 39.2 19.0 31.6 ns
Sleep apnea (yes) 14.3 13.7 21.4 – ns
Previous intragastric balloon (yes) 8.9 19.6 – – –
Reached 6 months post-ESG (yes) 61.6 78.4c 57.1 26.3 < 0.001
Suture (number) 7.5 ± 2.2 6.0 ± 1.2c 8.9 ± 2.2 8.9 ± 1.5 < 0.001
Diabetes includes insulin resistance, pre-diabetes, and type II diabetes
ORCD obesity-related chronic disease/condition, GERD gastroesophageal reflux disease, ns not statistically
significant
a Continuous variables in mean ± standard deviation; categorical variables in proportion (%)
bP values for continues variables are by ANOVA test; P values for categorical variables are by Chi-square
analysis
c Significantly different from the other centers
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Discussion
This international multicenter study of 112 consecutive pa-
tients who underwent endoscopic sleeve gastroplasty for treat-
ment of obesity demonstrates consistent efficacy and safety of
the procedure across the study centers, and is furthermore
consistent with reported outcomes in the published literature.
Thus, ESG is a safe and effective endoscopic bariatric proce-
dure with generalizability and reproducibility.
The incidence of obesity, which is recognized by theWorld
Health Organization as a disease, has nearly doubled since
1980, and obesity-related comorbidities have become a major
threat to human health [1]. Therefore, effective and readily
available endoscopic procedures such as ESG, offering a via-
ble, minimally invasive approach and clinically meaningful
weight loss, has the potential to bridge the gap between con-
servative dietary and lifestyle counseling and highly restric-
tive and resource-intensive surgical procedures.
As the first study summarizing weight loss outcomes of
ESG outside of the core facilities that pioneered the procedure,
we report comparable and consistent findings of approximate-
ly 15% TBWL and 50% EWL at 6 months post-procedure. In
Table 2 Change of weight and BMI at 1 month, 3 months, and 6 months post-ESG
Total Unadjusted Adjusted
AUS US1 US2 P value# AUS US1 US2 P value+
ΔWeight (kg) 1 m 9 ± 4.6 9.3 ± 3.7 9.1 ± 4.8 8.1 ± 6.4 ns 9.6 ± 2.5 8.2 ± 2.9 9.8 ± 4.7 ns
3 m 12.9 ± 6.4 12.5 ± 5.5 14.1 ± 8.5 12.3 ± 4.8 ns 12.9 ± 1.7 12.4 ± 2.6 13.6 ± 3.5 ns
6 m 16.4 ± 10.7 14.2 ± 6.2 22 ± 17.3 15.3 ± 1.4 ns 15.4 ± 2.8 17.9 ± 4.5 19.6 ± 8.2 ns
P value^ < 0.001 < 0.001 < 0.001 < 0.001
Δ BMI (kg/m2) 1 m 3.4 ± 3.9 3.2 ± 1.2 4.1 ± 6 2.4 ± 1.1 ns 3.1 ± 2.3 4.1 ± 2.7 2.7 ± 4.4 ns
3 m 4.5 ± 2 4.4 ± 1.8 4.8 ± 2.6 4.3 ± 1.5 ns 4.5 ± 0.5 4.3 ± 0.9 4.7 ± 1.2 ns
6 m 5.6 ± 3.2 5 ± 2.1 7.1 ± 5.1 5.9 ± 0.6 ns 5.3 ± 0.9 6.1 ± 1.4 7 ± 2.6 ns
P value^ < 0.001 < 0.001 < 0.001 < 0.001
%TBWL 1 m 8.4 ± 4.1 8.7 ± 2.7 7.8 ± 3.6 9.1 ± 8 ns 8.8 ± 2.5 7.5 ± 2.9 9.4 ± 4.7 ns
3 m 11.9 ± 4.5 11.9 ± 4.5 11.6 ± 5.1 12.4 ± 3.3 ns 12 ± 1.3 11.4 ± 2.1 12.5 ± 2.8 ns
6 m 14.9 ± 6.1 14 ± 5.6 16.3 ± 7.9 17.7 ± 1.7 ns 14.7 ± 2.1 15.2 ± 3.5 18.3 ± 6.3 ns
P value^ < 0.001 < 0.001 < 0.001 < 0.001
%EWL 1 m 28.2 ± 18.3 29.4 ± 10.8 22.8 ± 12.2 39.2 ± 38.7 0.015 28.6 ± 5.1 25.5 ± 6 34.3 ± 9.8 ns
3 m 39.9 ± 17.3 40.4 ± 17 34.2 ± 18.3 49.4 ± 13.1 ns 38.8 ± 4.2 40.5 ± 6.6 44.1 ± 8.9 ns
6 m 50.3 ± 22.4 49.2 ± 23.2 46.9 ± 20.3 72.1 ± 9.7 ns 48.5 ± 7.3 51.1 ± 12 65.2 ± 21.7 ns
P value^ < 0.001 < 0.001 < 0.001 < 0.001
TBWL ≥ 10% (%)a 1 m 25.8 29.5 22.2 23.1
3 m 62.2 61.2 59.1 72.7
6 m 80.8 79.4 78.6 100.0
TBWL ≥ 15% (%)b 1 m 5.6 4.5 5.6 7.7
3 m 35.4 34.7 36.4 36.4
6 m 53.8 44.1 64.3 36.4
EWL > 25% (%)c 1 m 52.7 65.9 36.1 53.8
3 m 78.0 77.6 68.2 100.0
6 m 86.5 85.3 85.7 100.0
Data available: 1 month N = 93; 3 months N = 82; 6 months N = 52
ΔWeight change of weight from pre-procedure,Δ BMI change of BMI from pre-procedure,%TBWL total body weight loss (%),%EWL excess weight
loss (%), ns not statistically significant
^ Repeat-measurement analysis, # ANOVA tests, + linear multivariable analysis adjusted by age, gender, initial BMI, and diagnosed obesity-related
chronic disease/condition
a TBWL ≥ 10%: prevalence of total body weight loss more than 10%, as long-term weight loss outcome predictor demonstrated by literature [19]
b TBWL ≥ 15%: prevalence of total body weight loss more than 15%, as weight loss efficacy threshold demonstrated byASGEBariatric Endoscopy Tast
Force [4]
c EWL > 25%: prevalence of excess weight loss more than 25%, as weight loss efficacy threshold demonstrated by ASGE Bariatric Endoscopy Task
Force [4]
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a multicenter study enrolling 248 patients at the 3 pioneering
centers, ESG was associated with 15% TBWL at 6 months
[19].
Lopez-Nava et al. were able to demonstrate that weight loss
at 6 months was highly predictive of further weight loss and
long-termweight maintenance. Reaching a TBWL ≥ 10%was
shown to predict weight maintenance up to 2 years post-
procedure [15]. We found that approximately 60% of patients
had greater than 10% TBWL at 3 months post-ESG and 80%
at 6 months. Since we have demonstrated similar short-term
efficacy as equivalent term results published in longer-term
studies, we anticipate long-term results in our patients will
be favorable.
Our findings suggest that ESG may offer superior effi-
cacy and reduced risk of major adverse events compared
to other endoscopic bariatric therapies. Minor adverse
events such as nausea, vomiting, and abdominal pain were
anticipated in ESG patients, thus, pharmaceutical prophy-
laxis was provided to all. Such minor adverse events are
expected in patients undergoing endoscopic bariatric ther-
apies, particularly those where the target site is the stom-
ach [11, 24–26]. When comparing the efficacy of ESG to
systematic reviews and meta-analyses of the most com-
monly utilized endoscopic bariatric therapy (intragastric
balloons), ESG outcomes appear superior. For example,
%TBWL appears lower with intragastric balloons at 12%
(EWL 25.4%) at 6 months follow-up [11, 24–26]. Most
notably, intragastric balloons have adverse events that per-
sist beyond the first 3–5 days such as gastroesophageal
reflux disease (GERD) (18.3%) as well as high intolerance
rates (often around 10%) requiring premature removal of
the device [26, 27]. Furthermore, more serious complica-
tions of IGB therapy include gastric ulceration, balloon
deflation and potential migration, pancreatitis, and rarely,
Fig. 3 Graphical depictions of a ΔWeight, b ΔBMI, c %TBWL, and d
%EWL at 1, 3, and 6 months post-ESG. Figures included all data points.
Outliers are defined as data points that are located 1.5 times outside the
interquartile range. Asterisk indicates an outlier, degree sign indicates two
outliers, and bullet indicates three outliers
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gastric perforation. Persistent mild adverse events and in-
tolerance have not been reported with ESG and were not
seen in our patient cohort. Of note, the most serious ad-
verse event in our series was in a known high-risk patient.
The high level of safety in our patients post-ESG requires
further study and characterization, particularly in compari-
son to existing EBTs.
For an EBT to have a meaningful impact on obesity, it
should reach a certain threshold of efficacy that is balanced
against the risks of the intervention. The Preservation and
Incorporation of Valuable endoscopic Innovation (PIVI)
thresholds to assess EBTs, set jointly by the ASGE and the
ASMBS, recommend efficacy targets of > 25% EWL at
12 months, and a safety threshold of < 5% risk of major com-
plication [4, 28]. ESG, as assessed in this study and as previ-
ously reported, meets these thresholds comfortably.
In addition, we acknowledge the wide distribution of
weight loss outcomes reported in our study, which might in-
dicate highly individual responses to treatment, or perhaps the
existence of specific subpopulations, or phenotypes, of
patients that affect the weight loss response to ESG. It should
be noted, however, that these cohorts include the first cases
performed at each center, and as such the presence of a learn-
ing curve may further contribute to the wide range of out-
comes, particularly at the 6-month time point [14, 21]. Our
multivariable analysis showed that males achieved better ab-
solute body weight loss than females, after adjusting for base-
line body size, age, medical history, and for those that previ-
ously underwent intragastric balloon therapy, type of balloon.
Since the proportion of males in bariatric settings has tradi-
tionally been low worldwide [2], we suggest the possible ef-
fect of gender difference has been overlooked. More investi-
gation into anthropometric differences (e.g., fat-free mass vs.
fat mass), behavior patterns, and biopsychosocial differences
is required to better predict outcomes.
Patients experienced with intragastric balloon/s for weight
loss reported significantly less weight loss than those naïve to
endoscopic bariatric procedures. Multiple potential factors
may explain this observation, including selection bias of a
relatively treatment-refractory group. Also, changes in gastric
Fig. 4 Graphical depictions of a
ΔWeight, b ΔBMI, c %TBWL,
and d %EWL at 1, 3, and
6 months post-ESG, categorized
by baseline BMI category.
Figures included all data points.
Outliers are defined as data points
that are located 1.5 times outside
the interquartile range. Asterisk
indicates an outlier, degree sign
indicates two outliers, and bullet
indicates three outliers
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wall thickness following intragastric balloon therapy may also
lead to altered efficacy and/or durability of ESG. Furthermore,
given that both intragastric balloon therapy and ESG induce
gastric restriction and delayed gastric emptying, it is possible
that this cohort represents a Bphenotype^ that is not responsive
to bariatric modalities employing this combination of physio-
logic manipulation. However, there is an absence of evidence
examining the consequences of specific bariatric endoscopic
procedures (e.g., intragastric balloons) on concurrent or con-
secutive weight loss interventions of any form. To our knowl-
edge, this is the first study reporting weight loss outcomes in
patients that underwent more than one type of endoscopic
bariatric procedure. Given that EBTs are likely to become
much more widespread due to the current obesity epidemic,
we predict more patients will undergo multiple EBT proce-
dures for intensive weight loss or to address weight recidi-
vism. We highlight here the urgent need to study the implica-
tions of various EBTs for future weight loss attempts in order
to identify optimal combinations and/or permutations for spe-
cific patient subsets, or Bphenotypes.^
It is worth noting that patients’ baseline body size was
associated with different weight loss outcomes, after adjusting
for all the other covariates. At 6 months post-procedure, al-
though observed to attain a much greater absolute weight loss,
patients with higher baseline BMI were not as close to their
ideal weight range as those with lower initial BMI; a finding
that has also been observed in the surgical literature [29, 30].
The findings have critical clinical implications. In the first
instance, these observations would suggest that early interven-
tion is key in optimizing the chances of normalizing weight.
Furthermore, we suggest health professionals practicing this
technique, and arguably those working with bariatric patients
generally, discuss weight loss outcomes with patients from the
outset to set realistic goals and manage expectations surround-
ing the magnitude of weight loss and the timeline to such
targets. Further research is required to examine the potential
for differential impacts on health outcomes following ESG, in
addition to weight loss, between patients of different baseline
BMI categories.
Limitations of our study include its retrospective nature, the
limited long-term follow-up, and the small subset of patients
with previous gastric balloon experience, which could poten-
tially lead to type II error. While our study was strengthened
by the multi-center design, there was no control group or
randomization. Since previous literature indicated the relative
infrequency of adverse events associated with the procedure,
we felt that a multicenter study would at least allow for detec-
tion of even infrequent adverse events, if they so occurred.
The loss to follow-up rate was comparable to other previous
investigations of bariatric procedures [2, 16, 19]. The current
study addresses proof of concept, generalizability, and safety
of ESG. Randomized controlled studies with longer-term fol-
low-up are needed.
Despite encouraging short-term weight loss and safety re-
sults, ESG’s role in weight management remains unclear. To
sum up, there have been no published studies directly com-
paring ESG to other bariatric procedures in terms of efficacy,
safety, or cost. Furthermore, to our knowledge, there has been
only one study assessing the changes in metabolic risk profile
following ESG [17]. Future research priorities should focus on
assessing the health outcomes following ESG, establishing its
cost effectiveness, and examining its performance against
conventional bariatric interventions, including lifestyle thera-
pies, in a randomized fashion. In addition, predictors of pro-
cedural success and optimization of after-care all require fur-
ther exploration.
Considering the significant weight loss observed, repro-
ducibility of the results among independent centers, absence
of intraprocedural events, and low prevalence of major ad-
verse events and complications, ESG appears to be a feasible,
effective, and safe treatment for obesity. The procedure, in its
current form, is thus suitable for incorporation into clinical
practice.
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Supplementary Table 1. Multi-variate associations between weight loss parameters and potential predictors at 1, 3, and 6 months post-ESG  
1 month 3 months 6 months 
Δ Weight (kg) Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
 
B Std. Error Beta 
  
B Std. Error Beta 
  
B Std. Error Beta 
  
(Constant) 2.5 2.6 
 
0.
9 
0.3
49 
4 4.4 
 
0.
9 
0.3
66 
-18.6 7.5 
 
-
2.
5 
0.0
17 
Centre -1.4 0.7 -0.2 -2 0.0
54 
-0.2 1.1 0 -
0.
1 
0.8
85 
2.2 2.5 0.1 0.
9 
0.3
82 
Age (by year) 0 0 -0.1 -
1.
2 
0.2
33 
0 0.1 0 -
0.
4 
0.6
87 
0 0.1 0 0.
4 
0.7
04 
Gender (Male) 3.9 0.8 0.4 4.
7 
0 4.1 1.5 0.3 2.
8 
0.0
07 
1.5 2.5 0.1 0.
6 
0.5
61 
Baseline BMI (by 
kg/m2) 
0.2 0.1 0.3 3.
8 
0 0.3 0.1 0.3 3.
3 
0.0
01 
1 0.2 0.7 6.
5 
0 
ORCD (Yes) -1.7 0.8 -0.2 -
2.
2 
0.0
3 
-1.7 1.3 -0.1 -
1.
3 
0.1
98 
-1.8 2.4 -0.1 -
0.
7 
0.4
61 
Suture (by 
number) 
0.1 0.2 0 0.
4 
0.6
81 
-0.2 0.4 -0.1 -
0.
4 
0.6
56 
-0.4 0.7 -0.1 -
0.
6 
0.5
31 
Bariatric history 
(Yes) 
-4 1.3 -0.3 -
2.
9 
0.0
04 
-4.8 2 -0.3 -
2.
5 
0.0
17 
-6.6 3 -0.2 -
2.
2 
0.0
36 
Δ BMI (kg/m2) Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
 
B Std. Error Beta 
  
B Std. Error Beta 
  
B Std. Error Beta 
  
(Constant) 2.1 3.1 
 
0.
7 
0.5
01 
2.1 1.5 
 
1.
4 
0.1
59 
-4.1 2.4 
 
-
1.
7 
0.0
92 
Centre (US/AUS) -0.3 0.8 -0.1 -
0.
4 
0.6
93 
-0.1 0.4 0 -
0.
2 
0.8
2 
0.8 0.8 0.2 1 0.3
11 
Age (by year) -0.1 0 -0.2 -
1.
4 
0.1
57 
0 0 0 -
0.
3 
0.7
56 
0 0 0 0.
2 
0.8
46 
2 
 
Gender (Male) 1.8 1 0.2 1.
9 
0.0
67 
0.7 0.5 0.2 1.
4 
0.1
78 
-0.1 0.8 0 -
0.
1 
0.9
11 
Baseline BMI (by 
kg/m2) 
0.1 0.1 0.1 0.
9 
0.3
68 
0.1 0 0.3 3.
1 
0.0
03 
0.3 0 0.7 6.
1 
0 
ORCD (Yes) -0.1 0.9 0 -
0.
1 
0.9
2 
-0.7 0.4 -0.2 -
1.
5 
0.1
37 
-0.6 0.8 -0.1 -
0.
9 
0.3
94 
Suture (by 
number) 
0.2 0.3 0.1 0.
6 
0.5
37 
-0.1 0.1 -0.1 -
0.
5 
0.6
25 
-0.1 0.2 -0.1 -
0.
7 
0.4
8 
Bariatric history 
(Yes) 
-1.5 1.6 -0.1 -1 0.3
37 
-1.8 0.7 -0.3 -
2.
7 
0.0
08 
-2.2 1 -0.3 -
2.
3 
0.0
26 
%TBWL Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
 
B Std. Error Beta 
  
B Std. Error Beta 
  
B Std. Error Beta 
  
(Constant) 10.1 2.3 
 
4.
3 
0 15.2 3.5 
 
4.
4 
0 7.7 5.7 
 
1.
4 
0.1
82 
Centre -1.3 0.6 -0.3 -
2.
2 
0.0
31 
-0.3 0.9 0 -
0.
3 
0.7
39 
1.3 1.9 0.1 0.
7 
0.5
1 
Age (by year) 0 0 -0.1 -1 0.3
12 
0 0 -0.1 -
0.
5 
0.6
47 
0 0.1 0.1 0.
4 
0.6
9 
Gender (Male) 1.8 0.7 0.3 2.
4 
0.0
18 
1.2 1.2 0.1 1 0.3
2 
-0.6 1.9 0 -
0.
3 
0.7
65 
Baseline BMI (by 
kg/m2) 
0 0.1 0 -
0.
1 
0.9
45 
0 0.1 0 -
0.
2 
0.8
7 
0.3 0.1 0.3 2.
3 
0.0
25 
ORCD (Yes) -1.3 0.7 -0.2 -
1.
9 
0.0
66 
-1.4 1 -0.2 -
1.
3 
0.1
85 
-2 1.8 -0.2 -
1.
1 
0.2
73 
Suture (by 
number) 
0.1 0.2 0.1 0.
5 
0.6
44 
-0.1 0.3 -0.1 -
0.
4 
0.6
99 
-0.3 0.5 -0.1 -
0.
6 
0.5
43 
Bariatric history 
(Yes) 
-3.6 1.2 -0.3 -3 0.0
04 
-4.8 1.6 -0.4 -
3.
1 
0.0
03 
-6.4 2.3 -0.4 -
2.
8 
0.0
08 
%EWL Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
3 
 
 
B Std. Error Beta 
  
B Std. Error Beta 
  
B Std. Error Beta 
  
(Constant) 76.8 8 
 
9.
6 
0 107.2 11 
 
9.
7 
0 106.5 19.4 
 
5.
5 
0 
Centre -2.8 2 -0.2 -
1.
4 
0.1
77 
1.9 2.9 0.1 0.
7 
0.5
01 
8.5 6.6 0.2 1.
3 
0.2 
Age (by year) -0.1 0.1 -0.1 -1 0.3
24 
-0.1 0.1 -0.1 -
0.
7 
0.4
79 
0.2 0.3 0.1 0.
6 
0.5
55 
Gender (Male) 3.3 2.5 0.1 1.
3 
0.1
93 
1.3 3.7 0 0.
4 
0.7
26 
-1.7 6.5 0 -
0.
3 
0.7
99 
Baseline BMI (by 
kg/m2) 
-1.1 0.2 -0.6 -
6.
2 
0 -1.5 0.2 -0.6 -
6.
4 
0 -1.2 0.4 -0.4 -3 0.0
05 
ORCD (Yes) -3.7 2.3 -0.2 -
1.
6 
0.1
12 
-4.1 3.3 -0.1 -
1.
3 
0.2
15 
-7.4 6.2 -0.2 -
1.
2 
0.2
39 
Suture (by 
number) 
-0.1 0.7 0 -
0.
1 
0.8
88 
-0.7 1 -0.1 -
0.
7 
0.4
78 
-2.1 1.7 -0.2 -
1.
3 
0.2
16 
Bariatric history 
(Yes) 
-10.7 4.1 -0.2 -
2.
6 
0.0
11 
-14 4.9 -0.3 -
2.
9 
0.0
06 
-20.7 7.9 -0.3 -
2.
6 
0.0
12 
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Supplementary Table 2. Weight loss outcomes of patients adjusted for sex and previous balloon experience   
Un-adjusted 
     
  
No previous balloon (N=102) Previous balloon (N=10) P-value# Female (N=77) Male (N=35) P-value# 
Δ Weight (kg) 1 month 9.3±4.7 6±1.8 <0.001 7.8±4.2 11.6±4.4 <0.001 
 
3 months 13.5±6.4 8.2±3.1 <0.001 11.3±4.7 16.2±8.1 <0.001 
 
6 months 17.6±11 9.7±4.1 <0.001 14.3±6.3 20.3±15.4 ns 
 
P-value^ <0.001 <0.001 
    
Δ BMI (kg/m2) 1 month 3.6±4 2.1±0.6 <0.001 2.8±1.2 4.8±6.4 <0.001 
 
3 months 4.7±2 2.9±1.1 <0.001 4.2±1.8 5.1±2.4 ns 
 
6 months 6±3.3 3.5±1.6 <0.001 5.2±2.3 6.4±4.5 ns 
 
P-value^ <0.001 <0.001 
    
%TBWL 1 month 8.6±4.2 5.7±1.8 <0.001 8±4.5 9.2±3 ns 
 
3 months 12.4±4.4 8.1±3.1 <0.001 11.6±4.3 12.5±5 ns 
 
6 months 15.9±5.9 9.3±4 <0.001 14.8±5.4 15.1±7.5 ns 
 
P-value^ <0.001 0±0 
    
%EWL 1 month 28.8±18.7 20.6±10.5 <0.001 28.9±21.3 26.8±9.9 ns 
 
3 months 41.2±17 30.7±17.4 <0.001 41.9±17.3 35.8±16.9 ns 
 
6 months 53.5±21.6 32.9±19.3 <0.001 53.7±22 43.9±22.3 ns 
 
P-value^ <0.001 <0.001 
 
<0.001 <0.001 
 
Footnote: 
^ Repeat-measurement analysis 
# ANOVA tests, adjustment not performed because of inadequate sample size 
ns: not statistically significant 
Δ Weight: change of weight from pre-procedure 
Δ BMI: change of BMI from pre-procedure 
%TBWL: total body weight loss (%) 
%EWL: excess weight loss (%) 
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Supplementary Figure 1. Graphical depictions of a. ΔWeight, b. ΔBMI, c. %TBWL, 
d. %EWL at 1, 3 and 6 months post-ESG, categorized by sexpre 
Footnote: 
Figures included all data points. Outliers are defined as data points that is located 1.5 
times outside the interquartile range.  
*  indicates an outlier 
º  indicates two outliers 
•  indicates three outliers 
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Supplementary Figure 2. Graphical depictions of a. ΔWeight, b. ΔBMI, c. %TBWL, 
d. %EWL at 1, 3 and 6 months post-ESG, categorized by presence or absence of 
previous bariatric therapy via intragastric balloon  
Footnote: 
Figures included all data points. Outliers are defined as data points that is located 1.5 
times outside the interquartile range.  
*  indicates an outlier 
º  indicates two outliers 
•  indicates three outliers 
 
 
  
Chapter 6 
 
 
Efficacy and Safety of Endoscopic Sleeve 
Gastroplasty: a Systematic Review and Meta-Analysis 
 
Hedjoudje A, Abu Dayyeh B, Cheskin LJ, Adam A, Galvao Neto M, 
Badurdeen D, Morales JR, Sartaretto A, Lopez-Nava G, Vargas E, 
Zhixian S, Fayad L, Farha J, Khashab MA, Kalloo AN, Alqahtani AR, 
Thompson CC, Kumbhari V 
 
 
Clin Gastroenterol Hepatol. [Epub ahead of print] 
Q18
Q2Q3
Clinical Gastroenterology and Hepatology 2019;-:-–-
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
5859
60
61
62
63
64
65
66
67
68
69
70
71Efficacy and Safety of Endoscopic Sleeve Gastroplasty:
A Systematic Review and Meta-Analysis
Abdellah Hedjoudje,* Barham Abu Dayyeh,‡ Lawrence J. Cheskin,§ Atif Adam,k
Manoel Galvão Neto,¶,# Dilhana Badurdeen,* Javier Graus Morales,**
Adrian Sartoretto,‡‡ Gontrand Lopez Nava,§§ Eric Vargas,kk Sui Zhixian,‡‡,¶¶
Lea Fayad,* Jad Farha,* Mouen A. Khashab,* Anthony N. Kalloo,*
Aayed R. Alqahtani,##,*** Christopher Thompson,‡‡‡ and Vivek Kumbhari*72
73
74
75
76
77
78
79
80
81*Division of Gastroenterology, Johns Hopkins Medicine, Baltimore, Maryland; ‡Mayo Clinic School of Medicine, Rochester,
Minnesota; §Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland;
kJohns Hopkins Weight Management Center, Department of Health, Behavior and Society, Johns Hopkins Bloomberg School
of Public Health, Baltimore, Maryland; ¶Herbert Wertheim College of Medicine, Florida International University, Miami, Florida;
#Endovitta Institute, São Paulo, Brazil; **Instituto Médico Europeo de la Obesidad, Madrid, Spain; ‡‡BMI Clinic, Double Bay,
Australia; §§Bariatric Endoscopy Unit, Madrid Sanchinarro University Hospital, Madrid, Spain; kkDivision of Gastroenterology
and Hepatology, Mayo Clinic, Rochester, Minnesota; ¶¶School of Public Health and Community Medicine, University of New
South Wales, Kensington, Australia; ##Department of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia;
***New You Medical Center, Riyadh, Saudi Arabia; and ‡‡‡Division of Gastroenterology, Brigham and Women’s Hospital,
Boston, Massachusetts82
83BACKGROUND & AIMS:Abbreviations used in this pap
interval; ESG, endoscopic sleev
LSG, laparoscopic sleeve gastr
R
84
85
86Bariatric surgery is the most successful treatment for obesity. However, many patients avoid
surgery due to its perceived invasive nature and fear of complications. Endoscopic sleeve
gastroplasty (ESG) is a seemingly less invasive option for patients with obesity. We performed a
systematic review and meta-analysis to evaluate the efﬁcacy and safety of ESG in adults.87
88METHODS:89We searched MEDLINE, Embase, Web of Science, and Cochrane Library through July 2019.
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nausea requiring hospitalization (n [ 18, 1.08%), upper gastrointestinal bleeding (n[9,
0.56%), and peri-gastric leak or ﬂuid collection (n [ 8, 0.48%).99
100CONCLUSIONS:101
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103In a systematic review and meta-analysis, we found ESG to produce clinically signiﬁcant weight
loss that was reproducible among independent centers and to have a low rate of severe adverse
events. ESGappears tobeaneffective intervention forpatientswithobesity, althoughcomparative
studies and randomized controlled trials are necessary. PROSPERO Identiﬁer: CRD42019121921104
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112In 2016, more than 1.9 billion adults 18 years of ageand older were overweight and 650 million were
obese.1 The global prevalence of obesity is alarming and
yet data suggest that these staggering statistics will only
continue to rise.2 Obesity associated comorbid conditionser: BMI, body mass index; CI, conﬁdence
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EV 5.6.0 DTD  YJCGH56695_proof  2including type 2 diabetes mellitus, hypertension, coro-
nary heart disease, stroke, and nonalcoholic fatty liver
disease all improve with weight loss.2 Diet, exercise, and
medications are often prescribed due to the lower cost
and favorable side effect proﬁle, but produce suboptimal© 2019 by the AGA Institute
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216results. Bariatric surgery is the gold standard for man-
agement of moderate to severe obesity; however, only
1%–2% of eligible patients undergo surgery each
year.3–6 Thus, a large proportion of obese patients who
are nonresponsive to lifestyle and pharmacologic in-
terventions are inadequately treated.3
Endoscopic bariatric therapies have emerged as a
novel method to ﬁll this void.8 For endoscopic therapies to
fulﬁl the unmet clinical need, there remains a requirement
for not only an effective and safe therapy, but also one
appealing to patients and clinicians. An endoscopic tech-
nique avoiding the placement and removal of a foreign
body may result in acceptable tolerability and durability,
thus increasing the likelihood of potential adoption. A
potential solution was developed termed endoscopic
sleeve gastroplasty (ESG). The ESG is an innovative
imitation of the laparoscopic sleeve gastrectomy.9 It is
offered to patients who are not candidates for bariatric
surgery based on body mass index (BMI) criteria, or are
apprehensive of “going under the knife” for fear of com-
plications. The volume of the stomach is reduced by
approximately 70% through plication of the greater cur-
vature of the stomach using an endoscopic suturing device
(OverStitch, Apollo Endosurgery, Austin, TX).10 The pro-
cedure typically takes an hour to perform, after which
discharge is possible the same day.
ESG is being increasingly adopted across the globe
despite the current evidence being limited to retrospec-
tive case series and case-control studies. Comparative
studies are lacking with no published data comparing
ESG with diet and lifestyle modiﬁcation therapy and only
a few studies comparing ESG to bariatric surgery.11,12
This is dissimilar to other endoscopic bariatric thera-
pies, including intragastric balloons and aspiration
therapy, in which level 1 evidence exists.13–16 Therefore,
there is a need to synthesize the available literature
pertaining to ESG to arm the clinician with the data
required to facilitate a data driven discussion with pa-
tients interested in the procedure. The aim of the sys-
tematic review and meta-analysis was to evaluate the
efﬁcacy of ESG for signiﬁcant and sustained weight loss
and deﬁne the risk of severe adverse events.217
218
219
220
221
222
223
224
225
226
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228
229
230
231
232Methods and Materials
Search Strategy
Adhering to the MOOSE (Meta-analysis of Observa-
tional Studies in Epidemiology) guidelines,17 studies
were identiﬁed by performing a comprehensive litera-
ture search of 3 electronic databases (MEDLINE through
PubMed, Web of Science, and the Cochrane library) with
the last search performed on July 1, 2019. The search
equation for PubMed was (“Gastroplasty” or “Overstitch”
or “endosleeve” or “Endoscopic sleeve gastroplasty” or
“Endoscopic bariatric therapy” or “Endoscopic suturing”
or “Bariatric endoscopy” or “Endobariatrics”) ANDREV 5.6.0 DTD  YJCGH56695_proof  2(“Weight loss” or “Obesity” or “Bariatric”) AND (“endo-
scopic”). Queries for other databases were adapted from
this search strategy. We attempted to identify additional
studies by reviewing the reference list of all included
studies, personal collections, and manual search to
retrieve other articles that may have been missed by the
initial search strategy. Two investigators (A.H., J.F.)
screened all titles and abstracts for relevance to the
study and reviewed the full text of the relevant studies.
Disagreements were resolved by consensus with the
intervention of a third reviewer (V.K.) when necessary.
Study Selection and Quality Assessment
Predeﬁned inclusion criteria were retrospective or
prospective studies, case-control or cohort studies, or
clinical trials (including randomized controlled trials)
with more than 20 patients and studies reporting clinical
outcomes of ESG in adult patients. Our exclusion criteria
were animal studies, commentaries, reviews or surveys,
overlapping patients, publications in a language other than
English or French, case reports, and letters or comments. If
multiple articles were on the same study sample with the
same exposure and outcome, the publication with the
largest sample size was retained. All studies were evalu-
ated for quality independently by 2 investigators (A.H.,
J.F.) using National Institutes of Health quality assessment
for before-after (pre-post) studies.12
Data extraction. One investigator (A.H.) using a stan-
dardized data extraction sheet extracted data from each
study. The data extraction form included (1) author
name, (2) year of publication, (3) setting (location), (4)
study design, (5) study period, (6) number of patients/
lesions, (7) patient demographics (age, gender, BMI,
weight, height, waist-circumference), (8) patient comor-
bidities, (9) number of sutures, (10) total body weight
loss (TBWL), (11) excess weight loss (EWL), (12) severe
adverse events, and (13) follow-up period. When pub-
lished information was insufﬁcient, the corresponding
author was contacted to obtain further information.
Outcome Measures
The studies reviewed measured weight loss efﬁcacy
with different scales, including relative weight loss, abso-
lute decrease in BMI, and relative EWL. To assess the
stability of these ﬁndings and identify sources of hetero-
geneity, preplanned subgroup analyses based on study
design, cohort size, BMI, and gender proportion were
performed. Safety was evaluated by calculating the severe
adverse event rate reported in the included studies.
Statistical Analyses
The proportions and 95% conﬁdence intervals (CIs)
for each categorical factor and the mean or median for
continuous data were obtained or calculated when7 September 2019  4:48 pm  ce OB
Q9
Q10
Q11
Table 1. Baseline Characteristics of Included Studies
Author, Year Setting Design Data Period
Cohort
Size Country Male Age (y)
BMI
(kg/m2) Suture
Graus-Morales,
2018
Single center Retrospective 01/2015–02/2016 148 Spain 27 (18.2) 41.5  10 35.1  5.5 4  0.2
Fayad, 2018 Single center Retrospective 05/2015–12/2016 54 United
States
31 (57.4) 48  12 43.0  8.9 NR
Sartorreto, 2018
(Australia)
Multicenter Retrospective 02/2016–05/2017 51 Australia 15 (29.4) 43  11.9 36.7  4.9 6.0  1.2
Sartorreto, 2018
(United States)
Multicenter Retrospective 02/2016–05/2017 19 United
States
3 (15.7) 41.9  9,6 33.6  4.0 8.9  1.5
Saumoy, 2017 Single center Prospective 08/2013–12/2016 128 United
States
42 (32.8) 43.6  11.3 38.9  6.9 8  5
Lopez-Nava,
2017
Single center Prospective 05/2013–03/2016 154 Spain 46 (29.8) 44.9  9.5 38.3  5.5 7  1
Abu Dayyeh,
2016
Single center Prospective 09/2012–03/2015 25 United
States
4 (16.0) 47.6  10 35.5  2.6 16  5
Alqahtani,
2018
Single center Prospective 12/2016- NR 1000 Saudi
Arabia
897 (89.7) 34.4  9.5 33.3  4.5 4.2  0.5
Barrichello, 2019 Multicenter Prospective 07/2017 – 08/2018 193 Multicenter 45 (23.3) 42.3  9.6 34.11  2.97 NR
Values are n (%) or mean  SD.
NR, not reported.
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348possible. The pooled means and proportions were then
computed using either ﬁxed-effects or random-effects
models, depending on study homogeneity or heteroge-
neity. Statistical heterogeneity was evaluated by means
of I2 statistics and Cochran Q test values.19 An I2 value
>50% was considered high statistical heterogeneity (I2
>50% and P < .05). For the main outcomes that failed
the homogeneity test, we searched for potential sources
of heterogeneity, including study setting, average age,
gender, number of sutures, baseline BMI and evaluated
these via metaregression analysis, where TBWL was the
summary outcome. For all analyses, if mean and stan-
dard deviation where not available, median was consid-
ered equivalent to mean, interquartile range was
converted to standard deviation by dividing by 1.35 and
range was transformed to standard deviation by dividing
by 4, in accordance with the Cochrane handbook.19
Funnel plots were generated to evaluate the possibility
of publication bias.20 The study was conducted in
accordance with the MOOSE recommendations for
reporting systematic reviews and meta-analyses for
observational studies.17 All statistical analyses were
performed using R software (R Foundation for Statistical
Computing, Vienna, Austria).21
Results
Study Selection, Characteristics, and Quality of
Included Studies
The ﬂow diagram for study selection is shown in
Supplementary Figure 1. In total, 1012 studies were
identiﬁed through our database query, of which 250
were duplicates. Of the remaining 762 studies, 685
irrelevant articles were excluded based on the titles andREV 5.6.0 DTD  YJCGH56695_proof  2abstracts. Full text review was then performed on the
remaining 77 studies using the predeﬁned inclusion and
exclusion criteria, after which 8 studies were retained.
Twelve studies had overlapping patients and were
therefore excluded. One study10 pooled results from 2
different countries (United States and Australia) without
overlapping patients and were included separately as 2
different cohorts. Finally, 8 studies7,10,11,22–25 with 9
different cohorts involving 1772 patients fulﬁlling all
inclusion criteria as described were included in our
meta-analysis. Study characteristics are summarized in
Table 1: 1110 (62.6%) patients were men, and the mean
age was 38.3  10.9 years. All 8 studies were cohort
studies: 3 retrospective10,11,22 and 5 prospective7,23–26;
none were randomized controlled trials. The studies
were all published from 2016 to 2019. Sample sizes at
baseline ranged from 25 to 1000. BMI at baseline was
between 33.3  4.5 kg/m2 and 43.0  8.9 kg/m2. All
studies except one25 showed a large female predomi-
nance. Results of the quality assessment of all included
studies were satisfying and are shown in Supplementary
Table 1. Absolute and relative TBWL was reported as a
mean  SD in all studies.Relative TBWL
TBWL was reported at 1 month in 5 cohorts,10,11,24,25
at 3 months in 4 cohorts,10,22,25 at 6 months in 8
cohorts,7,10,11,22–25 at 9 months in 3 cohorts,7,22,25 at 12
months in 5 cohorts,7,22,25 and at 18–24 months in 4
cohorts (Figure 1).7,22,24,25 When the random-effects
model was used, the pooled mean TBWL was 8.8%
(95% CI, 8.1%–9.5%) at 1 month (Cochran’s Q test P 
.01, I2 ¼ 85%), 11.2% (95% CI, 10.4%–12.14%) at 3
months (Cochran’s Q test P  .01, I2 ¼ 78.2%), 15.1%7 September 2019  4:48 pm  ce OB
Q12
Table 2. Subgroup Q14Analysis at Each Time Point for TWBL, Decrease in BMI, and EWL
Outcomes Time Point Trials
Cochran
Q Test
Q Test
P Value s2 I2 (%)
Pooled Proportion
(95% CI)
Percentage of TBWL At 1 mo 5 26.24 <.01 0.4517 84.8 8.77 (8.06–9.47)
At 3 mo 4 10.21 <.01 0.4467 70.6 11.28 (10.41–12.14)
At 6 mo 9 35.97 <.01 1.25 78.9 15.14 (14.29–16.00)
At 9 mo 3 5.15 08 0.6989 61.1 16.13 (14.90–17.37)
At 12 mo 6 18.44 <.01 1.6255 72.9 16.50 (15.19–17.82)
At 18–24 mo 4 8.99 03 4.0121 66.6 17.15 (14.64–19.67)
BMI reduction At 1 mo 5 100.90 <.01 0.1344 96.0 3.05 (2.71–3.40)
At 3 mo 4 24.27 <.01 0.0629 87.6 3.86 (3.58–4.1662)
At 6 mo 8 458.11 <.01 0.6489 98.5 5.65 (5.07–6.22)
At 9 mo 3 4.27 .12 0.0333 53.1 5.67 (5.40–5.96)
At 12 mo 5 266.57 <.01 0.9322 98.5 6.14 (5.24–7.04)
At 18–24 mo 4 30.50 <.01 0.583 90.2 6.56 (5.70–7.47)
EWL At 1 mo 4 87.04 <.01 69.1404 96.6 32.42 (23.50–41.34)
At 3 mo 4 10.89 .01 17.5837 72.5 47.07 (42.10–52.03)
At 6 mo 7 37.77 <.01 47.5125 84.1 57.71 (52.02–63.41)
At 9 mo 3 5.25 .07 36.1429 61.9 66.21 (57.54–74.87)
At 12 mo 5 12.95 <.01 39.1419 69.1 61.83 (54.75–68.93)
At 18–24 mo 3 6.44 .04 142.7103 69.0 66.92 (50.22–83.61)
BMI, body mass index; CI, conﬁdence interval; EWL, excess weight loss; TBWL, total body weight loss.
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463(95% CI, 14.3%–16.0%) at 6 months (Cochran’s Q test P
< .01, I2 ¼ 80%), 16.1% (95% CI, 14.9%–17.4%) at 9
months (Cochran’s Q test p ¼ .08, I2 ¼ 61%), 16.5%
(95% CI, 15.2%–17.8%) at 12 months (Cochran’s Q test
P < .01, I2 ¼ 73%), and 17.1% (95% CI, 14.6%–19.7%)
at 18–24 months (Cochran’s Q test P ¼ .03, I2 ¼ 67%).
The funnel plots for TBWL at 6 months shows that there
was no obvious publication bias detected for these
outcome measures (Supplementary Figure 3). However,
in the metaregression, only gender distribution (P ¼ .02)
was marginally associated with mean TBWL
(Supplementary Figure 4). The slope of the line of best ﬁt
declines with increasing male predominance, which
suggests that TBWL decreases as the proportion of men
increases. There was no statistically signiﬁcant associa-
tion between baseline BMI, setting (Europe/United
States), number of sutures used, cohort size, procedural
time, or length of follow-up.
Absolute Decrease in BMI. Decrease in BMI was re-
ported at 1 month in 5 cohorts,10,11,24,25 at 3 months in 4
cohorts,10,22,25 at 6 months in 8 cohorts,7,10,11,22–25 at 9
months in 3 cohorts,7,22,25 at 12 months in 5
cohorts,7,22–25 and at 18–24 months in 4 cohorts
(Figure 2).7,22,24,25 When the random-effects model was
used, the pooled BMI loss was 3.0 kg/m2 (95% CI,
2.7–3.4) at 1 month (Cochran Q test P < .01, I2 ¼ 96%),
3.9 kg/m2 (95% CI, 3.6–4.2) at 3 months (Cochran Q test
P < .01, I2 ¼ 88%), 5.6 kg/m2 (95% CI, 5.1–6.2) at 6
months (Cochran Q test P < .01, I2 ¼ 98%), 5.7 kg/m2
(95% CI, 5.4–6.0) at 9 months (Cochran Q test P ¼ .12,
I2 ¼ 53%), 6.1 kg/m2 (95% CI, 5.2–7.0) at 12 months
(Cochran Q test P < .01, I2 ¼ 98%), and 6.5 kg/m2 (95%
CI 5.7–7.4) at 18–24 months (Cochran Q test P < .01,
I2 ¼ 90%).REV 5.6.0 DTD  YJCGH56695_proof  2Relative EWL
EWL was reported at 1 month in 4 cohorts,10,24,25 at 3
months in 4 cohorts,10,22,25 at 6 months in 7
cohorts,7,10,22,24–26 at 9 months in 3 cohorts,7,22,25 at 12
months in 5 cohorts,7,22,24–26 and at 18–24 months in 3
cohorts (Figure 3).7,22,25 When the random-effects model
was used, the pooled EWL was 32.4% (95% CI, 23.5%–
41.3%) at 1 month (Cochran Q test P < .01, I2 ¼ 96%),
47.1% (95% CI, 42.1%–52.0%) at 3 months (Cochran Q
test P < .01, I2 ¼ 73%), 57.7% (95% CI, 52.0%–63.4%)
at 6 months (Cochran Q test P ¼ .01, I2 ¼ 84%), 66.2%
(95% CI, 57.5%–74.9%) at 9 months (Cochran Q test P ¼
.07, I2 ¼ 62%), 61.8% (95% CI, 54.7%–68.9%) at 12
months (Cochran Q test P < .01, I2 ¼ 69.1%), and 66.9%
(95% CI, 50.2%–83.6%) at 18–24 months (Cochran Q
test P ¼ .04, I2 ¼ 69%).Sensitivity Analysis, Subgroup Analysis and
Metaregression
We investigated the inﬂuence of a single study on the
overall percentage of TBWL by omitting 1 study at a
time. The omission of any one study showed no clinically
signiﬁcant difference in the results, indicating that the
results were statistically reliable. However, after omit-
ting the study of Alqahtani et al,25 heterogeneity of TBWL
decreased to 66% (Supplementary Figure 2). There was
no evidence of small study effect graphically based on
funnel plot with no gap on the bottom corners of the plot
(Supplementary Figure 3). One of the large cohort
study’s had a smaller treatment effect compared with
other large cohorts without clinical signiﬁcance.25 Lack7 September 2019  4:48 pm  ce OB
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Figure 1. Forest plots of the
included studies evaluating TBWL.
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Figure 2. Forest plots of the
included studies evaluating patient
BMI reduction.
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Figure 3. Forest plots of
the included studies evalu-
ating patient EWL.
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Figure 4. Forest plots of the included studies evaluating severe adverse event rate.
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928of publication bias was further conﬁrmed by Egger’s test.
Multiple preplanned subgroup analyses were performed
to assess for stability of these ﬁndings and identify po-
tential sources of heterogeneity (Table 3). Sample size,
study design, baseline BMI, and sex ratio did not explain
study heterogeneity. We performed a metaregression to
evaluate whether the number of sutures applied was
associated with amount of weight reduction. Metare-
gression showed no statistical correlation between
number of sutures and percentage of TBWL at 6 months.
Severe Adverse Events
Procedural severe adverse events were reported in all
studies included in the meta-analysis (Figure 4). The
pooled estimate of post-ESG severe adverse event rate
was 2.2% 95% CI, 1.57%–3.09%), with a moderate
heterogeneity (Cochran Q test P ¼ .08, I2 ¼ 45). No pa-
tient died from the procedure. Reported severe adverse
events were pain or nausea requiring hospitalization
(n ¼ 18, 1.08%), upper gastrointestinal bleeding (n¼ 9,
0.56%), perigastric leak or collection (n ¼ 8, 0.48%),
pulmonary embolism (n ¼ 1, 0.06%), and pneumo-
peritoneum (n ¼ 1, 0.06%).
Discussion
We report the results of a meta-analysis that evalu-
ates the efﬁcacy and safety of ESG. The data presented
suggest that ESG confers signiﬁcant and sustained weight
loss with an acceptable safety proﬁle. We report that at 6
months, mean TBWL was 15.1% (range, 14.3%–16.0%),
decrease in BMI was 5.6 kg/m2 (range, 5.1–6.2 kg/m2),
and relative EWL was 57.7% (range, 52.0%–63.4%).
Remarkably, these results were sustained at 18–24
months, though the number of patients with thisREV 5.6.0 DTD  YJCGH56695_proof  2duration of follow-up was limited. The pooled estimate of
post-ESG severe adverse event rate was low and esti-
mated at 2.2% (1.6%–3.1%).
Intense diet and lifestyle modiﬁcation with caloric
restriction, exercise and cognitive-behavioral therapy
remain the cornerstones of therapy for weight loss in
overweight and obese individuals.27 Though effective,
results of several meta-analyses suggest that there is a
considerable variability in the magnitude of weight loss
achieved.28,29 Furthermore, maintenance of weight loss
has been a point of concern and contention.30 A sys-
tematic review by Dombrowski et al31 demonstrated that
weight loss maintenance interventions using lifestyle
modiﬁcation and medications were slightly effective.
Moreover, weight regain was observed when medica-
tions were stopped.32 Roughly 20% of individuals who
were overweight or obese were successful at maintaining
weight loss up to 24 months.33 Interestingly, to date
there has been no head-to-head randomized controlled
trial comparing ESG with medications or intense diet and
lifestyle therapy.
The Preservation and Incorporation of Valuable
Endoscopic Innovation thresholds to assess endoscopic
bariatric therapy has been set jointly by the American
Society of Gastrointestinal Endoscopy and the American
Society for Metabolic and Bariatric Surgery. They
recommend efﬁcacy targets of greater than 25% EWL at
12 months and a <5% rate of severe adverse events.34,35
In our meta-analysis, overall pooled results and indi-
vidual trial results exceed these criteria despite hetero-
geneity in inclusion criteria, procedure, postprocedure
management and length of follow-up. Notably, due to the
lack of control groups in the included studies, we were
not able to assess efﬁcacy compared with a sham cohort.
Bariatric surgery is currently the most effective
intervention for treatment of obesity and obesity-
associated diseases. The Roux-en-Y gastric bypass has7 September 2019  4:48 pm  ce OB
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1044fallen out of favor, the more contemporary laparoscopic
sleeve gastrectomy (LSG) increased in popularity, while
the laparoscopic adjustable gastric band is now seldom
performed.37 Bariatric surgery is associated with suc-
cessful long-term maintenance of weight loss and
reduction in obesity-related comorbidities, as well as
improvement in quality of life.5 In a randomized trial
comparing Roux-en-Y gastric bypass vs LSG vs intensive
medical management in patients with BMI 27–43 kg/m2,
TBWL was 23%, 19%, and 5% at 5 years, respectively.38
However, despite its efﬁcacy, few eligible patients select
bariatric surgery as their treatment of choice due to
several factors: fear of “going under the knife,” “stigma of
altered anatomy,” and the perceived risk of adverse
events.
Patients and the majority of clinicians treating pa-
tients who are obese likely perceive the adverse event
rate of bariatric surgery to be disproportionate to what is
represented by published data. Furthermore, there is the
perception that endoscopic bariatric therapies confer a
substantially superior favorable risk-beneﬁt proﬁle when
compared with bariatric surgery, particularly in patients
with a relatively lower BMI. Therefore, ESG has been
considered by many as the preferred approach for early
intervention, such as to treat patients with BMI 30–35
kg/m2 or to prevent the development of obesity associ-
ated comorbidities. In the absence of high-quality ran-
domized controlled trial evidence comparing ESG with
bariatric surgery, one must be tempered when portray-
ing ESG in this manner. Even in patients with class 1
obesity (BMI 30–35 kg/m2), bariatric surgery, including
LSG, has demonstrated an excellent efﬁcacy and safety
proﬁle.39,40 Not only does it produce weight loss, but also
the data illustrate profound improvements in obesity
related comorbidities, including type 2 diabetes and its
associated micro- and macrovascular complications.39,40
Thus, what appears to be preventing bariatric surgery
from being performed in patients with class 1 obesity are
concerns regarding its safety proﬁle. Interestingly, the
30-day severe adverse event rate of bariatric surgery in
patients with class 1 obesity has been reported at 3.8%,
with a mortality rate of 0.5%.41 Our meta-analysis
revealed a 2.2% (95% CI, 1.6%–3.1%) rate of severe
adverse events with ESG. It conﬁrms that the rate of
severe adverse events of ESG is low, making it a suitable
option for those not willing to undergo bariatric surgery.
There is a paucity of data demonstrating an
improvement in obesity related metabolic comorbidities
in patients who undergo ESG. Sharaiha et al42 demon-
strated a reduction in markers of diabetes, hypertension,
fatty liver, and hypertriglyceridemia at 12 months post-
ESG. However, one can extrapolate from robust data
demonstrating that an improvement in metabolic pa-
rameters is seen with as little as 10% TBWL.43,44 Does
ESG induced TBWL of w17% then have the potential to
treat type 2 diabetes mellitus and reduce the risk of
other obesity related comorbidities such as coronary
heart disease and stroke? Further data is needed toREV 5.6.0 DTD  YJCGH56695_proof  2answer to this crucial question; however, ESG appears to
be a novel and promising treatment for obesity and its
comorbid conditions. In addition, the cost beneﬁt that
one would see with treating obesity and its associated
conditions with an outpatient procedure that takes
approximately 60 minutes could be substantial.
The evidence from this meta-analysis suggests that ESG
can be safely introduced into clinical practice for treatment
of obesity andobesity-associateddisease. Thedurability and
weight loss results of ESG at 12 months, suggest that this
endoscopic technique is effective, resulting in clinically sig-
niﬁcantweight loss, sustained over at least the intermediate
term. As with any procedure, there is a learning curve until
proﬁciency is achieved. By analyzing the ﬁrst 128 consecu-
tive patients at a tertiary-care academic medical center,
Saumoy et al23 found that efﬁciency (reﬁning performance
to decrease procedure time) for ESG was attained after an
average of 38 procedures, andmastery (absence of outliers)
after 55. Hill et al45 found that endoscopists experienced in
endoscopic suturing are expected to achieve a reduction in
procedure time and number of plications per procedure in
successive cases, with progress plateauing at 7 and 9 cases,
respectively. Based on these results, ESG has the potential to
be rapidly scaled, such that it can be used safely to help
tackle the global obesity epidemic.46
The strengths of our meta-analysis include a compre-
hensive and well-deﬁned search and a relatively large
number of patients. However, there are also several limi-
tations. First, we did not have access to individual partic-
ipant data; hence, all analyses were performed at a study
level. Like all meta-analyses, the results need to be inter-
preted bearing in mind that endoscopic treatment varies
based on patient characteristics (eg, age, sex, baseline
BMI) although we did control for this in the meta-
regression. Second, most of the studies are of retrospec-
tive design without controls, which can lead to biases. For
most of the studies, the high percentage of “lost to follow-
up” is likely to bias toward an overestimation of the
treatment effect. Third, the longest follow-up time avail-
able was 2 years; hence, long-term effects could not be
assessed or evaluated. Future studies with longer follow
up are needed. Fourth,most of the studies did not evaluate
and report on clinical comorbidities. These data are
paramount as improvement in metabolic parameters
translates into improved quality of life and decreased
health care costs. Fifth, it is noteworthy that in most arti-
cles, mild adverse events were considered “expected” and
were not reported. Although, these events are less con-
cerning clinically, reporting them may be of utility in
optimizing pre and post procedure prophylaxis regimens.
Sixth, there were no randomized controlled trials identi-
ﬁed. Seventh, a substantial statistical heterogeneity was
found. Sensitivity analysis, subgroup analysis, and meta-
regressionwere not able to ﬁnd a population or procedure
characteristics explaining it. Omitting the study from
Alqahtani et al,25 differing from other study by the number
of patients recruited and gender repartition, partly
reduced overall heterogeneity. Meta-regression, even7 September 2019  4:48 pm  ce OB
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1133though underpowered due to the small number, found
that male gender could be associated with a lower treat-
ment effect. However, owing to the excessive inﬂuence of
the study of Alqahtani et al,25 this result has to be inter-
preted cautiously. One of the reasons that could explain
statistical heterogeneity could be variability in the ESG
procedure. Since the ﬁrst ESG report, variable numbers of
sutures, orientation of sutures, spacing and frequency of
bites, and tightness of cinching have been reported. An
important element of all suture patterns is the distal to
proximal movement within each running suture that is
placed along the greater curvature, contracting the stom-
ach longitudinally to confer the intended gastric short-
ening while simultaneously narrowing the lumen.
Variation of the procedure has not been extensively eval-
uated in this meta-analysis and could partially explain
heterogeneity.
Future researchers should prioritize assessing health
outcomes following ESG, establishing its cost-
effectiveness and examining its performance against
conventional bariatric interventions, such as intense diet
and lifestyle, medications, and LSG, in a randomized
fashion. In addition, predictors of procedural success and
optimization of aftercare all require further exploration.
In summary, the quality of the available literature is
limited. However, given the signiﬁcant weight loss
observed, reproducibility of the results among indepen-
dent centers, and the low prevalence of severe adverse
events, ESG could be an effective treatment for obesity
that deserves to be further explored in comparative
studies and randomized controlled trials.1134
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Figure 2. Sensitivity ana-
lyses using the leave-one-
out analysis. CI, conﬁ-
dence interval; TE, .
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Supplementary Figure 3. Funnel plots used to obtain evi-
dence of total body weight loss at 6 months.
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Supplementary Figure 4. Random-effects metaregression of
total body weight loss according to male sex predominance.
The blue line represents a line of best ﬁt from metaregression.
The diameter of the circles reﬂects the weight of the individual
studies in the random-effects meta-regression. The slope of
the line of best ﬁt declines with increasing male predomi-
nance which suggests that total body weight loss decreases
as the proportion of male increase.
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Supplementary Table 1. Study Quality Assessment Based on NIH Scale
Criterion
Graus-
Morales,
2018
Fayad,
2018
Sartorreto,
2018
Saumoy,
2017
Lopez-
Nava,
2017
Abu
Dayyeh,
2016
Alqahtani,
2018
Barrichello
2019
1. Was the study question or objective
clearly stated?
Yes Yes Yes Yes Yes Yes Yes Yes
2. Were eligibility/selection criteria for the
study population prespeciﬁed and clearly
described?
Yes Yes Yes Yes Yes Yes Yes Yes
3. Were the participants in the study
representative of those who would be
eligible for the test/service/intervention
in the general or clinical population
of interest?
Yes Yes Yes Yes Yes Yes Yes Yes
4. Were all eligible participants that met the
prespeciﬁed entry criteria enrolled?
Yes Yes Yes Yes Yes Yes Yes Yes
5. Was the sample size sufﬁciently large to
provide conﬁdence in the ﬁndings?
Yes Yes Yes Yes Yes Yes Yes Yes
6. Was the test/service/intervention clearly
described and delivered consistently
across the study population?
Yes Yes Yes Yes Yes Yes Yes Yes
7. Were the outcome measures
prespeciﬁed, clearly deﬁned, valid,
reliable, and assessed consistently
across all study participants?
Yes Yes Yes Yes Yes Yes Yes Yes
8. Were the people assessing the outcomes
blinded to the participants’ exposures/
interventions?
No No No No No No No No
9. Was the loss to follow-up after baseline
20% or less? Were those lost to
follow-up accounted for in the analysis?
Yes No No No Yes Yes Yes Yes
10. Did the statistical methods examine
changes in outcome measures from
before to after the intervention? Were
statistical tests done that provided
p values for the pre-to-post changes?
Yes Yes Yes Yes Yes Yes Yes Yes
11. Were outcome measures of interest
taken multiple times before the
intervention and multiple times after
the intervention?
Yes Yes Yes Yes Yes Yes Yes Yes
NIH, National Institutes of Health.
Supplementary Table 2. Subgroup Analysis at Each Time Point for TBWL
Variable Subgroup Trials Q
Cochran
Q-Test
p-Value I2 (%) Model
Pooled Proportion
(95% CI)
Test for Subgroup
Difference
Q df
P
Value
Sample
size
<105 4 9.73 .02 69.2 RE 16.12 (14.62–17.61) 3.21 1 .073
105 5 15.18 .01 74 RE 14.54 (13.69–15.39)
Design Prospective 5 15.78 .01 75 RE 14.58 (13.68–15.49) 2.55 1 .110
Retrospective 4 10.63 .17 71.8 RE 16.01 (14.51–17.50)
BMI <36 kg/m2 5 27.36 .01 85 RE 15.22 (14.09–16.35) 0.031 1 .858
36 kg/m2 4 9.76 .02 69.3 RE 15.04 (13.53–16.56)
Male ratio <29% 4 9.13 .87 67.2 FE 15.74 (14.56–16.91) 0.78 1 .3776
29% 5 16.43 .01 76 RE 14.69 (113.44–15.95)
BMI, body mass index; CI, conﬁdence interval; FE, ﬁxed-effects model; RE, random-effects model.
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MOOSE ChecklistQ15 for Meta-analyses of Observational
Studies
Item
No Recommendation Reported on §
Reporting of background should include
1 Problem deﬁnition I § 1
2 Hypothesis statement I § 2
3 Description of study outcome(s) I § 3
4 Type of exposure or intervention
used
I § 2
5 Type of study designs used M § 1
6 Study population M § 2
Reporting of search strategy should include
7 Qualiﬁcations of searchers (eg,
librarians and investigators)
M § 1
8 Search strategy, including time
period included in the synthesis
and key words
M § 1
9 Effort to include all available studies,
including contact with authors
M § 3
10 Databases and registries searched M § 1
11 Search software used, name and
version, including special features
used (eg, explosion)
M § 5
12 Use of hand searching (eg, reference
lists of obtained articles)
M § 1
13 List of citations located and those
excluded, including justiﬁcation
M § 1
14 Method of addressing articles
published in languages other than
English
M § 2
15 Method of handling abstracts and
unpublished studies
NA
16 Description of any contact with
authors
NA
Reporting of methods should include
17 Description of relevance or
appropriateness of studies
assembled for assessing the
hypothesis to be tested
R § 1
18 Rationale for the selection and
coding of data (eg, sound clinical
principles or convenience)
M § 4
19 Documentation of how data were
classiﬁed and coded (eg, multiple
raters, blinding and interrater
reliability)
NA
20 Assessment of confounding (eg,
comparability of cases and
controls in studies where
appropriate)
NA
21 Assessment of study quality,
including blinding of quality
assessors, stratiﬁcation or
regression on possible predictors
of study results
NA
22 Assessment of heterogeneity R § 5
Continued
Item
No Recommendation Reported on §
23 Description of statistical methods (eg,
complete description of ﬁxed or
random effects models,
justiﬁcation of whether the chosen
models account for predictors of
study results, dose-response
models, or cumulative meta-
analysis) in sufﬁcient detail to be
replicated
M § 5
24 Provision of appropriate tables and
graphics
Tables 2–3,
Figures 1–4
Reporting of results should include
25 Graphic summarizing individual study
estimates and overall estimate
Figures 1–4
26 Table giving descriptive information
for each study included
Table 1
27 Results of sensitivity testing (eg,
subgroup analysis)
Tables 3
28 Indication of statistical uncertainty of
ﬁndings
Tables 2–3,
Figures 1–4
Reporting of discussion should include
29 Quantitative assessment of bias
(eg, publication bias)
R § 5
30 Justiﬁcation for exclusion
(eg, exclusion of non-English
language citations)
-
31 Assessment of quality of included
studies
Supp Table 1
Reporting of conclusions should include
32 Consideration of alternative
explanations for observed results
NA
33 Generalization of the conclusions
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ESG vs high-intensity diet and lifestyle therapy Cheskin et alObesity is a public health epidemic currently affecting
38% of adults and 17% of children and adolescents in the
United States.1,2 This is particularly problematic because
of the comorbidities associated with obesity, including
type 2 diabetes mellitus, hypertension, cardiovascular
disease, metabolic syndrome, and many forms of cancer.
Further, obesity is associated with higher all-cause mortal-
ity, morbidity, and depression and with lower health-
related quality of life.3-9
Treatment for obesity and its associated comorbidities
has most recently expanded into the ﬁeld of bariatric
endoscopy, which bridges a gap between diet and lifestyle
counseling and pharmaceutical treatment and the most
effective treatment for obesity, bariatric surgery10.
Endoscopic bariatric therapies are a group of minimally
invasive procedures designed to treat obesity without
irreversibly altering the gastric and/or intestinal anatomy.
Endoscopic sleeve gastroplasty (ESG) is emerging as a
safe and particularly effective endoscopic bariatric proced-
ure.11-16 By using a full-thickness endoscopic suturing sys-
tem, we found that ESG reduces stomach volume by
w70%, resulting in a tubular gastric cavity along the lesser
curvature, with the greater curvature closed off by plica-
tions from the gastroesophageal junction to the incisura
angularis (Fig. 1).17-20 Weight loss outcomes after ESG
are substantial, with a recent multicenter study (n Z
248) reporting percent total body weight loss (%TBWL)
of 15.2% and 18.6% at 6 and 24 months, respectively.13 A
multicenter study encompassing clinics in both the
United States and Australia reported similar success in
adopting ESG for weight control.16
Although now gaining traction worldwide, much is
left to learn when comparing this procedure with other
weight control strategies. Most notably, ESG has not
been directly compared with the current ﬁrst-line treat-
ment for obesity, described by the U.S. Department of
Health and Human Services as the combination of low-
calorie diet, increased physical activity, and behavioral
therapy.21 Multidisciplinary weight loss centers are best
suited for this comparative assessment. High-intensity
diet and lifestyle therapy (HIDLT) consists of regular indi-
vidualized counseling on diet, physical activity, and lifestyle
modiﬁcations to achieve weight loss in overweight and
obese adults. Generally, patients are seen weekly or
biweekly for some months before transitioning to monthly
visits. In addition, optional resources such as meal replace-
ment products, support groups, and psychotherapy may
be offered. Although comprehensive, major limitations of
HIDLT are high rates of noncompliance and withdrawal
from treatment.22
To assess ESG’s potential value as a treatment for
obesity, this study aimed to compare weight loss outcomes
of ESG with those of HIDLT. We hypothesized that patients
who underwent ESG would achieve greater %TBWL
through 12 months of follow-up compared with patients
enrolled in HIDLT.2 GASTROINTESTINAL ENDOSCOPY Volume -, No. - : 2019METHODS
Population
Study participants received elective obesity treatment at
a single academic institution, Johns Hopkins Medical Insti-
tutions (Baltimore, Md). We compared patients who
received HIDLT between 2013 and 2014 with a consecutive
series of patients who underwent ESG between 2016 and
2018. Patients undergoing ESG were also provided 12
months of low-intensity diet and lifestyle therapy (LIDLT);
however, attendance was not compulsory for inclusion in
this study. Both HIDLT and LIDLT were performed at the
Johns Hopkins Weight Management Center with the
same providers. Patients with eating disorders such as
night-eating syndrome, bulimia, and binge eating were
excluded from the study.
Patients enrolled in the HIDLT program at Johns Hop-
kins Weight Management Center were prescribed a low-
calorie, high-protein diet (prescribed intake of 800-1200
calories per day); participated in behavioral, nutritional,
and exercise counseling; and were offered optional re-
sources including psychotherapy, support groups, and
meal replacements. Weight loss medications were not pre-
scribed; however, medications known to induce weight
gain were replaced with either weight-neutral or weight-
negative alternatives. Patients were generally seen biweekly
for some months before progressing to monthly visits.
ESG was performed as an outpatient procedure by a sin-
gle endoscopist. The ESG technique as well as pre- and
postprocedure care has been described elsewhere16 and
remained constant throughout the duration of the study.
LIDLT consisted of the option to undertake 12 visits to
the Johns Hopkins Weight Management Center over the
course of 12 months after ESG. The cost of these visits
was included in the single, preprocedure payment for
ESG and 1 year of follow-up. In both groups, patients
paid out-of-pocket for their therapy because insurance
did not cover the costs of treatment in either group. The
cost of ESG and LIDLT over the course of 1 year was
$16,000. The estimated cost of HIDLT for 1 year was
$3200; however, this varied patient-to-patient as patients
paid per visit. This study was registered with the internal
review board (IRB00122220).
Statistical analysis
This study used a retrospective case-matched control
subjects design to compare outcomes. Patients who had
undergone ESG (cases) were matched in the analysis stage
with patients who had gone through HIDLT (control sub-
jects) to balance the key patient characteristics of prepro-
cedure body mass index (BMI), age, and gender between
the cases and control subjects (akin to what we would
see in a randomized controlled trial). We used kernel
matching because it matches members of the control
group with cases based on similarity of propensity
scores.23,24 Kernel matching addressed the problem ofwww.giejournal.org
Figure 1. A, Overall effect of endoscopic sleeve gastroplasty on a patient’s stomach. B, First suture placement, starting on the anterior wall and moving to
the posterior wall of the stomach. C, Narrowed lumen after 3 plications. Note the reduced volume of the lumen. D, Distal aspect of the sleeve created by
the sutures. Note the narrowed lumen. E, Proximal portion of the sleeve. Note the sleeve-like, noncompliant lumen.
Cheskin et al ESG vs high-intensity diet and lifestyle therapyselection bias by assuming unrelated outcome variables at
start; for matched patients the untreated outcomes should
be the same regardless of being a case or a control
subject.24,25 To optimize precision and minimize bias
because of lower quality matches, we used a variable
ratio matching technique (1 ESG case subject to 2-3
HIDLT control subjects “simultaneously”).26,27
Comparative analyses were run using data at baseline
and 1-, 3-, 6-, and 12-month follow-ups. The primary
outcome was %TBWL at each time point. This is calculated
as total body weight lost at each time point/baseline
weight. %TBWL metrics were also assessed by baseline
BMI categories: less than or equal to 40 kg/m2 versus
greater than 40 kg/m2.
All statistical analyses were conducted using STATA 13.0
(College Station, Tex, USA). Descriptive statistics are re-
ported as mean  standard deviation (SD) or proportionwww.giejournal.orgwhere appropriate. Univariate analysis and multivariate
regression analysis were performed to identify factors im-
pacting %TBWL. The c2 and Fisher exact tests were per-
formed for all categorical analysis, and Student t test or
Mann-Whitney U test was used for continuous variables.
Because BMI >40 kg/m2 is often used as a cutoff for insur-
ance coverage, we performed a subgroup analysis at 1, 3, 6,
and 12 months comparing patients based on their preoper-
ative BMI status: BMI <40 kg/m2 and BMI >40 kg/m2. P <
.05 were considered signiﬁcant. Sensitivity analyses were
also run to account for differential follow-up.
RESULTS
Patients
One hundred ﬁve patients (30 men) underwent ESG be-
tween March 2016 and November 2018. Two hundredVolume -, No. - : 2019 GASTROINTESTINAL ENDOSCOPY 3
TABLE 1. Descriptive statistics of baseline characteristics in each cohort
ESG (n [ 105) HIDLT (n [ 281) P value
Age, y 47.58  11.97 48.17  12.18 .665
Male 30 (28.57) 92 (32.74) Reference
Female 75 (71.42) 189 (67.26) .434
Body mass index, kg/m2 40.50  7.89 39.85  7.62 .467
Values are mean  standard deviation or n (%).
ESG, Endoscopic sleeve gastroplasty; HIDLT, high-intensity diet and lifestyle therapy.
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Figure 2. %TBWL at 4 time points from 1 to 12 months postprocedure in
the ESG cohort and after initiation of therapy in the HIDLT cohort. ESG,
Endoscopic sleeve gastroplasty; HIDLT, high-intensity diet and lifestyle
therapy; %TBWL, percent total body weight loss.
ESG vs high-intensity diet and lifestyle therapy Cheskin et aleighty-one patients (92 men) who underwent HIDLT be-
tween 2013 and 2014 were matched as control subjects.
The mean age across both cohorts was 48.0 years (SD,
12.1), and the mean preoperative BMI was 40.0 kg/m2
(SD, 7.7). Age is further broken down into categories
in Supplementary Table 1 (available online at www.
giejournal.org). There was no signiﬁcant difference in
mean BMI, mean age, or the ratio of male-to-female pa-
tients between the 2 groups (Table 1).
Some subjects in this study have been included in pre-
viously published research. Speciﬁcally, a learning curve
study has been published that includes the ﬁrst 21 of the
ESG patients included in this study.17 A multicenter study
by Sartoretto et al16 includes the ﬁrst 42 of the
consecutive ESG cohort of patients. Further, the ﬁrst 54
patients in the consecutive ESG cohort were included in
a study comparing ESG with laparoscopic sleeve
gastroplasty (LSG).28 Finally, the ﬁrst 58 patients from
the ESG cohort were included in a study comparing ESG
with intragastric balloon placement.29 Within these 58
patients were the entirety of patients included in the
previously published literature. Thus, 47 patients are
included in this cohort whose data have not been
published or presented elsewhere.
Weight loss
Both cohorts achieved signiﬁcant weight loss
throughout follow-up. The mean %TBWL at 1, 3, 6, and
12 months post-ESG was 9.3% (SD, 2.8; n Z 96), 14.0%
(SD, 4.5; n Z 73), 17.7% (SD, 6.4; n Z 63), and 20.6%
(SD, 8.3; n Z 43), respectively. The %TBWL at 1, 3, 6,
and 12 months after initiation of HIDLT was 7.0% (SD,
3.2; n Z 281), 11.3% (SD, 4.6; n Z 237), 14.7% (SD, 8.2;
n Z 155), and 14.3% (SD, 10.2; n Z 101), respectively.
Supplementary Table 2 (available online at www.
giejournal.org) further details the percentage of patients
lost to follow-up at each time point.
In multivariable analysis, controlling for age, sex, and
baseline BMI, mean %TBWL was signiﬁcantly greater in pa-
tients who underwent ESG versus HIDLT at 1, 3, 6, and 12
months (P < .001, P < .001, P Z .011, and P < .001,
respectively) (Fig. 2). Similarly, the percentage of
patients in each cohort that reached 5%, 10%, and 20%
TBWL at 12 months was signiﬁcantly greater in the ESG
group (Table 2). Of note, no patients underwent weight4 GASTROINTESTINAL ENDOSCOPY Volume -, No. - : 2019loss pharmacotherapy, subsequent resuturing, or bariatric
surgery during the study period.
Sensitivity analyses (Supplementary Table 2, available
online at www.giejournal.org) show that signiﬁcantly
more patients in the ESG group achieved 5%, 10%, and
20% TBWL as compared with HIDLT patients in 2 of 3
scenarios (scenarios 2 and 3), whereas in scenario 1
signiﬁcantly more patients in the ESG group achieved 5%
TBWL only. In each scenario, those not followed through
12 months were assumed to have not lost any more
weight since their last visit, so last known weight was
brought forward to the 12-month visit. In scenario 1, all
ESG patients (n Z 105) were included, whereas in sce-
nario 2 all HIDLT patients were included (n Z 281), and
in scenario 3 all ESG (n Z 105) and HIDLT (n Z 281) pa-
tients were included.
Subgroup analysis
In the subgroup analysis, %TBWL in patients with base-
line BMI 40 kg/m2 and BMI >40 kg/m2 were examined
separately. After adjusting for age at intervention and
gender, at 1 month and 3 months after intervention, pa-
tients in both BMI subgroups had superior %TBWL with
ESG compared with HIDLT (Table 3). In detail, ESG
patients with baseline BMI 40 kg/m2 and BMI >40 kg/www.giejournal.org
TABLE 2. Patients in each cohort who achieved 5, 10, and 20% TBWL at 12 months of follow-up
ESG (n) ESG patients* (%) HIDLT (n) HIDLT patients* (%) P value
>5% TBWL at 12 mo 41 95.35 79 79.0 .045
>10% TBWL at 12 mo 39 90.70 60 60.0 .002
>20% TBWL at 12 mo 24 55.81 27 27.0 <.001
ESG, Endoscopic sleeve gastroplasty; HIDLT, high-intensity diet and lifestyle therapy; TBWL, total body weight loss.
*Forty-three of 105 ESG and 100 of 281 HIDLT patients presented at 12 months for follow-up.
Cheskin et al ESG vs high-intensity diet and lifestyle therapym2 showed an identically superior %TBWL at 2.4% (P <
.001) than matched HIDLT patients at 1 month after
intervention. At 3 months after intervention, ESG patients
with baseline BMI 40 kg/m2 had a 3.3% greater %TBWL
than those in the corresponding HIDLT group, whereas
ESG patients with baseline BMI >40 kg/m2 had a 2.1%
greater %TBWL than those in the corresponding HIDLT
group. ESG patients with BMI 40 kg/m2 continued to
show signiﬁcantly greater %TBWL than those in the BMI-
matched HIDLT cohort at 6 and 12 months after interven-
tion. Speciﬁcally, those undergoing ESG saw 4.1% greater
TBWL at 6 months and 8.2% TBWL at 12 months. This dif-
ference was not seen in patients with baseline BMI >40 kg/
m2. Instead, there was no signiﬁcant difference in %TBWL
with ESG at 6 months and 12 months after intervention
compared with those in the corresponding HIDLT group
(Table 3).
Adverse events
Five moderate-to-severe adverse events (4.8%) occurred
in the ESG cohort, compared with zero in the HIDLT
group. Three events consisted of upper GI bleeding
because of gastric ulceration. In 1 case, the patient under-
went diagnostic endoscopy, admission, and monitoring for
48 hours. The other cases were resolved successfully with
medical management and did not require admission. One
patient developed perigastric ﬂuid collection, which was
successfully managed medically, as described by Barola
et al.30 Further, 1 patient experienced dehydration that
required readmission for intravenous hydration. No
adverse events required surgical intervention, and no
mortality occurred as a result of ESG.
DISCUSSION
Results of this analysis indicate that through 12 months
after intervention, patients who underwent ESG achieved
greater weight loss than patients who underwent HIDLT.
Although currently limited, the literature on ESG is
growing rapidly. Recently, multicenter studies have illus-
trated its safety, feasibility, and reproducible weight loss
outcomes.13,16 Further, reports of the learning curve for
ESG demonstrate its ability to be learned and
incorporated into practice by trained endoscopists.17,31
As ESG continues to gain traction worldwide, a
comprehensive understanding of its outcomes andwww.giejournal.orgrelative place among the battery of weight loss
treatments is important.
Because ESG is a relatively novel procedure, only 2
studies have compared the results of ESG directly with
that of another weight loss therapy. In the ﬁrst, ESG was
compared with LSG and laparoscopic adjustable gastric
banding. Of the 3 procedures compared, as an outpatient
procedure, ESG was found to have the lowest rate of
morbidity (P Z .01) and the shortest hospital stay.
Regarding relative efﬁcacy at 6- and 12-month follow-up,
weight loss after ESG was greater than that after laparo-
scopic adjustable gastric banding but less than after
LSG.32 More recently, our group compared ESG with LSG
in a case-matched cohort and found greater weight loss
in the LSG group, but with a greater rate of adverse events
and new-onset gastroesophageal reﬂux postprocedure.28
However, no studies have yet compared ESG directly
with diet and lifestyle therapy, the ﬁrst-line treatment of
obesity. Currently, a large multicenter randomized clinical
(the Multicenter ESG Trial [MERIT Trial, NCT03406975])
is underway comparing ESG with diet and lifestyle therapy.
Our study is the ﬁrst to compare ESG with diet and lifestyle
therapy using a retrospective, case-control analysis.
In interpreting these results, it is essential to consider
the notoriously high rates of noncompliance and with-
drawal from treatment in HIDLT programs.23,33 A meta-
analysis of weight loss interventions found compliance
rates of 63.1% in registered clinical trials and 59.6% in
observational studies.33 A previous meta-analysis on only
weight loss interventions containing a control group re-
ported a mean attrition rate of 31%.34 In our sample,
53% remained engaged after 6 months of therapy and
36% remained at 1 year. Therefore, ESG may be a
valuable alternative for patients who have had trouble
complying with HIDLT.
In contemplating the results of any weight loss treat-
ment, it is important to consider the multifactorial nature
of obesity. Environmental, genetic, psychological, social,
and cultural factors may contribute to an individual’s
weight to varying degrees.21 Further, personality traits
have been linked to weight loss outcomes. Disinhibition,
restraint, low novelty-seeking, internal locus of control,
and secure attachment style have all been associated with
increased compliance in weight loss programs and thus
more positive outcomes. Patients with opposite traits
(eg, external locus of control) have shown diminishedVolume -, No. - : 2019 GASTROINTESTINAL ENDOSCOPY 5
TABLE 3. Subgroup analysis examining %TBWL in patients with baseline BMI ≤40 kg/m2 and >40 kg/m2 separately
Change in TBWL (%)
95% Confidence
interval Change in TBWL (%)
95% Confidence
interval
1-month follow-up BMI <40 (n Z 215) BMI >40 (n Z 162)
Procedure HIDLT Reference Reference
ESG 2.431 1.456 3.406 2.500 1.365 3.634
Age <40 y .120 –.975 1.214 1.737 .374 3.100
41-55 .269 –.728 1.266 1.268 .107 2.429
>55 y Reference Reference
Sex Male Reference Reference
Female 1.505 .543 2.466 .350 –.675 1.375
3-month follow-up BMI <40 (n Z 166) BMI >40 (n Z 132)
Procedure HIDLT Reference Reference
ESG 3.271 1.641 4.901 2.201 .372 4.030
Age <40 y Reference Reference
41-55 1.712 –.099 3.524 3.195 .919 5.471
>55 y 1.303 –.279 2.885 2.113 .271 3.955
Sex Male Reference Reference
Female 1.823 .259 3.387 .768 –.885 2.421
6-month follow-up BMI <40 (n Z 110) BMI >40 (n Z 102)
Procedure HIDLT Reference Reference
ESG 4.036 .877 7.196 1.804 –1.528 5.136
Age <40 y 1.852 –1.912 5.616 5.983 1.535 10.432
41-55 2.250 –1.041 5.541 4.805 1.262 8.348
>55 y Reference Reference
Sex Male Reference Reference
Female –.234 –3.784 3.317 .136 –3.024 3.296
12-month follow-up BMI <40 (n Z 71) BMI >40 (n Z 72)
Procedure HIDLT Reference Reference
ESG 8.155 4.009 12.301 4.739 –.558 10.035
Age <40 y Reference Reference
41-55 2.896 –1.551 7.342 10.451 2.922 17.981
>55 y 3.530 –.681 7.740 5.504 –.722 11.729
Sex Male Reference Reference
Female –1.519 –5.625 2.586 12.951 6.869 19.034
ESG, Endoscopic sleeve gastroplasty; HIDLT, high-intensity diet and lifestyle therapy; TBWL, total body weight loss.
ESG vs high-intensity diet and lifestyle therapy Cheskin et allevels of compliance and thus less-substantial weight
loss.35-39 Thus, certain weight loss strategies may be
more effective in individuals with particular characteristics.
Along the same lines, many obese patients do not respond
to traditional strategies for weight loss. Given the diversity
of the obese population, ESG may begin to ﬁll some gaps
in the obesity treatment arsenal.
Based on subgroup analyses, ESG resulted in superior
weight loss at 1 year as compared with HIDLT in patients
with a BMI <40 kg/m2. However, no signiﬁcant difference
in weight loss was seen between patients undergoing
ESG or enrolling in HIDLT at 1 year for patients whose
initial BMI was >40 kg/m2. This suggests that ESG is6 GASTROINTESTINAL ENDOSCOPY Volume -, No. - : 2019more effective in patients with a BMI between 30 and 40
kg/m2. The logic for this observation is unknown. We hy-
pothesize that the effect of sleeve gastroplasty is less
profound in patients with a higher BMI because the restric-
tive effect is tempered by the counteracting neurohor-
monal effects that are altered with bariatric surgery. This
is worth exploring in future randomized control trials
because it will give us insight into which patients are supe-
rior candidates for endoscopic bariatric therapy. Currently,
for patients with a BMI >40 kg/m2, bariatric surgery re-
mains the criterion standard for treatment.40,41
The primary limitations of this study relate to the recent
adoption of ESG as a treatment modality. For instance, thewww.giejournal.org
Cheskin et al ESG vs high-intensity diet and lifestyle therapyshort duration of follow-up reported in this study is a lim-
itation, because this procedure was ﬁrst performed at the
reporting academic center 3 years before the date of the
analysis. The moderate sample of patients who have under-
gone ESG is thus also related to its recent adoption as a
treatment modality. This is also reﬂected throughout
follow-up as the number of patients at each successive
time point decreases. The ESG cohort consists of the ﬁrst
105 patients to undergo ESG at Johns Hopkins by a single
endoscopist. To our knowledge, however, no data support
the difference in weight loss outcomes based on proce-
dural experience of the practitioner. The single-center na-
ture of this study provides value and limitation. It is
valuable in that it provides consistency between HIDLT
and the LIDLT included with ESG. However, it limits the
generalizability of the results. Further, this study is limited
by the lack of data and thus analyses of the possible effects
of race, ethnicity, and comorbidities on weight loss out-
comes in each cohort. These represent interesting vari-
ables to consider in future research. Future research
should also aim to evaluate the costs of each treatment
cohort in an analytical manner. It is worth noting again
that because treatment in both cohorts was limited to pri-
vate payment methods, we infer that both cohorts are of
predominantly middle to high socioeconomic status.
Future research into the effects of socioeconomic status
on outcomes would be beneﬁcial.
ESG with LIDLT results in statistically and clinically supe-
rior weight loss to HIDLT. The patient population that
appears to derive the most beneﬁt from ESG are those
with a BMI <40 kg/m2. The adverse event rate associated
with ESG may be acceptable to many patients in light
of the superior weight loss as compared with HIDLT.
Future work is needed to assess ESG outcomes in a larger,
prospective, multicenter study, with longer follow-up
(NCT03406975).REFERENCES
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SUPPLEMENTARY TABLE 1. Breakdown of patient ages into categories
ESG HIDLT
P value(n [ 105) (n [ 281)
Age <40 y 29 (27.62) 73 (25.98)
Age 41-55 y 48 (45.71) 118 (41.99)
Age >55 y 28 (26.67) 90 (32.04)
Male 30 (28.57) 92 (32.74) Reference.
Female 75 (71.42) 189 (67.26) .434
Body mass index, kg/m2 40.50  7.89 39.85  7.62 .467
Values are mean  standard deviation or n (%).
ESG, Endoscopic sleeve gastroplasty; HIDLT, high-intensity diet and lifestyle therapy.
SUPPLEMENTARY TABLE 2. Follow-up at each time point
Endoscopic sleeve gastroplasty High-intensity diet and lifestyle therapy
Time point Follow-up sample Percentage included Time point Follow-up sample Percentage included
Baseline 106 100 Baseline 281 100.00
1 mo 96 90.57 1 mo 281 100.00
3 mo 73 68.87 3 mo 225 80.07
6 mo 63 59.43 6 mo 149 53.02
12 mo 43 40.57 12 mo 100 35.59
ESG (n) ESG patients* (%) HIDLT (n) HIDLT patients* (%) P value
Scenario 1y
>5% TBWL at 12 mo 94 89.52 79 79.0 .038
>10% TBWL at 12 mo 71 67.62 60 60.0 .202
>20% TBWL at 12 mo 28 26.67 27 27.0 .957
Scenario 2z
>5% TBWL at 12 mo 41 95.35 219 77.9 .008
>10% TBWL at 12 mo 39 90.70 143 50.9 <.001
>20% TBWL at 12 mo 24 55.81 31 11.0 <.001
Scenario 3x
>5% TBWL at 12 mo 94 89.52 219 77.9 .018
>10% TBWL at 12 mo 71 67.62 143 50.9 .002
>20% TBWL at 12 mo 28 26.67 31 11.0 .001
ESG, Endoscopic sleeve gastroplasty; HIDLT, high-intensity diet and lifestyle therapy; TBWL, total body weight loss.
*43 of the 105 ESG and 100 of the 281 HIDLT patients presented at 12-months for follow-up.
yAll ESG patients (nZ 105) were included. Those not followed up through 12 months were assumed to have not lost any more weight since last visit, so last known weight was
brought forward to the 12-month visit. Significantly more patients in the ESG group achieve 5% TBWL at 12 months.
zAll HIDLT patients (nZ 281) were included. Those not followed up through 12 months were assumed to have not lost any more weight since last visit, so last known weight
was brought forward to the 12-month visit. Significantly more patients in the ESG group achieved 5%, 10%, and 20% TBWL as compared with HIDLT patients.
xAll patients (ESG nZ 105 and HIDLT nZ 281) were included. Those not followed up through 12 months were assumed to have not lost any more weight since last visit, so last
known weight was brought forward to the 12-month visit. Significantly more patients in the ESG group achieved 5%, 10%, and 20% TBWL as compared with HIDLT patients.
www.giejournal.org Volume -, No. - : 2019 GASTROINTESTINAL ENDOSCOPY 8.e1
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Introduction
Obesity remains a global public health concern without a satis-
factory solution [1]. Endoscopic bariatric therapies (EBTs) have
gained standing among the armamentarium of weight loss
therapies because of their minimally invasive nature, reversibil-
ity, and applicability in patient populations otherwise ineligible
for bariatric surgery [2]. Endoscopic sleeve gastroplasty (ESG) is
an EBT that has achieved significant success in the past few
years; therefore, it is timely to compare it to the well-estab-
lished intragastric balloon (IGB) therapy, the most commonly
performed EBT in the United States and internationally [3–5].
The IGB is a space-occupying device that has been safely
used to induce weight loss [3–5]. A systematic review and
meta-analysis reported that patients undergoing IGB therapy
achieved 13.16% total body weight loss (TBWL) at 6 months
[6]. A more recent review demonstrated a 9.7% TBWL at 6
months, with decreasing efficacy after 6 months [4]. The pri-
mary limitation of IGB therapy is the common occurrence of
weight regain [7, 8], even in a clinical trial setting [9, 10], which
is thought to be due to the necessary removal of the balloon at
6 months. The most common adverse events associated with
the IGB are nausea/vomiting, abdominal pain, and gastro-
esophageal reflux disease (GERD) [3].
There are currently two FDA-approved, fluid-filled IGBs
available in the USA: the ReShape Integrated Dual Balloon Sys-
tem (ReShape Lifesciences, San Clemente, California, USA) and
the Orbera Intragastric Balloon System (Apollo Endosurgery,
Austin, Texas, USA; previously BioEnterics Intragastric Balloon).
Endoscopic sleeve gastroplasty versus intragastric
balloon insertion: efficacy, durability, and safety
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ABSTRACT
Background Intragastric balloon (IGB) placement and
endoscopic sleeve gastroplasty (ESG) are reported to be
safe and effective endoscopic bariatric therapies. This study
aimed to compare the patient demographics and therapeu-
tic outcomes between the IGB and ESG procedures.
Methods: This was a retrospective review of prospectively
collected data from consecutive patients between Decem-
ber 2015 and October 2017 who underwent IGB or ESG at a
single academic center. Fluid-filled IGBs implanted for a 6-
month duration were used. IGB and ESG patients were sub-
jected to identical post-procedure dietary instructions and
follow-up protocols. Body weight was recorded at 1, 3, 6,
and 12 months post-procedure.
Results A total of 47 patients underwent IGB insertion and
58 underwent ESG. The IGB cohort had a lower baseline
body mass index (BMI) than the ESG (34.5 vs. 41.5 kg/m2;
P <0.001) and a significantly lower proportion of men (2.1
% vs. 41.4%; P <0.001). IGB patients showed a mean (stand-
ard deviation [SD]) percentage total body weight loss (%
TBWL) that was significantly lower than ESG patients at 1
month (6.6% [2.6%] vs. 9.9% [2.4%]; P<0.001), 3 months
(11.1% [4.4%] vs. 14.3% [4.6%]; P=0.004), 6 months
(15.0% [7.6%] vs. 19.5% [5.7%]; P=0.01), and 12 months
(13.9% [9.0%] vs. 21.3% [6.6%]; P=0.005). The IGB cohort
also experienced significantly more adverse events compar-
ed with the ESG (17% vs. 5.2%; P=0.048).
Conclusions IGB placement and ESG result in clinically
meaningful weight loss. However, ESG appears to provide
clinically superior and more enduring weight loss with few-
er adverse events compared with an IGB.
Original article
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Although no head-to-head trial has been performed to com-
pare the ReShape to the Orbera, published prospective evi-
dence has found roughly comparable weight loss and adverse
event outcome data for the two systems [5, 10]. Additionally,
real-world multicenter studies have corroborated the weight
loss and adverse outcomes for IGBs with a %TBWL at 3 and 6
months, respectively, of 8.8% and 11.4% for the Reshape [11]
and 8.5% and 11.8% for Orbera [12].
Unlike IGB therapy, ESG is a volume-reduction procedure
performed using an endoscopic suturing system to reduce the
stomach lumen into a tubular configuration [13, 14]. A multi-
center study by Lopez-Nava et al. [15] showed a %TBWL of
15.2% at 6 months. Serious adverse events occurred in 2% of
patients, but were managed successfully without surgical inter-
vention. Another international multicenter study by Sartoretto
et al. [16] found a 14.9% TBWL at 6 months, with a 2.7% rate of
serious adverse events, confirming that ESG is a reproducible
and generalizable technique internationally.
Both the ESG and IGB procedures have been shown to be re-
latively safe and efficacious. Electing for one procedure over
the other has been solely based on patient preference, often
driven by relative costs. We were uniquely positioned to com-
pare the two procedures as both are performed at our institu-
tion, where patients are subjected to identical post-procedure
dietary instructions and follow-up protocols, making any differ-
ences seen likely to be due to the procedures themselves. We
hypothesized that ESG would result in superior and more en-
during weight loss compared with the IGB.
Methods
Patient population
This is a retrospective review of prospectively collected data un-
der IRB00122220 and IRB00120291. Consecutive patients who
underwent IGB placement or ESG between December 2015 and
October 2017at a single academic center (Johns Hopkins Med-
ical Institutions) were included.
All patients had an initial consultation where they were
provided with information on various weight loss options, in-
cluding diet and exercise programs, pharmacotherapy, EBT,
and bariatric surgery. Patients who were ineligible for bariatric
surgery or elected not to undergo bariatric surgery were subse-
quently offered endoscopic procedures. Endoscopic proce-
dures comprised ESG, IGB insertion, intragastric botulinum tox-
in injection, and aspiration therapy with the AspireAssist (As-
pire Bariatrics, King of Prussia, Pennsylvania, USA). The techni-
cality of all endoscopic treatment options, benefits, risks, and
adverse outcomes were reviewed. The decision to undergo
ESG vs. IGB placement was made by the patient, unless a con-
traindication existed. All procedures were self-pay, with the
IGB program priced at approximately US$8000 and the ESG
program approximately US$16 000.
Periprocedural and post-procedural care
All procedures were performed by a single endoscopist experi-
enced in endoscopic suturing (V.K.). The procedures were
same-day procedures with identical pre- and post-procedure
care, including diet, medications, and frequency of allotted nu-
tritional visits for follow-up.
The preoperative medications were omeprazole 40mg for 1
week and a single dose of aprepitant (Emend) 125mg given 3
hours before the procedure. All patients were prescribed a li-
quid diet from 1 day before and nothing by mouth after mid-
night on the night prior to their procedure.
The post-op medications were aprepitant 80mg once on the
first day post-procedure, hyoscyamine (Levsin) 0.125mg every
6 hours as needed for cramping, and ondansetron (Zofran) 4
mg every 6 hours as needed for nausea. Omeprazole 40mg
was continued daily for 6 weeks post-procedure. Patients also
received 2–3 L of fluid during their stay in the endoscopy suite.
Patients were instructed to remain on strict liquid diet for 3
days post-operatively, after which they were transitioned, at 2-
weekly intervals, into pureed diet, soft diet, and ultimately solid
diet if well tolerated.
All patients were enrolled post-procedure into a comprehen-
sive weight management program at the Johns Hopkins Weight
Management Center. The program consisted of 12 visits over 1
year with a multidisciplinary team comprising a medical weight
loss physician, registered dietitian, exercise physiologist, and
behavioral psychologist. Patients were encouraged to actively
participate in this program.
Intragastric balloon (IGB) insertion
Indications for IGB placement were a body mass index (BMI) >
27 kg/m2 in patients who had previously been unsuccessful in
losing weight through diet, and/or exercise, and/or medica-
tions. Contraindications included a history of gastroesophageal
surgery and active anticoagulation.
The choice of ReShape vs. Orbera balloon was based on pa-
tient preference. All procedures were performed in the endos-
copy suite with the patient under monitored anesthesia care.
The balloons were inserted endoscopically as per the manufac-
turers’ recommendations. For the ReShape balloon, 450mL of
normal saline was used in each balloon, except in patients
shorter than 64.5 inches, who received 375mL in each balloon
(▶Fig. 1). The Orbera balloon was filled with 600–650mL of
normal saline if the patient was taller than 64.5 inches and
550mL if shorter (▶Fig. 2). Balloons were extracted 6 months
after insertion, or earlier in the event of intolerance or adverse
events.
Endoscopic sleeve gastroplasty (ESG) procedure
Indications for ESG were a BMI >30 kg/m2 in patients who had
been previously unsuccessful in losing weight through diet,
and/or exercise, and/or medications. Contraindications includ-
ed a history of gastric cancer, a family history of gastric cancer,
active Helicobacter pylori infection, active gastric ulcer, gastric
intestinal metaplasia, vascular abnormalities, decompensated
organ failure, prior foregut surgery, and pregnancy/lactation.
All ESG procedures were performed with the patient under
general anesthesia. The technique used was the same as that
described by Sartoretto et al. [16] using the OverStitch full-
thickness endoscopic suturing system (Apollo Endosurgery,
Austin, Texas, USA). Before suturing, argon plasma coagulation
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was used to mark the intended suture line on the anterior and
posterior walls of the stomach. Sutures were placed in a retro-
grade fashion starting from the incisura angularis and progres-
sing to the fundus, reaching up to 1 cm from the gastroesopha-
geal junction. Six to nine sutures were used per patient and six
to nine full-thickness bites were taken with each suture. The
bites were taken lateral to the demarcated suture line, with
the following pattern; anterior wall to greater curvature to pos-
terior wall, and then repeated in the opposite direction 1 cm
proximally. The needle was then released and the suture was se-
cured with a cinching device (▶Fig. 3).
Outcomes
Patient demographics, initial weight, and comorbidities such as
diabetes, hypertension, GERD, and obstructive sleep apnea
were collected. The patients were contacted by the clinical
nurse via phone on days 1, 2, and 3 post-procedure, and at 1,
3, 6, and 12 months post-procedure.
Primary outcomes were %TBWL at each time point and ad-
verse events recorded at follow-up. Adverse events were re-
corded only if they required admission to hospital. Nausea, vo-
miting, and abdominal discomfort were an expected part of the
post-operative course and were not recorded, with patients
given necessary medications and instructions for their manage-
ment in advance.
Statistical analysis
Descriptive statistics for all demographic and clinical variables
are reported as mean (standard deviation [SD]), or proportion
where appropriate. For categorical variables, the chi-squared
test and Fisher’s exact test were used. Student’s t test or Mann –
Whitney U test were used for continuous variables. Chi-squared
tests were performed for all univariate analyses. All variables
were tested for normality using the Shapiro – Wilk test. Multi-
ple factor regression was done to predict %TBWL between ESG
and IGB groups based on patient age at time of study, BMI at
baseline, and sex. All statistical analyses were conducted using
STATA 14.0 (StataCorp LP, College Station, Texas, USA). A P val-
ue of <0.05 was considered significant.
Results
A total of 47 patients underwent IGB insertion and 58 under-
went ESG. In the IGB group, 14 patients received a ReShape
dual intragastric balloon and 33 an Orbera intragastric balloon.
▶Table1 shows the baseline characteristics of the patients in
both groups. The mean age was comparable between the two
groups; however, baseline BMI was significantly lower in the pa-
tients undergoing IGB placement compared with those under-
going ESG (34.5 kg/m2 vs. 41.5 kg/m2; P<0.001). In addition,
the IGB group had a significantly lower proportion of men than
the ESG group (2.1% vs. 41.4%; P <0.001). Patients who under-
went IGB placement had a significantly lower proportion of ob-
structive sleep apnea at baseline compared with patients in the
ESG group (2.1% vs. 15.5%; P=0.02). The proportion of pa-
▶ Fig. 1 Endoscopic image showing inflation of the ReShape
balloon.
▶ Table 1 Baseline characteristics of the 105 patients who underwent either endoscopic sleeve gastrectomy (ESG) or intragastric balloon (IGB)
insertion.
ESG
(n=58)
IGB
(n=47)
P value
Age, mean (SD), years 48.2 (11.8) 47.7 (12.4) 0.90
Sex, male, n (%) 24 (41.4%) 1 (2.1%) < 0.001
BMI, mean (SD), kg/m2 41.5 (8.2) 34.5 (6.7) < 0.001
Comorbidities
▪ Type 2 diabetes mellitus, n (%) 3 (5.2 %) 4 (8.5%) 0.51
▪ Hypertension, n (%) 17 (29.3%) 13 (27.7%) 0.80
▪ GERD, n (%) 11 (19.0%) 4 (8.5%) 0.12
▪ Obstructive sleep apnea, n (%) 9 (15.5%) 1 (2.1%) 0.02
SD, standard deviation; BMI, body mass index; GERD, gastroesophageal reflux disease.
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tients with GERD, type 2 diabetes mellitus, and hypertension at
baseline were similar between the two groups (▶Table1).
▶Table2 and ▶Fig. 4 show the %TBWL at each time point
compared with the baseline. IGB patients showed a significantly
lower mean %TBWL than ESG patients at 1 month (6.6% [2.6%]
vs. 9.9% [2.4%]; P<0.001), 3 months (11.1% [4.4%] vs. 14.3%
[4.6%]; P=0.004), 6 months (15.0% [7.6%] vs. 19.5% [5.7%]; P
=0.01), and 12 months (13.9% [9.0%] vs. 21.3% [6.6%]; P=
0.005). This difference persisted after controlling for sex, age,
and baseline BMI. Of note, between 6 and 12 months, patients
▶ Fig. 2 Endoscopic images showing the Orbera balloon: a being inflated; b after deployment.
▶ Fig. 3 Endoscopic images of the endoscopic sleeve gastroplasty (ESG) procedure: a argon plasma coagulation (APC) markings are placed to
help guide the bites; b the initial bite is performed (note the amount of tissue contained within the full-thickness bite); c the suture is then re-
loaded onto the needle driver; d a tissue helix (Apollo Endosurgery, Austin, Texas, USA) is used to retract the tissue; e the final bite is performed
back on the anterior wall; f the appearance of the gastric lumen after ESG has been completed.
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in the IGB cohort had a 7.3 pound (12.7 pound) increase in
weight, whereas patients in the ESG cohort lost on average 4.3
pounds (11.8 pounds) in weight (P=0.007). Multifactor regres-
sion established that undergoing ESG could significantly pre-
dict higher %TBWL at follow-up of 1, 3, 6, and 12 months (▶Ta-
ble3). There were no differences in %TBWL between men and
women when looking at the follow-up of either the ESG or IGB
groups.
There was a significantly greater rate of adverse events in
the IGB group compared with the ESG group (17% vs. 5.2%; P
=0.048). Adverse events following IGB insertion included early
removal because of: nausea and vomiting (n =4; 8.5%), ab-
dominal pain (n =1; 2.1%), abdominal pain with gastritis (n = 1;
2.1%), balloon hyperinflation (n =1; 2.1%), and a non-obstruct-
ing balloon resting in the antrum (n=1; 2.1%). Adverse events
for ESG included upper gastrointestinal bleeding (UGIB) in two
patients and a perigastric fluid collection in one patient. One
patient with UGIB was managed with a diagnostic endoscopy
and admission for 48-hour monitoring; the other was medically
managed. The perigastric fluid collection was successfully man-
aged medically with antibiotics, and follow-up imaging at 3
weeks showed complete resolution, as illustrated in an earlier
published case report [17]. No adverse events requiring surgi-
cal intervention occurred in either group and there was no mor-
tality associated with either procedure.
Discussion
IGB placement and ESG have gained significant popularity and
traction over the last 2 years, with various publications demon-
strating efficacy and safety for both [5, 8, 10, 15, 18]. However,
until now, there have been no studies comparing the outcomes
of these two EBTs. While cross-center comparisons are limited
by variability in post-procedure dietary instructions and pre-
and post-procedure care, this study is uniquely positioned to
ascertain the impact of the endoscopic therapy alone on
weight loss outcomes over a 12-month period.
ESG resulted in superior weight loss compared with IGB
placement over 12 months post-procedure. In our study, the
6-month %TBWL of 19.5% in the ESG group was consistent
with the values of 15.2% and 14.9% previously reported by Lo-
pez-Nava et al. [15] and Sartoretto et al. [16], respectively. Our
12-month follow-up %TBWL is 21.3%, similar to the outcomes
of 17.5% and 17.4% previously reported by Graus et al. [19]
and Kumar et al. [20], respectively. Our IGB group’s 6-month
%TBWL of 15% was comparable with the 11.4% reported by
Agnihotri et al. [12], and the 11.8% reported by Vargas at al.
[18], although higher than the values reported by Ponce et al.
(8.4%) [5] and Courcoulas et al. (10.2%) [10]. Our 12-month %
TBWL for the IGB group is 13.9%, and within the TBWL range
reported in the literature, as can be seen from the 14.7% re-
ported by Agnihotri at al. [18]
Our study demonstrates that %TBWL slows down at 6
months for ESG patients, and decreases after 6 months for IGB
patients. In the IGB group, this can be explained by the balloon
being removed at 6 months.
Weight recidivism after balloon removal is an expected out-
come [4, 7,8], as demonstrated in a review by Tate and Gelieb-
ter [4], who reported a decline in efficacy of IGB therapy after
the balloon’s removal at 6 months and subsequent weight re-
gain. Long-term data indicate that many patients have difficul-
ty maintaining weight loss following treatment with an IGB
[7, 8]. A large cohort study with 500 patients showed weight
was regained from a mean (SD) body weight of 103.69 kg
(26.70 kg) at time of removal to 112.53 kg (26.27 kg) 12
months later [7]. An international multicenter study also
showed a decrease in percentage excess weight loss (%EWL)
from 55.6% (58.8%) at 6 months to 29.1% (60.3%) at 3 years
follow-up [8]. When stratifying which patients should receive
an IGB vs. other therapy, weight recidivism after balloon re-
moval should be considered. Patients who have been unsuc-
cessful in achieving initial weight loss through diet and lifestyle
or medications will most likely benefit from an IGB; however,
▶ Table 2 Total body weight loss of patients followed up at 1, 3, 6, and
12 months post-procedure.
Time post-
procedure
Procedure Patients
followed
up, n (%)
Mean %
TBWL
(SD)
P value
1 month ESG 52 (89.7%) 9.9 (2.4) < 0.001
IGB 43 (91.5%) 6.6 (2.6)
3 months ESG 37 (63.8%) 14.3 (4.6) 0.004
IGB 35 (74.4%) 11.1 (4.4)
6 months ESG 25 (43.1%) 19.5 (5.7) 0.01
IGB 43 (91.4%) 15.0 (7.6)
12 months ESG 21 (36.2%) 21.3 (6.6) 0.005
IGB 20 (42.6%) 13.9 (9.0)
%TBWL, percentage of total body weight loss; SD, standard deviation; ESG,
endoscopic sleeve gastrectomy; IGB, intragastric balloon.
%
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▶ Fig. 4 Percentage total body weight loss (%TBWL) at 1, 3, 6,
and 12 months after either endoscopic sleeve gastrectomy (ESG) or
intragastric balloon (IGB) placement.
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▶ Table 3 Multifactor regression to predict percentage total body weight loss (%TBWL) between the endoscopic sleeve gastrectomy (ESG) and
intragastric balloon (IGB) groups based on patient age at time of study, body mass index (BMI) at baseline, and sex.
Model 1 Model 2 Model 3 Model 4
Coefficient
(95%CL)
P value Coefficient
(95%CI)
P value Coefficient
(95%CI)
P value Coefficient
(95%CI)
P value
30 days
ESG Reference Reference Reference Reference
IGB −3.21
(−4.24, −2.18)
< 0.001 −3.59
(−4.73, −2.46)
< 0.001 −3.63
(−4.76, −2.49)
< 0.01 −3.24
(−4.49, −2.00)
< 0.001
BMI −0.06
(−0.13, 0.01)
0.10 −0.06
(−0.13, 0.01)
0.09 −0.06
(−0.13, 0.01)
0.12
Female −0.02
(−0.06, 0.02)
0.37
Age −0.02
(−0.06, 0.03)
0.40 −1.14
(−2.52, 0.23)
0.10
90 days
ESG Reference Reference Reference Reference
IGB −3.20
(−5.33, −1.07)
0.004 −3.95
(−6.26, −1.63)
0.001 −3.94
(−6.27, −1.61)
0.001 −3.58
(−6.19, −0.98)
0.01
BMI −0.12
(−0.27, 0.03)
0.12 −0.12
(−0.28, 0.03)
0.12 −0.12
(−0.28, 0.03)
0.12
Female −0.90
(−3.80, 2.00)
0.54
Age 0.01
(−0.08, 0.10)
0.79 0.01
(−0.08, 0.10)
0.80
180 days
ESG Reference Reference Reference Reference
IGB −4.52
(−8.02, −1.02)
0.01 −5.03
(−8.89, −1.18)
0.01 −4.88
(−8.69, −1.06)
0.01 −4.28
(−8.63, 0.07)
0.053
BMI −0.08
(−0.33, 0.17)
0.54 −0.07
(−0.31, 0.18)
0.60 −0.06
(−0.31, 0.19)
0.61
Female −1.55
(−6.87, 3.78)
0.56
Age 0.11
(−0.03, 0.25)
0.12 0.11
(−0.03, 0.25)
0.12
360 days
ESG Reference Reference Reference Reference
IGB −7.36
(−12.33, −2.40)
0.01 −7.10
(−13.31, −0.89)
0.03 −7.22
(−13.68, −0.76)
0.03 −9.75
(−16.48, −3.01)
0.01
BMI 0.05
(−0.56, 0.66)
0.87 0.05
(−0.57, 0.66)
0.88 0.08
(−0.51, 0.68)
0.78
Female 7.01
(−0.18, 14.20)
0.06
Age −0.02
(−0.23, 0.19)
0.87 −0.03
(−0.23, 0.18)
0.79
CL, confidence limits.
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patients with difficulty maintaining the weight they have lost
may not. ESG, comparatively, has not been associated with
weight recidivism in our study or prior studies [15, 21–23].
Nevertheless, future studies will need to obtain more data on
the longer term weight outcomes for ESG.
Despite the weight recidivism, IGB therapy can certainly play
an important role as a bridging therapy to bariatric surgery or
to other surgery requiring weight loss (such as orthopedic sur-
gery, cardiac surgery, and transplant, among others). Addition-
ally, as compared to IGB therapy, ESG may make future revision-
al surgery more difficult, making IGB placement more appro-
priate where it is felt this may be necessary.
We found that ESG is associated with fewer adverse events
than IGB therapy. In our study, 17% of IGB patients experienced
adverse events requiring balloon removal. In a review by Tate
and Geliebter [4], the rate of adverse events following IGB
placement reached 28.2%, with a serious adverse event rate of
10.5%. Similarly to our study, the reasons reported for early bal-
loon removal were abdominal pain, nausea/vomiting, balloon
deflation, and balloon intolerance [3]. Therefore, patients with
a low threshold for nausea and pain are likely to better tolerate
an ESG. However, unlike IGB-associated adverse events, which
completely resolve after balloon removal, adverse events fol-
lowing ESG are more serious and concerning, and are more like-
ly to require medical management.
UGIB is a significant adverse event associated with ESG, as
previously reported in other studies [15]. Anticoagulation is an
absolute contraindication to IGB placement. Therefore, at our
center, IGBs are only placed in patients who can be safely taken
off anticoagulants 5 days before and remain off anticoagulants
for 1 week following the procedure. Perhaps, similar contraindi-
cations to anticoagulation need to be set in place for ESG pa-
tients owing to the risk of ulcer formation and resultant bleed-
ing. In addition, it may be safer for patients with an increased
risk of bleeding to undergo IGB placement rather than ESG.
Perigastric inflammatory fluid collection has been previously
associated with ESG [15] and should be suspected in patients
who present with severe abdominal pain or fever post-ESG.
Nausea and vomiting post-procedure increases the risk for de-
hydration in both groups and may require re-admission for in-
travenous hydration. At our center, patients received a mini-
mum of 2 L and a maximum of 3 L of fluids during their stay at
the endoscopy suite, thereby mitigating this risk.
The strength of our study is that although it is retrospective,
the two groups had one standardized care program and one
endoscopist. Ideally, to compare the outcomes of two tech-
niques, all other variables should be held constant. There were
no differences between the groups in pre- or post-procedural
care, and the 12-month ancillary weight management program
was identical following both interventions. Research on dietary
interventions that support long-term weight loss emphasizes
the importance of regular attendance at a weight management
program, which has been significantly associated with weight
loss [24]. This has been confirmed in previous research on pre-
dictors of ESG success, which shows that weight loss increases
significantly in patients with greater nutritional and psychologi-
cal follow-up [22]. Similarly, greater adherence to follow-up ap-
pointments and compliance with diet and exercise have been
shown to improve long-term IGB outcomes [7]. Therefore con-
trolling for the weight management care provided, as has been
done in this study, is essential to adequately compare two pro-
cedures.
An interesting incidental finding relates to patient choice of
procedure. The proportion of men undergoing ESG was 41.4%,
compared with 2.1% in the IGB group (P<0.001). As the choice
of procedure was a patient decision, this may indicate that ESG
is more appealing to men or that IGB therapy is more appealing
to women. Previous research has shown that only 20% of baria-
tric surgery patients are men [25]. This sex disparity is greater
in patients with a low socioeconomic status and patients of cer-
tain races [25]. On the other hand, older age and more comor-
bidities seem to be associated with less sex disparity [25].
Nevertheless, there seems to be an underutilization of bariatric
surgery among men, the reasons for which are not fully under-
stood. If ESG is indeed more appealing to obese men than other
bariatric interventions, increasing awareness and accessibility
of the procedure may increase its utilization.
We argue that our study with its retrospective, single-insti-
tutional, and observational design is a fairly accurate illustra-
tion of routine clinical practice for the comparison of two
EBTs. However, there are several limitations to the be addres-
sed, most notably the presence of selection bias. There were
baseline differences between the groups in terms of BMI and
sex. This reflects the true population preference for each proce-
dure, but limits our ability to compare the procedures.
Baseline BMI has been shown to significantly affect weight
loss outcomes, with higher BMIs predicting poorer weight loss.
We suspect that this potential bias could have influenced the
weight loss outcomes in this study and that the ESG group
might have more significant weight loss outcomes compared
with the IGB group if the two groups had had comparable base-
line BMIs. In addition, the difference in the cost of the proce-
dures may have influenced motivation. Patients willing to pay
more for ESG may have been more motivated at baseline.
Perhaps most importantly, this study has patient attrition.
Particularly, at the 6-month time point, there is a differential
loss to follow-up with greater follow-up in the IGB group. For
the IGB group, it can be argued from experience that loss to fol-
low-up at 6 months may be a consequence of a patient’s desire
to keep the balloon longer if they have had suboptimal weight
loss. Loss to follow-up in the ESG cohort at this time point is
more likely to occur in patients who are satisfied with their
weight loss. The anticipated direction of the results, if we ad-
just for this bias, would be in the same direction as our current
results (ESG showing greater weight loss than IGB therapy). It is
also worth mentioning that, despite these potential biases, our
data are consistent with the literature.
One final limitation is that patients were included from the
beginning of the ESG learning curve for the endoscopist. How-
ever, this is unlikely to have affected outcomes as a previous
study at our center with the same endoscopist showed a very
fast learning curve (7–9 patients) for ESG [26].
Both ESG and IGB placement have been shown to improve
obesity-related comorbidities, but there have been no com-
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parative studies thus far [23, 27]. Our study recorded comor-
bidity data at baseline, but future research may seek to com-
pare the effect of ESG vs. IGB placement on serum biomarkers
of obesity-related comorbidities at baseline and over time. Fi-
nally, we cannot comment on the tolerability of ESG compared
with IGB therapy, as this information was not collected.
Overall, our study shows that ESG and IGB placement are
both safe and effective for weight loss over a 12-month period.
However, the success of IGB placement is hampered by the
weight recidivism that occurs after balloon removal. One differ-
ence, from a practical clinical standpoint, is that ESG is a single
procedure, whereas IGB therapy requires two procedures: one
for balloon insertion and another for removal. Therefore, ESG
may be a more desirable EBT than an IGB in some settings ow-
ing to its safety, durability, and appeal to patients as a single
procedure.
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Baltimore, Maryland, USAGRAPHICAL ABSTRACTBackground and Aims: Endoscopic sleeve gastroplasty (ESG) reduces the gastric lumen to a size comparable
with that of laparoscopic sleeve gastrectomy (LSG). However, there is a paucity of research comparing outcomes
between the 2 procedures. Our study compared the 6-month weight loss outcomes and adverse events of ESG
with LSG in a case-matched cohort.
Methods: We retrospectively reviewed prospectively collected data for patients undergoing ESG or LSG at a single
academic center. Weight was recorded at 1 and 6 months postprocedure, and percent total body weight loss (%
TBWL) was calculated. Adverse events and new-onset Gastroesophageal Reﬂux Disease (GERD) were also recorded.
Results: A total of 54 ESG patients were matched with 83 LSG patients by age, sex, and body mass index. The
proportion of patients with GERD at baseline was similar in the 2 groups (16.7% in ESG group vs 25.3% in
LSG group, P Z .27). At the 6-month follow-up, %TBWL (compared with baseline) was signiﬁcantly lower in
the ESG group compared with the LSG group (17.1%  6.5% vs 23.6%  7.6%, P < .01). ESG patients had signif-
icantly lower rates of adverse events compared with LSG patients (5.2% vs 16.9%, P < .05). New-onset GERD was
also signiﬁcantly lower in the ESG group compared with the LSG group (1.9% vs 14.5%, P < .05).
Conclusions: ESG, aminimally invasive same-dayprocedure, achieved lessweight loss at 6months thanLSG,with the
caveat that LSG caused more adverse events and new-onset GERD than ESG. (Gastrointest Endosc 2019;89:782-8.)(footnotes appear on last page of article)Use your mobile device to scan this
QR code and watch the author in-
terview. Download a free QR code
scanner by searching “QR Scanner”
in your mobile device’s app store.
ROINTESTINAL ENDOSCOPY Volume 89, No. 4 : 2019
Downloaded for Anonymous User (n/a) at JOHNS HOPKINS UNIV
For personal use only. No other uses without permission. Laparoscopic sleeve gastrectomy (LSG) is the most com-
mon bariatric surgical procedure, representing 58.1% of
the 216,000 bariatric surgeries performed in 2016 accord-
ing to the American Society for Metabolic and Bariatric Sur-
gery.1 It has similar efﬁcacy to Roux-en-Y gastric bypass
with fewer adverse events.2,3 However, it is associated
with a complication rate of 13% (1-44) and a 9% (1-35)www.giejournal.org
ERSITY from ClinicalKey.com by Elsevier on June 03, 2019.
Copyright ©2019. Elsevier Inc. All rights reserved.
Fayad et al ESG versus LSGre-operation rate.2 Acute adverse events such as leak and
pulmonary embolism occur in 1.21% and .25% patients.4
Because bariatric surgery is an elective procedure, even
rare serious adverse events are disconcerting and can
make LSG less desirable. This leaves a large unmet need
that could be addressed with endoscopic bariatric
therapies (EBTs) such as endoscopic sleeve gastroplasty
(ESG).
ESG was ﬁrst reported in 2013; it was conceived as a
gastric restrictive procedure that mirrored the anatomic
changes produced by a LSG, with the hope that it would
attain similar clinical efﬁcacy in a minimally invasive
manner.5 Contrary to LSG, ESG maintains the anatomic
structure, innervation, and blood supply of the stomach
with potential for reversibility, repeatability, and
conversion to bariatric surgery if necessary. Revision of
ESG if weight regain occurs has also been successful.6
ESG has been gaining acceptance, with several thousand
procedures performed to date. Several studies have
subsequently studied the clinical efﬁcacy, tolerability, and
safety of ESG.7-10 ESG remains, however, a relatively novel
procedure that requires further clinical validation, particu-
larly in the context of prospective controlled trials. Never-
theless, the largest multicenter retrospective studies by
Lopez Nava et al8 and Sartoretto et al11 have reported
percent total body weight loss (%TBWL) of 15.2% and
14.9% at 6 months, respectively. Furthermore, the rate of
adverse events has been low in both, at 2% to 2.7%,
respectively.8,11
GERD is a common and distressing problem in obese
patients that usually resolves with weight loss.12,13 Howev-
er, there has been increasing concern among bariatric sur-
geons regarding the development of new-onset GERD
post-LSG,14,15 with a frequency as high as 47.06% and both-
ersome symptoms (>4 on a Likert scale) in 21%.14
According to an expert survey, GERD was a cause for
conversion surgery in 2.9%  8.2% of cases.15 A meta-
analysis conﬁrmed a slight trend of increasing new-onset
GERD after LSG.16
Because ESG is relatively new, there is a paucity of
research comparing the 2 procedures. Previously, only 1
study, by Novikov et al,10 that compared the outcomes of
ESG with LSG. This nonmatched cohort study
demonstrated that LSG achieved superior %TBWL
compared with ESG at 6 months (23.48% vs 14.37%, P <
.001) and 12 months (29.28% vs 17.57%, P < .001). A
subgroup analysis at 12 months demonstrated similar
weight loss outcomes in patients with a body mass index
(BMI) <40 kg/m2. Length of stay (.34  .73 days vs 3.09
 1.47 days, P < .001) and adverse event rate (2.20% vs
9.17%, P < .05) were signiﬁcantly less in the ESG group
compared with the LSG group.10 The aim of this study
was to compare weight outcomes, adverse events, and
new-onset GERD over a 6-month follow-up period in a
case-matched cohort of ESG and LSG patients.www.giejournal.org
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Patient population
Data were analyzed retrospectively from 2 prospectively
collected databases of patients who underwent ESG or LSG
at a single academic center (Johns Hopkins Medical Institu-
tions). Consecutive patients who underwent LSG between
May 2015 and December 2016 with at least 6 months of
follow-up data were compared with patients who under-
went ESG between February 2016 and August 2017. Pa-
tients were referred to our center for obesity
management and seen in an outpatient setting by a bariat-
ric surgeon or bariatric endoscopist. They were offered
EBT, such as ESG, intragastric balloon, aspiration therapy,
or intragastric botulinum toxin injection, and laparoscopic
weight loss options such as Roux-en-Y gastric bypass, LSG,
or laparoscopic gastric banding. Patients who presented for
ESG were offered a referral to bariatric surgery if they ﬁt
the eligibility criteria for bariatric surgery. The choice of
procedure was made by the patient in conjunction with
the physician after proper education and discussion of
technical aspects, risks, and costs. This study was approved
by the Ofﬁce of Human Subjects Research Institutional Re-
view Board at Johns Hopkins Medical Institutions
(IRB00122220).
The authors acknowledge that study subjects in this
study have been included in previously published research.
Some of the ESG cohort patients have been included in an
earlier published multicenter study by Sartoretto et al.11 In
addition, a learning curve study has been published that
includes some of the initial patients from this study.17
Finally, a video report describing the technical aspects of
ESG has been published.18 Importantly, each of the
aforementioned studies addresses a different clinical
question and provides distinctive insights. There is a dire
need to study ESG compared with other existing
therapies, including intragastric balloons and high-
intensity diet and lifestyle therapy.
Periprocedural and postprocedural care
Endoscopic sleeve gastroplasty. Patients were
required to take omeprazole 40 mg once daily for 1
week before the procedure and aprepitant (Emend, Merck
and Co, Kenilworth, NJ) 80 mg 3 hours before. Patients
were prescribed a liquid diet 1 day before and had nothing
by mouth after midnight the day of the procedure. Post-
procedure, patients were placed on a liquid diet for 3
days. If tolerated, they were transitioned to pureed, soft,
and then solid diet at 2-week intervals. At discharge, on-
dansetron (Zofran, GlaxoSmithKline, Brentford, UK) 4
mg every 6 hours and hyoscyamine (Levsin) .125mg every
6 hours were prescribed as needed for nausea and cramps,
respectively. Patients were also prescribed aprepitant
(Emend) 80mg to be taken at days 1-3 postprocedure
and omeprazole 40 mg once daily for 6 weeks. All ESGVolume 89, No. 4 : 2019 GASTROINTESTINAL ENDOSCOPY 783
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ESG versus LSG Fayad et alpatients were enrolled in a year-long weight management
program that consisted of 12 visits with a multidisciplinary
team at the Johns Hopkins Weight Management Center.
The team included a behavioral psychologist, registered
dietitian, exercise physiologist, and an expert weight loss
physician.
Laparoscopic sleeve gastrectomy. Patients who un-
derwent LSG were placed on a liver reduction diet for 2
weeks preoperatively. This is a structured low-calorie and
low carbohydrate diet with the goal of reducing the liver
size. Preoperatively, patients were prescribed 2
sennosides-docusate (Senokot-S, Avrio Health, Stamford,
Conn) 8.6- to 50-mg tablets by mouth daily for 2 weeks.
The day before surgery, patients were on a clear liquid
diet up until midnight and instructed to drink a 20-ounce
Gatorade (Pepsico, Purchase, NY) on the night before sur-
gery and 2 hours before the scheduled surgery start time.
On the morning of surgery, patients were given low-
molecular-weight heparin and a second-generation cepha-
losporin or its equivalent intravenously. Postoperatively
they started a full liquid diet for 1 week followed by a pu-
reed diet for 3 weeks and then a soft diet for 4 weeks as
tolerated. At discharge, ondansetron (Zofran, GlaxoS-
mithKline, Brentford, UK) 4 mg every 6 hours and oxyco-
done 5 mg every 4 hours were prescribed to be taken as
needed for abdominal pain. Patients were instructed to
take pantoprazole (Protonix, Pﬁzer, New York, NY) 40
mg daily for 3 months. They were also prescribed
sennosides-docusate (Senokot-S) 8.6 to 50 mg 2 tablets
daily and polyethylene glycol (MiraLAX, Bayer AG, Leverku-
sen, Germany) 17 mg daily up to 1 month until bowel
movements normalized. For patients with a gallbladder, ur-
sodeoxycholic acid (Ursodiol, Dublin, Republic of Ireland)
300 mg was prescribed twice daily for 6 months. Patients in
the LSG group were also required to take a multivitamin
supplement containing iron, folic acid, and thiamine every
day. In addition, they were required to take calcium 3
times daily, vitamin D3 once daily and vitamin B12 sublin-
gual daily or intramuscularly once a month.
Nutritionist follow-up postprocedure included a phone
call at 1 week and an in-person visit at 3 weeks. Patients
were required to follow up with their surgeon at 3, 6, 12,
18, and 24 months and then yearly after that. Unlike ESG
patients, LSG patients did not have an ancillary weight
management program associated with their procedure.
However, they all had a requirement of 3 to 6 months of
diet and lifestyle therapy at a weight management center
before the procedure.
ESG procedure
All ESGs were performed as same-day procedures by a
single endoscopist with signiﬁcant experience in endo-
scopic suturing (V.K.). The procedural technique was iden-
tical to that described by Sartoretto et al.11 The procedure
was performed with the patient under general anesthesia.
The suture line was ﬁrst demarcated using argon plasma784 GASTROINTESTINAL ENDOSCOPY Volume 89, No. 4 : 2019
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vice, OverStitch (Apollo Endosurgery, Austin, Tex), was
used to place sutures starting from the incisura angularis
up to the gastric fundus. Each suture was used to take 6 to
9 bites in the following direction: anterior wall, greater cur-
vature, posterior wall, and then 1 cm proximally in the oppo-
site direction: posterior wall, greater curvature, anterior
wall. Once complete, the suture was pulled and “knotted”
using a cinching device. Around 6 to 9 sutures were used
in each patient until a tubular lumen was achieved.
LSG procedure
LSG procedures were performed by experienced bariatric
surgeons at this institution. The operation was performed
with the patient under general anesthesia followed by place-
ment and then immediate removal of an orogastric tube to
suction out the stomach. Theoperationwas then commenced
with a 45-degree viewing laparoscope that was inserted after
the placement of 4 blunt-tip trocars under direct vision. The
patient was placed in reverse Trendelenburg, and the liver
was retracted. The branches of the gastroepiploic and short
gastric vessels were divided starting approximately 6 cm
from the pylorus and then going cephalad toward the left
crus of the diaphragmusing an energy sealing and dividing de-
vice. A 40Fbougiewas then inserted into the stomach, and the
stomach was divided vertically using a laparoscopic stapler
making sure the ﬁrst 1 or 2 ﬁrings were slightly away from
the incisura angularis to decrease the risk of stricture forma-
tion. The stapler was then used to divide the rest of the stom-
ach vertically until separated at the angle of His. Clips or a
suture was placed on the staple line to stop any bleeding.
The resected part of the stomach was then removed through
the largest trocar site after which the fascia was closed with in-
terrupted sutures. The trocars were removed and thewounds
closed with subcuticular sutures with glue.
Outcomes
Baseline weight, BMI, and comorbidities were recorded
for each patient. Comorbidities recorded included hyper-
tension, diabetes, GERD, and sleep apnea. Data on new-
onset GERD and adverse events were also collected.
GERD diagnosis was based on the clinical judgment of
the examining physician. New-onset GERD was deﬁned
as a new diagnosis of GERD postprocedure in patients
who did not previously have GERD. Adverse events were
only included if they occurred during the initial hospitaliza-
tion or required readmission. In both procedures abdom-
inal discomfort, nausea, and vomiting were considered
an anticipated part of the postoperative course, and pa-
tients were provided with medications in advance to treat
these symptoms. The primary outcome of interest was
%TBWL at 1 and 6 months.
Statistical analysis
Patients undergoing ESG (cases) were matched in the
analysis stage with patients undergoing LSG (controlwww.giejournal.org
ERSITY from ClinicalKey.com by Elsevier on June 03, 2019.
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TABLE 1. Baseline BMI, sex, age, and comorbidities in ESG and LSG groups
ESG group (n [ 54) LSG group (n [ 83) P value
Baseline characteristics
Median age, y (range) 48 (24-72) 47 (30-67) .87
Male/female, n/N (%) 23/31 (42.6/57.4) 24/59 (28.9/71.1) .1
Median BMI, kg/m2 (range) 43.07 (30.2-65.6) 44.12 (29.73-64.46) .44
Comorbidities
Type 2 diabetes mellitus, % 3.7 20.48 .02*
Hypertension, % 27.8 50.60 .01*
GERD, % 16.7 25.30 .27
Obstructive sleep apnea, % 18.5 40.96 .02*
BMI, Body mass index; ESG, endoscopic sleeve gastroplasty; LSG, laparoscopic sleeve gastrectomy.
*Statistically significant at p <.05.
Fayad et al ESG versus LSGsubjects). Each case (ESG patient) was matched with 3
control subjects (LSG patients) based on age, sex, and pre-
operative BMI. To ensure adequate sample sizes and mini-
mize loss of cases, we used matching with replacement.
Matching with replacement is a method that allows use
of the same control subject (LSG patient) for multiple
cases (ESG patients). Final analysis included only matched
cases and control subjects. Thus, although matching was
3:1 (control subjects-to-cases), the total resultant number
of control subjects (LSG patients) included was not 3 times
the number of cases (ESG patients) used. Matching with
replacement can result in bias because multiple matched
control subjects are no longer independent, and this has
to be accounted for in the analysis. This was dealt with
using inverse probability of treatment weighting using
propensity scores.19-21
Univariate analysis and multivariate regression analysis
were performed to identify factors impacting %TBWL and
likelihood of adverse events. Analysis of variance, Fisher
exact tests, and c2 tests were performed. Because BMI
>40 kg/m2 is often used as a cut-off for insurance coverage,
we performed a subgroup analysis at 6 months comparing
patients based on their preoperative BMI status: BMI <40
kg/m2 and BMI >40 kg/m2. P < .05 was considered signif-
icant. All statistical analysis was conducted using STATA
14.0 (StataCorp LP, College Station, Tex).RESULTS
A total of 54 ESG patients were matched with 83 LSG pa-
tients. Table 1 shows the baseline characteristics of the
patients including age, sex, BMI, and comorbidities in the
2 groups. Comorbidities at baseline were signiﬁcantly
different between the 2 groups. ESG patients had a
signiﬁcantly lower proportion of type 2 diabetes mellitus
(3.7% vs 20.5%, P < .05), hypertension (27.8% vs 50.6%,
P < .05), and obstructive sleep apnea (18.5% vs 40.9%,
P < .05) than the LSG group. The proportion of patientswww.giejournal.org
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ESG group vs 25.3% in the LSG group, P Z .27).
At the 1-month follow-up, 52 of 54 ESG patients and all
83 LSG patients were retained and evaluated. At the
6-month follow-up, 35 of 54 ESG patients and 70 of 83 LSG
patients were evaluated. Figure 1 shows the %TBWL at 1
and 6 months. At the 1-month follow-up, there was a signif-
icantly greater %TBWL in the ESG group than in the LSG
group (9.8%  2.5% vs 6.6%  2.4%, P < .001). However,
at the 6-month follow-up, %TBWL was signiﬁcantly lower in
the ESG group compared with the LSG group (17.1% 
6.5% vs 23.6% 7.6%, P < .00). At 6 months, 72.2% of
ESG patients and 88.57% of LSG patients achieved >15%
TBWL. We performed a subgroup analysis at 6 months
comparing patients based on their preoperative BMI sta-
tus: BMI <40 kg/m2 and BMI >40 kg/m2. In patients with
BMI >40, %TBWL remained signiﬁcantly lower in the
ESG group than the LSG group (coefﬁcient, –8.25; P <
.001; 95% conﬁdence interval, –10.49 to –6.00). However,
in patients with BMI <40, %TBWL was borderline signiﬁ-
cantly different between the ESG group and the LSG group
(coefﬁcient, –2.98; PZ .05; 95% conﬁdence interval, –5.88
to –.09). Mean age and sex had no signiﬁcant effect on the
%TBWL at the 1- or 6-month follow-up for both BMI sub-
groups. Table 2 shows the weight lost in pounds and the
percent reduction in BMI in both groups.
Overall, ESG patients had a signiﬁcantly lower rate of
adverse events than LSG patients (5.2% vs 16.9%, P <
.05). In the ESG group there were no adverse events during
the initial in-hospital recovery period, and all patients were
discharged on the same day. Adverse events requiring read-
mission included 2 cases of upper GI bleeding and 1 peri-
gastric inﬂammatory ﬂuid collection, as described in a
previous case report.22 None of the described adverse
events required surgical intervention. In the LSG group,
adverse events that occurred during initial hospitalization
included hypotension (1), need for transfusion (2), and
dehydration (1). Adverse events requiring readmission
included dehydration (2), abdominal pain (2), intractableVolume 89, No. 4 : 2019 GASTROINTESTINAL ENDOSCOPY 785
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Figure 1. Percent total body weight loss (%TBWL) in patients after endoscopic sleeve gastroplasty (ESG) and laparoscopic sleeve gastrectomy (LSG) at 1
and 6 months.
TABLE 2. Total body weight lost and percent reduction in body mass index at 1 and 6 months
1 Month
P value
6 Months
P value
ESG group LSG group ESG group LSG group
Mean SD Mean SD Mean SD Mean SD
Total body weight lost, lbs 24.98 6.68 19.33 8.02 <.001 44.92 6.68 69.62 28.96 <.001
Reduction in body mass index, % 9.40 2.42 6.65 2.41 <.001 17.2 5.56 23.72 7.62 <.001
SD, Standard deviation; ESG, endoscopic sleeve gastroplasty; LSG, laparoscopic sleeve gastrectomy.
ESG versus LSG Fayad et alnausea and vomiting (3), upper GI bleeding (1), and acute
pancreatitis (2). New-onset GERD postprocedure was signif-
icantly lower in the ESG cohort than the LSG cohort
(1.9% vs 14.5%, P < .05).DISCUSSION
Among the wide array of devices and techniques that
have been developed in EBT, ESG in particular has gained
momentum as a promising technique that mimics an
already accepted surgical procedure. It achieves similar
early gastric restriction using a minimally invasive trans-
oral approach.17 This study is the ﬁrst to compare a
surgical procedure with an analogous endoscopic
alternative in a case-matched cohort.
ESG produced desirable %TBWL at each time point. At
30 days, ESG produced greater %TBWL than LSG (9.8% 
2.5% vs 6.6%  2.4%, P < .001). Although statistically signif-786 GASTROINTESTINAL ENDOSCOPY Volume 89, No. 4 : 2019
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the superiority was short-lived. Our 6-month %TBWL out-
comes for ESG and LSG (17.1%  6.5% vs 23.6%  7.6%,
respectively) were consistent with ﬁndings from a similar
comparative study by Novikov et al,10 who demonstrated
a %TBWL of 14.37% and 23.48% at 6 months for ESG
and LSG, respectively. Stratiﬁcation by BMI also
demonstrated a change in weight loss outcomes in this
study. In patients with BMI <40 kg/m2, %TBWL at 6
months was slightly better for LSG than ESG groups. This
conﬁrms ﬁndings by Novikov et al,10 who demonstrated
comparable %TBWL at 1 year for BMI <40 kg/m2
between ESG and LSG. ESG is a thus a good option,
particularly in this subset of patients, because most are
not eligible for LSG.
Our study validated that ESG has a signiﬁcantly lesser
rate of adverse events than LSG. Adverse events previously
seen with ESG include perigastric leak, perigastric inﬂam-
matory ﬂuid collection, extragastric hemorrhage, upperwww.giejournal.org
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Fayad et al ESG versus LSGGI bleeding, pneumoperitoneum, pneumothorax, and pul-
monary embolism.8,9,11 The rate of adverse events is low
(2% and 2.7%), making ESG a safer alternative to LSG,
especially in high-risk patients.8,9,11 ESG is not without
risk, and endoscopists performing this procedure must
remain vigilant; nonetheless, our ﬁndings conﬁrm that
ESG is safer than LSG.
One major disadvantage of LSG is the potential for the
development of GERD postoperatively. A systematic re-
view and meta-analysis by Oor et al16 concluded that
there was a slight trend toward increasing GERD
symptoms post-LSG with 0% to 34.9% of patients devel-
oping new-onset GERD. According to a 2014 expert survey
by the Fifth International Consensus Conference, as many
as 23.3% of experts consider GERD to be a contraindica-
tion to LSG; 32.8% believe that patients with GERD should
have pH monitoring and manometry before LSG.15 In
contrast, there are no data to suggest that ESG
contributes to new-onset GERD. Our study showed a
signiﬁcantly lower proportion of new-onset GERD in the
ESG cohort compared with the LSG cohort. Previous
studies have shown that a higher BMI seems to be protec-
tive for new-onset GERD after LSG, whereas worsening of
symptoms was noted when there were severe heartburn
symptoms when standing preoperatively.14
Of note, there is a large overlap in the population
eligible for ESG and LSG. Insurance coverage has often
been the driving force that determines choice of proced-
ure. However, other factors to take into consideration
are differences in postoperative care between the 2 pro-
cedures. ESG patients take omeprazole for 6 weeks post-
procedure but otherwise do not require any other
medications. LSG patients, on the other hand, must
take multiple medications, including pantoprazole,
sennosides-docusate, polyethylene glycol, and ursodeoxy-
cholic acid for 1 to 6 months, in addition to lifelong vitamin
supplementation. ESG is likely a better option for patients
who are less likely to comply with medications and lifelong
vitamin supplementation.
At our institution, ESG is almost exclusively a self-pay pro-
cedure but is signiﬁcantly less expensive than a self-pay LSG
procedure. It is difﬁcult to adequately compare the cost dif-
ference between the 2 procedures because LSG is covered
by insurance for a substantial segment of the obese popula-
tion. At the present time, ESG is a less-costly procedure for
patients who do not carry insurance coverage for an LSG or
who do not meet the BMI or other requirements of their in-
surance plan for bariatric surgery. However, with increasing
evidence supporting the efﬁcacy and safety of ESG, it may
be more cost-effective from a societal perspective than
LSG. This makes ESG valuable in reaching a larger segment
of the obese population and in reaching them earlier, at
lower BMIs (as low as 30-35 kg/m2).
In the era of personalized medicine, we must consider
the many factors that inﬂuence one’s choice of a weight
loss program. These include total weight lost, adversewww.giejournal.org
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cost. Although LSG remains superior in terms of weight
lost and resolution of obesity-related comorbidities, ESG
is minimally invasive, lower risk, less costly, and does not
appear to contribute to the development of postoperative
GERD.
One major strength of our study is that it is case-matched.
Because it is known that baseline BMI is a predictor of
magnitude of weight loss,23 an important consideration in
evaluating outcomes is that the population of patients
who undergo ESG and LSG differ signiﬁcantly in baseline
BMI. In the 2 largest multicenter ESG studies, mean
baseline BMI reported by Sartoretto et al11 and Lopez-
Nava et al7 was 37.9  6.7 kg/m2 and 37.8  5.6 kg/m2,
respectively. In comparison, bariatric surgery patients
typically have a greater mean BMI, 43.9  2.9 kg/m2 as
reported by Kang and Le3 in their meta-analysis. Thus, to
compare the outcomes of ESG with LSG, it is imperative
to case match patients by BMI in the 2 cohorts.
One limitation to our study is the difference in the med-
ical management between the 2 groups. The inclusion of
ESG patients in a weight management program postproce-
dure may have improved the weight loss outcomes in the
ESG group, resulting in a confounding bias.
In addition, GERD outcomes may have been inﬂuenced
by this difference, because patients are counseled about
GERD during these visits. However, we note some factors
mitigating this potential bias. Patients in the ESG group un-
derwent only a low-intensity diet and lifestyle therapy,
which was not mandatory. During this time, patients in
the LSG group also underwent medical management at 1
week, 3 weeks, 3 months, and 6 months. Thus, even in
the most consistent patient, the groups only differed by
2 visits for medical management within these 6 months.
Additionally, there was signiﬁcant loss to follow-up in the
ESG group, indicating that many patients did not attend
these visits. Although the 2 programs were not identical,
we believe the aforementioned factors signiﬁcantly reduce
this bias, particularly pertaining to GERD, because LSG
patients are counseled about GERD as well during their
medical visits.
Several other limitations must be acknowledged. First,
the study has all limitations inherent to a retrospective
chart review, including loss to follow-up. Unfortunately,
because of a small sample size, particularly with ESG pa-
tients, in addition to patient attrition, our results have a
risk for Type I error. This risk is more pronounced in the
subanalysis of patients stratiﬁed by BMI. In addition,
GERD was diagnosed clinically, and patients did not un-
dergo objective studies such as pH monitoring or upper
endoscopy for diagnosis. Also, GERD severity was not as-
sessed. Finally, duration of follow-up was limited to
6 months. Thus, it is difﬁcult to compare these 2 proced-
ures in terms of durability in the absence of 12 months
or greater follow-up. It is unclear whether the results at
6 months would translate to similar results at later follow-up.Volume 89, No. 4 : 2019 GASTROINTESTINAL ENDOSCOPY 787
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ESG versus LSG Fayad et alWith improvement in techniques and weight loss out-
comes of EBTs such as ESG, it will become imperative
for bariatric surgeons and bariatric endoscopists to work
together to better deﬁne which procedure is preferable
for different groups of patients. This study is one of the
ﬁrst to address this question. We have conﬁrmed that
both LSG and ESG can produce signiﬁcant weight loss,
with an acceptable safety proﬁle, over a 6-month period.
As expected, LSG resulted in superior weight loss, with
the caveat that it also had a higher rate of adverse events
and new-onset GERD. ESG was less costly and minimally
invasive. Future studies are needed to compare ESG with
LSG in a randomized controlled trial as well as a cost-
effectiveness analysis comparing the 2 procedures.
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NEW METHODS: Experimental Endoscopy288Gastric mucosal devitalization reduces adiposity and improves
lipid and glucose metabolism in obese ratsGASTAndreas Oberbach, MD, PhD, DrPH, MPH,1,2,3 Nadine Schlichting, PhD,3,4 Marco Heinrich, PhD,3,4
Yvonne Kullnick, MSc,3,4 Ulf Retschlag, MSc,4 Stefanie Lehmann, PhD, MPH,3,4 Mouen A. Khashab, MD,1
Anthony N. Kalloo, MD,1 Vivek Kumbhari, MD1
Leipzig, Saxony, Germany; Baltimore, Maryland, USABackground and Aims: The gastric mucosa is an endocrine organ that regulates satiation pathways by expres-
sion of orexigenic and anorexigenic hormones. Vertical sleeve gastrectomy (VSG) excludes gastric mucosa and
reduces gastric volume. Our study aimed to investigate the independent effects of altering gastric mucosa on
obesity and its related comorbidities.
Methods: Gastric mucosa devitalization (GMD) of 70% of the stomach was achieved by argon plasma coagulation
in a high-fat diet rat model and was compared with VSG and sham surgery. In an 8-week follow-up study, we quan-
tiﬁed body weight, visceral adiposity, insulin resistance index, cholesterol proﬁles, and free fatty acid proﬁles by
enzyme-linked immunosorbent assay (ELISA). Following a 2-hour oral glucose tolerance test, the kinetics of ghre-
lin, glucagon-like peptide-1, peptide YY, and serum and liver bile acid levels were measured. Liver lipid content
was quantiﬁed by ELISA.
Results: GMD resulted in signiﬁcant reductions in body weight, visceral and subcutaneous adipose tissue, and
hepatic steatosis as well as an improvement in lipid metabolism. GMD resulted in signiﬁcant reductions in
food intake and intestinal malabsorption of free fatty acids, both contributing to improved body composition
and metabolic proﬁle. Mechanistically, GMD resulted in a signiﬁcant reduction in serum palmitate levels as
well as an increase in serum and liver bile acid levels, known to alter glucose and lipid metabolism. Similar
changes were noted when VSG rats were compared with sham surgery rats.
Conclusions: Devitalization of gastric mucosa, independent of altering gastric volume, was able to reduce
obesity-related comorbidities. The gastric mucosa may be a potential target for treating obesity and its associated
comorbidities.(footnotes appear on last page of article)Roux-en Y gastric bypass and vertical sleeve gastrectomy
(VSG), despite being anatomically different, result in similar
improvements in metabolic proﬁle.1-3 One element common
to both surgeries is the exclusion or excision of the gastricmu-
cosa.3 The gastric mucosa secretes orexigenic (ghrelin) and
anorexigenic (leptin, obestatin, and nesfatin-1), making it a
complex regulator of food intake as well as glucose and lipid
metabolism.4-6 Increased insulin secretion and improved insu-Use your mobile device to scan this
QR code and watch the author in-
terview. Download a free QR code
scanner by searching “QR Scanner”
in your mobile device’s app store.
ROINTESTINAL ENDOSCOPY Volume 87, No. 1 : 2018lin sensitivity are observed in diabetic obese patients immedi-
ately after VSG, before any weight loss.7-9 Additionally, VSG
results in improved lipid metabolism, particularly reduction
in secretion of triglycerides in a weight-independent
manner.10,11 This supports the hypothesis that the beneﬁts
of VSG are a result of changes of gastric origin and are neither
meal related nor weight change related.
To investigate the hypothesis that gastric mucosa is an
independent regulator of obesity-related comorbidities,
we used a high-fat diet (HFD) rat model and designed a
method of gastric mucosal devitalization (GMD) to selec-
tively obliterate the gastric mucosa, without altering gastric
volume or intestinal anatomy. To assess the independent
effects of gastric mucosa we included a rat model of
VSG, which combines excision of gastric mucosa with the
addition of a reduction in gastric volume.www.giejournal.org
Oberbach et al Effect of altering gastric mucosa in obese ratsMATERIALS AND METHODS
Animals
All animal procedures followed the international guide-
lines for the prevention of animal cruelty12 and were
approved by the Landesdirektion Leipzig, the local
authority for animal care.13 We used 4-week-old male
Sprague-Dawley rats (nZ 110; MEZ, Medical Experimental
Center, University of Leipzig, Leipzig, Germany; 100-150 g).
Rats were fed either an HFD (Research Diets, energy from
fat 45%, carbohydrate 35%, and protein 20%; ssniff-
Spezialdiaeten; Soest, Germany) or a standard chow diet
(CD) (Research Diets, energy from fat 11%, carbohydrate
66%, protein 23%; ssniff-Spezialdiaeten). Rats were housed
under controlled conditions (12:12-hour light-darkness cy-
cle, 50%-60% humidity, 25C, free access to water and
food except where noted). At the end of each study, animals
were killed by placement in a CO2 chamber for 10 minutes.
The allocation of animals is described in Supplemental
Figure 1, available online at www.giejournal.org.
First, we validated a previously developed rat model of
obesity characterized by increased body weight, visceral
and subcutaneous adiposity, hepatic steatosis, dyslipide-
mia, and disturbed glucose metabolism.14,15 Twenty rats
were randomized into 2 groups receiving either CD
(n Z 10) or HFD (n Z 10) with free access to food and
water. Weight gain and food intake were monitored twice
a week over 11 weeks. Second, we stratiﬁed rats that had
been fed the HFD for 11 weeks (n Z 90) into 3 interven-
tion groups (GMD, n Z 30; VSG, n Z 30; sham surgery,
n Z 30) in order to assess various outcomes
(Supplemental Fig. 1). From each cohort, 10 rats were
randomized to be killed at 2, 4, or 8 weeks after
intervention. HFD was continued in all intervention
groups until death. The day before death, fecal samples
were collected over 24 hours.Interventions
An identical anesthesia protocol was used (intraperito-
neal injection of ketamine 100 mg/kg, xylazine 10 mg/kg,
and atropine 0.1 mg/kg) for all interventions. Following
completion of the designated intervention, the stomach
was reintegrated into the abdominal cavity, and the
abdominal wall was closed.VSG
A laparotomy incision was performed and the stomach
mobilized outside the abdominal cavity. Loose gastric con-
nections to the spleen and liver were released along the
greater curvature, and the suspensory ligament supporting
the upper fundus was severed. The lateral 70% of the stom-
ach was excised by using a TX30B 30 mm staple gun (John-
son & Johnson Medical GmbH, Norderstedt, Germany),
leaving a tubular gastric remnant in continuity with the
esophagus and duodenum.www.giejournal.orgGMD
Argon plasma coagulation (APC) was used to perform
GMD. The anesthetized animals were ﬁxed on a metal
plate, which was coupled with a neutral electrode. After a
laparotomy incision and mobilization of the stomach
outside the abdominal cavity, a small gastric incision in
the fundus was followed by insertion of a 2-mm rigid endo-
scope (STORZ 1232AA Hopkins II, Storz, Germany) and a
1.5-mm APC-probe (VIO 300D/APC2-HF-generator; ERBE
Elektromedizin, Tubingen, Germany). The activated probe
was then ﬁred (pulsed APC, effect 2 at 25 W with an argon
ﬂow rate of 0.2 L/minute) by a non-contact technique for a
duration of 30 seconds. We decided to ablate 70% of the
surface area of the stomach along the greater curvature
aspect to match the amount of mucosa removed at VSG.
The area treated could be visualized by the operator with
the use of the endoscope and from outside because of
the plasma beam of the activated probe (Supplemental
Fig. 2, available online at www.giejournal.org).
A single operator performed all GMD procedures and
only after the operator was able to achieve proﬁciency in
the technique (homogeneous ablation of 70% of the
gastric mucosa in ex vivo and in vivo models) was the
formal study commenced.Sham surgery
A laparotomy incision was made and the stomach mobi-
lized outside the abdominal cavity. A gastric incision was
performed to allow the entry of a 8F catheter, and the
stomach was lavaged with 20 mL of sterile water at 37C.
Postoperative care. Postoperative care included daily
subcutaneous injection of antibiotics (0.1 mL/100 g
ceftriaxon-ratiopharm 1.0; ratiopharm GmbH, Ulm, Ger-
many) for 5 days and daily admixing of analgesic (0.5 mL
metamizol [ratiopharm GmbH] þ 30 mL 20% glucose þ
70 mL water) to the water for 3 days. HFD was resumed
ad libitum on post-intervention day 2. Weight, food, and
water intake were assessed daily for 2 weeks and then
twice weekly. An oral glucose tolerance stimulation test
(OGTT) was performed after a 10-hour fast in the last post-
operative week, with samples being drawn every 30 mi-
nutes for 2 hours. Animals were killed at the 2, 4, and 8
week timepoints.
Phenotypical characterization, methods of blood plasma
analysis, the details of protein and lipid analysis by using
enzyme-linked immunosorent assay, and activity assays as
well as detailed methods of tissue histology are shown in
Supplementary Methods 1 (available online at www.
giejournal.org).Statistical analysis
Data analysis was performed by using Prism version 5.0
(GraphPad Software; La Jolla, Calif). Statistical differences
were calculated by an independent t test if comparing
CD and HFD after 11 weeks and analysis of variance withVolume 87, No. 1 : 2018 GASTROINTESTINAL ENDOSCOPY 289
Effect of altering gastric mucosa in obese rats Oberbach et alpost hoc test procedures if comparing GMD, VSG, and
sham surgery at different time points. A P value < .05
was considered statistically signiﬁcant. The data are shown
as mean  standard deviation. Signiﬁcant differences be-
tween the groups are indicated by bars and/or an asteric
(P < .05). One asteric signiﬁed a P value < .05, 2 a P value
< .01, 3 a P value < .001, and 4 a P value < .0001.RESULTS
Characterization of the models
GMD. Our technique using APC resulted in selective
devitalization of the gastric mucosa without alteration of
the deeper tissue layers, particularly the muscularis propria
(Supplemental Fig. 2, available online at www.giejournal.
org). Histologic examination at 2, 4, and 8 weeks
revealed regenerative changes of the gastric mucosa
(Fig. 1), with hormone-secreting cells demonstrating a
trend to normalization (Fig. 2). At all follow-up time points,
gross examination of the stomach of GMD-treated rats re-
vealed that gastric volume was unchanged compared with
sham surgery rats (Supplemental Fig. 3, available online at
www.giejournal.org).
HFD results in increased body weight and
disordered metabolism
HFD resulted in a signiﬁcant increase in body weight
(30%), visceral adiposity (133%), and subcutaneous
adiposity (172%) compared with a CD after 11 weeks
(Fig. 3). There was signiﬁcantly increased impaired
glucose tolerance as calculated by homeostatic model
assessment for insulin resistance (HOMA-IR) (57%) and
measured by 2-hour OGTT (33%) in HFD (Table 1).
Comparing CD with HFD, there were signiﬁcant in-
creases in triglyceride, total cholesterol, low-density lipo-
protein (LDL) cholesterol, and free fatty acid (FFA)
levels. In addition, we identiﬁed a signiﬁcant increase in in-
dividual FFA components including saturated FFA, such as
palmitate in HFD rats (Table 2). Liver lipid content in HFD
rats revealed a signiﬁcant increase (1.3-fold; P Z .04)
(Fig. 4).
Effects of GMD in HFD rats
Body weight and adiposity. GMD resulted in a signif-
icant reduction in body weight (43%, 27%, 14%) compared
with sham surgery at 2, 4, and 8 weeks, respectively
(Fig. 3A). Examination of visceral and subcutaneous
adipose tissue revealed a signiﬁcant reduction in the
GMD group compared with sham surgery, with similar
ﬁndings noted in VSG rats compared with sham surgery
rats (Fig. 3B and C). In detail, GMD resulted in a
signiﬁcant reduction in visceral adipose tissue (81%, 58%,
53%) at 2, 4, and 8 weeks, respectively, compared with
sham surgery. When the morphologic ﬁndings at 8
weeks were compared with those of sham surgery, GMD290 GASTROINTESTINAL ENDOSCOPY Volume 87, No. 1 : 2018had grossly diminished adiposity of the greater omentum
and surrounding intestinal organs, a ﬁnding also seen in
VSG (Fig. 5).
Food intake and metabolic alterations
Daily food intake was diminished in GMD (35%)
compared with sham surgery at 2 weeks, with a similar
ﬁnding at 4 weeks. However, at 8 weeks, GMD and sham
surgery were similar with regard to consumptive behavior
(Table 1). Similar values and trends were noted in VSG.
GMD resulted in a signiﬁcant reduction in fasting
glucose throughout the 8-week period of observation
(Table 1). To demonstrate changes in glucose
metabolism, we report HOMA-IR and the area under the
curve (AUC) (based on 2-h OGTT) in Table 1. At 4
weeks, GMD demonstrated a signiﬁcant reduction in
HOMA-IR (44%) compared with that of sham surgery.
Furthermore, at 8 weeks, both GMD (43%) and VSG
(57%) exhibited signiﬁcantly lower HOMA-IR compared
with sham surgery (Table 1). There were no signiﬁcant
differences with regard to C-reactive protein (CRP) or
interleukin-6 (IL-6) for the duration of follow-up (Table 1).
Regulation of serum orexigenic and
anorexigenic hormones
There was a high biologic variation in the abundance of
serum ghrelin, glucagon-like peptide 1 (GLP-1), and pep-
tide YY when measured after rats were fasted for 10 hours
or following oral glucose stimulation by a 2-hour OGTT
(Supplemental Table 1, available online at www.
giejournal.org). Fasting total serum ghrelin levels were
signiﬁcantly reduced in GMD (41%, 34%, 40%) compared
with sham surgery at 2, 4, and 8 weeks, respectively.
However, fasting active ghrelin levels were not
signiﬁcantly different between GMD, VSG, and sham
surgery (Supplemental Table 1, available online at www.
giejournal.org) during the follow-up period. At 2 and 4
weeks, the 2-hour OGTT (presented as AUC) in the
GMD group revealed a signiﬁcant reduction in total ghre-
lin (2 weeks 30%; 4 weeks 40%) and active ghrelin (2 weeks
68%; 4 weeks 31%) levels compared with sham surgery.
Glucose stimulation by OGTT revealed signiﬁcantly
increased total GLP-1 levels at 8 weeks in GMD (83%)
compared with sham surgery, whereas levels of active
GLP-1 did not differ signiﬁcantly (Supplemental Table 1).
Peptide YY levels were increased signiﬁcantly in GMD
and VSG in both fasting (GMD 56%, VSG 111%) and
after a 2-hour OGTT (GMD 67%, VSG 91%) at 4 weeks
compared with sham surgery (Supplemental Table 1).
The VSG group maintained a signiﬁcantly elevated
peptide YY level at 8 weeks compared with that of sham
surgery.
Serum and liver lipid proﬁle
There was a signiﬁcant reduction in triglyceride and
total cholesterol levels in both GMD and VSG ratswww.giejournal.org
Figure 1. Regeneration of rat gastric mucosa after treatment with gastric mucosa devitalization (GMD). A, Image of untreated rat stomach illustrates a
thick layer of mucosa. B, Immediately after GMD, the mucosa was essentially completely devitalized (arrowhead). C-E, Regeneration of the mucosal layer
over the 8-week follow-up period. GMD, gastric mucosal devitalization. (H&E, orig. mag. 10).
Figure 2. Expression of ghrelin-positive cells in rat stomach mucosa after gastric mucosa devitalization (GMD) treatment. A, Immunoﬂuorescence image
of untreated rat stomach mucosa against ghrelin (red) displays moderate expression (arrows). B, Immediately after GMD was performed, there was com-
plete devitalization of the mucosa with no detectable ghrelin-positive cells. C, Two weeks after GMD, the mucosa was nearly completely devitalized with a
paucity of detectable ghrelin-positive cells. D, At 4 weeks, the mucosa illustrated signs of regeneration and the presence of a slightly increased number of
ghrelin-positive cells. E, At 8 weeks, the mucosa was even more reorganized, with a further increased number of ghrelin-positive cells. Nuclei are stained
with DAPI (blue). GMD, gastric mucosa devitalization (DAPI, orig. mag. 10).
Oberbach et al Effect of altering gastric mucosa in obese ratscompared with sham surgery rats over the 8-week
period of observation (Table 2). GMD was able to
signiﬁcantly lower LDL cholesterol levels at 4 weeks
(69%) and 8 weeks (57%) compared with sham surgerywww.giejournal.org(Table 2). Although there was no signiﬁcant difference
in the total level of FFA in GMD or VSG compared
with sham surgery, the toxic saturated FFA palmitic
acid was signiﬁcantly reduced by GMD (36%) and VSGVolume 87, No. 1 : 2018 GASTROINTESTINAL ENDOSCOPY 291
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Figure 3. Gastric mucosal devitalization (GMD) produces a signiﬁcant reduction in body weight and visceral and subcutaneous adiposity compared with
sham surgery rats. Animals were killed after 11 weeks of feeding (chow diet, high-fat diet) to measure body composition at 15 weeks. After intervention
(GMD, vertical sleeve gastrectomy [VSG], sham surgery), animals were killed at 2, 4, and 8 weeks. A, GMD rats had a signiﬁcant reduction in body weight
at 2, 4, and 8 weeks. B, There was a signiﬁcant reduction in visceral adiposity in GMD rats compared with sham surgery rats at 2, 4, and 8 weeks. Similar
changes were noted when VSG rats were compared with sham surgery rats. C, There was a signiﬁcant reduction in subcutaneous adiposity in GMD rats
compared with sham surgery rats at 2, 4 and 8 weeks. Similar changes were noted when VSG rats were compared with sham surgery rats. GMD, gastric
mucosal devitalization; VSG, vertical sleeve gastrectomy; SH, sham surgery; HFD, high-fat diet.
Effect of altering gastric mucosa in obese rats Oberbach et al(35%) at 8 weeks (Table 2). GMD resulted in a decrease
in liver lipid accumulation compared with sham surgery
at 4 weeks (63%) and 8 weeks (33%), respectively
(Fig. 4A).292 GASTROINTESTINAL ENDOSCOPY Volume 87, No. 1 : 2018Bile acids and cholecystokinin
GMD resulted in a signiﬁcant increase in serum
(176%) and liver (75%) bile acid levels at 2 weeks
(Fig. 6). However, these differences were not sustainedwww.giejournal.org
TABLE 1. Characteristics of the study population phenotype. Values are Mean ± SD.
11-week diet Intervention after HFD
CD HFD HFD D GMD HFD D VSG HFD D SH
Age, wk 15 17, 19, 23
Daily food intake, g 22.7  1.3 22.7  1.8 2 wk 16.3  3.1* 18.9  2.2* 24.9  1.8
4 wk 17.7  2.3* 18.8  1.7* 21.9  0.8
8 wk 22  1 22  2.2 23  2.3
Daily water intake, mL 30.6  2.5 30.7  1.3 2 wk 24.5  3.7* 24.9  1.6* 29.1  1.9
4 wk 22.6  6.6 24.2  2.5 25.5  1.9
8 wk 29.5  2.2 29.8  4.6 26.8  2
Urine volume, mL/24 h 9  4 5  1* 2 wk 21  4* 18  6* 12  5
4 wk 21  12* 10  4 10  6
8 wk 6  4 7  2 6  2
Creatinine clearance, mL/min 1.06  0.25 1.05  0.42 2 wk 0.6  0.29 1.18  0.8 0.95  0.41
4 wk 1.29  0.75 1.13  0.75 0.93  0.52
8 wk 1.19  0.71 0.89  0.32 0.88  0.48
Fasting glucose, mmol/L 4.6  0.4 5.7  0.7* 2 wk 5.1  0.5* 6.2  0.8 6.4  0.7
4 wk 5.7  0.5* 6.3  0.5 6.3  0.5
8 wk 5.3  0.4* 5.7  0.6* 6.3  0.5
Fasting insulin, mmol/L 1.38  0.42 1.76  0.45 2 wk 1.25  0.04 0.98  0.43 0.99  0.3
4 wk 1.24  0.42* 1.63  0.75 2.05  0.57
8 wk 1.11  0.69 0.82  0.28* 1.74  0.7
HOMA-IR 1.4  0.5 2.2  0.6* 2 wk 1.4  0.1 1.3  0.5 1.4  0.6
4 wk 1.5  0.6* 2.1  0.9 2.7  0.8
8 wk 1.3  0.8* 1.0  0.4* 2.3  0.9
AUC 2 h OGTT 445  50 591  101* 2 wk 461  55* 722  88 697  76
4 wk 661  176 621  91 625  69
8 wk 431  46 640  85* 443  39
C-reactive protein, mg/mL 0.61  0.26 0.56  0.16 2 wk 0.55  0.13* 0.76  0.23 0.79  0.13
4 wk 0.59  0.11 0.66  0.22 0.69  0.23
8 wk 0.62  0.16 0.82  0.7 0.7  0.48
Interleukin-6, pg/mL 257  27 216  34 2 wk 152  64 185  47 205  58
4 wk 247  87 167  30 204  65
8 wk 283  82 280  101 253  58
Characteristics of the animal groups after 15 weeks and after surgery. Values are means  SD of dietary groups (CD, HFD) and intervention groups (GMD, VSG, sham surgery).
Significant differences (P < .05) between GMD and VSG compared with sham surgery are indicated by asterisks.
SD, Standard deviation; HFD, high-fat diet; CD, chow diet; GMD, gastric mucosa devitalization; VSG, vertical sleeve gastrectomy; SH, sham surgery; HOMA-IR, homeostatic model
assessment of insulin resistance; AUC 2 h OGTT, area under the curve based on 4 time points (baseline, 30 min, 60 min, 120 min) 2-hour oral glucose tolerance test.
Oberbach et al Effect of altering gastric mucosa in obese ratsfor the remainder of follow-up (Fig. 6A and B). GMD
resulted in a signiﬁcant increase (455%) in
cholecystokinin (CCK) levels at 4 weeks compared with
sham surgery (Fig. 6C).
Intestinal malabsorption of FFA and bile acids
GMD produced a progressive increase in the concentra-
tion of fecal FFA compared with that of sham surgery rats
for the duration of follow-up. At 8 weeks, GMD rats had a
signiﬁcantly increased concentration of fecal FFAwww.giejournal.orgcompared with those of sham surgery rats. Similar ﬁndings
were observed in VSG rats compared with sham surgery
rats (Supplemental Fig. 4, available online at www.
giejournal.org).DISCUSSION
The present work assessed whether gastric mucosa is a
critical regulator of obesity and its related comorbidities,Volume 87, No. 1 : 2018 GASTROINTESTINAL ENDOSCOPY 293
TABLE 2. Lipid profile of the study population. Values are Mean ± SD.
11-wk diet Intervention after HFD
CD HFD HFD D GMD HFD D VSG HFD D sham surgery
Age, wk 15 17, 19, 23
Triglyceride levels, mmol/L 0.85  0.56 1.45  0.83* 2 wk 0.39  0.35* 0.71  0.32 0.94  0.48
4 wk 0.62  0.26* 0.48  0.31* 1.11  0.6
8 wk 0.85  0.26* 0.64  0.22* 1.53  0.88
Total cholesterol, mmol/L 2.75  1.46 4.3  1.7* 2 wk 2.66  0.86 1.92  0.66* 2.72  0.55
4 wk 1.24  0.45* 2  0.88* 3  0.87
8 wk 1.37  0.69* 1.6  0.61* 2.72  0.95
HDL-cholesterol, mmol/L 1.21  0.55 1.41  0.5 2 wk 0.98  0.72* 1.14  0.42* 1.84  0.66
4 wk 0.62  0.27* 0.71  0.26* 1.27  0.5
8 wk 0.7  0.6* 0.66  0.39* 1.42  0.41
LDL-cholesterol, mmol/L 1.68  0.97 2.59  0.8* 2 wk 1.61  0.53* 0.86  0.42 1.07  0.4
4 wk 0.51  0.34* 1.27  0.72 1.67  0.53
8 wk 0.52  0.31* 0.87  0.44 1.21  0.7
Free fatty acid levels, mmol/L 0.69  0.36 1.13  0.37* 2 wk 0.37  0.11* 0.5  0.3* 0.76  0.25
4 wk 0.63  0.35 0.38  0.09* 0.73  0.36
8 wk 0.82  0.16 0.98  0.2 0.81  0.35
Saturated fatty acid levels
Stearic acid, mmol/L 0.31 0.05 0.71  0.28* 2 wk 0.62  0.14 0.41  0.12 0.62  0.21
4 wk 1.05  0.47 0.63  0.27 1.03  0.54
8 wk 0.81  0.13* 0.74  0.1* 1  0.21
Palmitic acid, mmol/L 0.59  0.08 1.26  0.53* 2 wk 1.2  0.27 0.72  0.13 1.02  0.49
4 wk 1.72  0.58 1.14  0.32 1.36  0.33
8 wk 1.21  0.34* 1.23  0.32* 1.9  0.79
Measurements in the animal groups after 15 weeks and after intervention. Values are means  SD of dietary groups (CD, chow diet; HFD, high-fat diet) and intervention groups
(GMD, gastric mucosa devitalization; VSG, vertical sleeve gastrectomy; SH, sham surgery). Significant differences (P < .05) between GMD and VSG compared with SH are
indicated by asterisks.
SD, Standard deviation; HFD, high-fat diet; CD, chow diet; GMD, gastric mucosa devitalization; VSG, vertical sleeve gastrectomy; HDL, high-density lipoprotein; LDL, low density
lipoprotein.
Effect of altering gastric mucosa in obese rats Oberbach et alindependent of alteration in gastric volume. We present
novel data that GMD was associated with signiﬁcant im-
provements in body weight, visceral adiposity, liver lipid
content, and serum metabolic proﬁles. Additionally, GMD
results in diminished food intake, elevated serum bile
acid and CCK levels, and increased intestinal fat malabsorp-
tion. This raises the prospect that the gastric mucosa could
be a new target for those developing less-invasive meta-
bolic therapies.
Our rat model of GMD demonstrated selective ablation
of the gastric mucosa without ulceration, scarring, or histo-
logic impairment of the deeper tissue layers, and hence no
alteration in gastric volume was observed (Fig. 1 and
Supplemental Fig. 3, available online at www.giejournal.
org). As expected, gross and histologic examination of the
mucosa exhibited regeneration at 2, 4, and 8 weeks. This
correlated with a trend toward normalization in the
hormone functioning capacity of the mucosa (eg, AUC for
total ghrelin) (Fig. 2). There was no apparent
inﬂammatory milieu created with the GMD procedure,294 GASTROINTESTINAL ENDOSCOPY Volume 87, No. 1 : 2018with CRP and IL-6 levels being similar to those of sham sur-
gery. Therefore, there is no evidence to suggest that the
changes in eating behavior and weight loss in the GMD
cohort were the result of rats being subjected to a toxic state.
Animal models have beneﬁts as well as caveats. First,
as the average rat’s lifespan is 2.5 to 3 years, every day in
the life of a rat is equivalent to 35 human days.16
Therefore, an 8-week follow-up period in rats is compa-
rable to 5.4 years in humans. Therefore, it is expected
that there is normalization of gut hormone levels over
such period of time, a phenomenon noted in humans
undergoing metabolic surgery17-19 In fact, it is note-
worthy that food intake was signiﬁcantly reduced in
GMD rats at 4 weeks after intervention (comparable to
2.7 years in humans). Second, changes in food intake
behavior in rats cannot be directly translated to hu-
mans.20 In the clinical setting, patients undergo
intensive diet and exercise regimens after metabolic
surgery. On the contrary, rats in this study were
continued on an HFD ad libitum, potentiallywww.giejournal.org
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Figure 4. Gastric mucosal devitalization (GMD) resulted in a signiﬁcant reduction in liver lipid content and size. A, Liver lipid content was measured at 2,
4, and 8 weeks after surgery. GMD rats had signiﬁcantly reduced liver lipid content at 4 and 8 weeks compared with sham surgery rats. The increase in
lipid content at 2 weeks was likely a consequence of liver metabolism of fat as a result of rapid reduction in visceral adiposity after intervention. B,
Hematoxylin & eosin staining demonstrates the increased intracellular amount of lipid droplets in high-fat diet rats compared with chow diet rats
(H&E, orig. mag. 40). Immunoﬂuorescence illustrates lipid droplet concentration and size at 4 weeks (Nile red stain, orig. mag. 40). GMD results
in a dramatic reduction in the concentration and size of lipid droplets. CD, chow diet; HFD, high-fat diet; GMD, gastric mucosa devitalization; VSG, vertical
sleeve gastrectomy; SH, sham surgery.
Oberbach et al Effect of altering gastric mucosa in obese ratsdiminishing the effectiveness of the procedure. Third,
rats continue to grow and gain weight throughout
their lifetimes, a phenomenon not seen in humans.
The explanation for the mechanisms behind the
improved body composition and metabolic proﬁle seen
in GMD rats was not the objective of this study. Regardless
of the exact mechanism, the ﬁndings observed are likely to
be explained by a combination of direct and indirect effects
of GMD on the GI tract. Direct effects are related to
changes in gastric origin (eg, ghrelin), whereas indirect ef-
fects are a result of GMD’s downstream effects on the in-
testine (eg, GLP-1, CCK), liver, peripheral tissues, and the
brain.
Ghrelin is an orexigenic hormone that is predominantly
secreted by X/A-like cells of the gastric mucosa (predomi-
nantly in the gastric fundus in humans).5,21-25 GMD re-
sulted in a signiﬁcant and durable reduction in total
serum ghrelin levels after an OGTT compared with sham
surgery; however, active ghrelin levels were reduced within
the ﬁrst 4 weeks only, corresponding to observed changes
in food intake (Table 1 and Supplemental Table 1). In rats,
ghrelin immunoreactive cells are most abundant in the
lesser and greater curvature of the gastric body, with no
immunoreactive cells found in the fundus of the
stomach.26,27 Furthermore, cell density is highest
along the lesser curvature. GMD in rats was performed
with APC being applied predominantly along thewww.giejournal.orggreater curvature. Therefore, the effects of this procedure
could be superior in a clinical setting. However, the path-
omechanism behind ghrelin’s inﬂuence on weight loss
interventions is vigorously debated, with 1 rodent study
revealing that the beneﬁts of VSG are ghrelin
independent.28
GMD rats did not increase food intake over sham sur-
gery rats to compensate for the reduced fat mass, a phe-
nomenon associated with weight loss as a result of
chronic calorie restriction.29,30 Therefore, it appears
that GMD rats defend a new lower body weight. This
new set-point is 1 consequence of a change in the cen-
tral regulation of gut hormones.31,32 It is fascinating
that similar ﬁndings were noted in VSG rats, who,
despite having a diminished gastric volume, were able
to increase food intake to comparable quantities as
sham surgery rats. This provides further evidence for
the irrelevance of gastric volume on the outcomes of
metabolic surgery. A potential explanation may be
derived from the concept that gastric nutrient percep-
tion is not exclusively mechanosensitive. Rodent studies
have demonstrated expression of taste receptors on
ghrelin cells in the gastric mucosa, and alterations in
taste receptor signalling may inﬂuence food intake and
gastric motility.33,34
Additionally, alterations in transient receptor
potential channels within the gastric mucosa have beenVolume 87, No. 1 : 2018 GASTROINTESTINAL ENDOSCOPY 295
Figure 5. Gastric mucosal devitalization (GMD) rats had a lower body weight and reduced intrabdominal adiposity compared with sham surgery rats. The
morphologic ﬁndings at 8 weeks postoperative were compared with those of sham surgery. GMD rats appeared smaller in size compared with sham sur-
gery rats. Additionally, GMD rats had grossly diminished adiposity of the greater omentum and surrounding intestinal organs. Findings were quantiﬁed in
Figure 2. HFD, high-fat diet; SH, sham surgery; GMD, gastric mucosal devitalization; VSG, vertical sleeve gastrectomy.
Effect of altering gastric mucosa in obese rats Oberbach et aldemonstrated to inﬂuence gastric motility and nutrient
tolerance.35,36 In addition to the aforementioned, it is likely
that there are other yet unrecognized receptors in the
gastric mucosa that will be rendered ineffective with GMD.
The indirect effects of GMD are a result of changes in
anorexigenic hormones (CCK, GLP-1, peptide YY), bile
acids, peripheral and liver lipid content, and in intestinal
fat absorption. GMD results in elevations in postprandial
CCK levels, released as a result of duodenal exposure to
fat and protein-rich chyme. The elevation in CCK levels
may have contributed to the improved liver lipid and
glucose metabolism observed in GMD rats because of its ef-
fects on bile acid synthesis.37 Furthermore, CCK likely
contributed to the reduction in food intake as a result of
centrally acting effects on satiation.38 Additionally, GMD
resulted in an elevation in total GLP-1 levels in the postpran-
dial state at 8 weeks. The elevation in GLP-1 levels and the
hormone’s effects on satiation also may explain the
observed reduced food intake inGMD rats.39,40 Additionally,
elevated GLP-1 levels likely contributed to the observed
improved glucose metabolism as indicated by the reduction
in HOMA-IR.41,42 However, there was no corresponding
elevation in postprandial active GLP-1 levels. The interpreta-
tion of GLP-1 in the pathophysiology behind VSG is unclear,
with GLP-1 receptor knockout models demonstrating296 GASTROINTESTINAL ENDOSCOPY Volume 87, No. 1 : 2018improvement in glucose homeostasis43 Other factors such
as reduced visceral adiposity and increased serum and
liver bile acid levels also likely led to the glucose mediated
beneﬁts observed in GMD rats.10,44
Consistent with reductions in visceral adiposity, GMD
resulted in signiﬁcant reductions in serum and liver lipid
content and size (Fig. 4). These ﬁndings may be
secondary to the reduction in visceral adipose tissue,
leading to altering of adipose tissue macrophages and
ceramide levels, which are directly correlated with
hepatic steatosis.45,46 Additionally, a reduction in hepatic
steatosis may be due to increased serum bile acid
levels.10,47 Importantly, GMD resulted in a signiﬁcant
reduction in the toxic serum FFA palmitic acid, despite
the persistence of HFD, and conceivably resulted in
improving glucose metabolism.48,49
Intestinal malabsorption of fat in GMD rats was demon-
strated by a signiﬁcant increase in the concentration of
fecal FFA compared with sham surgery rats at 8 week
follow-up (Supplemental Fig. 4). This may explain the
reduced visceral adiposity and improved serum and
liver lipid proﬁles seen in GMD rats. Although the
exact mechanisms behind intestinal malabsorption and
other metabolic parameters are still to be elucidated,
these observed effects have important translationalwww.giejournal.org
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Figure 6. Serum and liver total bile acids and cholecystokinin after 2 hours oral glucose tolerance stimulation test. Bile acids are signalling molecules that
regulate lipid, glucose, and energy metabolism. A, Gastric mucosa devitalization (GMD) resulted in an early increase in serum bile acid levels at 2 weeks
(176%). B, GMD resulted in an early increase in liver bile acid levels at 2 weeks (75%). C, GMD resulted in a signiﬁcant increase in cholecystokinin at 4
weeks compared with sham surgery (455%). CD, chow diet; HFD, high-fat diet; GMD, gastric mucosal devitalization; VSG, vertical sleeve gastrectomy;
SH, sham surgery.
Oberbach et al Effect of altering gastric mucosa in obese ratsrelevance in the ﬁght against obesity and its related
comorbidities.
This current work is novel in that it identiﬁes the gastric
mucosa as a critical regulator of obesity and its metabolic
effects. The key observation is that GMD produces a reduc-
tion in body weight, reduction in visceral adiposity,
improved serum lipid and glucose proﬁles, and reduced
liver lipid accumulation contentdall pivotal facets of anywww.giejournal.orgmetabolic therapy. Although the gastric mucosa has the
ability to regenerate, the advantage of an endoscopic pro-
cedure is the ease at which repeated interventions can be
performed.
Therefore, it appears that altering gastric mucosa should
be considered as a possible target for the development of a
less-invasive intervention in the treatment of obesity and
metabolic disease.Volume 87, No. 1 : 2018 GASTROINTESTINAL ENDOSCOPY 297
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Effect of altering gastric mucosa in obese rats Oberbach et alSUPPLEMENTARY METHODS 1
PHENOTYPICAL CHARACTERIZATION AND
BLOOD PLASMA ANALYSIS
Blood was sampled from the retroorbital space after the
animals were anesthetized with ether or direct cardiac
puncture immediately after death. Fasting glucose and fast-
ing insulin levels were measured by using commercial
assay kits (Glucose Colorimetric Assay Kit, Cayman Europe,
Estonia; Rat Insulin ELISA, ALPCO Diagnostics, Salem, NH).
The homeostatic model assessment of insulin resistance
(HOMA-IR) was calculated according to the method
described by Cacho et al.1 Plasma levels of triglycerides,
total cholesterol, high-density lipoprotein (HDL)-
cholesterol, and total free fatty acids (FFA) were
measured by using enzymatic assay kits (Serum
Triglyceride Quantiﬁcation Kit, Total Cholesterol and
HDL-Cholesterol Assay Kit, Cell Biolabs, San Diego, Calif;
Free Fatty Acid Quantiﬁcation Kit, BioVision, Milpitas,
Calif). Low-density lipoprotein (LDL)-cholesterol was calcu-
lated according to Friedewald’s formula.15 Single chain
fatty acids were measured by using enzymatic assay kits
(Labor Dr Bayer, Leinfelden-Echterdingen, Germany). GI
hormones were measured by commercial enzyme-linked
immunosorbent assay (ELISA) kits (ghrelin: Rat/mouse (to-
tal and active), Millipore, Billerica, Mass, GLP-1: Rat/mouse
(total and active), Millipore, Billerica, Mass, PYY: Mouse/Rat
ELISA, Alpco Diagnostics, NH). Creatinine (blood and
urine), interleukin-6 (IL-6) and C-reactive protein (CRP)
were measured by using commercial biochemical and
ELISA assay kits (Creatinine [serum] and Creatinine
[urinary] Assay Kit, Cayman Europe; Rat IL-6, Quantikine
ELISA Kit, R&D Systems, Wiesbaden-Nordenstadt,
Germany; AssayMax Rat C-Reactive Protein (CRP) ELISA
Kit, Assaypro, St. Charles, Mo). Serum bile acids and chole-
cystokinin were measured by using ELISA assay kits (Rat
Total Bile Acids Assay Kit, BIOTREND Chemikalien
GmbH, Köln, Germany; Cholecystokinin (CCK) EIA Kit,
Phoenix Europe GmbH, Karlsruhe, Germany).REFERENCE
1. Cacho J, Sevillano J, de Castro J, et al. Validation of simple indexes to
assess insulin sensitivity during pregnancy in Wistar and Sprague-
Dawley rats. Am J Physiol Endocrinol Metab 2008;295:E1269-76.PROTEIN AND LIPID ANALYSIS BY USING ELISA
AND ACTIVITY ASSAYS
Tissue samples were snap frozen in liquid nitrogen and
stored at -80C until further use. Tissue was homogenized299.e1 GASTROINTESTINAL ENDOSCOPY Volume 87, No. 1 : 2018with Ultra Turrax (VWR International, Darmstadt, Ger-
many), sonicated on ice 3 times for 3 to 5 seconds each
with 9 cycles at 80% energy by using a Sonoplus (Bandelin,
Berlin, Germany). The Appendices homogenates were
centrifuged at 14,000 g for 10 minutes, and protein concen-
tration was determined (Pierce BCA Protein Assay Kit, Life
Technologies, Darmstadt, Germany). From tissue, the lipid
content, adipophilin, lipase activity, and liver bile acids
were measured according to manufacturer’s instructions
(Lipid Quantiﬁcation Kit, Cell Biolabs; Rat Adipose Differ-
entiation Related Protein ELISA, BlueGeneBiotech,
Shanghai, China; Lipase Activity Assay Kit, Sigma-Aldrich,
Taufkirchen, Germany; Rat Total Bile Acids Assay Kit,
BIOTREND Chemikalien GmbH).Tissue histology
Stomach histology was evaluated by using hematoxylin
& eosin (H&E) staining in 8-mm parafﬁn sections. Liver his-
tology was performed on 8-mm parafﬁn sections and cryo-
genic sections. Images were vizualized at a Leica Diaplan
microscope (Leica Microsysteme, Wetzlar, Germany)
equipped with a digital color camera DP25 (Olympus,
Hamburg, Germany) by using a 10 objective and Cell^ P
morphometry software (Olympus Soft Imaging Solutions,
Muenster, Germany).Confocal immunoﬂuorescence analysis
Indirect immunoﬂuorescence was performed with
adequate Cy2- conjugated secondary antibody (goat
antimouse IgG; Dianova, Hamburg, Germany). Confocal
scans were taken at a Zeiss LSM-5 Pascal (Carl Zeiss,
Jena, Germany). Multitrack scanning avoided
“bleeding through” of the ﬂuorescence in double-labeling
experiments. The detection system was calibrated on
control stains with no primary antibody. Cell nuclei
were stained with DAPI (IS Mounting Medium DAPI,
Dianova).www.giejournal.org
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Supplemental Figure 1. Allocation of animals demonstrated as a ﬂow
diagram. CD, chow diet; HFD, high-fat diet; GMD, gastric mucosa devital-
ization; VSG, vertical sleeve gastrectomy; SH, sham surgery.
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Supplemental Figure 2. Principle and histology of gastric mucosal devitalization (GMD) in rat stomach before (A), during (B), and 8 weeks after (C) the
GMD procedure. A, A surgical entrance is created through a 1-cm ventral incision. The instruments were inserted into the mobilized stomach, which
shows normal anatomic areas. Hematoxylin & eosin (H&E) staining revealed prominence of the mucosal layer. 1, mucosa; 2, muscularis mucosae; 3, sub-
mucosa; 4, muscularis propria. B, The GMD procedure was performed on the stomach while outside the abdominal cavity. The tissue changed from a
pink to golden brown color after devitalization (arrows). H&E staining immediately after the procedure demonstrated devitalization of the mucosa. C, At
8 weeks after intervention, the rats showed signiﬁcantly reduced amounts of abdominal fat. The stomach retained only small cicatrices from the access of
instruments. GMD, gastric mucosal devitalization.
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Supplemental Figure 3. Gross appearances of the explanted stomach at
8-week follow-up. There was no apparent difference in volume between
sham surgery (SH) (A) and gastric mucosal devitalization (GMD) (B) stom-
achs. Vertical sleeve gastrectomy (VSG) stomachs (C) demonstrated
a signiﬁcantly reduced volume in relation to both GMD and SH. GMD,
gastric mucosal devitalization; VSG, vertical sleeve gastrectomy; SH, sham
surgery.
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Supplemental Figure 4. Gastric mucosal devitalization (GMD) results in a progressive increase in concentration of fecal-free fatty acids (FFA) compared
with sham surgery (SH). At 8 weeks, GMD rats had a signiﬁcantly increased concentration of fecal FFA compared with SH rats. Similar ﬁndings were
observed in vertical sleeve gastrectomy (VSG) rats compared with SH rats. FFA, free fatty acids; CD, chow diet; HFD, high-fat diet; GMD, gastric mucosa
devitalization; VSG, vertical sleeve gastrectomy; SH, sham surgery.
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SUPPLEMENTAL TABLE 1. Active and total GI hormones of the study population. Values are Mean ± SD.
11-week diet Intervention after HFD
CD HFD HFD D GMD HFD D VSG HFD D SH
Age, wk 15 17, 19, 23
Fasting total ghrelin, ng/mL 3.23  1.59 3.01  1.06 2 wk 2.28  1.5* 2.06  0.73* 3.88  1.53
4 wk 1.17  0.23* 0.96  0.24* 1.76  0.46
8 wk 0.84  0.3* 1.38  0.56 1.41  0.54
Fasting active ghrelin, ng/mL 0.55  0.3 0.66  0.22 2 wk 0.53  0.38* 0.91  0.6 1.6  0.9
4 wk 0.47  0.19 0.45  0.2 0.42  0.23
8 wk 0.44  0.16 0.37  013 0.45  0.31
AUC total ghrelin 929  340 880  173 2 wk 681  222* 686  228* 976  295
4 wk 369  74* 253  42* 615  210
8 wk 267  63 433  136 326  72
AUC active ghrelin 188  72 178  55 2 wk 99  33* 264  60 314  103
4 wk 101  11* 137  64 147  37
8 wk 140  48* 97  32 77  26
Fasting total GLP-1, pmol/L 15.7  6.9 14.6  5.9 2 wk 41.5  18.4* 27.2  15.6 21.6  5.7
4 wk 41.5  7 33.6  9.5 39.4  11.6
8 wk 30.7  10.8* 28.2  16.1* 13.6  7.6
Fasting active GLP-1, pmol/L 3.4  1.3 2.1  0.4* 2 wk 6.2  3.6 6.4  2.3 5.7  1.8
4 wk 3.5  1.3 4.6  1.6 3.3  1.1
8 wk 5  1.8 4.8  1.7 5.9  4.8
AUC total GLP-1 231  81 265  93 2 wk 710  361* 412  206 357  101
4 wk 681  142 692  254 711  195
8 wk 622  265 1918  968* 340  203
AUC active GLP-1 70  28 49  8* 2 wk 133  69 93  22 103  21
4 wk 69  25 138  33* 64  19
8 wk 107  32 128  43 105  53
Fasting peptide YY, ng/mL 0.32  0.13 0.4  0.26 2 wk 1.02  0.64* 1.06  0.69* 0.42  0.25
4 wk 0.28  0.08* 0.38  011* 0.18  0.04
8 wk 0.4  0.14 0.45  0.19 0.51  0.29
AUC peptide YY 103  28 88  31 2 wk 283  153* 242  140 142  20
4 wk 110  48* 126  32* 66  18
8 wk 136  36 225  74* 133  57
Measurements in the animal groups after 15 weeks and after intervention. Values are means  SD of dietary groups (CD, HFD) and intervention groups (GMD, VSG, SH).
Significant differences (P < .05) between GMD and VSG compared with SH are indicated by asterisks.
SD, Standard deviation; HFD, high-fat diet; CD, chow diet; GMD, gastric mucosal devitalization; VSG, vertical sleeve gastrectomy; SH, sham surgery; AUC, area under the curve
based on 4 time points (baseline, 30 min, 60 min, 120 min) 2-hour oral glucose tolerance stimulation; GLP-1, glucagon-like peptide -1.
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ABSTRACT
Background and study aims In lieu of the drawbacks of
metabolic surgery, a method of mimicking resection of the
gastric mucosa could be of value to those with obesity-
related cardiovascular disease (CVD). Our study aims to in-
vestigate the effect of gastric mucosal devitalization (GMD)
on blood pressure (BP) and cardiovascular lipid deposition
in a rat model of obesity.
Methods GMD of 70% of the stomach was achieved by ar-
gon plasma coagulation. GMD was compared to sleeve gas-
trectomy (SG) and sham (SH) in a high-fat-diet-induced rat
model of obesity (48 rats). At 8 weeks, we measured nonin-
vasive BP, renin, vessel relaxation and ghrelin receptor reg-
ulation in the aorta. In addition, we quantified cardiac lipid
deposition and lipid droplet deposition in cardiac muscle
and aorta.
Results GMD and SG were observed to have similar reduc-
tions in body weight, visceral adiposity, and serum lipid
profile compared to SH rats. GMD resulted in a significant
reduction in arterial BP compared to SH. Furthermore,
there were significant reductions in plasma renin activity
and percentage of phenylnephrine constriction to acetyl-
choline at the aortic ring in GMD rats compared to SH, pro-
viding insights into the mechanisms behind the reduced BP.
Interestingly, the reduced BP occurred despite a reduction
in endothelial ghrelin recteptor activation. Cardiac lipid
content was significantly reduced in GMD rats. Lipid de-
position, as illustrated by Nile Red stain, was reduced in car-
diac muscle and the aorta.
Conclusion GMD resulted in a significant improvement in
BP, renin and cardiovascular lipid deposition. GMD deserves
further attention as a method of treating obesity-related
CVD.
Original article
Supplementary material, Supplementary Table 1
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https://doi.org/10.1055/a-0990-9683
* These authors contributed equally
Oberbach Andreas et al. Gastric mucosal devitalization… Endoscopy International Open 2019; 07: E1605–E1615 E1605
Published online: 25.11.2019
Introduction
Despite increased public awareness of the epidemic of obesity,
the percentage of the population afflicted with obesity and its
associated comorbidities, particularly cardiovascular disease
(CVD), continues to rise [1]. Widely accepted methods of treat-
ing obese patients with CVD are diet and lifestyle therapies,
pharmacotherapy and metabolic surgery [2]. Metabolic sur-
gery, also know as bariatric surgery, is currently the most effec-
tive treatment for obesity and its associated cardiovascular co-
morbidities, such as hypertension, cerebrovascular disease,
congestive heart failure and myocardial infarction [3, 4] The
benefits of metabolic surgery go beyond their ability to simply
produce weight loss and these surgeries alter critical signaling
and metabolic pathways [5–7]. However, as they are invasive
and involve multiple irreversible alterations to the gastrointes-
tinal tract, widespread dissemination is unlikely to occur [8, 9].
Furthermore, metabolic surgery, due to its risk profile, is not a
suitable strategy to prevent obesity-related CVD. Therefore,
there arises a need to decipher the component of metabolic
surgery that yields the greatest benefit to facilitate develop-
ment of targeted minimally invasive therapies [10, 11].
We have been investigating the hypothesis that excision of
the gastric mucosa is the key component to weight-indepen-
dent mechanisms observed after sleeve gastrectomy (SG)
[12–14]. Our previously published works have investigated an
alternative to excision, devitalization of the gastric mucosa, in
an obese rat and porcine model [12, 13]. We have elucidated
that gastric mucosal devitalization (GMD) in a high-fat diet in-
duced rat model of obesity resulted in reduced body weight
and visceral adiposity, improved serum lipid profile and mar-
kers of insulin resistance, and reduced liver lipid content [12].
In our porcine study, we demonstrated that GMD resulted in
significant relative reductions in body weight and visceral adip-
osity, as well as a significant reduction in liver, skeletal and car-
diac muscle lipid droplet (LD) deposition [13]. In light of these
encouraging outcomes, we investigated the influence of GMD
on the most sinister of obesity-related comorbidities, cardio-
vascular-related diseases.
Our hypothesis was that GMD would result in a reduction in
blood pressure as well as reduction in LD deposition in cardiac
muscle and aorta. Blood pressure was a selected outcome due
to hypertension’s known association with debilitating comor-
bidities such as heart, cerebrovascular, and renal disease [15].
Quantification of LD deposition in cardiac muscle was evaluat-
ed because cardiac lipotoxicity is a key contributor to heart fail-
ure, a sinister and often irreversible morbidity [16]. To investi-
gate our hypothesis that the gastric mucosa is a valuable target
for treatment of CVD, we used our previously validated high-fat
diet (HFD) rat model and method of GMD to selectively eradi-
cate the gastric mucosa, without altering gastric volume or
intestinal anatomy [12]. To assess the independent effects of
the gastric mucosa, we included a rat model of SG, which com-
bines excision of gastric mucosa with the addition of a reduc-
tion in gastric volume.
Materials and methods
Animals
All rat procedures followed international guidelines for preven-
tion of animal cruelty and were approved by the “Landesdirek-
tion” Leipzig, the local authority for animal care [17]. Four-
week-old male Sprague-Dawley rats (n =48; MEZ, Medical Ex-
perimental Center, University of Leipzig, Leipzig, Germany;
100–150g) were used. Further details can be found in the Sup-
plementary Methods section.
Study design
We used our diet-induced rat model of obesity characterized by
increased body weight, visceral and subcutaneous adiposity,
dyslipidemia and impaired glucose metabolism [12, 18, 19]. In
Part 1, we validated our HFD-induced model of obesity. Sixteen
rats were randomized into two groups receiving either chow
diet (CD, n =8) or high-fat diet (HFD, n=8) with free access to
food and water. Body weight, body mass index (BMI), visceral
and subcutaneous adiposity, glucose, insulin, homeostatic
model assessment for insulin resistance (HOMA-IR) and inflam-
matory markers were measured after an additional 11 weeks. In
Part 2, we compared GMD, SG, sham (SH) and CD. We used an-
other 24 rats that had been fed a HFD for 11 weeks and ran-
domized them into three intervention cohorts (GMD, n=8; SG,
n =8; sham (SH), n =8) and one CD cohort (CD, n=8) to assess a
variety of outcomes after an additional 8 weeks. HFD was con-
tinued in all intervention groups during the subsequent 8-week
period until sacrifice (age 23 weeks).
Outcomes assessed included body composition and serum
metabolic profile, serum orexigenic and anorexigenic hor-
mones, blood pressure and plasma renin, aortic function after
concentration-dependent stimulation. endothelial ghrelin re-
ceptor abundance in the aorta and abundance of lipid content
and lipid droplet associated proteins in cardiac muscle and aor-
ta. Detailed descriptions of the methods of measurement of the
above outcomes can be found in the Supplementary Methods
section.
Interventions
The interventions were performed in an identical manner to
that reported in our original GMD study in a rat model and fur-
ther details can be found in the methods and Supplementary
Methods section of that manuscript [12].
Gastric mucosal devitalization (GMD)
After a laparotomy incision and mobilization of the stomach
outside the abdominal cavity, a small gastric incision in the fun-
dus was followed by insertion of a 2-mm rigid endoscope and a
1.5-mm argon plasma coagulation (APC) probe (VIO 300D/
APC2-HF-generator; ERBE Elektromedizin, Tubingen, Germa-
ny). The activated probe was then fired (Pulsed APC, effect 2 at
25W with an argon flow rate of 0.2 L/min) using a non-contact
technique for 30 seconds. We selectively ablated 70% of the
surface area of the stomach along the greater curvature aspect
to match the amount of mucosa removed at SG.
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Sleeve gastrectomy (SG)
A laparotomy incision was performed and the stomach mobi-
lized outside the abdominal cavity. The lateral 70% of the stom-
ach was excised using a TX30B 30-mm staple gun (Johnson &
Johnson MEDICAL GmbH, Norderstedt, Germany) leaving a tub-
ular gastric remnant in continuity with the esophagus and duo-
denum.
Sham surgery (SH)
A laparotomy incision was made and the stomach mobilized
outside the abdominal cavity. A gastric incision was performed
to allow entry of an 8 Fr catheter and the stomach lavaged with
20mL of sterile water at 37 °C.
Postoperative care
Postoperative care included daily subcutaneous injection of an-
tibiotics (0.1mL/100g ceftriaxone-ratiopharm 1.0, Ratiopharm
GmbH, Ulm, Germany) for 5 days and daily admixing of analge-
sic (0.5mL Metamizol (Ratiopharm GmbH, Ulm, Germany) + 30
mL 20% glucose +70mL water to the water for 2 days). Diet was
resumed ad libitum on post-intervention Day 2.
Statistical analysis
Data analysis was performed using GraphPad Prism v6.0
(GraphPad Software, La Jolla, California, United States).
Data are shown asmean± SD. Significant differences between
the groups are indicated by bars and/or asterisks (P< .05). One
asterisk signifies P < .05, two asterisks P < .01, three asterisks
P< .001 and four asterisks P< .0001. Further details on statistical
analysis can be found in the Supplementary Methods section.
Results
Part 1, Validation of the model
HFD results in increased body weight and cardiovascular
alterations
HFD resulted in a significant increase in body weight (31%),
visceral adiposity (39%) compared to CD after 11 weeks (▶Ta-
ble1). Serum lipid and glucose profiles were appropriately de-
ranged in HFD rats. There were no differences in abundance of
serum gut hormones (ghrelin, GLP-1 and PYY) after 11 weeks of
HFD. Noninvasive systolic (132±3mmHg vs 116±4mmHg, P<
0.001) and diastolic (99±4mmHg vs 92±3mmHg, P<0.01)
blood pressure were significantly increased in HFD compared
to CD (▶Fig. 1a). Further results are found in the Supplemen-
tary Results section.
▶ Table 1 Characteristics of the study population phenotype.
mean ± SD 11-weeks diet 8 weeks after intervention
CD HFD HFD+GMD HFD+SG HFD+SH CD
n 8 8 8 8 8 8
Age (weeks) 15 15 23 23 23 23
Body weight (g) 424 ±56 555±35* 521±62* 586±49 616±35 549± 34*
BMI (g/cm²) 0.7 ± 0.07 0.79±0.03* 0.73±0.06* 0.75± 0.06* 0.81±0.02 0.75±0.04*
Visceral body fat (g) 6.2 ± 2.5 14.8 ±5.3* 10.8 ±5.5* 13.2 ± 6.3* 26.1 ±8.6 11.7 ±4.8*
Triglycerides (mmol/L) 0.80 ±0.59 1.53±0.69* 0.78±0.17* 0.68± 0.2* 1.63±0.91 0.79±0.26*
Total cholesterol (mmol/L) 2.49 ±0.89 3.75±1.06* 1.2 ±0.49* 1.49± 0.54* 2.95±0.76 2.72±0.47
HDL cholesterol (mmol/L) 1.24 ±0.39 1.36±0.38 0.37±0.3* 0.41± 0.25* 1± 0.24 0.92±0.28
LDL cholesterol (mmol/L) 0.89 ±0.52 1.69±0.70 * 0.48±0.3* 0.77± 0.36 1.21±0.76 1.44±0.22
Fasting glucose (mmol/L) 4.9 ± 0.6 5.9 ±0.4* 5.3 ±0.4* 5.7 ±0.6* 6.4 ± 0.5 5.0 ±0.3*
Fasting insulin (mmol/L) 1.35 ±0.5 2.19±0.8* 0.93±0.6* 0.75± 0.2* 1.99±0.7 1.03±0.2*
HOMA-IR 1.42±0.6 2.77±1.1* 1.06±0.6* 0.93± 0.3* 2.69±0.9 1.10±0.2*
CRP (mg/mL) 0.55±0.2 0.40±0.1 0.66±0.1 0.87± 0.7 0.75±0.5 1.22±0.7
IL-6 (pg/mL) 243 ±26 231±33 293±81 292±100 255±62 217± 62
Measurements in the animal groups at 15 weeks of age (11 weeks of HFD) and 23 weeks of age (8 weeks after intervention). Values are means +SD of dietary groups
(CD, chow diet; HFD, high-fat diet) and intervention groups (GMD, gastric mucosa devitalization; SG, sleeve gastrectomy; SH, sham surgery). Significant differences
(P < .05) between GMD and SG compared with SH are indicated by asterisks. CD, chow diet; HFD, high-fat diet; GMD, gastric mucosal devitalization; SG, sleeve gas-
trectomy; SH, sham operation; BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment of in-
sulin resistance; AUC 2h oGTT, area under the curve based on five timepoints (baseline, 15min, 30min, 60min, 120min) of 2-hour oral glucose tolerance test; CRP,
C-reactive protein; IL-6 ,interleukin 6.
*1 Values are mean+SD
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Part 2 – Randomized comparison effects of GMD, SG
and SH in HFD rats
Results of our technique of using APC to selectively devitalize
the gastric mucosa, without damage to deeper tissue layers or
alteration in gastric volume have been previously reported [12].
Body composition and serum metabolic profile
GMD resulted in a significant reduction in body weight (521±
62g vs 616±35g, P <0.01) and visceral adiposity (10.8 ±5.5 g
vs 26.1±8.6g, P<0.001) compared to SH at 8 weeks (▶Table
1). There was a significant reduction in triglycerides and total
cholesterol in both GMD and SG compared to SH rats (▶Table
1). GMD was able to significantly lower LDL cholesterol at 8
weeks compared to SH (0.48±0.3mmol/L vs 1.21±0.76mmol/
L, P<0.05). Fasting glucose and fasting insulin were significant-
ly lower in GMD (5.3 ±0.4mmol/L vs 6.4 ±0.5mmol/L, P<0.001;
0.93±0.6mmol/L vs 1.99±0.7mmol/L, P<0.001) and SG (5.7 ±
0.6mmol/L vs 6.4 ±0.5mmol/L, P<0.05; 0.75±0.2mmol/L vs
1.99±0.7mmol/L, P<0.01) rats compared to SH. To illustrate
changes in insulin resistance, HOMA-IR was also significantly
lower in GMD (1.06±0.6 vs 2.69±0.9, P<0.001) and SG (0.93±
0.3 vs 2.69±0.9, P<0.001) rats compared to SH. There were no
significant differences with regards to C-reactive protein (CRP)
and Interleukin-6 (IL-6) (▶Table 1).
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▶ Fig. 1 Regulation of blood pressure and renin activity in the study population. Measurements in the animal groups at 15 weeks of age (11
weeks of HFD) and 23 weeks of age (8 weeks after intervention). a Noninvasive measurement of blood pressure using a tail cuff setup revealed
an increased systolic and diastolic blood pressure in rats after 11 weeks of feeding HFD compared to CD rats. Eight weeks after intervention,
GMD treated rats showed significant reduction of both pressure values compared to SH. b Plasma renin activity was not altered after receiving
11 weeks HFD. Eight weeks after intervention, renin activity was significantly reduced in GMD and SG rats. CD, chow diet; HFD, high-fat diet;
GMD, gastric mucosal devitalization; SG, sleeve gastrectomy; SH, sham operation
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Regulation of serum orexigenic and anorexigenic
hormones
There was a high biological variation in abundance of serum
ghrelin, GLP-1 and PYY when measured after being fasted for
10 hours or following oral glucose stimulation by a 2-hour oral
glucose tolerance test (OGTT) (Supplementary Table1). Fast-
ing total serum ghrelin levels were significantly reduced in
GMD compared to SH at 8 weeks (0.81±0.29ng/mL vs 1.43±
0.58ng/mL, P<0.05). However, fasting active ghrelin levels
were not significantly different between GMD, SG and SH (Sup-
plementary Table 1). The 2-hour OGTT (presented as area un-
der the curve [AUC]) in the GMD group did not reveal a signifi-
cant reduction in total ghrelin, but surprisingly, did show a sig-
nificant increase in active AUC active ghrelin compared to SH
(132 ± 45 vs 81±25, P<0.05) (Supplementary Table 1).
With regards to the other measured gut hormones, fasting
total GLP-1 was significantly higher in GMD compared to SH
(29.2 ± 6.3 pmol/L vs 14.9±7.2pmol/L, P <0.05) (Supplemen-
tary Table1). The 2-hour OGTT revealed a significant increase
in total GLP-1 in SG compared to SH rats (29±17pmol/L vs
14.9±7.2 pmol/L, P<0.05). Such statistical significance was
not reached in the GMD cohort. Neither fasting nor 2-hour
OGTT Neuropeptide PYY was not significantly different be-
tween the intervention cohorts (Supplementary Table1).
Blood pressure and plasma renin
Systolic and diastolic blood pressure were significantly
decreased in GMD rats compared to SH (117±5mmHg vs 131±
3mmHg, P <0.001) and (95±3mmHg vs 106±6mmHg, P<
0.001), respectively (▶Fig. 1a). Systolic blood pressure was sig-
nificantly reduced in SG compared to SH rats (124±4mmHg vs
131±6mmHg, P<0.01) with reductions in diastolic blood pres-
sure not meeting statistical significance (▶Fig. 1a). Plasma re-
nin activity was significantly lower in the GMD cohort compar-
ed with SH (4.75±1.16ng/mL/hr vs 8.24±2.63ng/mL/hr, P<
0.01). A similar reduction in SG rats was also observed (5.57±
1.27ng/mL/hr vs 8.24±2.63ng/mL/hr, P<0.05).
Aortic function after concentration dependent
stimulation
The aortic rings were previously unspecifically stimulated with
80nM KCl to visualize the maximal contraction. The ratio of
KCl/baseline during initial contraction with KCl is presented in
▶Fig. 2a. There were no differences observed between the in-
tervention groups. The phenylephrine (PE)-dependent contrac-
tion is plotted relative to the baseline of each group. There was
a significant difference in the maximal contractile response of
the thoracic aorta to PE between the intervention groups with
the response being significantly higher in the GMD and SG
groups compared to SH (1.54±0.14 vs 1.22±0.15, P<0.01)
and (1.54±0.16 vs 1.22±0.15, P <0.001), respectively (▶Fig.
2b). The acetylcholine (ACh)-dependent relaxation was plotted
relative to the respective maximal PE contraction (100nM). Va-
sodilation in response to ACh illustrated a left shift with respect
to the GMD and SG cohorts compared with SH, indicating an in-
creased sensitivity to vasodilatory stimulus (▶Fig. 2c). The in-
serts are calculated AUC and represent the change in contrac-
tion depending on concentration of the relative stimulus from
Ach (▶Fig. 2c). There was a significant reduction in AUC with
regard to the vasodilation response to Ach in the GMD and SG
groups compared to SH, (481±81 vs 601±65, P<0.05) and
(480±107 vs 601±65, P<0.05), respectively. There was no dif-
ference between the GMD and SG groups.
Endothelial ghrelin receptor in rat aorta
Ghrelin has been shown to have a depressant effect on vascular
reactivity, thus promoting a vasodilatory response and subse-
quent reduction in BP in the rat aorta. Therefore, in view of the
anticipated reduction in circulating ghrelin in the GMD and SG
rats compared to SH, we sought to investigate the ghrelin re-
ceptor response to the various interventions. For reference, we
illustrate histopathological characteristics of the rat aorta in
▶Fig. 3a. The endothelial layer (no. 2) is where the GHSR recep-
tor is located. Fluorescence microscopy of the aortic wall is
seen in ▶Fig. 3b. Grossly, there is the appearance that GMD
and SG have a decreased abundance of GHSR in the endothe-
lium compared to SH. Western Blot confirmed there was a sig-
nificantly reduced expression of GHSR in GMD and SG rats com-
pared to SH (▶Fig. 3c). Quantitatively, the GHSR/ G3DPH for
GMD was significantly lower than SH (0.21±0.12 [AU] vs 7.32
±5.69 [AU] [P <0.01]). Similar findings were observed when SG
was compared to SH (0.27±0.09 [AU]vs 7.32±5.69 [AU] [P<
0.05]) (▶Fig. 3d).
Regulation of lipid content and lipid droplet
associated proteins in cardiovascular tissue
Measures of cardiac LD content were attained through several
mechanisms. Cardiac LD content was significantly reduced in
the GMD cohort compared to SH (10.9±5.2 μg/mg vs 26.1 ±
7.6 μg/mg, P<0.001) (▶Fig. 4a). Similar findings are seen
when SG is compared to SH (13.9 ±8.6 μg/mg vs 26.1±7.6μg/
mg, P <0.01). As a frame of reference, we illustrate H&E of car-
diac muscle in ▶Fig. 4b. Immunofluorescence was performed
to grossly illustrate the abundance of LD content and size (Nile
Red stain) in cardiac tissue as well as expression of LD associat-
ed proteins PLIN 1 and PLIN 2 after the respective interventions
(▶Fig. 4c). GMD resulted in a reduction in LD concentration
and size compared to SH. Additionally, PLIN 1 appeared re-
duced in cardiac muscle in GMD rats compared to SH, however,
PLIN 2 was increased in the GMD cohort. In ▶Fig. 4d, PLIN 1
and 2 were quantified by Western Blot. GMD resulted in a sig-
nificant reduction in PLIN 1 compared to SH (2.29±2.34 [AU]
vs 10.23±4.61 [AU], P<0.001) (▶Fig. 4e). With respect to
PLIN 2, GMD resulted in a significant increase compared to SH
(28.27±8.02 [AU] vs 7.09±4.13 [AU], P<0.001). Similar find-
ings were observed in the SG cohort (▶Fig. 4e).
Immunofluorescence with Nile Red stain of cardiac muscle
and aorta is illustrated in ▶Fig. 5. The LD content appears re-
duced in the GMD cohort compared to SH with similar changes
observed in the SG cohort (▶Fig. 5a). Aortic LD content was
also significantly reduced in the GMD cohort compared to the
SH with similar changes observed in the SG cohort (▶Fig. 5b).
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▶ Fig. 2 Ex vivo study of response of the aorta in rats after concentration-dependent stimulation. Measurements in the animal groups at 15
weeks of age (11 weeks of HFD) and 23 weeks of age (8 weeks after intervention). a Aortic rings were stimulated with 80 mM KCl to visualize
their maximal contraction (mean±SEM). b Phenylepinephrine (PE)-dependent contraction is plotted relative to the baseline of each group. The
stimulation was finished when contraction reaches >70% of KCl-contraction. c Acetylcholine (Ach)-dependent relaxation is plotted relative to
the respective maximal PE-contraction (100 nM). Insets are calculated area under the curve (AUC; mean±SEM) and represent the change in
contraction depending on the concentration of the relative stimulus Ach. Statistical tests used were the t-test and one-way ANOVA with a post-
hoc Tukey’s – Kramer test and P<0.05.
CD, chow diet; HFD, high-fat diet; GMD, gastric mucosal devitalization; SG, sleeve gastrectomy; SH, sham operation
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▶ Fig. 4 Regulation of lipid content and lipid droplet-associated proteins perilipin 1 and perilipin 2 in cardiac muscle. Measurements in the ani-
mal groups at 15 weeks of age (11 weeks of HFD) and 23 weeks of age (8 weeks after intervention). Values are means + SD of dietary groups (CD,
chow diet; HFD, high-fat diet) and intervention groups (GMD, gastric mucosa devitalization; SG, sleeve gastrectomy; SH, sham surgery). Sig-
nificant differences (P< .05) between GMD and SG compared with SH are indicated by asterisks. a Cardiac lipid content in the respective inter-
vention groups. Note, GMD rats had significantly reduced cardiac lipid content at 8 weeks compared to SH. b HE-stain illustrates the structural
characteristics of cardiac muscle. c Immunofluorescence of cryo-slices illustrate lipid droplet concentration and size (Nile red stain) as well as
expression of lipid droplet associated proteins PLIN1 and PLIN2 after 8 weeks of intervention (green). d,e Lipid droplet associated proteins were
quantified by Western Blot. CD, chow diet; HFD, high-fat diet; GMD, gastric mucosal devitalization; SG, sleeve gastrectomy; SH, sham operation;
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Discussion
Our previous work demonstrated that devitalization of the gas-
tric mucosa, independent of reduction in gastric volume, re-
duced adiposity and improved lipid and glucose metabolism
[12, 13]. As a result of the observed improvement in the afore-
mentioned metabolic effects, we hypothesized that GMD
would also result in a reduction in important cardiovascular
parameters such a blood pressure and cardiovascular LD de-
position. In a diet-induced HFD rat model of obesity, we pres-
ent novel data that GMD was indeed associated with significant
improvements in blood pressure, plasma renin, as well as cardi-
ac and aortic LD deposition. Therefore, devitalization (or poten-
tially any other method to eliminate or exclude) of the gastric
mucosa deserves further attention as a method to treat obesity
associated CVD.
In NHANES 1999–2010, 35.5% of obese individuals had hy-
pertension and a direct causative relationship exists between
overweight/obesity and hypertension [20–24]. GMD signifi-
cantly reduced both systolic and diastolic BP (▶Fig. 1a). This is
notable as high BP is the leading cause of death worldwide [25].
Furthermore, a strong direct relationship exists between the
level of BP and risk of comorbidities and death [26, 27]. Fortu-
nately, becoming normal weight has been shown to reduce
risk of developing hypertension to a level similar to those who
have never been obese and a linear association exists between
reduction in systolic BP and risk of mortality from CVD [28–
30].
The possible mechanisms behind reduction in BP observed
in GMD are likely explained by the combination of hormonal ef-
fects as well as effects on vascular endothelium (▶Fig. 1, ▶Fig.
2, ▶Fig. 3). Plasma renin activity was significantly lower in GMD
than SH rats (▶Fig. 1), indicating its influence in the observed
relative reduction in BP through its effects on the renin-angio-
tensin system, a major regulatory system of cardiovascular
function. Furthermore, a reduction in renin has cardiovascular
effects that are greater than expected by its ability to lower
blood pressure alone [31, 32]. A lowering of renin activity
would be expected to exert potent antiatherosclerotic effects,
delay the onset of type 2 diabetes and reduce frequency of at-
rial fibrillation and stroke [31, 33]. The mechanism being the re-
duction in renin observed in GMD rats was not ascertained,
however, it is known that even modest weight loss (5%) can re-
sult in a 47% reduction in plasma renin [34].
Vascular endothelium plays an essential role in regulation of
vascular tone and hence BP. Activation of muscarinic receptors
in the endothelium by Ach increases the production of nitric
oxide, leading to vessel relaxation. Our study showed GMD re-
sulted in an increase in endothelium-dependent vasodilation
in response to Ach compared to SH (▶Fig. 2), likely contribut-
ing to lowering of BP.
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▶ Fig. 5 Nile Red stain of cardiac muscle and aorta. a Fluorescence staining with Nile Red illustrating cardiac muscle lipid content. b Fluores-
cence staining with Nile Red illustrating aortic wall lipid content. CD, chow diet; HFD, high-fat diet; GMD, gastric mucosal devitalization; SG,
sleeve gastrectomy; SH, sham operation.
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High expression of GHSR in the heart, kidney and blood ves-
sels is evidence of ghrelin involvement in BP regulation [35]. In
detail, circulating ghrelin levels inversely correlate with blood
pressure, in part, due to its direct vasodilatory activities
through nitric oxide and nitric oxide-independent mechanisms
[35]. Therefore, in light of the finding that fasting serum ghrelin
was significantly reduced in GMD rats compared to SH (Supple-
mentary Table 1), we sought to assess the impact on blood
pressure. Surprisingly, the abundance of GHSR on the endothe-
lium of the rat aorta was significantly lower in GMD rats com-
pared to SH (▶Fig. 3). This may have been expected to have a
negative impact on BP, but was not observed. Such dissociative
findings have been observed in studies evaluating ghrelin and
GHSR, a testament to their complex interplay [35].
Obesity-associated perturbations in cardiac muscle and sys-
temic lipid metabolism are important contributors to cardio-
vascular complications of obesity [16]. In concordance with
the reduction in visceral adiposity, serum lipid profile and liver
LD deposition seen in our earlier work, we further demonstrate
a significant reduction in cardiac muscle LD deposition in GMD
rats compared to SH (▶Fig. 4, ▶Fig. 5). Accumulation of lipid in
non-adipose cells of the cardiovascular system results in cellu-
lar dysfunction and death, otherwise known as lipotoxicity [16].
Increased LD deposition results in endoplasmic reticulum
stress, alterations in autophagy, de novo ceremide synthesis,
oxidative stress, inflammation and changes in gene expression
[16]. These alterations in myocardiac structure and function di-
rectly impair cardiac function, resulting in heart failure [36]. In
addition to a reduction in cardiac muscle LD, we illustrate
grossly a reduction in quantity and size of LD in the aorta.
Therefore, the significant reductions in cardiac muscle and aor-
tic LD deposition have the potential to translate to clinically
meaningful improvements in patients with obesity-associated
CVD.
PLIN1 and PLIN2 are located on LD particle surfaces, hence,
they are they are considered marker proteins for LDs [38]. They
are both present in overabundance within the heart in patients
with coronary artery disease [39]. GMD resulted in a reduction
in PLIN1 but an increase in PLIN2 compared to SH (▶Fig. 4). The
reduction in PLIN1 would imply a potential clinical benefit. The
increase in PLIN2 is more difficult to interpret. Data exist de-
monstrating that PLIN2 is elevated in patients with CVD and
atherosclerosis [40]. On the contrary, PLIN2 has been shown to
improve insulin sensitivity in skeletal muscle, though this find-
ing has not been demonstrated in cardiac muscle [41]. Further
investigation into the interpretation of perilipins is warranted.
Animal models of disease have advantages as well as suffer
inherent limitations. As opposed to humans, the inclusion of
appropriate control groups such as sham surgery, as well as
the ability to control for certain factors (environment, diet) are
clear benefits. In addition, the rat model has widely available as-
says and antibodies allowing for detailed serum and tissue eval-
uation. However, the relatively young age of the rats does not
allow for assessment of reversibility of chronic disease states,
limiting translatability to humans. From an outcomes perspec-
tive, calculation of cardiac function was not performed, a find-
ing that may have allowed demonstration of the effects of lipo-
toxicity on cardiac function.
Conclusion
Herein, we demonstrate that a method of selective eradication
of the gastric mucosa, without alteration in the volume of the
stomach, results in a significant reduction in blood pressure,
plasma renin activity, and cardiac as well as aortic lipid droplet
deposition. This builds on our previous work that GMD results
in a reduction in visceral adiposity as well as an improvement
in lipid and glucose metabolism. The collective metabolic and
cardiovascular benefits observed in this high-fat-diet-induced
obese rat model deserves investigation in humans. Our pre-
vious work in a large animal model demonstrating technical
feasibility, efficacy and safety of GMD, provides evidence that
it is time to translate GMD to a clinical setting (NCT03526263).
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Gastric mucosal devitalization for obesity Kumbhari et alINTRODUCTION
The worldwide prevalence of overweight and obesity in
children, adolescents, and adults has reached pandemic pro-
portions.1 Metabolic surgery, such as Roux-en-Y gastric
bypass (RYGB) or sleeve gastrectomy (SG), is the most
effective and durable weight loss and metabolic therapy.2,3
Metabolic surgery alters the physiologic regulation of
body fat mass, demonstrating the critical role of the GI
tract in the regulation of metabolic function.4 The
mechanisms of action are neither mechanical restriction
nor macronutrient malabsorption and remain poorly
understood.5,6 Furthermore, there appears to be weight-
dependent and weight-independent mechanisms of
action.7,8 Unfortunately, because of its invasiveness and
irreversibility, metabolic surgery is severely underused.9
The development of minimally invasive ﬂexible endoscopic
methods to mimic the effect of metabolic surgery provides
an opportunity to fulﬁll the large unmet need.10
The primary site of regulation of glucose and lipid meta-
bolism remains ambiguous. Human and rodent studies of
RYGB allude to the importance of bypassing the duo-
denum.11 Conversely, SG does not alter nutrient ﬂow
across the duodenum yet induces similar metabolic effects
to RYGB, signifying that the stomach may be a critical
regulator of glucose and lipid homeostasis.2,5 Some have
proposed that the accelerated nutrient transit through the
GI tract seen with SG causes more undigested nutrients to
reach the distal ileum resulting in postprandial increase in
glucagon-like Peptide 1; however, mechanistic evidence
for this is lacking.12 A common element to both surgeries
is the exclusion or resection of the gastric mucosa, an
often-underappreciated neuroendocrine organ.13-15
Our group has been investigating the hypothesis that exci-
sion of the gastricmucosa is a key contributor to the improve-
ment in obesity-related comorbidities perceived after
SG.16,17 We previously demonstrated, in an obese rat model,
that the gastricmucosa is an independent regulator of glucose
and lipid metabolism.18 In that study, gastric mucosal
devitalization (GMD) reduced body weight and visceral
adiposity, improved serum lipid and glucose proﬁles, and
reduced liver lipid content.18 Considering those promising
results, our goal was to translate our technique of GMD into
a large animal model to assess its technical feasibility,
efﬁcacy, and safety. The porcine model was chosen because
it has similar GI anatomy to humans and allows utilization of
commercially available endoscopic equipment. Furthermore,
porcine models are a familiar platform to investigate
endoscopic bariatric therapies before pilot clinical studies.19,20METHODS
Study design
We performed a 3-arm prospective randomized
controlled trial with an 8-week follow-up period. A total176 GASTROINTESTINAL ENDOSCOPY Volume 88, No. 1 : 2018of 23 healthy litter-matched male German saddleback
pigs aged 11 weeks and weighing 30 to 35 kg were
obtained from a commercial, closed-herd pig vendor
(Lehr- und Versuchsgut Oberholz, Großpösna, Saxony,
Germany). This breed of domestic pig was chosen because
of their relatively high body fat mass. Two pigs underwent
GMD; one was killed immediately after the procedure and
the other at 4 weeks to assess gastric histology and
perform immunoﬂuorescence for ghrelin (Fig. 1). For the
purposes of the trial, 21 pigs were randomized equally
into 3 groups: GMD (n Z 7), SG (n Z 7), and sham
(SH) (n Z 7) (Fig. 1).
The primary outcome was a reduction in the propor-
tional change in body weight. Prespeciﬁed secondary out-
comes included absolute body weight, abdominal visceral
adiposity, abdominal subcutaneous adiposity, organ lipid
content, and serum ghrelin level.
The study conditions of the animals are described in
detail in the Supplementary Methods (available online at
www.giejournal.org). All animal procedures followed the
international guidelines for the prevention of animal
cruelty and were approved by the Landesdirektion
Leipzig, the local authority for animal care.21,22
Interventions
Gastric mucosal devitalization. Similar to our pre-
viously published study in an obese rat model, we elec-
ted to use argon plasma coagulation (APC) to devitalize
the gastric mucosa.18 To allow for selective ablation of
the gastric mucosa and to minimize a tissue effect in
deeper gastric wall layers, a submucosal ﬂuid cushion
(0.9% isotonic saline solution/1% methylene blue) was
created before APC.23 Based on a literature search23,24
together with the results of a detailed pilot porcine
dose-ﬁnding study,25 we calculated that pulsed APC
effect 2 at 120 W with an argon ﬂow rate of 1 L/minute
by non-contact technique (VIO 300D/APC2-HF-gener-
ator; Erbe Elektromedizin, Tübingen, Germany) of the
entire gastric body and fundus appeared technically
feasible, effective, and safe. The dose-ﬁnding study
allowed the GMD operator to gain proﬁciency in the
technique such that a homogeneous ablation could be
performed.
Pigs were placed in the supine position and a 2-channel
therapeutic gastroscope was inserted (GIF2T160; Olympus
Europe, Hamburg, Germany). The 2-channel scope
allowed for adequate suctioning of intraluminal gasses while
simultaneously applying APC. Before application of APC, a
510K cleared (K143306) needleless injection system
(ﬂexible Erbewaterjet probe, outer diameter 1.3mm, length
1.2 m connected with ERBEJET 2; Erbe Elektromedizin,
Tübingen, Germany) was used to create the submucosal
ﬂuid cushion by placing the needleless catheter at an angle
of 45 to the mucosa and injecting the ﬂuid at 60 bar
for 5 seconds (Fig. 2A). Subsequently, a 510K cleared
(K060163) catheter with an outer diameter of 3.6 mm,www.giejournal.org
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Figure 1. Study design. A total of 23 healthy litter-matched male pigs were used. Between weeks 11 and 12, pigs were randomized into 3 groups
(GMD, SG, and SH). Although the intervention was performed at 12 weeks of age, it is referred to as the baseline or week 0 when reporting results.
Two GMD pigs underwent scheduled assessment for histopathology: one immediately after the procedure and the other at week 4. For the pur-
poses of the trial, 21 pigs were randomized equally into 3 groups: GMD (nZ 7), SG (nZ 7), and SH (nZ 7). Body weight was measured daily. MRI
to assess visceral and subcutaneous adiposity was performed at baseline and at 8 weeks after the intervention. Organ lipid content and serum
ghrelin were measured at week 8 after the intervention. GMD, Gastric mucosal devitilization; MRI, magnetic resonance imaging; SG, sleeve
gastrectomy; SH, sham.
Figure 2. Equipment used for gastric mucosal devitalization (GMD). Commercially available accessories were used for the GMD procedure. The waterjet
probe (A) is connected to the ERBEJET2 via a connector (arrowhead) and allows for submucosal injection. The Erbe FiAPC probe has an outer diameter
of 3.6 mm (B) allowing for wide-ﬁeld argon plasma coagulation of the gastric mucosa. View of the 3.6-mm probe within a 3.7-mm channel endoscope with
the ceramic tip housed in the distal tip (C). The black ring (arrow) indicates a distance 10 mm from the tip. The ceramic tip protects the outer casing
from thermal damage (arrowheads).
Kumbhari et al Gastric mucosal devitalization for obesitylength 220 mm and a ceramic heat-resistant tip was con-
nected to the Erbe VIO 300 D and was used to deliver APC
(Erbe Elektromedizin, Tübingen, Germany) (Fig. 2B and
C). APC was delivered homogeneously until the tissue was
a light-yellow color, which was determined to be the optimal
in the dose-ﬁnding study.25 This process of submucosal ﬂuid
creation and subsequent APC was performed in a distal to
proximal fashion such that no area was left untreated
(Fig. 3A). The entire gastric body and fundus except
diverticulum ventriculi was treated.
Sleeve gastrectomy. Laparoscopic SG was performed
in a similar manner as undertaken in humans. A laparo-
scopic approach using three 12-mm and two 5-mm trocars
was used. The greater curvature of the stomach was
denuded with ultrasonic shears, including the short
gastric vessels and the posterior attachments of thewww.giejournal.orgfundus. This was begun 4 cm proximal to the pylorus
and continued until the gastric fundus was completely
mobilized and the entire angle of His was visualized along
with the left crura.
A gastric tube was created over a 2-channel therapeutic
gastroscope (GIF2T160; Olympus Europe, Hamburg, Ger-
many) by repeated ﬁring of linear cutting staples from
the distal antrum (4 cm from the pylorus) to the His angle
with complete removal of the greater curvature and the
fundus.26 An Echelon compact linear cutter (60 mm) was
used, loaded with ECR60D cartridges, which delivered 6
rows of stapling clips (Ethicon Endo-Surgery, Somerville,
NJ). Green reloads (4.1 mm) were used throughout.
Stapling devices and cartridges were the same as used in
clinical SG. No staple line reinforcements or additional
steps to strengthen the staple lines were done.27Volume 88, No. 1 : 2018 GASTROINTESTINAL ENDOSCOPY 177
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Figure 3. GMD from an endoscopic, macroscopic gross specimen, and histopathologic perspective. This ﬁgure highlights the changes in the gastric
mucosa over the duration of the study. Argon plasma coagulation was delivered homogenously until the tissue was a light-yellow color based on the re-
sults of a previous dose-ﬁnding study (A). HE staining immediately after the procedure conﬁrmed mucosal devitilization (A). Gross examination of the
stomach at 4 weeks demonstrated mucosal hyperemia and regeneration of the gastric mucosa with mild scaring limited to the watershed territory (B).
Histologic analysis revealed near-complete mucosal regeneration aside from the watershed territory (B). At 8 weeks, there was no hyperemia but scat-
tered areas of scarring existed (C). Histologic analysis revealed signiﬁcant mucosal regeneration but not complete compared with the SG and SH groups.
GMD, Gastric mucosal devitalization; HE, hematoxylin and eosin; SG, sleeve gastrectomy; SH, sham.
Gastric mucosal devitalization for obesity Kumbhari et alSham. The pigs in the SH group underwent the same
anesthetic protocol as the GMD and SG pigs but no inter-
vention was performed. The anesthetic time was 90 mi-
nutes in concordance with the approximate mean
procedural times for GMD.
Specimen processing and analysis
A detailed description of the methods used to perform
histopathology, quantiﬁcation of organ lipid content,
quantiﬁcation of ghrelin, and magnetic resonance
imaging quantiﬁcation of adiposity are given in the
Supplementary Methods.
Statistical analysis
Based on previously published data comparing percent-
age weight gain in GMD with SH (133.5  12.9 vs 155.6 
8.3) in a porcine model at 4 weeks, we estimated the sam-
ple size to be 7 for the GMD and SH groups, assuming a
power of 0.85, alpha of 0.05 on a 2-sample 2-sided test
t test.25,28 We assumed that SG would be at least as effec-
tive as GMD in reducing weight gain; thus in order to
compare SG with SH, we assumed that we would also
need 7 patients in the SG group. The 8-week duration of
follow-up was chosen to allow detection of a difference
between the GMD and SG groups if one did exist.
Data analysis was performed using Prism version 5.0
(GraphPad Software; La Jolla, Calif). Statistical differences
were calculated by analysis of variance with post hoc test
procedures if comparing GMD, SG, and SH at different178 GASTROINTESTINAL ENDOSCOPY Volume 88, No. 1 : 2018time points. A P value <.05 was considered statistically
signiﬁcant. The data are shown as means and standard
deviation. Signiﬁcant differences between the groups are
indicated by bars and/or an asterisk (P < .05).RESULTS
Technical feasibility and safety
All 23 pigs successfully underwent and survived their
designated interventions and were killed per protocol.
There were no changes in physiologic parameters
observed during or after the intervention, including elec-
trocardiogram, heart rate, respiration rate, temperature,
blood pressure, and oxygen saturation. There were no
intra- or post-procedural adverse events observed. The an-
imals were upright, alert, responsive, defecating, urinating,
drinking, and tolerating oral intake within 24 hours after
the procedure and for the remainder of follow-up. Animals
did not exhibit signs of sepsis or peritonitis.
Gross examination and histologic analysis in
GMD pigs
At necropsy, gross examination of the stomach in the
GMD cohort at 4 and 8 weeks demonstrated regeneration
of the gastric mucosa without ulceration or stricture forma-
tion. There were mild areas of patchy scar formation with a
preponderance on the greater curvature aspect at the junc-
tion of the proximal gastric body and fundus. Histologicwww.giejournal.org
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Figure 4. Gross appearance and body weight outcomes 8 weeks after the intervention. There was a visible difference in the appearance of the pigs in the
3 groups at 8 weeks; the GMD (A) and SG (B) pigs were relatively smaller than the SH pigs (C). A signiﬁcant reduction in mean proportional body weight
between GMD and SH was seen at weeks 4 and 8 (D). There was no signiﬁcant difference between SG and GMD at 4 weeks although a difference did exist
at week 8 (D). The difference in mean absolute body weight between baseline and week 8 illustrates that both GMD and SG pigs had less weight gain
compared with SH pigs and that SG was statistically superior to GMD (E). GMD, Gastric mucosal devitilization; SG, sleeve gastrectomy; SH, sham.
Kumbhari et al Gastric mucosal devitalization for obesityanalysis demonstrated virtual absence of active inﬂamma-
tion as well as minimal ﬁbrosis and scar formation. At 4
weeks, mucosal regeneration was heterogeneous
(Fig. 3B). Notably, ﬁbrotic changes were limited to the
junction of the proximal gastric body and fundus
(Fig. 3B). At 8 weeks, mucosal regeneration was still
incomplete with a disorganized mucosal layer
throughout, particularly in the region of the junction of
the proximal gastric body and fundus (Fig. 3C).
Comparative efﬁcacy
Body weight. There was a visible difference in the
appearance of pigs in the 3 groups (n Z 21) at 8 weeks;
the GMD and SG pigs were relatively smaller in size
(Fig. 4A to C). Because pigs have a strong predisposition
to gain weight, comparisons were made between the
treatment groups at speciﬁed time intervals as opposed
to within each group. Furthermore, the results are
presented as the mean proportional change in body
weight (Fig. 4D).
There was a signiﬁcant reduction in weight gain with
GMD versus SH at 4 weeks (16.7%; 95% conﬁdence inter-
val [CI], 7.8%-25.6%; P < .05) and 8 weeks (36.9%; 95% CI,
19.4%-54.6%; P < .05) (Fig. 4D). Similarly, comparing SG
with SH, there was a signiﬁcant reduction in weight gain
at 4 weeks (21.0%; 95% CI, 12.2%-29.9%; P < .05) and
8 weeks (66.6%; 95% CI, 49.0%-84.3%; P < .05). When
comparing the 2 intervention groups, there was nowww.giejournal.orgsigniﬁcant reduction in weight gain between SG and
GMD at 4 weeks (4.3%; 95% CI, 4.6%-13.2%; P Z not
signiﬁcant). However, a signiﬁcant reduction in weight
gain of SG over GMD was observed at 8 weeks (29.9%;
95% CI, 12.2%-47.4%; P < .05). The differences in
absolute body weight between the cohorts at 8 weeks
are shown in Figure 4E.
Visceral and subcutaneous adiposity. As a result of
the rapid growth of the pigs used in this study, compari-
sons were made between the groups at baseline and
8-week follow-up as opposed to within each group
(Fig. 5A to C). The absolute values of visceral adipose
tissue (VAT) and subcutaneous adipose tissue (SAT) at 8
weeks are depicted in Figure 5D and E. Regarding VAT at
8 weeks, there was a signiﬁcant reduction when GMD
was compared with SH (1.8%; 95% CI, 1.4%-2.3%;
P < .05) and SG compared with SH (2.2%; 95% CI,
1.8%-2.7%; P < .05). There was no signiﬁcant reduction
at 8 weeks between SG and GMD (0.3%; 95% CI, 0.1%
to 0.8%; P Z not signiﬁcant) (Fig. 5D).
Regarding SAT at 8 weeks, there was a signiﬁcant reduc-
tion when GMD was compared with SH (4.2%; 95% CI,
1.0%-7.3%; P < .05) and SG compared with SH (7.5%;
95% CI, 4.4%-10.7%; P < .05). A statistically superior reduc-
tion was seen when SG was compared with GMD at
8 weeks (3.4%; 95% CI, 0.2%-6.5%; P < .05) (Fig. 5E).
Organ lipid proﬁle. Changes in organ (liver, skeletal
muscle, heart muscle) lipid content as a result of theVolume 88, No. 1 : 2018 GASTROINTESTINAL ENDOSCOPY 179
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Figure 5. Visceral and subcutaneous adiposity 8 weeks after the intervention. As a result of the rapid growth of the pigs used in this study, comparisons
are made between the groups at the 8-week follow-up as opposed to comparisons with baseline (A, B, and C). There was a signiﬁcant reduction in visceral
adiposity between GMD and SH (D). Remarkably, there was no signiﬁcant difference between GMD and SG (D). With regard to subcutaneous adiposity,
there was a signiﬁcant reduction between GMD and SH (E). There was also a reduction in subcutaneous adiposity in SG compared with GMD. GMD,
Gastric mucosal devitilization; SG, sleeve gastrectomy; SH, sham.
Gastric mucosal devitalization for obesity Kumbhari et alGMD procedure are illustrated in Figure 6. There was a
signiﬁcant increase in the liver lipid/protein ratio in the
GMD group compared with SH (2.9 mg/mg; 95% CI, 0.6-
5.1 mg/mg; P < .05) (Fig. 6A).This is presumably the
result of gluconeogenesis that occurs in the liver, likely
occurring in the context of a growing pig. Quantiﬁcation
of skeletal and heart muscle content at 8 weeks
demonstrated a signiﬁcant reduction in the lipid/protein
ratio in the GMD cohorts compared with SH. In detail,
GMD resulted in a signiﬁcant mean reduction in the ratio
of skeletal muscle lipid/protein content compared with
SH (2.0 mg/mg; 95% CI, 0.7-3.4 mg/mg; P < .05) (Fig. 6B).
GMD also resulted in a signiﬁcant mean reduction in the
ratio of heart muscle lipid/protein content compared
with SH (1.2 mg/mg; 95% CI, 0.4-1.9 mg/mg; P < .05)
(Fig. 6C).
Tissue and serum ghrelin proﬁle. Ghrelin was quan-
tiﬁed in the gastric mucosa and in the serum at 8 weeks
after the procedure. Immunohistologic staining of ghrelin
in the gastric mucosa at 8 weeks revealed a signiﬁcant
reduction of ghrelin-positive molecules in the GMD cohort
(Fig. 7A and B). In serum, we quantiﬁed both biologically
active forms (acyl and unacyl) of ghrelin at 8 weeks after
the intervention. There was no statistically signiﬁcant
difference in acetylated ghrelin between the cohorts
(Fig. 7C). There was, however, a statistically signiﬁcant180 GASTROINTESTINAL ENDOSCOPY Volume 88, No. 1 : 2018reduction in unacylated ghrelin when GMD was
compared with SH (46.1 pg/mL; 95% CI, 29.3-62.9 pg/mL;
P < .05). There was also a signiﬁcant reduction in
unacylated ghrelin when SG was compared with SH (17.9
pg/mL; 95% CI, 0.4-35.4 pg/mL; P < .05). Consistent with
devitalization of the entire gastric body and fundus, there
was a signiﬁcant reduction of unacylated ghrelin when
GMD was compared with SG (28.2 pg/mL; 95% CI, 10.7-
45.7 pg/mL; P < .05) (Fig. 7C).DISCUSSION
The obesity pandemic, being a global public health
concern, has appropriately captured the attention of the
major GI societies.29 Furthermore, as the GI tract is a
critical metabolic regulator of obesity and its metabolic
comorbidities, GI endoscopy societies have taken special
initiatives to assess currently available and future
endobariatric therapies.30 Although weight reduction is
an important outcome, a disproportionate emphasis has
been placed on it as opposed to improvements in
obesity-related comorbidities.31 To date, there is a
paucity of endobariatric therapies that signiﬁcantly
improve the metabolic proﬁle of a patient who is obese
in a safe and enduring manner.32-34www.giejournal.org
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Figure 6. Organ lipid content in the GMD and SH cohorts. Changes in organ (liver, skeletal muscle, heart muscle) lipid content as a result of the GMD
procedure. Consistent with gluconeogenesis and early relative changes in metabolism, there was a signiﬁcant increase in the liver lipid/protein ratio in the
GMD group compared with SH (A). Peripherally, GMD resulted in signiﬁcant a mean reduction in the ratio of skeletal lipid/protein content compared with
SH (B). GMD also resulted in a signiﬁcant mean reduction in the ratio of heart muscle lipid/protein content compared with SH (C). GMD, Gastric mucosal
devitilization; SG, sleeve gastrectomy; SH, sham.
Kumbhari et al Gastric mucosal devitalization for obesityThe optimal GI target for an endobariatric therapy has
been based around the mechanisms of action of surgical
analogs.35 The component of the small bowel that has
the greatest inﬂuence on lipid and glucose metabolism
is under debate and has resulted in 2 distinct theories:
the foregut and hindgut hypotheses.4 Endobariatric
therapies such as the duodenojejunal bypass liner and
duodenal mucosal resurfacing have assessed the foregut
hypothesis, demonstrating limited effectiveness and
clinical utility.36,37 More recently, however, an endobariat-
ric therapy assessing the hindgut hypothesis has shown
promise as a metabolic therapy.20 To debate whether
the stomach or the small bowel is the optimal target is
likely obsolete because it appears that multiple segments
of the gut may contribute to the GI regulation of energy
metabolism, perhaps with inherent redundancies that
explain the similar beneﬁts of multiple anatomically
different interventions.4
The current work was the logical progression to our pre-
viously published proof-of-concept study, which estab-
lished that devitalizing the gastric mucosa (without
reduction in gastric volume) in obese metabolically
disturbed rats resulted in a signiﬁcant reduction in relative
body weight and obesity-related comorbidities.18 The
results of this porcine study further enhance our
appreciation of the gastric mucosa as a metabolicallywww.giejournal.orgactive organ and its utility as a potential target in the
ﬁght against obesity. GMD was successfully performed
with a ﬂexible endoscope using commercially available
accessories in a purely transoral fashion. It was well
tolerated with minimal induced scarring. When scarring
was detected, it was predominantly seen in the greater
curvature aspect of the widest part of the stomach
(junction of the proximal body/fundus) and appears to
correlate with the stomachs “watershed” territory of
arterial supply. Our study is unique in that we
randomized pigs to a metabolic surgical arm (SG) as a
comparator to decipher whether GMD had metabolic
beneﬁts out of proportion to the relative weight loss
incurred.
The primary outcome positively demonstrated a signiﬁ-
cant reduction in body weight when GMD was compared
with SH at 4 and 8 weeks. When GMD was compared
with SG, there were similarities in relative body weights
at 4 weeks although not at 8 weeks. A plausible explanation
for this may be that regeneration of the gastric mucosa in
the weeks after therapy began to negate the effects of the
intervention by week 8. Although a secondary outcome, a
noteworthy ﬁnding of our study was the signiﬁcant reduc-
tion in visceral adiposity in the GMD cohort compared with
SH at 8 weeks. The reduction in visceral adiposity conceiv-
ably represents an improved metabolic state, the ultimateVolume 88, No. 1 : 2018 GASTROINTESTINAL ENDOSCOPY 181
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Figure 7. Immunoﬂuoroescence for ghrelin and serum ghrelin at 8 weeks after the intervention. Immunoﬂuorescence of ghrelin-secreting cells is pre-
sent in abundance within the gastric mucosal layer of the fundus (A). Eight weeks after GMD, there was regeneration of the gastric mucosal layer but a
persistent reduction in ghrelin-stained cells (B). We quantiﬁed both biologically active forms (acyl and unacyl) of ghrelin in serum at 8 weeks after the
intervention (C). There was a statistically signiﬁcant difference in unacylated ghrelin when GMD was compared with SH. Consistent with devitalization of
the entire gastric body and fundus, there was a signiﬁcant difference between GMD and SG. GMD, Gastric mucosal devitilization; SG, sleeve gastrectomy;
SH, sham. *Represents P < .05.
Gastric mucosal devitalization for obesity Kumbhari et algoal of any endobariatric intervention. Notably, in contrast
to relative body weight, visceral adiposity was similar when
GMD was compared with SG at both week 4 and week 8. It
is conceivable that this is explained by a delayed recovery
in the abundance and functional capacity of neurohor-
monal cells in a similar manner to what was seen in our
rodent study.18 GMD did not result in a similar reduction
in subcutaneous adiposity at 8 weeks compared with SG.
We stipulate that the more metabolically idle SAT may
have hindered the GMD effect more than SG possibly as
a result of a less-pronounced metabolic impact. It must
be acknowledged that this study was not designed to
assess the mechanisms behind the beneﬁts of GMD, pre-
venting further supposition.
The profound effect of GMD on reducing organ lipid
content illustrates its potential as a metabolic therapy
and correlates with the noted reduction in visceral
adiposity. Detailed analysis in skeletal and heart muscle
revealed consistent ﬁndings, suggesting that the impact
of GMD was systemic. The increased liver lipid/protein ra-
tio at 8 weeks signiﬁes the increased gluconeogenesis and
resultant liver lipid accumulation that is seen in the weeks
and months after metabolic interventions such as bariatric
surgery. We postulate that in the months that follow, the
liver lipid content would be diminished in the GMD cohort
compared with SH.
The reduction in abundance of serum ghrelin at 8 weeks
demonstrates that the mucosa in GMD pigs was success-
fully devitalized. Furthermore, the signiﬁcant lowering of
serum ghrelin at 8 weeks demonstrates that despite
renewal of the mucosa, regeneration of ghrelin-secreting
cells did not occur at the same rate. Notably, despite SG
having a signiﬁcantly higher abundance of serum ghrelin,
there was a signiﬁcant relative reduction in body weight
and similar VAT compared with GMD. This suggests that182 GASTROINTESTINAL ENDOSCOPY Volume 88, No. 1 : 2018ghrelin may not be a critical regulator of the weight and
metabolic improvements seen with metabolic surgery.
The gastric mucosa is a hormonally active organ, and it is
likely that other hormones (both those that are known
and unknown) play a signiﬁcant role in metabolic regula-
tion. However, detailed interpretation of our ghrelin re-
sults cannot be undertaken because the behavior of
ghrelin in the porcine model does not clearly correlate
with the human phenotype, and hence we did not perform
feeding experiments in our study.38,39
Obesity is now recognized as a chronic and relapsing
disease process.40 Even after enduring metabolic surgery,
weight recidivism is not uncommon.41,42 Thus, it is a
reasonable expectation that endobariatric therapies are
also destined to experience a similar fate. Hence, the supe-
rior endobariatric therapy should be designed to be repeat-
able in a safe and effective manner. GMD may be
vulnerable to limited durability because of the regenerative
capacity of the gastric mucosa. However, humans live
approximately 10 times longer than the pig model used
in this study. Hence, an equivalent 8-week follow-up in
these pigs is comparable with several-fold longer follow-
up in humans. To hinder the potential for weight recidi-
vism, GMD could possibly be repeated on one or more
occasions, but the safety and efﬁcacy of such a strategy
are still to be proven. Moreover, because GMD does not
alter the GI anatomy, future endoscopic and surgical ther-
apies could conceivably be performed if necessary.
GMD has the potential for translation to humans with
several beneﬁts over currently available endobariatric ther-
apies. As GMD does not involve the deployment of a
foreign object, there is no need for a second endoscopy
for the purpose of object removal.43,44 Moreover, objects
that reside in the GI tract such as intragastric balloons or
duodenojejunal bypass liners are frequently associatedwww.giejournal.org
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tolerability, safety, and widespread dissemination.44,45 In
addition, the absence of an implant facilitates its use as
bridge therapy before surgery.
We acknowledge that there are several limitations of our
study, mainly as a result of the inherent challenges of the
porcine model. First, the pigs used were not metabolically
disturbed and had only a small amount of visceral
adiposity. Second, due to the young age of the pigs
used, weight gain was universal, even in the SG group.
Third, pigs had free access to food and did not participate
in a diet or exercise program. Therefore, due to these 3 fac-
tors, a detailed metabolic panel and detailed hormone
analysis were not performed as the results would have
limited meaningful interpretation in the context of this
study. These limitations may impede the translational rele-
vance of the results to patients with obesity, although theo-
retically, the beneﬁts observed in our study could be
expected to be further exaggerated in patients who are
metabolically deranged and comply with a concomitant
diet and lifestyle program.
In conclusion, GMD was technically feasible and safe
when performed in a model with similar GI anatomy to hu-
mans. Despite this minimally invasive technique being in
its infancy, as exhibited by only using commercially avail-
able equipment, its effectiveness over SH in terms of a
relative reduction in body weight and visceral adiposity
was impressive. Even more striking was that when GMD
was compared with SG, although the relative weight
loss was similar at 4 weeks and signiﬁcantly less at 8 weeks,
there were similar reductions in visceral adiposity at 8
weeks. This suggests that the beneﬁts of GMD are out of
proportion to what would be expected with weight loss
alone. Clinical studies in patients who are obese are neces-
sary to verify these encouraging ﬁndings. Ultimately, wide-
spread dissemination of GMD as an endobariatric therapy
will likely hinge on a highly efﬁcient method (thermal or
non-thermal) of treating the gastric mucosa.ACKNOWLEDGMENTS
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Study conditions
Environmental acclimation at 22  1C, 30% to 70%
relative humidity, 14:10 hours (light:dark cycle) and
approximately 15 air changes/hour for 1 week before study
commencement. Pigs were housed in pairs in 24 ft2 indoor
runs and fed standard diet (Raiffeisen Kraftfutterwerke
Süd, Würzburg, Germany). Water was provided ad libitum
throughout the study.
Food was withheld beginning 12 hours prior to the inter-
vention. On the day of the procedure, pigs were sedated
with an intramuscular injection of tiletamine, zolazepam, keta-
mine, and xylazine (TKX) at 1 mL/20 kg. Once sedated, pigs
were intubated, venous blood was drawn, and maintenance
ﬂuidswere administered through amarginal ear vein catheter.
General anesthesia was maintained with isoﬂurane and me-
chanical ventilation was provided. During the intervention,
electrocardiogram, rectal temperature, blood pressure, heart
rate, oxygen saturation, and end tidal CO2 were monitored
by the veterinary technician anesthetist every 5 minutes.
Medications were administered after the procedure as
follows: as an analgesic, buprenorphine was administered
intravenously twice daily for 3 days at a dosage of 0.01 to
0.04 mg/kg body weight. A proton pump inhibitor (esome-
prazole) was administered daily orally at a dosage of 40 mg
for the 8-week follow-up period. As antibiotic prophylaxis
(2.5 mg/kg body weight; enroﬂoxacin) was injected daily
into the neck musculature for 3 days after the intervention.
All animals recovered and underwent daily inspection to
assess general appearance and food consumption. In each
group, after a restricted diet (milk slurry) for 4 days after
the procedure, standard food was then provided ad libitum
to all groups. Weight was measured daily and blood serum
for assessment of ghrelin was aspirated once a week. At 8
weeks, pigs were sedated with TKX and euthanized with
pentobarbital-sodium at 450 mg/5.0 kg body weight intra-
venously and necropsy was performed. The peritoneal cav-
ity was grossly inspected and the stomach and liver
resected en bloc. A sample of skeletal muscle was taken
from the quadriceps. The stomach was ﬁxed in formalin
and underwent histologic evaluation.
Histopathology
Tissue histology was evaluated using hematoxylin and
eosin staining in 8-mm parafﬁn sections. Images were visu-
alized with a Leica Diaplan microscope (Leica Microsys-
teme, Wetzlar, Germany) equipped with a digital color
camera DP25 (Olympus, Hamburg, Germany) using a
10 objective and Cell^P morphometry software (Olympus
Soft Imaging Solutions, Muenster, Germany).
Quantiﬁcation of organ lipid content
Lipid droplets in tissue were visualized by Nile red ﬂuo-
rescence staining (Life Technologies GmbH, Darmstadt,
Germany) on 8-mm cryosections. Confocal scans werewww.giejournal.org Vtaken with a Zeiss LSM-5 Pascal (Carl Zeiss, Jena,
Germany). Quantiﬁcation of the lipid/protein ratio was
calculated using tissue samples that were snap frozen in
liquid nitrogen and stored at 80C until further use. Tis-
sue was homogenized with an Ultra Turrax homogenizer
(VWR International, Darmstadt, Germany), sonicated on
ice 3 times for 3 to 5 seconds each with 9 cycles at 80%
energy using a Sonoplus (Bandelin, Berlin, Germany).
The homogenates were centrifuged at 14,000  g for 10
minutes, and protein concentration was determined
(Pierce BCA Protein Assay Kit, Life Technologies,
Darmstadt, Germany). From tissue, the lipid content was
measured according to the manufacturer’s instructions
(Lipid Quantiﬁcation Kit, Cell Biolabs, Calif, USA).
Quantiﬁcation of ghrelin
Serum acylated and unacylated ghrelin was measured by
commercial ELISA kits according to the manufacturer’s in-
structions (acylated Ghrelin (pig) Enzyme Immunoassay
kit, unacylated Ghrelin (pig) Enzyme Immunoassay kit;
Bertin Pharma, Montigny le Bretonneux, France). For
assessment of ghrelin immunoﬂuorescence, tissue sections
were incubated overnight at 4C with primary antibody
against ghrelin (goat polyclonal antibody; Abcam, Cam-
bridge, UK). Indirect immunoﬂuorescence was performed
with adequate Cy2-conjugated secondary antibody
(donkey anti goat IgG; Dianova, Hamburg, Germany).
Confocal scans were taken with a Zeiss LSM-5 Pascal
(Carl Zeiss, Jena, Germany). Multitrack scanning avoided
bleed-though of the ﬂuorescence in double-labelling ex-
periments. The detection system was calibrated on control
stains with no primary antibody. Cell nuclei were stained
with DAPI (IS Mounting Medium DAPI, Dianova).
Magnetic resonance imaging quantiﬁcation of
adiposity
Visceral and subcutaneous adiposity was quantiﬁed by
magnetic resonance imaging (MRI) immediately before
the procedure and on the day of sacriﬁce. The content of
abdominal visceral and subcutaneous adipose tissue (VAT
and SAT, respectively) was measured by MRI as described
by Thormer et al.1 Animals are placed in a supine position
in a 3 T MRI scanner (Philips Achieva 3T XR, Philips
Healthcare, Eindhoven, the Netherlands). Imaging was
performed using a built-in, whole-body quadrature coil.
An in-phase/opposed-phase gradient echo sequence was
used to acquire a total of 50 axial magnetic resonance
images covering the entire abdomen from the diaphragm
down to the femoral heads. To determine VAT and SAT, a
fully automated, 3-stage method was implemented with
MATLAB (MathWorks, Natick, Mass, USA).
SUPPLEMENTARY REFERENCE
1. Thormer G, Bertram HH, Garnov N, et al. Software for automated MRI-
based quantification of abdominal fat and preliminary evaluation in
morbidly obese patients. J Magn Reson Imaging 2013;37:1144-50.olume 88, No. 1 : 2018 GASTROINTESTINAL ENDOSCOPY 184.e1
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Introduction
Obesity is a major global health concern and growing epidemic,
associated with serious obesity-related comorbidities such as
diabetes, metabolic syndrome, hypertension, and tremendous
financial impact [1–4]. In the armamentarium of obesity thera-
pies, laparoscopic sleeve gastrectomy (SG) has taken a central
role in the fight against obesity and its related comorbidities.
SG was the most commonly performed bariatric surgery in the
United States from 2013 to 2017, with a trend of increasing uti-
lization to almost 60% of all bariatric procedures [5]. The phys-
iological, hormonal, and structural changes that contribute to
SG-induced weight loss, if well understood, can be manipulated
to achieve targeted, minimally invasive strategies for treating
obesity.
Gastric mucosal devitalization (GMD): translation to a novel
endoscopic metabolic therapy
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ABSTRACT
Background and study aims The metabolic effects of bar-
iatric surgery may partially result from removal of the gas-
tric mucosa, an often underappreciated endocrine organ.
Using argon plasma coagulation (APC), we may be able to
selectively devitalize (ablate) the mucosa. The aim of this
study was to identify the optimal tissue color that would
correspond to selective gastric mucosal devitalization
(GMD) using ex-vivo human stomach specimens.
Patients and methods Stomach specimens were obtained
at sleeve gastrectomy. Prior to APC application, a submu-
cosal fluid cushion was created. APC was then applied over
a 2×2-cm area to the fundus and body, aiming for the three
indicator colors (white, golden, brown). Pathological analy-
sis was then performed independently and in a blinded
fashion by two pathologists to determine the depth of mu-
cosal and submucosal percent thermal injury and mucosal
percent cell death.
Results Six patients were enrolled. There was a significant
correlation between tissue color and mucosal percent ther-
mal injury. The highest percent mucosal thermal injury was
seen with brown (99.6%, 95% CI: 98.7, 100), followed by
golden (92.5%, 95% CI: 85.5, 99.5), and then white (75.2%,
95% CI: 58.3, 92.1, P <0.01). Submucosal thermal injury was
seen in 88.9% of the slides. Greater than minimal submuco-
sal injury (> 10% depth) was found significantly more with
brown tissue color (91.6%) than golden (75%) or white
(33.3%, P <0.05). However, 91.7% of the entire sample set
< 50% injury.
Conclusion GMD is achievable using APC without thermal
injury to muscularis propria. A golden color results in suffi-
cient mucosal injury with only superficial injury to the sub-
mucosa.
Clinical.Trials.gov
NCT03526263
TRIAL REGISTRATION: Single arm, interventional clinical trial
NCT03526263 at clinicaltrials.gov
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Endoscopic sleeve gastroplasty (ESG) uses endoscopic sutur-
ing to reduce the lumen of the stomach, resulting in a size sim-
ilar to that achievable during SG [6, 7].This procedure achieves
the restrictive component of the SG in a minimally invasive
manner. However, comparative studies have shown superior
weight loss outcomes with SG as compared to ESG [8, 9]. The
explanation for this difference may lie in the main anatomical
difference between the two procedures. During SG, a signifi-
cant portion of the stomach is excised, completely removing
with it an important and often underappreciated endocrine
organ, the gastric mucosa. The gastric mucosa has a potentially
large role to play when seeking to create more targeted, safer
and minimally invasive weight loss therapies.
One method of targeting the mucosa is use of argon plasma
coagulation (APC), an ablation technique that uses thermal en-
ergy from ionized argon gas to coagulate or ablate gastrointes-
tinal tissue, which has been used safely and successfully for var-
ious indications in the gastrointestinal tract [10, 11]. To mini-
mize risk of deep thermal injury, experiments have attempted
submucosal injection of normal saline prior to devitalization
[12–14]. In an ex vivo porcine study, this resulted in tissue
damage confined to the submucosa [13]. In vivo, damage
extended to the muscularis propria 1 week post-ablation if no
injection was performed and was limited to the submucosa
with prior injection at 1 week [12]. Finally, ex-vivo human stud-
ies have confirmed that submucosal injection is protective of
the muscularis propria in the stomach and esophagus [14, 15].
These findings indicate that submucosal injection may be a use-
ful method of reducing risk of muscularis propria damage from
APC but in these studies, selective ablation of mucosa was not
attempted.
Gastric mucosal devitalization (GMD) is an endoscopic pro-
cedure that uses APC to selectively ablate the gastric mucosa
while using submucosal fluid injection to keep the deeper lay-
ers intact [16, 17]. GMD has been validated by our group in rat
and porcine models of obesity with very promising metabolic
and weight outcomes. After the success of GMD in animal mod-
els, it was time to translate this procedure to humans, ex vivo.
The objective was to determine what dosage of APC with sub-
mucosal injection can selectively devitalize the human gastric
mucosa, without injuring the deep submucosa or any portion
of the muscularis propria. There is a known progression of tis-
sue color from white to golden to brown and eventually black
with increasing doses of APC. This study’s primary aim was to
identify the optimal tissue color (white, golden, brown) that
would correspond to selective GMD without damage to the
deep submucosa or muscularis propria using ex vivo human
stomach specimens. Secondary aims included identifying opti-
mal technical parameters (submucosal injection volume and
energy settings) to facilitate selective mucosal devitalization.
Patients and methods
This study was performed under IRB00089675 at the Johns
Hopkins Medicine Institutional Review Board and registered on
clinicaltrials.gov under NCT03526263. Patients were enrolled
in the study after being scheduled to undergo laparoscopic SG
as part of routine clinical care at Johns Hopkins Bayview Medical
Center.
Patients were consented for the research study at the time
of obtaining their consent for surgery. As this was an ex vivo
study on a resected SG specimen, no compensation was offered
to patients. The cost of surgery was covered by a patient’s in-
surance and there was no extra procedural element that added
time to surgery. During routine surgery, after the greater cur-
vature of the stomach was excised as per normal surgical tech-
nique, the specimen was taken from the operating room into
the laboratory where experimentation was performed.
SG specimen preparation
The SG specimen was taken immediately from the operating
room (within 10 minutes of excision) and immersed in warmed
normal saline. Then, the specimen was cut along the suture line
to expose the body and fundus. It was washed using warm sal-
ine to remove any residual clotted blood. The SG specimen was
then flattened onto the neutral electrode (NessyPlate 170cm2)
to avoid folds on the serosal side and to improve conduction.
The neutral electrode was connected to the electrosurgical
unit (ESU) and wrapped in aluminum foil to further improve
conductivity.
Specimen treatment
In each SG specimen, the protocol called for six areas of devita-
lization, three in the fundus and three in the body (▶Fig. 1).
Prior to each devitalization, a submucosal injection using nor-
mal saline (0.9% NaCl) mixed with methylene blue was first per-
formed with a flexible waterjet probe connected to an ERBEJET2
(ERBE Elektromedizin GmbH, Tübingen, Germany). The ERBEJET
is a needleless waterjet injection system that is used to create a
submucosal fluid cushion underneath the mucosa to protect
▶ Fig. 1 Excised SG specimen after submucosal injection and gas-
tric mucosal devitalization (GMD) by means of submucosal injec-
tion and argon plasma coagulation of three areas in the body and
three areas in the fundus. Each gastric fundus and each gastric
body had three ablated areas (one white, one golden and one
brown) representing the three different devitalization dosages.
The black pin indicates the body and the red pin indicates the
fundus. The white pin was placed to indicate an area that was
treated only with submucosal injection as control for histological
analysis. A colored pin (green, blue or yellow) was placed near
each ablated area and was used by the pathologist to label the
tissue slides (for example, a section taken from the fundus and
labeled with a blue pin would be titled “fundus blue”). From each
area, microsopic sections were made for analysis.
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the muscularis propria from thermal damage of APC during in-
terventional endoscopic procedures of the gastrointestinal
tract. An additional advantage of injection in this study was to
flatten out, stretch, and thin out the mucosa for more efficient
and complete ablation of larger surface areas. In all specimens,
submucosal injection was performed with the effect setting 50.
Volume of injection (mL) varied in each devitalization, depend-
ing on the amount needed to create an appropriate cushion.
Once the cushion was created, APC was applied using the
ERBE VIO 300D ESU in combination with the APC2 module and
a 3.6-mm FiAPC probe (▶Fig. 2), with a larger outer diameter of
the distal tip than the 2.3-mm catheter, for better efficiency of
devitalization of a larger surface area. The APC settings applied
were Pulsed APC, Effect 2, flow rate 1 L/minutes, 60 to 75W.
Three areas of the fundus and three areas of the body were ab-
lated in each stomach specimen aimed to be a size of 1 ×1 cm.
Devitalization with APC was performed at a 90-degree angle, at
a distance of 2 to 4mm from the tissue. Indicator colors used
were white, golden, and brown as assessed visually by the pro-
ceduralist. Therefore, each gastric fundus and gastric body had
three ablated areas (one white, one golden and one brown).
The SG specimen was then taken to the Johns Hopkins pathol-
ogy lab for gross and histopathological analysis to determine
depth of devitalization. Only a small portion of the resected SG
specimen was treated with APC, such that the remainder was
suitable for routine pathological analysis as per the standard of
care. A colored pin (green, blue or yellow) was placed near each
ablated area and used by the pathologist to label the tissue slides
(for example, a slide taken from the fundus and labeled with a
blue pin would be titled “fundus blue”) (▶Fig. 1). A black pin
was placed to indicate the body and a red pin to indicate the fun-
dus. Each slide was reviewed by two independent pathologists
and results were aggregated into an average. The pathologist
who carried out the histopathological examination did not parti-
cipate in tissue slide preparation. The pins were placed randomly
to keep the reading pathologist unaware of the color of the tis-
sue and the devitalization settings. In every patient, two random
biopsy samples were also included as a control. Two sections
were cut from each lesion and formalin fixed, paraffin embed-
ded, and H&E stained. The study was performed using a staged
approach. Pathological results for every two consecutive pa-
tients were analyzed at the same time and the devitalization
method was adjusted in the subsequent patients based on the
histopathological analysis results obtained in the previous two
patients.
Outcomes
Outcomes recorded in this study included percent cell death
and percent depth of thermal injury as determined by the pa-
thologists. Thermal injury was defined as abnormal and distort-
ed cellular outlines and architecture that would not otherwise
be seen in a normal biopsy. Cell death was defined as thermal
injury that had resulted in apparent cellular death defined as
loss and distortion of tissue structure resulting in a compressed
appearance and absence of nuclei in cells. Percent thermal in-
jury and percent cell death were defined as percent depth of
thermal injury and cell death relative to the entire depth of the
mucosa (▶Fig. 3). Percent submucosal injury could not be ac-
curately quantified due to submucosal edema. Thus, the sub-
mucosal injury was dichotomized into a binomial variable using
a threshold of 10%, with less than 10% considered minimal
injury. The threshold was chosen at 10% because clinically, the
submucosa can serve as a buffer zone between the mucosa and
muscularis propria where some injury is acceptable. Length of
the excised stomach was also recorded.
Statistical analysis
Statistical analysis was conducted using STATA 15.0 (StataCorp
LP, College Station, Texas, United States). Tests of hypothesis
for categorical variables were performed using χ 2 test. Tests
of hypotheses for continuous variables were performed using
Student’s t test for dependent and independent samples. Line-
ar regression analysis was used to assess correlations between
continuous variables. P <0.05 was considered significant.
▶ Fig. 2 a Flexible APC filter integrated probe for mucosal ablation with axial probe tip.b The 3.6 FiAPC has an outer diameter (OD) of 3.6mm/
10.8 FR, a length of 2.2m/7.2 ft, with an axial (straight fire) beam. The FiAPC 3.6 is a modified version of the commercially available 2.3 FiAPC
Probe. The probe tip OD is 3.6mm instead of 2.3mm. An integrated ceramic tip has been added for higher thermal stability. Both FiAPC probes
work in conjunction with the APC 2-Module and the VIO 300D to ablate tissue. c, d Ablation track on pig stomach tissue (body. d The track of
the 3.6mm probe is approximately 20% wider than the track of 2.3 probe c allowing for more efficient area ablation.
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Results
Six patients were enrolled in this study, resulting in 36 speci-
mens (18 from the gastric body and 18 from the fundus). On
average, length of the excised SG specimen was 19.3 cm (SD=
1.96). In the first two patients, devitalization was performed at
60W. At 60W, the muscularis propria was not damaged, so
wattage was increased to 75W for the remainder of the study
aiming, for greater effectiveness. In addition, the fluid cushion
was significantly reduced in the remainder of the study, from a
mean of 11.1mL in the first two patients to a mean of 3.9mL in
the last four patients. The correlation between the number of
seconds of APC devitalization and the resultant tissue color
was not statistically significant, but number of seconds was
greater in brown tissue (13.9 seconds, 95% CI: 9.2, 18.5), than
golden (10.9 seconds, 95% CI: 6.79, 15.04), than white (8 sec-
onds, 95% CI: 5.04, 10.95), P=0.11.
Slides from the random biopsies acting as control were all
read by the pathologists as normal biopsies with 0% thermal in-
jury. Analysis of the treatment slides revealed significant ther-
mal injury of varying degrees in addition to submucosal edema,
which represented persistence of the fluid cushion created by
submucosal injection prior to devitalization (▶Fig. 4). To deter-
mine whether fluid injection alone can cause mucosal injury, a
one-time pathological analysis was performed on a SG speci-
men that was only injected but not ablated. The result was sub-
mucosal edema without any mucosal damage.
Mucosal thermal injury was found in all of the samples. Mean
mucosal percent depth of thermal injury was 89.1 ±20.4%. Mu-
cosal cell death was seen in most of the samples (97.2%). Mean
percent mucosal cell death was 26.9 ±13.5%. Mucosal percent
depth of thermal injury did not correlate with volume of injec-
tion (coef.: – .45, P=0.57, 95% CI: –2.1, 1.2), number of seconds
of devitalization (coef.: 0.04, P=0.94, 95% CI: – .97, 1.04), or
wattage applied (coef.: .47, P=0.33, 95% CI: – .5, 1.4). However,
there was a significant correlation between tissue color and mu-
cosal percent depth of thermal injury. The greatest mucosal per-
cent depth of thermal injury was seen with brown (99.6%, 95%
CI: 98.7, 100), followed by golden (92.5%, 95% CI: 85.5, 99.5),
and then white (75.2%, 95% CI: 58.3, 92.1, P<0.01).
Submucosal thermal injury was seen in 88.9% of the samples.
However, 33.3% of the samples had minimal (≤10%) injury and
91.7% of the samples had ≤50% injury. The greatest submucosal
injury assessed in all samples was 55%. Greater than minimal
submucosal injury (> 10%) was found significantly more with
brown tissue color (91.6%) than golden (75%) and white (33.3
%, P <0.05). Importantly, all sections revealed an intact muscu-
laris propria with no evidence of thermal injury or cell death
(▶Fig. 5).
An incidental finding on pathological analysis was lifting of
the mucosal cells off the basement membrane as can be seen
in ▶Fig. 6. Lifting may be an artifact; however, because 44.4%
of samples exhibited this finding, it is worthy of note.
Discussion
The findings confirm that gastric mucosal devitalization using
APC is achievable in the human stomach, using the superficial
submucosa as a buffer zone, without damage to the muscularis
propria. At 60 to 75W, devitalization to white, golden, or brown
colors resulted in sufficient depth of mucosal thermal injury
and extent of cell death. The submucosa exhibited superficial
thermal injury in addition to edema, an expected finding result-
ing from submucosal injection that was carried out prior to de-
vitalization to protect the muscularis propria.
Importantly, this study found an association between tissue
color and mucosal and submucosal thermal injury, with greater
thermal injury found in darker tissue color. The association be-
tween tissue color and thermal injury suggests that color is an
appropriate indicator for pathological effect, confirming com-
▶ Fig. 4 Image of a pathology slide of gastric mucosa after GMD
showing the fluid cushion in the submucosa underneath resulting
in submucosal edema. Edema is an effect expected from persist-
ence of the fluid cushion after submucosal injection and the suc-
cessive argon plasma coagulation (Scale: 0.5mm).
▶ Fig. 3 Image of a pathology slide of gastric mucosa after GMD
showing areas of “cell death” versus “thermal injury.” The cell
death region is characterized by loss and distortion of tissue
structure showing a “mushy” appearance and absence of nuclei in
cells. The thermal injury region is characterized by altered cell ar-
chitecture with fragmented and elongated nuclei (Scale: 0.5mm).
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mon clinical experience. Tissue color was found to be a reliable
and feasible method of determining depth of devitalization,
which would allow its use as a clinical indicator for endoscopic
GMD by the endoscopist throughout the intervention.
It has been shown that the extent of gastric tissue damage
from APC is associated with pulse duration and power settings
[14, 18]. However, this study found the same effect at 60 and
75W, and the authors would suggest to aim for a dose between
60 to 75W in vivo for GMD to achieve a necessary depth of de-
vitalization without compromising patient safety. Similarly, be-
cause all tissue colors correlated with mucosal thermal injury
without muscularis propria injury, any tissue color is feasible
and may be used in vivo. We found no evidence to show that
the muscularis propria is injured with any color due to the pro-
tective effect of the submucosal cushion. However, we expect
the effect of devitalization to continue to increase for 3 days
post-devitalization, as apoptosis continues to occur in living
tissue. Thus, we suggest using golden as the appropriate color
indicator in vivo, because it achieves sufficient mucosal injury
and with an acceptable amount of submucosal injury. It also al-
lows for a margin of error, as minor overtreatment towards
brown or minor undertreatment towards white, will not com-
promise the procedures safety nor efficacy.
GMD performed in a rat model was able to achieve signifi-
cant relative weight reduction as well as reduction in the lipid
content of liver, subcutaneous, and visceral adipose tissue
[17]. In a porcine model, GMD was also able to achieve relative
weight loss and reduction in lipid content of heart and skeletal
muscle. Notably, in that study, porcine mucosa regenerated
after 8 weeks, but with a persistent reduction in serum ghrelin
levels [16]. Ghrelin-producing cells of the gastric mucosa tar-
geted by GMD may have taken longer to regenerate that other
mucosal cells, contributing to continued metabolic effects and
weight loss. Indeed, the endocrine effect caused by removal of
the gastric mucosa is likely more complex and deserves further
study to be fully understood.
Efficacy findings from the animal studies in addition to the
safety findings from this ex vivo human study suggest that this
procedure has the potential to be both safe and effective in vivo
for treatment of obesity. When considering clinical adoptabil-
ity, concern may arise regarding procedure time to achieve full
devitalization. This is mitigated by two factors. First, studying
the size of the excised stomach has allowed us to note that the
surface area to ablate was less than originally thought. In the
rat and porcine studies, 70% of the mucosa was targeted for
devitalization. However, in humans, if devitalization is targeted
only along the same distribution as the removed stomach dur-
ing SG, it would take significantly less time. Second, the novel
3.6-mm APC catheter (as opposed to the 2.3-mm catheter)
plays a role, as it has a ceramic tip for improved heat resistance
and it also allows for a wider area of ablation to facilitate more
efficient devitalization. The data presented may be translatable
to other gastric mucosal diseases. For example, submucosal
injection followed by ablation to a golden color can be recom-
mended to treat mucosal pathology in the stomach such as gas-
tric antral vascular ectasia (GAVE) and flat dysplasia not easily
amenable to resection.
This study provides valuable information that supports per-
forming the procedure in vivo; however, it has limitations. The
main limitations relate to the study set-up. Conductance of the
system may have been reduced ex vivo. Despite attempts to
warm the SG specimen, the final temperature may have been
lower than body temperature, which may have also affected
conduction. In addition, because the stomach is a closed space
and the procedure was performed in open air, the argon gas
effect may have been diminished. In vivo, blood flow may pro-
vide a heat sync effect that may also affect the results. Another
limitation is that the view with the endoscopic is different than
with the naked eye and the color variation may be different in
vivo, limiting interpretation. Finally, interpretation of color re-
mains relatively subjective. Nevertheless, color seems to be
the most reliable clinical indicator. Because the number of sec-
onds of devitalization did not correlate with the final color or
the pathological outcome, the number of seconds cannot be
used as a reliable parameter representing “dose.” Thus, despite
▶ Fig. 6 Image of a pathology slide demonstrating the “lifting” of
the mucosa off the basement membrane (Scale: 0.5mm).
▶ Fig. 5 Image of a pathology slide of gastric mucosa after GMD
showing an intact muscularis propria (Scale: 0.1mm).
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its apparent subjectivity, use of color as the dose measure is
suggested.
The results of this study, in conjunction with the results from
our pig and the rat obesity model showing reduction of body
weight and visceral adiposity indicate that GMD is ready to be
replicated in vivo in the human stomach [16, 17]. The 3.6-mm
APC catheter is very promising as it allows a wider surface area
of devitalization in a short time. In the future, selective mucosal
devitalization may be achievable through other thermal meth-
ods (such as cryotherapy) or non-thermal methods (by poten-
tially finding injectable substances into the mucosa/submucosa
or a gel solution being sprayed onto the mucosa). At the mo-
ment, however, devitalization with APC preceded by submuco-
sal injection of normal saline, which is known to be harmless to
the gastric wall, seems to be the most optimal method.
Conclusion
This study demonstrates that APC after submucosal injection
can achieve mucosal devitalization in a human stomach speci-
men at any indicator color safely with superficial submucosal in-
jury and without injury to the muscularis propria. This corro-
borates the safety of the procedure and opens the door for
GMD as a primary obesity therapy that targets the gastric muco-
sa.We suggest using golden as the appropriate color indicator in
vivo because it achieves the greatest efficacy of mucosal injury
with an acceptable amount of superficial submucosal injury.
Future studies are underway aiming to confirm technical feasi-
bility, tolerability, and safety of GMD in vivo (NCT03638843).
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Discussion 
 
 
The overarching hypothesis of this thesis was that although endoluminal gastric space 
occupying and restrictive interventions result in weight loss, weight-independent improvements in 
obesity related comorbidities require eradication of the gastric mucosa. This thesis comprises 
studies aimed at further understanding and contextualising the efficacy and safety of available 
endoluminal weight loss techniques, as well as the potential role of gastric mucosal devitalization 
as a novel approach to manage obesity and its associated comorbidities.  
 
Thus far, no country has succeeded in reversing its obesity epidemic. In 2015, 603.7 million 
adults were obese worldwide.1 Decreased quality of life and life expectancy and increased 
morbidity have led to adverse economic and health consequences, with an astounding 20.6% of 
the United States’ national health expenditure spent on treatment of obesity-related diseases.2, 3 
There is an ever-increasing number of adults hoping to lose weight that find themselves caught 
between intense lifestyle modification therapy and bariatric surgery. Patients inherently prefer 
non-surgical options, however, they are often dissatisfied with lifestyle modification therapy due 
to its less than desirable outcomes.4 Pharmacotherapy has provided a potential bridge, but its 
utilisation is limited due to associated cost, high incidence of side effects and suboptimal weight 
loss. Current pharmaceutical approaches are far less effective than bariatric surgery, with 30% of 
patients that are prescribed the highest dose still failing to achieve clinically significant weight 
loss.5 The most effective treatment of obesity and its associated metabolic comorbidities is 
bariatric surgery. Unfortunately, only a small fraction of obese patients consider surgery, as it is 
perceived to be invasive and patients often fear the possibility of suffering a complication.6, 7 
 Despite the poor adoption of bariatric surgery, it delivers insight into the profound 
influence of the gastrointestinal tract on food consumption habits and metabolism. The underlying 
mechanisms of action of bariatric surgery are now understood to be more than merely a result of 
restricting oral intake or provoking malabsorption. If this were the case, those who undertook 
bariatric surgery would be ravenous and miserable, a state not experienced despite patients losing 
up to 25% of their total body weight by 6 months.8, 9 Detecting the precise anatomical, cellular and 
molecular changes induced by bariatric surgery is essential to developing techniques that are 
effective, well tolerated, safe and appealing to patients. In the interim, the most appropriate 
alternative is to modify the gastrointestinal tract to simulate the physiologic alterations (not simply 
the physical alterations) of bariatric surgery.10 One should be mindful that the induced physiologic 
effects of bariatric surgery may not be a simple consequence of the physical or anatomical 
modifications that occur. 
 
Endoluminal weight loss and metabolic therapies, such as intragastric balloons (IGB) and 
endoscopic sleeve gastroplasty (ESG), result in clinically significant weight loss.9, 11-13 However, 
the same degree of weight loss and weight-independent benefits observed with bariatric surgery 
are not achieved with endoluminal therapies.9, 14 This may be the result of clinicians and device 
manufacturers focusing efforts on developing endoluminal procedures that mimic the restrictive 
aspects of bariatric surgery, rather than imitating the profound and often immediate physiologic 
changes that ensue. As an example, type 2 diabetic patients who undergo laparoscopic sleeve 
gastrectomy (LSG) regularly attain remission of diabetes within 1 month of surgery, despite 
achieving <10% total body weight loss (TBWL) by that time.15-17 Another example is the superior 
metabolic profile observed in patients who undergo bariatric surgery as compared to patients who 
achieve comparable weight loss through intense caloric restriction during an equivalent time 
period.18, 19 
 
 
At this time, no published randomized controlled trial (RCT) exists comparing outcomes 
between endoluminal therapies and bariatric surgery. This maybe the result of the acknowledged 
inferiority of endoluminal therapies or the belief that accomplishing similar outcomes to those that 
undergo bariatric surgery are unattainable. As evidenced by the surmised data in CHAPTER 1, the 
outcome of interest for endoluminal therapies has traditionally been weight loss, as opposed to 
improvement in the metabolic comorbidities associated with obesity.20, 21 Nevertheless, this has 
been recognised and in the last decade several promising techniques emulating the physiologic 
changes of bariatric surgery are emerging. These include approaches targeting the neurohormonal 
aspects of the proximal luminal gastrointestinal tract: the mucosal surface of the stomach and 
duodenum.22-26 
 
 The overarching hypothesis of this thesis was tested with the use of the IGB as a model for 
space occupation of the stomach and ESG as a model for gastric volume reduction. The IGB and 
ESG are currently the most frequently performed endoluminal weight loss therapies throughout 
the Unites States and the World. Since their approval, regulatory authorities have provided detailed 
oversight, with close attention being paid to severe adverse events.27, 28 Bariatric therapies: 
surgical, endoluminal and pharmaceutical, have conventionally been considered “elective.” Thus, 
severe adverse events have been deemed unacceptable by both potential patients and referring 
clinicians. Ethical discussions pertaining to the stigma and attitudes towards bariatric therapies are 
beyond the scope of this thesis, but their recognition is essential to contextualising the serious 
adverse event thresholds set by regulatory bodies, clinicians and patients. There appears to be a 
movement by the aforementioned groups towards accepting lower efficacy thresholds for bariatric 
therapies in preference for improved safety and tolerability. The fluid-filled IGBs were approved 
in 2015 and are examples of the lower tolerated efficacy threshold with total body weight loss 
(TBWL) at 12 months being 7.6% for both.29, 30 Since CHAPTER 1 was published, two additional 
endoluminal therapies have received FDA approval in the United States: TransPyloric Shuttle 
(BAROnova Inc., Goleta, California, United States) and Plenity (Gelesis100, Gelesis Inc., Boston, 
Massachusetts, United States).  
 
The TransPyloric Shuttle is a removable intragastric implant that is intended to facilitate 
weight loss via intermittent obstruction of the pylorus, which delays gastric emptying. The device 
is inserted and retrieved with a flexible endoscope. The device dwell time is 12 months, which is 
6 months longer than the IGBs.  In an open labelled RCT, TBWL at 12-month follow up was 9.5% 
in the TransPyloric Shuttle cohort, which was 6.7% superior to the control group.31 In the 
TransPyloric Shuttle cohort, 39.7% of participants achieved >10% TBWL. The overall incidence 
of device or procedure related serious adverse events was low at 2.82%.31 
 
Plenity is a weight loss capsule that is innovative in that it is an endoluminal therapy that 
does not require a flexible endoscope. This hopefully represents the first of many novel future 
approaches that are void of a procedure. The capsule is swallowed 20 - 30 minutes prior to lunch 
or dinner with 500mL of water. The contents of the capsule, when mixed with water, expand to 
100x their size, which results in approximately 25% of the gastric volume being occupied. As the 
contents of the capsule progress through the gastrointestinal tract, they shrink and are passed in 
the stool. The results of a double-blind placebo controlled RCT revealed that when combined with 
a hypocaloric diet and 30 minutes of moderate exercise a day, patients lost 6.4% TBWL at 6 
months, a 2.1% superiority over placebo.32 Of interest, a small group of early responders (defined 
as 3% TBWL by week 8) achieved 9.9% TBWL by 6 months. Despite the overall small 
incremental benefit over placebo, the FDA likely approved this on the basis of its unparalleled 
safety profile with no reported serious adverse events.33 
 
Approval of the fluid-filled IGBs in 2015, and more recently the TransPyloric Shuttle and 
Plenity, provide important and timely insights when considering current and future endoluminal 
weight loss and metabolic therapies. The overwhelming majority of patients in these pivotal 
studies did not achieve 10% TBWL at 6- or 12-months, a threshold that has scientifically been 
proven to induce biochemically, clinically and histologically significant improvements in the 
metabolic comorbidities associated with obesity.34, 35 Data from high intensity diet and lifestyle 
intervention studies using softer biochemical endpoints suggest that a lower TBWL of 7% confers 
an improved metabolic state. However, due to the costs and risks associated with flexible 
endoscopic and surgical weight loss, a mean TBWL of 10% seems a more appropriate threshold 
for procedural therapies.36, 37    
 
Despite its infallible safety profile, rates of attrition are high in those undergoing diet and 
lifestyle modification therapy.38, 39 Therefore, even if high intensity lifestyle modification is an 
effective approach, adoption will be poor. This was the likely rationale for the thresholds set by 
the American Society of Gastrointestinal Endoscopy Task Force on Endoscopic Bariatric Therapy 
in 2011.21 In their White Paper, endoluminal weight loss therapies must achieve a mean minimum 
threshold of 25% excess weight loss (equivalent to approximately 5% TBWL) at 12 months with 
a maximum serious adverse event rate of 5%.21 These are the benchmarks that have been 
implemented by the FDA, and they provide insight into the rationale used by clinicians and 
industry when innovating and designing studies for endoluminal weight loss and metabolic 
therapies. These relatively low benchmarks encourage a large number of groups to develop 
endoluminal weight loss therapies/devices due to the ease at which regulatory approval may be 
attained. However, though the number of technologies may be substantial, those that will likely 
result in biochemically, clinically and histologically meaningful improvements may be low. 
Therefore, although potentially initially stifling to the endoluminal weight loss field, adopting 
higher thresholds may drive industry toward developing superior approaches that will be better 
received by bariatric surgeons, gastroenterologists, the broader medical community and most 
importantly, patients.  
 
This thesis interrogated the efficacy and safety of gastric endoluminal weight loss and 
metabolic therapies available in the United States. CHAPTER 2 and CHAPTER 5 evaluated the 
outcomes of ReShape IGB and ESG by way of large multicentre studies.12, 40 The efficacy of these 
therapies were represented in a variety of outcomes, though the two emphasized were % TBWL 
and the % of patients achieving >10% TBWL. In both studies, the mean TBWL was >10%, with 
>60% of patients achieving >10% TBWL. This implies that across multiple geographical locations 
and types of centres (academic or private), gastric space occupation (IGB) and gastric volume 
reduction (ESG) confer clinically significant weight loss. However, as highlighted in the 
discussion of both studies, there is a need to further assess the changes in metabolic profile that 
occur in response to the weight loss observed. Such multicentre studies are now underway with 
me being the principal investigator for Johns Hopkins, a participating site (NCT03406975).  
 
An important observation with regards to CHAPTER 2 and CHAPTER 5 is that the 
outcomes occurred in the context of patients making a financial commitment to the procedurally 
based therapy.12, 40 This, together with the retrospective nature of the study design, likely account 
for the substantially improved clinical efficacy as compared to the observed results of their 
respective RCTs.29, 30 This poses a conundrum for both the clinicians who offer these therapies as 
well as the responsible healthcare organisations (payers) that provide coverage for them (Medicare, 
health insurance companies, etc). In detail, if payers elect to cover these procedural therapies, then 
the clinical outcomes may be more similar to what was seen in the pivotal trials, and hence inferior 
to those of out of pocket paying patients. Conversely, if payers don’t cover these procedures, many 
patients who could potentially benefit will be denied the opportunity to do so. This will result in 
poor adoption of the procedure and thus the desperate need to treat obese patients will continue to 
go unmet. Furthermore, if payers do not cover the cost of these procedures and patients chose to 
proceed using a self-pay model, the patients could be liable for costs associated with treating 
adverse events, which would also limit adoption. 
 
The high rate of post-procedural symptoms noted in the patients of CHAPTER 2, though 
frequently self-limited, are concerning.12 CHAPTER 3 was designed to objectively elucidate the 
mechanical alterations caused by fluid filled balloons in an attempt to improve patient selection 
and better control post-IGB tolerability.41 The increased gastric emptying time of solids was not a 
new finding and has prompted some to prohibit those with baseline increased gastric emptying 
from receiving the IGB.42 Interestingly, despite a large foreign body in the stomach, the lower 
oesophageal sphincter pressure was not reduced and the DeMeester score was not statistically 
significantly increased. Despite the study involving intensive objective testing, the precise 
mechanical alterations that are associated with fluid-filled IGB implantation remain ambiguous. 
 
The limited dwell time of the IGB together with its post-procedural symptoms make many 
clinicians unenthusiastic about offering the therapy. One can postulate that the presence of a 
foreign body occupying space in the stomach, or anywhere in the gastrointestinal tract for that 
matter, will inevitably be poorly tolerated. CHAPTER 1 illustrated that therapies that required the 
placement of a device (IGB, duodeno-jejunal bypass liner, etc) resulted in poor patient tolerability 
and a high adverse event rate.20 Thus, future innovation in this field should ideally entail a method 
that does not result in the placement of a foreign body. Also, any foreign body placed in the 
gastrointestinal tract will likely have a limited dwell time, which will impact the durability of its 
effectiveness. Additionally, the majority of endoluminal weight loss and metabolic techniques that 
require a foreign body will need to be subsequently removed, exposing patients to potential 
complications. CHAPTER 8 compared the efficacy and safety of a gastric space occupation 
procedure that entails a foreign body implant limited to a 6-month dwell time (IGB) with a gastric 
volume reduction procedure with no sizable foreign body implant (ESG).43 As expected, ESG was 
associated with superior efficacy, durability, and less adverse events. 
 
Endoluminal therapies have been positioned as a relatively low risk, minimally invasive 
approach for the treatment of obesity, with superior outcomes as compared to diet and lifestyle 
modification therapy.21 Therefore, many champions of endoluminal therapies propose that they 
are an appropriate approach to treating patients who are earlier on in their disease, i.e. those that 
have class 1 obesity (BMI 30–35 kg/m2). Likewise, proponents of endoluminal therapies claim 
that flexible endoscopic procedures are technically easy to perform and hence can be learnt by a 
large number of clinicians in a relatively short period of time. This could allow for more rapid 
treatment of the hundreds of millions of patients worldwide that would benefit from weight loss, 
as compared to the much smaller number that could theoretically be treated with surgery due to 
the relatively small number of trained bariatric surgeons. This thesis examined each of the 
aforementioned suppositions with the following paragraphs providing further insights. 
 
The outcomes documented in CHAPTER 6 confirmed that ESG is safe with a low rate of 
severe adverse events (<5%), is minimally invasive, as it can be performed as an outpatient 
procedure in the endoscopy unit, and is effective as it results in clinically significant weight loss.44 
CHAPTER 7 confirmed that ESG conferred greater weight loss than high intensity diet and 
lifestyle therapy.45 In this case-matched study, ESG was still statistically and clinically 
significantly superior despite the extraordinarily high weight loss in the diet and lifestyle 
modification group. A prospective study is underway to corroborate these results (NCT03406975).  
 
CHAPTER 9 upheld the assumptions that ESG was less invasive than the most frequently 
performed bariatric surgery (LSG).9 All ESG procedures were performed as an outpatient 
procedure without the need for an inpatient stay, as compared to LSG which required patients to 
have at least one overnight inpatient admission. Furthermore, the natural orifice transoral 
technique, negating any abdominal wall or gastric incisions, enforces the minimally invasive 
notion. The study also supported the fact that ESG was associated with statistically and clinically 
significantly lower risks than LSG. Furthermore, LSG was associated with a significantly higher 
rate of incident gastroesophageal reflux disease (GERD), a significant disease with associated 
development of de novo Barrett’s oesophagus in the post LSG patient.46, 47  
 
The assumptions regarding the minimally invasive and low risk nature, as well as the 
adequate efficacy of ESG appear endorsed by this thesis. Additionally, the assumption that ESG 
is less invasive than bariatric surgery, with an improved safety profile, has been substantiated. 
Furthermore, CHAPTER 7 revealed that ESG patients saw superior weight loss as compared to 
patients undergoing diet and lifestyle modification, specifically within the subgroup of patients 
with a baseline BMI <40 kg/m2.45 CHAPTER 9’s subgroup analysis in patients with a baseline 
BMI <40 kg/m2 found no statistically significant difference in % TBWL between ESG and LSG, 
though a trend towards the superiority of LSG was seen.9  Therefore, it appears that in patients 
who are ordinarily not candidates for bariatric surgery (those with class 1 and class 2 obesity), 
ESG provides an effective approach to weight loss. ESG has been considered by many as the 
preferred approach for “early intervention,” such as to treat class 1 obesity, prevent the 
development of obesity associated comorbidities and potentially even be contemplated as an 
option for those wanting to prevent the transition into higher obesity classes.  
 
In the absence of a high quality RCT comparing ESG to bariatric surgery in patients with 
class 1 obesity (BMI 30-35 kg/m2), one must be tempered when portraying ESG as a preferred 
approach to LSG for “early intervention.” There is robust data demonstrating that bariatric surgery 
prevents obesity-related comorbidities including type 2 diabetes and its associated micro- and 
macrovascular complications.48-51 Thus, what appears to prevent bariatric surgery from widespread 
adoption in patients with class 1 obesity are concerns regarding its safety profile. However, there 
is data to demonstrate the acceptable safety of bariatric surgery in patients with class 1 obesity.52 
In a United States based study, Metabolic and Bariatric Surgery Accreditation and Quality 
Improvement Program data sets were used to assess 30 day post-operative safety profile of patients 
who underwent bariatric surgery between 2015 and 2016. A total of 8,628 cases with a mean pre-
operative BMI of 33.7 kg/m2 were analysed; of these, 6,243 underwent LSG.52 The composite 
severe adverse event rate for the entire cohort was 3.8%, and it was as low as 2.9% in the LSG 
cohort. The mortality rate was 0.5% for both the entire cohort as well as the LSG cohort.52 These 
results are striking when compared to those seen in CHAPTER 6, where the serious adverse event 
rate with ESG was only slightly lower at 2.3%.44 The minor difference may be even more 
impressive when considering that the LSG cohort likely had a much higher rate of obesity-related 
comorbidities. 
 
The increasing evidence supporting the safety and efficacy of bariatric surgery in patients 
with BMI 30-35 kg/m2 resulted in the American Society for Bariatric and Metabolic Surgery 
(ASMBS) updating its position statement on bariatric surgery for patients with class 1 obesity in 
2018.53 The ASMBS now recommends that bariatric surgery be offered to patients with BMI 30-
35 kg/m2 who have obesity-related comorbidities not adequately treated with non-surgical 
methods. Furthermore, a strong recommendation for bariatric surgery was made for patients with 
class 1 obesity and type 2 diabetes.53 Even non-surgical societies, such as the American Diabetes 
Association (ADA), have now recommend bariatric surgery in patients with type 2 diabetes and 
BMI 30-35 kg/m2 who are not adequately treated with non-surgical methods.54 Interestingly, 
endoluminal therapies have not been incorporated into any of the position statements or guidelines 
published by leading medical associations (American Heart Association, ADA, The Obesity 
Society, ASMBS, etc).  
 
This thesis did not investigate the outcomes for patients with BMI <30 kg/m2 who 
underwent endoluminal weight loss and metabolic therapies. Aside from Plenity, no endoluminal 
therapy has been FDA approved for patients with BMI <30 kg/m2.33 One may believe that 
endoluminal therapies would confer a favourable risk/benefit profile to bariatric surgery for this 
subgroup. There are several published surgical series in which patients undergo bariatric surgery 
for BMI <30 kg/m2 A Taiwanese study of 80 patients with type 2 diabetes and a BMI <30 kg/m2 
with a mean HbA1c of 9% underwent bariatric surgery.55 The mean TBWL at 12 months was 17% 
with a mean reduction in BMI from 27 to 23 kg/m2. Complete remission of type 2 diabetes was 
seen in only 25%, significantly less when compared with surgical cohorts with BMI 30-35 kg/m2 
(50%) and BMI >35 kg/m2 (79%) undergoing bariatric surgery.55 A systematic review and meta-
analysis on Asian patients with type 2 diabetes and a BMI <30 kg/m2 also revealed modest 
improvements in weight loss with a BMI reduction of 2.9 kg/m2 and a reduction in HbA1c of 2.4% 
at 12 months.56 Intriguingly, there is more published data on bariatric surgery in overweight 
patients than endoluminal therapies. However, a Brazilian study of 26 overweight patients with a 
mean baseline BMI of 28.6 who underwent IGB therapy has been published.57 The mean TBWL 
at 6 months was 12%, which is similar to the weight loss seen in obese patients in CHAPTER 2.12 
 
There appears to be an opportunity for endoluminal therapies to become the preferred 
approach in treating overweight patients (BMI 25-30 kg/m2 ) with obesity-related metabolic 
comorbidities. Currently, the endobariatric community is focusing efforts on patients who are 
obese, though the superiority of endoluminal therapies would likely be better illustrated if the focus 
of research and innovation shifted to the lower BMI categories. A favourable risk/benefit ratio 
must always be at the forefront, as even relatively low to moderate rates of morbidity and mortality 
from endoluminal weight loss therapies will be met with severe criticism. It is also imperative to 
abstain from performing therapies that impede or prevent the patient from undergoing future 
bariatric surgery. As the accepted indications for bariatric surgery appear to be increasing and the 
BMI cut-offs lowering, the overlap in the number patients who desire endoluminal therapies but 
are current or likely future candidates for bariatric surgery will increase. The bariatric surgical 
community would respond harshly if they were unable to offer “salvage” bariatric surgical 
procedures in those who underwent prior endoluminal therapies. Indeed, there are published 
reports and series of patients who have had prior endoluminal plication based therapies such as 
ESG, TOGA and POSE (described in detail in CHAPTER 1), and then underwent bariatric 
surgery.20, 58-60 These publications, though small in number, suggest that “salvage” bariatric 
surgery is technically feasible and safe. Hence, concerns regarding endoluminal therapies 
impeding or preventing bariatric surgery do not appear founded, thus supporting the logic of 
pursuing research and innovation in the lower BMI categories. 
 
The final supposition was that endoluminal therapies have an advantage over bariatric 
surgery, as widespread dissemination is a greater possibility due to the technical ease at which they 
can be performed. IGBs are accepted as being technically simple to deliver and remove, with 
CHAPTER 2 demonstrating successful insertion and removal in all patients with follow-up data.12 
ESG has been considered by many observers as being technically challenging, with the suturing 
system being cumbersome and difficult to use. CHAPTER 4 rebuffed this belief as the ESG 
learning curve in a an endoscopist experienced with the endoscopic suturing system was between 
7 to 9 cases to attain efficiency with respect to time, number of sutures used and time per plication 
of each suture.61 With innumerable dedicated live procedure and hands-on courses available, the 
learning curve even in endoscopists with little or no experience with endoscopic suturing prior to 
ESG appears to be approximately 10 cases. This study was pivotal in encouraging endoscopists to 
learn ESG. It also facilitated the development of training curriculums and criteria for hospital 
credentialing. The procedure itself entails significant repetition, likely contributing to the brisk 
learning curve. CHAPTER 5 was the first study to validate ESG outside the three pioneering 
centres, giving confidence to the growing number providers who currently perform this procedure 
worldwide.40 Therefore, the most commonly performed endoluminal therapies, IGB and ESG, are 
able to be learnt relatively economically, making widespread adoption achievable.  
 
If extensive dissemination is required for endoluminal therapies to halt the obesity 
epidemic, then the techniques available need to be appealing to clinicians and patients. As 
illustrated by the poor utilisation of bariatric surgery, having an effective and safe technique is not 
sufficient. Both IGB and ESG appear to have certain appeal, though there are many potential 
patients who are apprehensive. A common perception is that IGB therapy is intolerable and 
temporary. Similarly, many believe that the stomach will stretch following ESG. Additionally, 
both of these procedures are criticized for not demonstrating long-term weight loss.  
 
A therapy that is non-surgical, performed under consciousness sedation, well tolerated, 
achieves long-term TWBL >10%, is indicated for obese and morbidly obese patients, is technically 
easy to perform, and has a low rate of adverse events would plausibly be well adopted by clinicians 
and patients. Sadly, as aspiration therapy (described in CHAPTER 1) illustrates, this is not the 
case.20 The multicentre U.S. pivotal trial compared 111 patients who underwent treatment with the 
AspireAssist (Aspire Bariatrics, King of Prussia, Philadelphia, United States) in addition to 
lifestyle counselling with 60 patients who underwent lifestyle counselling alone. The mean TBWL 
at 12 months for completers in the AspireAssist group was 14.2% compared to 4.9% in the 
lifestyle-counselling group.62 The most common adverse events were mild and included peristomal 
pain, stoma granulation tissue formation, irritation and infection. As outlined in an editorial I wrote 
in response to the study, aspiration therapy should remind those innovating in the endoluminal 
bariatric field of the importance of developing techniques that will be well received.63  
 
The durability of endoluminal weight loss therapies has been criticised by many. 
Commentators highlight the fact that weight loss tends to plateau at 6 to 12 months, even with the 
most effective therapies. CHAPTER 6 illustrates that TBWL with ESG was 15%, 17% and 17% 
at 6, 12 and 18-24 months, respectively.44 However, similar findings can be seen in patients who 
undergo bariatric surgery. As an example, in the context of a high quality RCT where intensive 
diet and lifestyle modification therapy is strongly encouraged, patients undergoing bariatric 
surgery plateau and began to regain weight as early as 12-24 months post-surgery.64 In fact, there 
are now several flexible endoscopic techniques used to treat patients who have experienced weight 
recidivism after bariatric surgery.65-67  Therefore, it cannot be expected that, even with close post-
procedural observation, weight loss will continue beyond 12 months with endoluminal therapies.  
 
The response from the advocates of endoluminal therapies has generally been that in the 
event of primary failure or weight recidivism, the patient can undergo a repeat procedure, an 
alternative endoluminal procedure, pharmacotherapy, or even bariatric surgery. However, there is 
little data to support such a position. There are reports in which a repeat  ESG has been performed 
for primary failure and weight regain after ESG, with the results modest at best.58, 68  Similar 
modest incremental weight reduction has been demonstrated when consecutive balloons are used 
to promote longer-term weight loss.69, 70  CHAPTER 5 described the outcome of 10 patients with 
a history of IGB therapy who underwent ESG.40 The weight loss in these patients was statistically 
and clinically significantly less than patients who had not had a history of IGB, a finding not 
previously reported. Similar results were seen in a small pilot study of ESG being performed to 
treat patients with weight recidivism after LSG.71 Therefore, endoluminal management of patients 
with primary failure of weight loss or weight regain requires further study. 
 
Despite their efficacy, the number of patients per month undergoing IGB placement has 
already plateaued in the United States. ESG is gathering momentum, but there may be too few 
endoscopists performing this procedure to make a significant impact on the obesity epidemic. 
Aspiration therapy has been poorly received and does not currently appear suitable for clinical 
adoption. The recently approved TransPyloric Shuttle could be effective when used outside of a 
clinical trial, but tolerability is a concern due it being a foreign body implant. Plenity confers 
suboptimal weight loss, though it is the first endoluminal weight loss therapy that does not require 
a procedure. Therefore, no currently approved endoluminal therapies will appreciably address 
obesity and its associated comorbidities on a widespread scale. Even when interested patients 
qualify, the majority will not receive therapy as payers are not currently reimbursing endoluminal 
therapies for weight loss. After discussion with payers in the United States, it is apparent that data 
demonstrating improvement in obesity-related metabolic comorbidities will be critical to obtaining 
reimbursement for endoluminal therapies. To date, there is a paucity of evidence supporting 
clinically meaningful improvements in the metabolic profile as a result of these therapies. When 
metabolic improvements were observed, they appeared to be a direct result of weight loss, as 
opposed to weight-independent mechanisms. 
 
There remains a desperate need to develop an endoluminal weight loss technique that is 
effective, well-tolerated, safe and appealing to patients. Optimally, the technique should be 
performed with technical ease, have no retained foreign body, and result in a clinically significant 
improvement in the metabolic profile. By investigating the likely underlying mechanisms of 
bariatric surgery, and recognising the suboptimal metabolic changes observed with current 
endoluminal therapies, the gastric mucosa marked itself as a potential target. The gastric mucosa 
was particularly inviting to study as the endoscopist has unimpeded access to it. 
 
Gastric mucosal devitalization (GMD) presents a potential paradigm shift in the 
management of obesity and its associated metabolic comorbidities. It is truly novel among the field 
of endoluminal bariatric therapies, where the focus has previously been to reduce the effective 
volume of the stomach (i.e. IGB, ESG etc). When I synthesised the notion of GMD, I was tempted 
to immediately perform the technique in a large animal model (porcine) to assess its technical 
feasibility, safety and efficacy. However, I felt that carefully investigating the technique in a 
logical and stepwise manner might allow for a deeper understanding of the mechanisms behind 
the metabolic improvements seen with bariatric surgery. Therefore, I made the decision to perform 
experiments in rats, because a large number of mechanistic studies had been previously published 
using that model. Rats were ideal because they offered the opportunity to perform experiments 
under the conditions of diet induced obesity.72-74 Furthermore, reagents to analyse serum, tissue, 
urine and faeces were readily available.72-74  
 
CHAPTER 10 reported the results of a randomized controlled trial comparing GMD with 
a sleeve gastrectomy (SG) and sham cohort in an obese rat model.24 It was observed that 
devitalization of the gastric mucosa, without alteration in gastric volume, resulted in a similar 
metabolic profile to SG. Importantly, GMD resulted in a reduction in body weight, reduction in 
visceral adiposity, improved serum lipid and glucose profiles and reduced liver lipid content. 
Serum gut hormones were evaluated but surprisingly, there was no discernible trend identified.24 
The results of the study affirmed the hypothesis that loss of gastric mucosa is a key contributor to 
the decreased food intake and the improvement in obesity-related metabolic comorbidities 
observed after LSG.  
 
Bariatric surgery, including LSG, is the most effective treatment for obesity and its 
associated cardiovascular comorbidities; such as hypertension, congestive heart failure and 
myocardial infarction.75 Similar to type 2 diabetes, bariatric surgery is an underutilised therapy for 
the treatment of cardiovascular disease. However, an alternative and conceivably more desirable 
endoluminal approach maybe better received. I hypothesised that GMD would result in a reduction 
in important cardiovascular parameters such as blood pressure and cardiovascular lipid deposition. 
Initially presented in abstract form in 2015 at the American Heart Association annual meeting, 
CHAPTER 11 presented data to demonstrate that GMD was associated with significant 
improvements in blood pressure, plasma renin activity and cardiac and aortic lipid deposition in a 
metabolically disturbed obese rat model.76, 77 These findings provided additional enthusiasm for 
the approach. Intriguingly, the specific component of the gastric mucosa that was responsible for 
the observed benefits remains unclear. In particular, there was no strong evidence to support the 
theory that the frequently measured gut hormones (ghrelin, GLP-1, PYY) were responsible for the 
observed effects. However, neither CHAPTER 10 nor CHAPTER 11 were specifically designed 
to identify the precise constituents of the gastric mucosa that contributed to the outcomes.24, 77 
Indeed, in view of the multiple redundancies in appetite and metabolic regulation, a single 
particular constituent will likely not be responsible for these profound effects. 
 
The data from rodent models showed GMD held promise as future potential therapy for 
obesity and its associated comorbidities. Therefore, there arose a need to ascertain if these findings 
could be translated to humans. The next logical step was verification in a large animal model. 
CHAPTER 12 reported the results of a randomized controlled trial comparing GMD with LSG 
and a sham cohort in a porcine model. GMD was successfully performed using standard 
commercially available flexible endoscopic equipment. The species selected had a moderate 
proportion of subcutaneous adiposity, though had little visceral adiposity. GMD pigs achieved a 
similar reduction in visceral adiposity to LSG pigs at the time of sacrifice, despite GMD pigs 
having a higher relative body weight. Furthermore, GMD resulted in a pronounced improvement 
in organ lipid content in the liver, heart and peripheral skeletal muscle. These metabolic alterations 
can be considered to be astounding considering that the pigs consumed food ad libitum and did 
not engage in any lifestyle modification. Additionally, as these pigs were not metabolically 
disturbed, one may expect an even more profound metabolic improvement in patients with obesity 
and/or type 2 diabetes. Perhaps the most important finding in the study was that there appeared to 
be weight-independent benefits of GMD, a crucial goal of any endoluminal weight loss and 
metabolic therapy. 
 
The porcine study findings declared that GMD was a potential future clinical therapy for 
patients with obesity and its associated comorbidities. The previously filed provisional patent was 
subsequently published as a utility patent which enabled medical device companies to become 
interested in this research [APPENDIX]. The patent was subsequently licensed through Johns 
Hopkins University to an electrosurgical company – ERBE [APPENDIX]. Through collaboration 
with ERBE, a large bore argon plasma coagulation (APC) catheter with a robust ceramic tip has 
been developed. This catheter has been 510K cleared and is ready for clinical use in the United 
States. The availability of a device able to facilitate GMD in humans led to the development of an 
institutional review board (IRB) approved clinical trial (NCT03526263, NCT03638843) 
[APPENDIX].  
 
Notwithstanding the insights gained in preclinical studies, translating GMD to humans 
raised several questions. What are the optimal argon plasma coagulation (APC) parameters to 
effectuate selective devitalization of the gastric mucosa? Would the entire greater curvature of the 
stomach need to be treated for a worthy therapeutic effect? When will the gastric mucosa 
regenerate and thus return to being hormonally active? As the procedure is a minimally invasive 
endoluminal therapy, could it be repeated? These questions will be the basis of an industry funded 
study spanning the next 2 years. However, prior to performing GMD in the clinical setting, it was 
essential to ascertain the answer to the first question relating to optimal dosing parameters. 
 The experiments in CHAPTER 13 were performed to ensure the endoscopist could perform 
GMD in an effective and safe manner. The results demonstrate that after a submucosal injection 
of normal saline, APC performed at 60-75 watts to reach a golden colour would achieve sufficient 
mucosal devitalization whilst limiting thermal injury to the superficial submucosa. Tissue colour 
was used as the preferred indicator of depth of ablation as it is the current method used clinically 
when APC is performed to treat a variety of gastric mucosal pathologies. If the dosing parameters 
were based on ablation time and power settings, there would likely be greater variability in tissue 
effect. This study confirmed no correlation between the duration of ablation to tissue colour or 
pathological findings. The next step is to perform a subsequent clinical study to confirm the 
technical feasibility, tolerability, and safety of GMD using APC to achieve a golden colour in-vivo 
(NCT03638843). 
 
Prior to the in launch of the IRB approved clinical study, the decision was made to request 
an investigation device exemption (IDE) from the FDA. The purpose of attaining the IDE was to 
obtain “the treatment of obesity” as an indication for using the ERBE APC system. This will 
provide additional protection for clinicians performing the clinical study as well as the company 
supporting the study. The IDE process is currently underway at the FDA, and it is anticipated that 
the clinical trial will commence in late 2019. 
 
It must be recognized that GMD could be performed using a variety of methods (thermal 
and non-thermal) as indicated in the published utility patent [APPENDIX]. APC is only one such 
method, and functions as merely a model to demonstrate the clinical efficacy of such an approach. 
If clinical studies confirm that GMD is effective, a myriad of techniques could be adopted to 
achieve selective GMD. Examples include cryotherapy, radiofrequency ablation, a therapeutic gel 
or powder placed topically, or even a substance injected into the submucosa to impair the function 
of the mucosa. Indeed, in years to come, a swallowable liquid to selectively coat the gastric mucosa 
(one that depends on a low pH for example) could be consumed prior to ingestion of calories.  
 
At the current time, as APC is widely available and easy to use to treat pathology in the 
gastric mucosa, it would be logical to continue to advance this technology. Crucially, if APC was 
efficiently performed in a homogenous manner with real-time feedback as to ablation depth, 
confidence and widespread adoption of GMD with APC would likely occur. In 2017, a 3.4 million 
EUR grant was awarded to fund the development of a new optical tissue detection modality that 
could be integrated into the APC catheter [APPENDIX]. This could provide further confidence for 
those interested in precise control of ablation depth. A prototype was created, and it has been used 
in animal studies with promising results.  
 
This thesis is a compilation of select published works that have resulted in the development 
of a radical new endoluminal weight loss and metabolic approach, which is now on the verge of a 
clinical trial. The published works have also significantly contributed to the field by investigating 
the efficacy and safety of gastric space occupation (IGB) and gastric volume reduction (ESG). 
Furthermore, the thesis also provides data to drive clinicians and industry to think beyond gastric 
space occupation and volume reduction, in favour of more elegant approaches that confer 
significant metabolic benefits. Developing these approaches into techniques that will be effective, 
well-tolerated, safe and appealing will be essential to treating patients with obesity. 
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6. Tieu AH, Saxena P, Singh VK, Lennon AM, Kumbhari V, Messallam A, El Zein M, Kalloo AN, Khashab MA. 
Fenestration of a covered metal stent during cystoduodenostomy using argon plasma coagulation. Endoscopy. 
2014; 46 Suppl 1UCTN:E512-3 
7. Kumbhari V*, Greenup A, Abi-Hanna D. Gastrointestinal: endoscopic treatment of an infected pancreatic 
pseudocyst post-insertion of a covered self-expandable metal stent (CSEMS). J Gastroenterol Hepatol. 2014; 
29(11):1851 
8. Kumbhari V*, Storm AC, Tieu AH, Saxena P, Messallam AA, El Zein MH, Azola A, Khashab MA, Okolo PI 
3rd. Percutaneous flexible endoscopic necrosectomy for a retroperitoneal abscess. Endoscopy. 2014; 46 Suppl 1 
UCTN:E340-1 
9. Kumbhari V*, Storm AC, Saxena P, Canto MI, Azola A, Messallam AA, O'Broin-Lennon AM, Khashab MA. 
EUS-guided angiotherapy. Gastrointest Endosc. 2014;80(1):164-5   
10. Kumbhari V*, Storm AC, Saxena P, Okolo PI 3rd. Closure of a persistent gastric leak using a cardiac septal 
occluder. Endoscopy. 2014; 46 Suppl 1 UCTN:E147-8 
11. Saxena P, Jeffers A, Mitchell SE, Pawlik TM, Law JK, Kumbhari V, Khashab MA, Singh VK. A minimally 
invasive technique utilizing percutaneous and endoscopic rendezvous for successful treatment of a proximal bile 
leak following partial hepatectomy. Endoscopy. 2014; 46 Suppl 1 UCTN:E212-3 
12. Saxena P, Aguila G, Kumbhari V, Khashab MA. Untying the knot: technique of unraveling a guidewire knot 
created during EUS-guided biliary drainage. Endoscopy. 2014; 46 Suppl 1 UCTN:E140-1 
13. Saxena P, Azola A, Kumbhari V, Kalloo AN, Khashab MA. Percutaneous through-the-stent assisted ERCP in 
patients with Roux-en-Y gastric bypass. Gastrointest Endosc. 2014; 80(1):163 
14. Kumbhari V*, Storm AC, Okolo PI 3rd, Saxena P, Kalloo AN, Khashab MA. Efficient retrograde enteroscopy 
using a novel through-the-scope balloon. Surg Endosc. 2014; 28(9):2745-6 
15. El Zein MH, Kumbhari V, Tieu A, Saxena P, Messallam AA, Azola A, Li Z, Weiss M, Khashab MA. Duodenal 
perforation as a consequence of biliary stent migration can occur regardless of stent type or duration. Endoscopy. 
2014; 46 Suppl 1 UCTN:E281-2 
16. Saxena P, Kumbhari V, Khashab MA. EUS-guided drainage of a mediastinal abscess. Gastrointest Endosc. 
2014; 79(6):998-9 
17. Messallam AA, Kumbhari V, Saxena P, Azola AM, Kalloo AN, Khashab MA. Large bleeding rectal varices 
treated with endoscopic ultrasound-guided coiling and cyanoacrylate injection. Endoscopy. 2014; 46 Suppl 1 
UCTN:E28-9 
18. Kumbhari V*, Abi-Hanna D, Bassan M. Gastrointestinal: endoscopic ultrasound of a pancreatic lesion in situs 
inversus. J Gastroenterol Hepatol. 2014; 29(2):229 
19. Kumbhari V*, Azola A, Okolo PI 3rd, Hughes A, Saxena P, Bapat V, Storm AC, Yung R, Khashab MA. Closure 
of a chronic tracheoesophageal fistula by use of a cardiac septal occluder. Gastrointest Endosc. 2014; 80(2):332 
20. Saxena P, Kumbhari V, Khashab MA. EUS-guided drainage of a giant hemorrhagic pseudocyst by a through-
the-scope esophageal metal stent. Gastrointest Endosc. 2014; 79(2):202-3 
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21. Campos JM, Moon R, Teixeira A, Ferraz AA, Ferreria F, Kumbhari V. Endoscopic management of massive 
hemorrhage 12 h post laparoscopic roux-en-y gastric bypass. Obes Surg. 2015; 25(10):1981-3  
22. Ngamruengphong S, Kumbhari V, Tieu AH, Haito-Chavez Y, El-Zein MH, Aguila G, Khashab MA. EUS-
guided rescue of early dislodgement of a lumen-apposing stent. Gastrointest Endosc. 2015; 82(6):1124 
23. Kumbhari V*, Tieu AH, Azola A, Saxena P, Ngamruengphong S, El Zein MH, Khashab MA. Double peroral 
endoscopic myotomy for achalasia. Gastrointest Endosc. 2015; 82(5):953 
24. Kumbhari V*, Tieu AH, Ngamruengphong S, Aguila G, Schweitzer MA, Khashab MA, Singh VK. Endoscopic 
management of stomal stenosis after Roux-en-Y gastric bypass. Gastrointest Endosc. 2015; 82(4):747 
25. Kumbhari V*, Tieu AH, Azola A, Ngamruengphong S, El Zein MH, Khashab MA. Novel endoscopic approach 
for a large intraluminal duodenal ("windsock") diverticulum. Gastrointest Endosc. 2015; 82(5):961 
26. Kumbhari V*, Tieu AH, Cai JX, Okolo PI 3rd, Schweitzer MA, Khashab MA. Novel technique for the 
management of staple line leaks after sleeve gastrectomy. Gastrointest Endosc. 2015; 82(4):748 
27. Kumbhari V*, Cai JX, Tieu AH, Kalloo AN, Khashab MA. Over-the-scope clips for transoral gastric outlet 
reduction as salvage therapy for weight regain after Roux-en-Y gastric bypass. Endoscopy. 2015; 47 Suppl 1 
UCTN:E253-4   
28. Kumbhari V*, Tieu AH, Khashab MA. EUS-guided biliary drainage made safer by a combination of 
hepaticogastrostomy and antegrade transpapillary stenting. Gastrointest Endosc. 2015; 81(4):1015-6 
29. Onyimba F, Kumbhari V, Tieu A, Cai J, Abdegelil A, Reddy A, Khashab MA, Okolo P. Benign distal jejunal 
stricture treated by a partially covered esophageal stent with the use of spiral enteroscopy. Endoscopy. 2015; 47 
Suppl 1 UCTN: E172.   
30. Kumbhari V*, Tieu AH, Saxena P, Khashab MA, Okolo PI 3rd. Closure of a large, persistent enterocutaneous 
fistula by use of a ventricular septal occluder. Gastrointest Endosc. 2015; 81(5):1269-70.   
31. Kumbhari V*, Saxena P, Azola A, Messallam AA, El Zein MH, Khashab MA. Submucosal tunneling 
endoscopic resection of a giant esophageal leiomyoma. Gastrointest Endosc. 2015; 81(1):219-20 
32. Saxena P, Kumbhari V, El Zein M, Kalloo AN, Khashab MA. EUS-guided biliary drainage with antegrade 
transpapillary placement of a metal biliary stent. Gastrointest Endosc. 2015; 81(4):1010-1 
33. Khashab MA, Tieu AH, Azola A, Ngamruengphong S, El Zein MH, Kumbhari V. EUS-guided 
gastrojejunostomy for management of complete gastric outlet obstruction. Gastrointest Endosc. 2015; 82(4):745 
34. Ngamruengphong S, Kumbhari V, Tieu AH, Amateau SK, Okolo PI 3rd. Endoscopic reversal of gastric bypass 
for severe malnutrition after Roux-en-Y gastric bypass surgery. Gastrointest Endosc. 2015; 82(4):746 
35. Kumbhari V*, Storm AC, Cuka N, Okolo PI 3rd. Solitary polypoid colonic neuromatosis. Gastrointest Endosc. 
2015; 81(3):762-4 
36. Saxena P, Azola A, Kumbhari V, Kalloo AN, Khashab MA. EUS-guided rendezvous and reversal of complete 
rectal anastomotic stenosis after Hartmann's reversal. Gastrointest Endosc. 2015; 81(2):467-8 
37. Bukhari M, Kumbhari V, Haito-Chavez Y, Chen YI, Ngamruengphong S, Saxena P, Khashab MA. Novel 
technique to relax the lower esophageal sphincter during challenging peroral endoscopic myotomy (POEM). 
Endoscopy. 2016; 48(Suppl 1):E252 
38. Barola S, Agnihotri A, Khashab MA, Kumbhari V*. Perigastric fluid collection after endoscopic sleeve 
gastroplasty. Endoscopy. 2016; 48(S 01):E340-E341 
39. Tieu AH, Kumbhari V, Ngamruengphong S, Haito-Chavez Y, Chen YI, Bukhari M, Khashab MA. Two-stage 
endoscopic approach for the management of a large symptomatic epiphrenic diverticulum in the setting of 
achalasia. Gastrointest Endosc. 2016; 84(5):848-849 
40. Ngamruengphong S, Kumbhari V, Tieu AH, Haito-Chavez Y, Bukhari M, Hajiyeva G, Ismail A, Aguila G, Chen 
YI, Khashab MA. A novel "balloon/snare apparatus" technique to facilitate easy creation of fistula tract during 
EUS-guided gastroenterostomy. Gastrointest Endosc. 2016; 84(3):527 
41. Saxena P, El Zein M, Makary M, Kumbhari V, Khashab MA. Submucosal tunneling and en bloc endoscopic 
resection facilitates laparoscopic transgastric removal of a large GI stromal tumor at the esophagogastric junction. 
Gastrointest Endosc. 2016; 84(1):179-80 
42. Haito-Chavez Y, Kumbhari V, Ngamruengphong S, De Moura DT, El Zein M, Vieira M, Aguila G, Khashab 
MA. Septotomy: an adjunct endoscopic treatment for post-sleeve gastrectomy fistulas. Gastrointest Endosc. 2016; 
83(2):456-7 
43. Ngamruengphong S, Hanada Y, Brewer Gutierrez O, Bukhari M, Chen YI, Kumbhari V, Khashab MA. 
Submucosal tunneling endoscopic resection of a gigantic esophageal leiomyoma. Endoscopy. 2017; 49(12):E298-
E299 
44. Sanaei O, Ngamruengphong S, Chen YI, Bukhari M, Brewer Gutierrez O, Kumbhari V, Khashab MA. 
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Endoscopic ultrasonography-guided freestyle rendezvous recanalization of a complete postoperative rectosigmoid 
anastomotic obstruction with a lumen-apposing metal stent. Endoscopy. 2017; 49(9):E206-E207 
45. Barola S, Tadimeti H, Chen YI, Ngamruengphong S, Khashab MA, Kalloo AN, Kumbhari V*. Pancreatic 
carcinoma diagnosed by peroral pancreatoscopy using the spyglass system. Am J Gastroenterol. 2017;112(6):836 
46. Agnihotri A, Barola S, Flickinger J, Khashab MA, Kumbhari V*. Novel technique to manage recurrent peg-j 
tube dislodgement with full-thickness endoscopic suturing. Am J Gastroenterol. 2017; 112(5):815-816 
47. Fayad LE, Chen YI, Chavez YH, Kumbhari V, Khashab MA. Endoscopic ultrasound-guided transjejunal 
rendezvous access to the common bile duct. Endoscopy. 2017; 49(6):611-612 
48. Agarwal A, Fang S, Pezhouh MK, Kumbhari V, Khashab MA, Ngamruengphong S. Full-thickness resection of a 
rectal scar using a modified over-the-scope clip after piecemeal resection of intramucosal cancer. Endoscopy. 
2017; 49(6):E151-E152 
49. Barola S, Agnihotri A, Chang Chiu A, Kalloo AN, Kumbhari V*. Spontaneous hyperinflation of an intragastric 
balloon 5 months after insertion. Am J Gastroenterol. 2017; 112(3):412 
50. Barola S, Magnuson T, Schweitzer M, Chen YI, Ngamruengphong S, Khashab MA, Kumbhari V*. Endoscopic 
suturing for massively bleeding marginal ulcer 10 days post roux-en-y gastric bypass. Obes Surg. 2017; 
27(5):1394-1396 
51. Brewer Gutierrez OI, Moran R, Yang J, Sanaei O, Kalloo AN, Kumbhari V, Khashab MA. Successful single-
session cricopharyngeal and Zenker's diverticulum peroral endoscopic myotomy. Endoscopy. 2018;50(8):E220-
E221 
52. Fayad L, Simsek C, Khashab MA, Kalloo AN, Kumbhari V. Gastrointestinal: Intragastric balloon: Gastric outlet 
obstruction or resting in the antrum?. J Gastroenterol Hepatol. 2019; 34(1)8. 
53. Moran RA, Brewer Gutierrez OI, Yang J, Kedsirichairat T, Sanaei O, Kumbhari V, Khashab MA. 
Endoscopically guided percutaneous suturing to facilitate closure of a large gastrocutaneus fistula with an over-
the-scope clip. Endoscopy. 2018; 50(11):E309-E311 
54. Kerdsirichairat T, Vosoughi K, Ichkhanian Y, Ngamruengphong S, Kalloo AN, Kumbhari V, Khashab MA. 
Endoscopic full-thickness resection with omental patch closure for a gastric stromal tumor in the gastric cardia. 
Endoscopy. 2019 Oct;51(10):E278-E279 
 
 
Book Chapters [BC] - * first and/or corresponding author 
1. Kumbhari V*, Kalloo AN. Natural orifice translumenal endoscopic surgery (NOTES). In Gastroenterology. 
Yamada T (ed). 6th Ed. Wiley-Blackwell 2016 
2.  Kumbhari V*, Kalloo AN. Natural orifice translumenal endoscopic surgery (NOTES). In Atlas of 
Gastroenterology. Yamada T (ed).  5th Ed. Wiley-Blackwell 2016  
3. Tieu AH, Kumbhari V, Khashab MA. The Management of Mallory Weiss Syndrome. In Current Surgical 
Therapy. Cameron JL, Cameron AM (eds). 12th Ed. Elsevier 2017 
4. Badurdeen D, Kumbhari V, Zundel N. Intragastric balloon history. In Intragastric Balloon for Weight 
Management: A Practical Guide. Campos JM, Usuy EN, Galvão Neto MP, Silva LB (eds). Springer 2018 
 
Books, Textbooks [BK] 
None 
 
Other Publications: 
 
Proceeding Reports [PR] 
None 
 
Guidelines/Protocols, Consensus Statement, Expert Opinion, Consortium Articles [GL] 
1. Kumar N, Dayyeh BA, Dunkin BJ, Neto MG, Gomez V, Jonnalagadda S, Kumbhari V, Larsen MC, Pannala R, 
Ryou MK, Sullivan SA, Wilson EB, Thompson CC. ABE/ASGE position statement on training and privileges for 
primary endoscopic bariatric therapies. Gastrointest Endosc. 2019 [Epub ahead of print] 
 
 
Editorials [ED] - * first and/or corresponding author 
1. Kumbhari V*, Saxena P, Khashab MA. Self-expandable metallic stents for bleeding esophageal varices. Saudi J 
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Gastroenterol. 2013; 19(4):141-3 
2. Kumbhari V*, Abu Dayyeh BK. Keeping the fistula open: paradigm shift in the management of leaks after 
bariatric surgery? Endoscopy. 2016; 48(9):789-91 
3. Kumbhari V*, Okolo PI III. Aspiration therapy for weight loss: is the squeeze worth the juice? Am J 
Gastroenterol. 2017; 112(3):458-589 
4. Badurdeen DS, Kumbhari V*. Endoscopic sleeve gastroplasty and its application to China. J Dig Dis. 2017; 
18(10):551-555 
5. Kahan S, Kumbhari V. A Weight Loss Device That Looks Like a Pill. Obesity. 2019; 27(2):189 
6. Sharaiha RZ, Kumbhari V*. Are We Moving in the Right Direction by Altering Gastric Motility for Weight 
Loss? Clin Gastroenterol Hepatol. 2019. [Epub ahead of print]  
 
Methods and Techniques [MT] - * first and/or corresponding author 
1. Cai JX, Khashab MA, Okolo PI 3rd, Kalloo AN, Kumbhari V*. Full-thickness endoscopic suturing of staple-line 
leaks following laparoscopic sleeve gastrectomy. Endoscopy. 2014; 46 Suppl 1 UCTN:E623-4 
2. Kumbhari V*, Azola A, Saxena P, Modayil R, Kalloo AN, Stavropoulos SN, Khashab MA. Closure methods in 
submucosal endoscopy. Gastrointest Endosc. 2014; 80(5):894-5 
3. Khashab MA, Kumbhari V, Kalloo AN, Saxena P. Peroral endoscopic myotomy: a 4-step approach to a 
challenging procedure. Gastrointest Endosc. 2014; 79(6):997-8 
4. Kumbhari V*, Tieu AH, Saxena P, Khashab MA. Flexible endoscopic Zenker's diverticulotomy. Gastrointest 
Endosc. 2015; 81(6):1477 
5. Kumbhari V*, Tieu AH, Khashab MA. Common indications for transoral flexible endoscopic suturing. 
Gastrointest Endosc. 2015; 81(4):1000 
6. Li L, Piontek KB, Kumbhari V, Ishida M, Selaru FM. Isolation and profiling of microRNA-containing exosomes 
from human bile. J Vis Exp. 2016; (112) 
7. Khashab MA, El Zein M, Ngamruengphong S, Haito Chavez Y, Kumbhari V, Ismail A, Tieu AH, Aguila G, 
Singh VK, Lennon AM, Canto MI, Kalloo AN. Double endoscopic bypass by using lumen-apposing stents (with 
videos). Gastrointest Endosc. 2016; 83(2):435-9   
8. Barola S, Chen YI, Ngamruengphong S, Kalloo AN, Khashab MA, Kumbhari V*. Technical aspects of 
endoscopic sleeve gastroplasty. Gastrointest Endosc. 2017; 85(4):862 
9. Barola S, Scweitzer MA, Chen YI, Ngamruengphong S, Khashab MA, Kumbhari V*. Demonstrations of 
transoral gastric outlet reduction: 2-fold running suture technique. VideoGIE. 2017; 2(1):2-3 
10. Barola S, Chen YI, Ngamruengphong S, Khashab MA, Kumbhari V*. Technique of endoscopic suturing of an 
enteral feeding tube to manage recurrent dislodgement. VideoGIE. 2017; 2(3):64-65 
11. Farha J, Fayad L, Kadhim A, Şimşek C, Badurdeen DS, Ichkhanian Y, Itani MI, Kalloo AN, Khashab 
MA, Kumbhari V*. Gastric Per-Oral Endoscopic Myotomy (G-POEM) for the Treatment of Gastric Stenosis 
Post-Laparoscopic Sleeve Gastrectomy (LSG). Obes Surg. 2019 Jul;29(7):2350-2354. 
 
Research Letters/White Papers/Brief Reports [RL] - * first and/or corresponding author  
1. Wang B, Rajendra S, Pavey D, Sharma P, Merrett N, Wu X, Snow ET, Kumbhari V, Ball MJ, Robertson IK. 
Viral load and integration status of high-risk human papillomaviruses in the Barrett's metaplasia-dysplasia-
adenocarcinoma sequence. Am J Gastroenterol. 2013; 108(11):1814-6 
2. Kumbhari V*, Saxena P, Khashab MA. A new through-the-scope balloon-assisted deep enteroscopy platform. 
Gastrointest Endosc. 2014; 79(4):694. 
3. Kumbhari V*, Oberbach A. Is excision of the gastric mucosa responsible for the superior outcomes of sleeve 
gastrectomy compared with gastric plication? Surg Obes Relat Dis. 2015 May-Jun; 11(3):732 
4. Kumbhari V*, Heinrich M, Khashab MA, Kalloo AN, Oberbach A. Gastric restriction and delayed gastric 
emptying may not be the keys to an effective endoscopic metabolic therapy. Gastrointest Endosc. 2015; 
82(1):185-6 
5. Khalil B, Kumbhari V*. Comment on "Patients with roux-en-y gastric bypass require increased sedation during 
upper endoscopy". Clin Gastroenterol Hepatol. 2016; 14(1):165 
6. Kumbhari V*, Singh VK. Response. Gastrointest Endosc. 2016;84(3):550-1 
7. Kumbhari V*, Singh VK. Response. Gastrointest Endosc. 2017; 85(1):268-269 
8. Kumbhari V*, Khashab MA. Reply to Eleftheriadis and to Sharma et al. Endoscopy. 2017 Dec;49(12):1284.  
9. Badurdeen DS, Fayad L, Kalloo AN, Kumbhari V*. The forgotten fundus-response to - obesity treatment with 
botulinum toxin- is not effective: a systematic review and meta-analysis. Obes Surg. 2018; 28(1):262-263 
 13 
10. Abu Dayyeh BK, Neto MG, Lopez-Nava G, Sharaiha RZ, Kumbhari V, Wilson EB. Endoscopic sleeve 
gastroplasty is safe and effective: pitfalls of a flawed systematic review. Surg Obes Relat Dis. 2019 
Aug;15(8):1423-1424. 
 
Published Curricula [PC] 
None 
 
Media Releases/Interview [MR] 
1. Stutz, Christine. “Shrinking Waistlines”. Baltimore Style Magazine. Apr 2016; 99-100. Print 
2. Beaulieu, Debra. “From the gut: gastroenterology opportunities in obesity management”. HealthLeaders Media. 
Oct 2016; 62-64. Print 
3. WUSA. Obesity Continues to be a major problem in the US. Published Nov 2017 
(https://www.wusa9.com/video/news/health/obesity-continues-to-be-major-problem-in-the-us/65-2812633) 
4. Cara, Ed. June 2018 “The diabetes cure that most insurance companies won’t pay for”. GIZMODO. Retrieved 
from https://gizmodo.com/the-diabetes-cure-that-most-insurance-companies-wont-pa-
1826946364?rev=1529422639399 
5. Kee, Caroline. July 2018 “Here’s What Happens To Your Body When You Eat Super Hot Peppers”. 
BizzFeed.newshttps://www.buzzfeednews.com/article/carolinekee/worlds-hottest-peppers-health-benefits 
 
Other Media [OM]  
1. Kumbhari V. Balloon weight loss program: Q &A. Published 2015 
(https://www.youtube.com/watch?v=ZfN1fMviClQ); this video has been viewed 11,523 times 
2. Kumbhari V. Transoral gastric outlet reduction. Published 2016 
(https://www.youtube.com/watch?v=shvPknE4Ydo); this video has been viewed 5,709 times 
3. Kumbhari V. What is endoscopic sleeve gastroplasty and how does it work? Published 2016 
(https://www.youtube.com/watch?v=9SGp04I1gPw&t=173s); this video has been viewed 69,731 times 
4. Kumbhari V. Aspiration therapy. Published 2017 (https://www.youtube.com/watch?v=s6wukYZ1UM0); this 
video has been viewed 3,721 times 
 
Extramural Funding 
 
Research Extramural Funding – Current  
06/01/17 – 06/01/19 ORBERA™ Post-Approval Study: A prospective, multicenter, open-label, post-approval 
study of the safety and effectiveness of ORBERA™ as an adjunct to weight reduction for 
obese adults (22 years of age and older) with a Body Mass Index (BMI) of ≥ 30 kg/m2  
 IRB00112762 
 Apollo Endosurgery  
 $204,262.65 
 Principal investigator  
 Percent effort: 27% for 3 years 
 
01/03/18- 01/03/20        Gastric Mucosal Devitalization as a Primary Obesity Therapy       
 IRB00089675 
 Johns Hopkins University 
 $ 170,133.21 
 Principal Investigator 
 15% for 2 years  
 
08/01/18 – 08/01/21 Multi-center ESG Randomized Interventional Trial (MERIT-Trial) 
 IRB00159493 
 Apollo Endosurgery  
 Johns Hopkins University 
 $411,398.06  
 Principal investigator  
 Percent effort: 6.47% for 3 years 
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Research Extramural Funding – Previous 
None 
 
Educational Extramural Funding 
None 
 
Clinical Extramural Funding 
None 
 
System Innovation or Quality Improvement Extramural Funding 
None 
 
INTRAMURAL Funding 
None 
 
CLINICAL ACTIVITIES  
 
Clinical Focus 
Dr Kumbhari is extensively involved in developing novel endoscopic techniques which improve outcomes in patients 
who have obesity. Furthermore,  he is involved in innovating new methods to endoscopically treat patients who have 
suffered an adverse event post bariatric surgery. These two areas of expertise have resulted in Dr Kumbhari 
representing the field on a national level (board member and annual course director for Association for Bariatric 
Endoscopy) and international level (member of the organizing committee for the International Federation Society of 
Obesity annual conference). Dr Kumbhari imparts his knowledge through his published works, lectures as well as live 
procedure demonstrations at national and international meetings. 
 
Certification 
Medical Licensure 
2007 – 2016  Medical License, Australia, MED0001198224 
2013-Present Maryland Medical License, Number D0079874 
2018-Present District of Columbia Medical License, Number MD045787 
 
Boards Certification 
2006   United States Medical Licensing Examination Step 1 
▪ Two digit score 98, three digit score 242 
2011   United States Medical Licensing Examination Step 2 CS 
▪ Pass 
2011   United States Medical Licensing Examination Step 2 CK 
▪ Two digit score 99, three digit score 268 
2011   Education Certificate for Foreign Medical Graduates (ECFMG) Certification 
▪ Certificate number 0-681-533-6 
2014   United States Medical Licensing Examination Step 3 
▪ Pass, three digit score 245 
2012    Fellow of the Royal Australasian College of Physicians 
▪ Fellowship number F13190 
2015    Certificate for completion of Advanced Endoscopy Fellowship, Johns Hopkins 
2019   Board Certified in Internal Medicine 
▪ ABIM ID 437124 Score 547 
 
 
Specialty Certification 
2014  Basic Life Support (BLS) 
2014  Advanced Cardiac Life Support (ACLS) 
 
 15 
Clinical Responsibilities 
1/16 – 6/18  Director of Endoscopy at Johns Hopkins Bayview Medical Center 
7/15 – Present  Director of Bariatric Endoscopy for Johns Hopkins Medical Institutions 
7/15 – 3/18  Clinical: 70% 
    Weight Loss Clinic (½ day/ week) 
   Dr. Kumbhari sees new, as well as post-procedure return patients, and is responsible for the 
   supervision and teaching of advanced endoscopy fellows, gastroenterology fellows and 
   visiting physicians and scientists. 
   Complications of Surgery-Bayview Clinic (½ day/week) 
   Dr. Kumbhari sees new and return patient with complex health issues following bariatric 
   surgery, and patient requiring interventional endoscopy treatment. 
   Whitemarsh Ambulatory Center (½ day/week) 
   Intragastric balloon insertions and removals 
   Interventional Endoscopy (3 day/week: 2 at BVMC, 1 at JHH) 
   Complex/advanced cases including EUS, ERCP, DBE, EMR and ESD 
   Inpatient gastroenterology and endoscopy attending (4 weeks/year) 
   Responsible for seeing inpatient MEG, consult patients, and performing endoscopy 
   procedures on all inpatients. 
 
3/18 – Present  Clinical: 70% 
    Weight Loss Clinic-Sibley (½ day/ week) 
   Dr. Kumbhari sees new, as well as post-procedure return patients, and is responsible for the 
   supervision and teaching of advanced endoscopy fellows, gastroenterology fellows and 
   visiting physicians and scientists. 
   Complications of Surgery Clinic- Sibley (½ day/week) 
   Dr. Kumbhari sees new and return patient with complex health issues following bariatric 
   surgery, and patient requiring interventional endoscopy treatment 
   Interventional Endoscopy (3 day/week: 2 at Sibley, 1 at JHH) 
   Complex/advanced cases including EUS, ERCP, SBE, EMR and ESD 
   Inpatient gastroenterology and endoscopy attending 
   Responsible for seeing inpatient MEG, consult patients, and performing endoscopy 
procedures on all inpatients. Dr Kumbhari is also on-call for advanced endoscopy at Sibley 
1 in 2. 
 
Clinical Productivity 
7/15 – 3/18  Dr Kumbhari’s target clinical effort assignment is 70%, however, his clinical effort variance 
is +10% since commencing as an Attending physician. From December 1st 2015- June 30th 
2016 (7/12 months), he treated 616 patients generating 4513 wRVUs (minimal threshold 
3216 wRVUs). In the entire year of 2016-17, he treated 888 patients generating 6982 wRVUs 
(minimal threshold 5513 wRVUs). In 2017-18, he treated 955 patients generating 7016 
wRVUs (minimal threshold 5513 wRVUs). In 2018- February 2019 (8/12 months), he treated 
620 patients generating 5245 wRVUs. To annualize 2018-2019, he will treat a projected 930 
patients generating 7868 wRVUs for this financial year (minimal threshold 5513 wRVUs). 
 
Clinical Draw  
7/15 – Present           Dr Kumbhari draws patients from across the nation as well as overseas. In light of the unique 
clinical attributes and national and international recognition, he is referral base is vast. The 
following data is as per billing data from the JHU SOM website, which seemingly 
underestimates the true proportion of international and overseas patients treated. However, 
from December 2015 to February 2019, as an Attending physician, he has seen a total of 2613 
patients, of which 552 (21%) came from states outside of the hospital where they were seen. 
He has also seen 52 (2%) of patients from countries such as The Netherlands, Russia, Kuwait, 
Qatar, Saudi Arabia, Jordan, Egypt, UAE, Canada, India, Egypt, Ghana as well as others.  
 
Membership in or examiner for specialty board 
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None 
 
Clinical Program Building / Leadership 
7/15 – Present  Concierge Weight Loss Program 
 Director of the Concierge Weight Loss Program. It is one of the few programs in North 
America that offers a multidisciplinary approach with multiple services centralized in one 
building housing a nutritionist, psychologist, exercise physiologist, an endoscopist, a clinical 
nurse coordinator, dedicated administrative staff and a medical weight loss specialist. This 
ensures seamless collaboration between clinicians and researchers, ensuring that every patient 
seen in clinic is receiving personalized, comprehensive care before and after endoscopic 
weight loss procedures. This program has also garnered national and international attention, 
with patients coming from all over the United States, in addition to Canada, South America, 
Europe and the Far East. Under Dr. Kumbhari’s leadership and guidance, the concierge 
weight loss program has expanded across five locations within the Johns Hopkins Health  
System, including ambulatory surgical centers. His expertise has attracted physicians 
domestically and internationally, leading to the creation of a structured 2-4 week long 
observership with comprehensive teaching. Through this program Dr. Kumbhari has also 
been able to study new methods of endoscopic weight loss in collaboration with the 
Department of Bariatric Surgery and the Bloomberg School of Public Health. 
 
1/16 – 6/18   Therapeutic Endoscopy program- Bayview Medical Center 
   Director of Endoscopy. With experience in a range of services and his expertise in therapeutic 
endoscopic therapies, Dr Kumbhari led the expansion and growth of the endoscopy unit and 
brought on procedures such as double balloon enteroscopy, endoscopic mucosal resection, 
endoscopic submucosal dissection, endoscopic full thickness resection, endoscopic 
ultrasound and endoscopic suturing, all of which were previously not available at Bayview 
Medical Center. This growth enabled an increase in unit utilization, and growth in patient 
volume by approximately 15%. Due to the increase capability of the endoscopy unit, inter-
hospital transfers and the costs associated with these have nearly eradicated. His work has 
resulted in the addition of a second therapeutic endoscopist to the unit, allowing for 
therapeutic endoscopy coverage five days a week.  
 
3/18 – Present  Flexible Endoscopic Surgery program – Sibley Memorial Hospital 
Dr Kumbhari brought his experience in flexible endoscopic therapies to the DC area resulting 
in new procedures being available to support patients, gastroenterologists and surgeons in the 
region. Dr Kumbhari led the expansion and growth of the endoscopy unit and brought on 
procedures such as balloon enteroscopy, endoscopic mucosal resection, endoscopic 
submucosal dissection, endoscopic full thickness resection, endoscopic ultrasound and 
endoscopic suturing, all of which were previously not available at Sibley Memorial Hospital. 
Although his targeted clinical effort at Sibley Memorial Hospital is only 40%, he has had a 
profound impact in terms of increasing volume and revenue for the endoscopy unit as well as 
negating the need for patients to be transferred to Johns Hopkins Hospital for advanced 
endoscopic procedures. 
 
Clinical Demonstration Activities  
 
5/16 – Present  Advanced Endoscopy Observerships (structured with funds collected by the GI Division) - 
Turkish Gastroenterology Society. Observers watch an array of advanced therapeutic 
procedures performed by Dr Kumbhari. The duration of their observership is 2 months. To 
date, 14 observers have completed this observership which has been well received and is 
funding is to continue for the foreseeable future. Based on these oberserverships, observers 
have returned to Turkey and have performed a variety of the novel methods they observed. 
12/16 – Present  Internal Endoscopic suturing single day observerships for national and international 
physicians. Dr Kumbhari conducts monthly structured observerships for those wishing to 
commence endoscopic suturing at their respective practice or university. Physicians come 
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both nationally and internationally. To date, he has completed 23 such observerships with 2-3 
physicans attending on each occasion. Each observership consists of a 2 hour didactic 
component and physicians observing 3-4 live endoscopic suturing procedures (endoscopic 
sleeve gastroplasty and transoral gastric outlet reduction). 
2/18 – Present External Endoscopic Suturing national and international proctorships. Dr Kumbhari has 
functioned as a 1:1 proctor for first in human procedures such as endoscopic sleeve 
gastroplasty and transoral gastric outlet reduction both nationally (Chicago x 2, Raleigh, 
Charlottesville) and internationally (Australia: Sydney, Brisbane, Melbourne). 
5/18 – Present Bariatric Endoscopy Observerships (structured with funds collected by the GI Division)  – To 
date, 5 Physicians from India, Taiwan, China and Australia have completed this observership. 
Observers spend 1 month in a bariatric clinic, observe bariartric procedures (endoscopic and 
surgical) and attend dedicated hands on training sessions arranged by Dr Kumbhari. This 
formal program has resulted in the commencement of bariatric programs at several of the 
physicians respective universities. 
 
 
Development of nationally/internationally recognized clinical standard of care  
None 
   
EDUCATIONAL ACTIVITIES 
Educational Focus  
My educational focus is in the fields of bariatric endoscopy, managing complications of 
bariatric surgery and novel techniques in advanced therapeutic endoscopy. Education is 
performed through lectures at national as well as international conferences, hands on training 
at national and international conferences and performing live endoscopic procedures at 
national and international endoscopy courses. Furthermore, a variety of webinars and videos 
have been published and uploaded to Youtube for both patient and physician education.  
 
Teaching 
Teaching is performed not only within JHU, but also at a national and international level. 
Teaching is in the form of didactics, hands on training, observerships and proctorships. The 
national and international courses are listed under classroom instruction. 
 
Classroom Instruction 
JHMI/Regional  
2015 – Present Gastroenterology Fellows Didactics, Lecturer, Endoscopic Retrograde Cholangiopancreatography, 
   Division of Gastroenterology, Johns Hopkins Hospital 
2016 - Present  Gastroenterology Fellow Didactics, Lecturer, Endoscopic Bariatric Therapies, Division of 
   Gastroenterology, Johns Hopkins Hospital 
National  None 
 
International None 
 
Clinical Instruction 
JHMI/Regional  
2010 – 2011  Gastroenterology Inpatient & Consult Service, Gastroenterology Fellow, St. George Hospital 
2012 – 2013   Gastroenterology Inpatient & Consult Service, Gastroenterology Fellow, Bankstown Hospital 
2015 – 2018    Gastroenterology Endoscopy Nurses Meetings, Assistant Professor, Johns Hopkins Hospital 
2015 – 2018  Gastroenterology Inpatient & Consult Service, Endoscopy Attending, Johns Hopkins Hospital 
2016 – Present  Multidisciplinary Endoscopic Weight Loss Conference, Division of Gastroenterology and 
   Bloomberg School of Public Health, Johns Hopkins Hospital 
National  None 
 
International None 
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CME instruction 
JHMI/Regional  
9/13  Division of Gastroenterology, Johns Hopkins University School of Medicine, Grand Rounds, Lecturer, 
“Management of perforations, leaks and fistulae”, Baltimore, MD. 
10/13  Society of Gastroenterology Nurses and Associations, Regional Conference, Lecturer, “New frontiers 
in therapeutic small bowel enteroscopy”, Chesapeake Bay, MD 
11/13  Division of Gastroenterology, Johns Hopkins University School of Medicine, 39th Annual Johns 
Hopkins Topics in Gastroenterology and Hepato-Biliary Update Conference, Lecturer, “Tissue closure 
techniques: managing fistulae and perforations”, Baltimore, MD 
11/13  Division of Gastroenterology, Johns Hopkins University School of Medicine, 39th Annual Johns 
Hopkins Topics in Gastroenterology and Hepato-Biliary Update Conference, Lecturer, “Endoscopy for 
the bariatric patient”, Johns Hopkins Hospital, Baltimore, MD 
11/13  Division of Gastroenterology, Johns Hopkins University School of Medicine, 39th Annual Johns 
Hopkins Topics in Gastroenterology and Hepato-Biliary Update Conference, Lecturer, “Interactive 
video endoscopy cases”, Baltimore, MD 
3/14  Division of Gastroenterology, Johns Hopkins University School of Medicine, 14th Annual 
Gastroenterology and Hepatology: “Viva La Vida” course, Lecturer, “Upper GI variceal bleeding” San 
Juan, PR 
3/14  Division of Gastroenterology, Johns Hopkins University School of Medicine, 14th Annual 
Gastroenterology and Hepatology: “Viva La Vida” course, Lecturer, “Interventional endoscopy 
interactive cases”, San Juan, PR 
5/14  Society of Gastroenterology Nurses and Associations, Regional Conference, Lecturer, “Endoscopic 
bariatric therapies”, Chesapeake Bay, MD 
3/15  Division of Gastroenterology, Johns Hopkins University School of Medicine, 15th Annual 
Gastroenterology and Hepatology: “Viva La Vida” course, Lecturer, “Using the endoscope to achieve 
weight loss”, San Juan, PR 
3/15  Division of Gastroenterology, Johns Hopkins University School of Medicine, 15th Annual 
Gastroenterology and Hepatology: “Viva La Vida” course, Lecturer, “Endoscopy interactive cases”, 
San Juan, PR 
3/15  Society of Gastroenterology Nurses and Associations, Multiregional Meeting (DELMARVA), 
Lecturer, “Endoscopic bariatric therapies”, Ocean City, MD 
3/15  Society of Gastroenterology Nurses and Associations, National Meeting, Lecturer, “Endoscopic 
bariatric therapies”, Baltimore, MD 
9/15  Division of Gastroenterology, Johns Hopkins University School of Medicine, 41st Annual Johns 
Hopkins Topics in Gastroenterology and Hepato-Biliary Update Conference, Lecturer, “Challenging 
obesity: expert perspectives on the roles of available and emerging therapies”, Baltimore, MD 
9/15  Division of Gastroenterology, Johns Hopkins University School of Medicine, 41st Annual Johns 
Hopkins Topics in Gastroenterology and Hepato-Biliary Update Conference, Lecturer, “The evolving 
era of endoscopic metabolic therapies”, Baltimore, MD 
9/15  Division of Gastroenterology, Johns Hopkins University School of Medicine, 41st Annual Johns 
Hopkins Topics in Gastroenterology and Hepato-Biliary Update Conference, Lecturer, “Closing holes 
we caused and those we did not”, Baltimore, MD 
9/15  Division of Gastroenterology, Johns Hopkins University School of Medicine, 41st Annual Johns 
Hopkins Topics in Gastroenterology and Hepato-Biliary Update Conference, Lecturer, “Challenging 
endoscopy cases”, Baltimore, MD 
9/15  Division of Gastroenterology, Johns Hopkins University School of Medicine, 41st Annual Johns 
Hopkins Topics in Gastroenterology and Hepato-Biliary Update Conference, Lecturer, “Challenging 
polypectomies. Tips and tricks”, Baltimore, MD 
1/16  Division of Gastroenterology and Department of Surgery, Johns Hopkins University School of 
   Medicine, 33rd Annual Medical and Surgical Gastroenterology, A multidisciplinary Approach, 
   Lecturer, “How to approach complications of bariatric surgery”, Aspen, CO 
1/16  Division of Gastroenterology and Department of Surgery, Johns Hopkins University School of 
   Medicine, 33rd Annual Medical and Surgical Gastroenterology, A multidisciplinary Approach, 
   Lecturer, “Diagnostic and therapeutic capability of EUS in 2016: When to Refer?”, Aspen, CO 
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1/16  Division of Gastroenterology and Department of Surgery, Johns Hopkins University School of 
   Medicine, 33rd Annual Medical and Surgical Gastroenterology, A multidisciplinary Approach, 
   Lecturer, “Interactive Cases”, Aspen, CO. 
3/16  Division of Gastroenterology, Johns Hopkins University School of Medicine, 16th Annual 
Gastroenterology and Hepatology: “Viva La Vida” course, Lecturer, “Sphincter of Oddi manometry to 
predict treatment of SOD”, San Juan, PR 
3/16  Division of Gastroenterology, Johns Hopkins University School of Medicine, 16th Annual 
Gastroenterology and Hepatology: “Viva La Vida” course, Lecturer, “Dilate intestinal strictures”, San 
Juan, PR 
3/16   Division of Gastroenterology, Johns Hopkins University School of Medicine, 16th Annual 
Gastroenterology and Hepatology: “Viva La Vida” course, Lecturer, “I perform sphincter of Oddi 
manometry for SOD”, San Juan, PR 
11/16  Division of Gastroenterology, Johns Hopkins University School of Medicine, 42nd Annual Johns 
   Hopkins Topics in Gastroenterology and Hepato-Biliary Update Conference, Lecturer, “Endoscopy 
   and Obesity”, Baltimore, MD 
11/16  Division of Gastroenterology, Johns Hopkins University School of Medicine, 42nd Annual Johns 
   Hopkins Topics in Gastroenterology and Hepato-Biliary Update Conference, Lecturer, “Capsule or 
   Endoscopy for the Small Bowel Bleed”, Baltimore, MD 
11/16  Johns Hopkins University School of Medicine, A Women’s Journey Conference, Lecturer, “The 
   shape of things to come”. Baltimore, MD 
3/17  Division of Gastroenterology, Johns Hopkins University School of Medicine, 17th Annual 
Gastroenterology and Hepatology: “Viva La Vida” course, Moderator for “Symposium: Obesity”, San 
Juan, PR 
3/17  Division of Gastroenterology, Johns Hopkins University School of Medicine, 17th Annual 
Gastroenterology and Hepatology: “Viva La Vida” course, Lecturer, “Endoscopic approaches to 
obesity”, San Juan, PR 
3/17  Division of Gastroenterology, Johns Hopkins University School of Medicine, 17th Annual 
Gastroenterology and Hepatology: “Viva La Vida” course, Lecturer, “Can endoscopic interventions be 
used to treat metabolic syndrome” San Juan, PR. 
3/17  Division of Gastroenterology, Johns Hopkins University School of Medicine, 17th Annual 
Gastroenterology and Hepatology: “Viva La Vida” course, Lecturer, “Gastric perforation after EMR”, 
San Juan, PR  
3/17  Division of Gastroenterology, Johns Hopkins University School of Medicine, 17th Annual 
Gastroenterology and Hepatology: “Viva La Vida” course, Lecturer, “Video interactive cases from the 
Johns Hopkins Hospital”, San Juan, PR 
3/17  Division of Gastroenterology, Johns Hopkins University School of Medicine, 17th Annual 
Gastroenterology and Hepatology: “Viva La Vida” course, Lecturer, “Sphincter of Oddi pain”, San 
Juan, PR 
6/17  American Society of Metabolic and Bariatric Surgery, Controversies in Bariatric Surgery Conference 
   and ASMBS Annual Membership Meeting, Lecturer, “The role of endoscopy in bariatric surgery”, 
   Annapolis, MD 
6/17  American Society of Metabolic and Bariatric Surgery, Controversies in Bariatric Surgery Conference 
   and ASMBS Annual Membership Meeting, Lecturer, “Intragastric balloon for weight loss: is it worth
   it?”, Annapolis, MD 
11/17  Division of Gastroenterology, Johns Hopkins University School of Medicine, 43rd Annual Johns 
Hopkins Topics in Gastroenterology and Hepato-Biliary Update Conference, Lecturer, “The Evolving 
Era of Endoscopic Metabolic Therapies”, Baltimore, MD 
11/17  Division of Gastroenterology, Johns Hopkins University School of Medicine, 43rd Annual Johns 
Hopkins Topics in Gastroenterology and Hepato-Biliary Update Conference, Lecturer, “Endoscopic 
Therapy for GERD”, Baltimore, MD 
3/18  Division of Gastroenterology, Johns Hopkins University School of Medicine, 18th Annual 
Gastroenterology and Hepatology: “Viva La Vida” course, Lecturer, “Update in endoscopic approaches 
for weight loss”, Cancun, Mexico 
3/18  Division of Gastroenterology, Johns Hopkins University School of Medicine, 18th Annual 
Gastroenterology and Hepatology: “Viva La Vida” course, Lecturer, “Challenging bariatric 
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endoscopic cases”, Cancun, Mexico 
3/18  Division of Gastroenterology, Johns Hopkins University School of Medicine, 4th Annual Update in 
Advances in Endoscopy, Gastroenterology and Hepatology, Lecturer, “Approved endoscopic bariatric 
therapies”, Washington, DC 
3/18  Division of Gastroenterology, Johns Hopkins University School of Medicine, 4th Annual Update in 
Advances in Endoscopy, Gastroenterology and Hepatology, Lecturer, “Subepithelial GI lesions: 
management and role of EUS”, Washington, DC 
6/18  Anne Arundel medical Center, Bariatric Emergencies, Lecturer, “Endoscopic management of 
   bariatric emergences”, Annapolis, MD 
1/19  Division of Gastroenterology and Department of Surgery, Johns Hopkins University School of 
Medicine, 36th Annual Medical and Surgical Gastroenterology, A Multidisciplinary Approach, 
   Lecturer, “My PSC Patient has a Dominant Stricture: What Should I do?”, Beaver Creek, CO 
1/19   Division of Gastroenterology and Department of Surgery, Johns Hopkins University School of 
Medicine, 36th Annual Medical and Surgical Gastroenterology, A Multidisciplinary Approach, 
   Lecturer, “How to Take Big Polyps Out Without Having to Call a Surgeon”, Beaver Creek, CO 
1/19  Division of Gastroenterology and Department of Surgery, Johns Hopkins University School of 
Medicine, 36th Annual Medical and Surgical Gastroenterology, A Multidisciplinary Approach, 
   Lecturer, “Optimal Therapy for Achalasia: Heller Myotomy versus POEM”, Beaver Creek, CO 
3/19  Division of Gastroenterology, Johns Hopkins University School of Medicine, 5th Annual Update on 
Advances in Endoscopy, Gastroenterology and Hepatology, Lecturer, “Bariatric Surgery 
Complications-Endoscopic Management Options”, Washington, DC 
3/19   Division of Gastroenterology, Johns Hopkins University School of Medicine, 5th Annual Update on 
Advances in Endoscopy, Gastroenterology and Hepatology, Lecturer, “Endoscopy in Portal 
Hypertension – An Update”, Washington, DC 
3/19  Division of Gastroenterology, Johns Hopkins University School of Medicine, 19th Annual 
Gastroenterology and Hepatology: “Viva La Vida” course, Lecturer, “Endoscopic Palliation for 
Colorectal Cancer”, Cancun, Mexico 
3/19  Division of Gastroenterology, Johns Hopkins University School of Medicine, 19th Annual 
Gastroenterology and Hepatology: “Viva La Vida” course, Lecturer, “Evolving Directions for Bariatric 
Endoscopy”, Cancun, Mexico 
10/19 Division of Gastroenterology, Johns Hopkins University School of Medicine, 45th Annual Johns 
Hopkins Topics in Gastroenterology and Hepato-Biliary Update Conference, “Managing 
Complications of Bariatric Surgery”, Baltimore, MD 
10/19 Division of Gastroenterology, Johns Hopkins University School of Medicine, 45th Annual Johns 
Hopkins Topics in Gastroenterology and Hepato-Biliary Update Conference, “Endoscopic Bariatric 
Therapies: What is State-of-the-Art in 2019?”, Baltimore, MD 
 
National   
 
5/14  Inoue, 5th POEM International Conference, Lecturer, “Fluoroscopy to assess extent of
 cardiomyotomy, Chicago, IL 
7/14 American Neurogastroenterology and Motility Society, Annual Motility Meeting, Lecturer, “Peroral 
endoscopic myotomy and endoFLIP”, Baltimore, MD 
3/15 Inoue, 6th POEM International Conference, Lecturer, “POEM as a day procedure – using contrast to 
check closure and discharge”, Washington, DC 
5/15 American Society of Metabolic and Bariatric Surgery (ASMBS), Maryland Chapter Meeting, Lecturer, 
“Understanding endoscopic management of postoperative leaks”, Annapolis, MD 
5/16  Society of Gastroenterology Nurses and Associations, Annual Conference, Lecturer, “The role of 
endoscopy in obesity and bariatric surgery complications”. Seattle, WA 
3/17 Society of Gastroenterology Nurses and Associations, Multiregional Meeting (DELMARVA), 
Lecturer, “Cholangioscopy”, Fairfax, VA 
3/17 Society of Gastroenterology Nurses and Associations, Multiregional Meeting (DELMARVA), 
Lecturer, “Bariatric Endoscopy”, Fairfax, VA 
4/17 American College of Gastroenterology, 2017 ACG Eastern Regional Postgraduate Course, Lecturer, 
“Managing Complications of Weight Loss Surgery”, Washington, DC 
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5/17 Society of Gastroenterology Nurses and Associations, 44th Annual Course, Lecturer, “Endoscopic 
Bariatric Therapies”, New Orleans, LA 
6/17  American Society of Gastrointestinal Endoscopy (ASGE), ASGE Star Suturing Course: 
Fundamentals of Endoscopic Suturing, Lecturer, “Suturing and Endoscopic Sleeve Gastroplasty”, 
Chicago, IL 
6/17  American Society of Gastrointestinal Endoscopy (ASGE), ASGE Star Suturing Course: 
Fundamentals of Endoscopic Suturing, Lecturer, “Bariatric endoscopy today: from theory to 
practice”, Chicago, IL 
8/17 Association for Bariatric Endoscopy/American Society for Gastrointestinal Endoscopy, ABE/ASGE 
Webinar, Lecturer, “Recently approved endoscopic bariatric therapies:  Aspire Assist System and 
Obalon Balloon System”, Chicago, IL 
12/17  Association for Bariatric Endoscopy/American Society for Gastrointestinal Endoscopy, ABE/ASGE 
Webinar, Lecturer, “Endoscopic management of surgical complications”, Chicago, IL 
12/17  New York Society of Gastrointestinal Endoscopy, NYSGE Meeting, Lecturer, “Role of endoscopy in 
bariatric surgery”, New York, NY 
3/18  Brigham and Women's Hospital, 2018 Flexible Endoscopic Surgery Course, Lecturer, “The new era 
of cholangioscopy”, Miami, FL 
3/18   Virginia Bariatric Society, Spring Meeting, Lecturer, “Endoscopic sleeve gastroplasty and endoscopic 
management of complications”, Richmond, VA 
4/18  Ambulatory Surgery Center Association (ASCA), ASCA 2018 Conference, Lecturer, “Is endoscopic 
sleeve gastroplasty right for your ASC?”, Boston, MA 
5/18  American Society for Gastrointestinal Endoscopy, ASGE STAR Certificate Program: Suturing, 
Lecturer, “Suturing and endoscopic sleeve gastroplasty”, Chicago, IL 
6/18  American Society for Gastrointestinal Endoscopy, 2018 Digestive Disease Week, Lecturer, 
“Endoscopic interventions in the management of obesity”, Washington, DC 
6/18  American Society for Gastrointestinal Endoscopy, 2018 Digestive Disease Week, Lecturer, 
“Recognition and management of complications following bariatric surgery”, Washington, DC 
6/18  Association for Bariatric Endoscopy (ABE), Annual Meeting, Lecturer, “Video pearls for endoscopic 
bariatric procedures”, Washington, DC 
6/18  American Society for Gastrointestinal Endoscopy, 2018 Digestive Disease Week, Lecturer, “Primary 
endoscopic therapies for obesity”, Washington, DC 
6/18  Medical University of South Carolina, Digestive Endoscopy Updates after DDW, Lecturer, 
“Endoscopic bariatric therapies”, Charleston, SC 
7/18   American Society for Gastrointestinal Endoscopy, ASGE ABE Course: Endoscopic Bariatric 
Therapies Position Your Practice for Success, Lecturer, “Technical pearls for performing endoscopic 
sleeve gastroplasty”, Chicago, IL 
8/18  Florida Hospital, Center for Interventional Endoscopy, Orlando Live Endoscopy, Lecturer, 
“Endoscopic Management of Pancreatic Fluid Collections: When to choose drainage over 
debridement”, Orlando, FL 
8/18  Florida Hospital, Center for Interventional Endoscopy, Orlando Live Endoscopy, Lecturer, “Top 5 
Indications in Diagnostic Endoscopy”, Orlando, FL 
8/18  Florida Hospital, Center for Interventional Endoscopy, Orlando Live Endoscopy, Lecturer, 
“Endoscopic Bariatric Therapies”, Orlando, FL 
12/18  New York Society of Gastrointestinal Endoscopy, NYSGE Meeting, Lecturer, “Managing 
Complications of Bariatric Procedures”, New York, NY 
12/18   New York Society of Gastrointestinal Endoscopy, NYSGE Meeting, Lecturer, “Obtaining 
Reimbursement for Bariatric Endotherapy”, New York, NY 
1/19  American College of Gastroenterology, ACG 2nd Year Fellows Course, Lecturer, 
“Endoscopic Therapy of Obesity”, Washington, DC 
2/19  5th Annual North Meets South: A Gastrointestinal Medical and Surgical Symposium, Lecturer, 
“Endoscopic Treatment Option’s for Barrett’s Esophagus”, Orlando, FL 
2/19  5th Annual North Meets South: A Gastrointestinal Medical and Surgical Symposium, Lecturer, 
“Endoscopic Approaches to Bariatrics”, Orlando, FL 
5/19  American Society of Bariatric and Metabolic Surgery: Virginia State Chapter Annual Meeting, 
Lecturer, “Therapeutic Endoscopy for Weight Management”, Williamburg, VA 
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5/19  American Society of Bariatric and Metabolic Surgery: Virginia State Chapter Annual Meeting, 
Lecturer, “Therapeutic Endoscopy for Management of Complications of Bariatric Surgery”, 
Williamburg, VA 
5/19  American Society for Gastrointestinal Endoscopy, 2019 Digestive Disease Week, Lecturer, 
“Endoscopic Restrictive and Space Occupying Therapies”, San Diego, CA 
5/19  American Gastroenterology Association, 2019 Digestive Disease Week, Lecturer, “Implementing 
Obesity Management into your Daily Practice”, San Diego, CA 
5/19  Society for Surgery of the Alimentary Tract, 2019 Digestive Disease Week, Lecturer, “Bariatric GI, 
Barrett’s/GERD, Pre and/or Post-op”, San Diego, CA 
7/19  14th International NOSCAR Summit, Lecturer, “Post-surgical leaks: Keeping the fistula open and 
avoiding functional compromises”, Chicago, IL 
7/19  14th International NOSCAR Summit, Lecturer, “Recidivists and Non-Responders: The future of 
endoscopic interventions and management”, Chicago, IL 
8/19  13th Annual St Louis Live Therapeutic Endoscopy Course, Lecturer, “Therapeutic EUS in Pancreatic 
and Biliary Disease”, St Louis MI 
8/19  6th Annual Orlando Live EUS 2019, Lecturer, “Diagnostic EUS literature update”, Orlando, FL 
8/19  6th Annual Orlando Live EUS 2019, Lecturer, “Interventional EUS literature update”, Orlando, FL 
9/19  Mayo Clinic Scottsdale GI Grand Rounds “Endoscopic Therapies for Primary Weight Loss”, 
Scottsdale, Arizona 
10/19  Beth Israel Deaconess GI Grand Rounds “Endoscopic Therapies for Primary Weight Loss”, Boston, 
Massachusetts   
 
 
International  
 
10/15  International Federation for the Surgery of Obesity (IFSO), XVII Congress of the Brazillian Society 
of Bariatric and Metabolic Surgery (SBCBM) and II IFSO-LAC intermediate, Lecturer, 
“Endoluminal management of leaks and stenosis post sleeve gastrectomy: stent, balloon dilation and 
septotomy”, Belem, Brazil. 
10/15  International Federation for the Surgery of Obesity (IFSO), XVII Congress of the Brazillian Society 
of Bariatric and Metabolic Surgery (SBCBM) and II IFSO-LAC intermediate, Lecturer, “Endoscopic 
treatment of obesity in the USA”, Belem, Brazil. 
10/15  International Federation for the Surgery of Obesity (IFSO), XVII Congress of the Brazillian Society 
of Bariatric and Metabolic Surgery (SBCBM) and II IFSO-LAC intermediate, Lecturer, “Endoscopic 
management of sleeve gastrectomy alterations”, Belem, Brazil. 
10/15  Inoue, POEM and ARMS Conference, Lecturer, “Provocative amyl nitrite testing during HREM 
differentiates achalasia from a tight fundoplication”, Barcelona, Spain. 
11/16  Turkish Gastrointestinal Society, Annual Meeting, Distinguished Lecturer, “ERCP 2016”, Antalya, 
Turkey 
11/16   Turkish Gastrointestinal Society, Annual Meeting, Keynote Lecturer, “Bariatric Endoscopy”, 
Antalya, Turkey 
5/17  Ecuatorian Institute of Digestive Diseases, VI Course of Live Endoscopy, Lecturer, “Primary 
endoluminal weight loss procedures: where are we?”, Guayaquil, Ecuador 
5/17 Ecuatorian Institute of Digestive Diseases, VI Course of Live Endoscopy, Lecturer, “EUS in the 
management of pancreatic pseudocyst”, Guayaquil, Ecuador 
5/17 Ecuatorian Institute of Digestive Diseases, VI Course of Live Endoscopy, Lecturer, “Endoscopy in 
the treatment of Bariatric Complications”, Guayaquil, Ecuador 
6/17 Nanfang Hospital-Southern Medical University, 2017 Southern Digestive Disease and Endoscopy 
Forum, Lecturer, “Endoscopic bariatric and metabolic therapies: what is state of the art in 2017”, 
Guangzhou, China 
9/17  Shaneed Beheshti University of Medical Sciences, 2nd Biannual International Endosonography 
Meeting, Lecturer, “EUS-FNA/FNB needles & puncture Techniques”, Tehran, Iran. 
9/17 Shaneed Beheshti University of Medical Sciences, 2nd Biannual International Endosonography 
Meeting, Lecturer, “EUS in ampullary tumor”, Tehran, Iran. 
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9/17  Shaneed Beheshti University of Medical Sciences, 2nd Biannual International Endosonography 
Meeting, Lecturer, “Celiac plexus neurolyisis and block”, Tehran, Iran. 
9/17 Shaneed Beheshti University of Medical Sciences, 2nd Biannual International Endosonography 
Meeting, Lecturer, “Mediastinal anatomy by radial and linear scopes”, Tehran, Iran. 
9/17  HM Sanchinarro University Hospital, 4th International Course: Madrid International Bariatric 
Endoscopy, Lecturer, “Endoscopic sleeve gastroplasty learning curve”, Madrid, Spain 
9/17 HM Sanchinarro University Hospital, 4th International Course: Madrid International Bariatric 
Endoscopy, Lecturer, “Endosuturing published data”, Madrid, Spain 
11/17 Venezuelan Congress of Gastroenterology, 2017 International Conference of Bariatric Endoscopy, 
Lecturer, “Primary endoscopic weight loss therapies”, Caracas, Venezuela 
12/17 Turkish Gastrointestinal Society, Annual Meeting, Lecturer, “Endoscopic management of surgical 
complications”, Antalya, Turkey 
12/17 Turkish Gastrointestinal Society, Annual Meeting, Lecturer, “ERCP 2017”, Antalya, Turkey 
6/18  IMAGE Endoscopy, 9th International Live Endoscopy Course, Lecturer, “Establishing new frontiers 
in therapeutic endoscopy: bariatric, metabolic and anti-reflux”, Milan, Italy 
7/18  Southern Medical University, Nanfang Hospital, The 2018 Southern Forum on GI Disease and 
Endoscopy, Lecturer, “ Interventional EUS in 2018 – What’s New”, Guangzhou, China 
9/18  Clemenceau Medical Center, 6th Annual Gastroenterology Symposium, Lecturer, “Complications of 
Therapeutic Procedures: Clip, Stent, or Operate”, Beirut, Lebanon 
9/18  Clemenceau Medical Center, 6th Annual Gastroenterology Symposium, Lecturer, “Will Endoscopic 
Bariatric Procedures Replace Bariatric Surgery?”, Beirut, Lebanon 
9/18 Venezuelan Congress of Gastroenterology, 2018 International Conference of Bariatric Endoscopy, 
Lecturer, “Endoscopic Management of Complications of Bariatric Surgery”, Caracas, Venezuela 
9/18  International Federation Society of Obesity,  23rd IFSO World Congress 2018, Lecturer, “The current 
role of endoscopy in the management of complications”. Dubai, United Arab Emirates 
9/18  International Federation Society of Obesity,  23rd IFSO World Congress 2018, Lecturer, “Endoscopic 
options for revisional weight loss”. Dubai, United Arab Emirates 
9/18  International Federation Society of Obesity,  23rd IFSO World Congress 2018, Post Graduate Course: 
Bariatric Endoscopy for weight loss, weight regain and management of complications, Lecturer, 
“Intragastric Balloons under evidence based scrutiny”, Dubai, United Arab Emirates 
9/18  International Federation Society of Obesity,  23rd IFSO World Congress 2018, Post Graduate Course: 
Bariatric Endoscopy for weight loss, weight regain and management of complications, Lecturer, 
“Bariatric Endoscopy on a clinical practice: How it fits”, Dubai, United Arab Emirates 
11/18  Sydney Adventist Hospital, Bariatric & Metabolic Endoscopy Symposium, Speaker. “Evolution of 
Gastroplasty”, Sydney, Australia 
11/18  Sydney Adventist Hospital, Bariatric & Metabolic Endoscopy Symposium, Speaker. “ESG – 
Physiologic Changes and Study Outcomes”, Sydney, Australia 
11/18  Sydney Adventist Hospital, Bariatric & Metabolic Endoscopy Symposium, Speaker. “State-of-the-art: 
Future Directions in Bariatric Endoscopy”, Sydney, Australia 
11/18  Turkish Gastrointestinal Society, Annual Meeting, Lecturer, “Endoscopic Therapies for Obesity in 
2018” Antalya, Turkey 
4/19  4th Masterclass in Gastroenterology, Hepatology and Related Diseases Conference, Lecturer, 
“Management of Weight Regain after Bariatric Surgery”, Abu Dhabi, United Arab Emirates 
4/19  4th Masterclass in Gastroenterology, Hepatology and Related Diseases Conference, Lecturer, 
“Endoscopic Management of Complications post Bariatric Surgery”, Abu Dhabi, United Arab 
Emirates 
9/19  International Federation Society of Obesity, 24th IFSO World Congress 2019, Post Graduate Course: 
Bariatric Endoscopy Pathway: from treatment of complications to primary procedures, Lecturer, 
“Sleeve gastrectomy leaks treatment with septotomy”, Madrid, Spain 
9/19  International Federation Society of Obesity, 24th IFSO World Congress 2019, Post Graduate Course: 
Bariatric Endoscopy Pathway: from treatment of complications to primary procedures, Lecturer, 
“Sleeve Gastrectomt leaks (and stenosis) endoluminal treatmenr. So many options…Can we have an 
unbiased treatment flowchart?”, Madrid, Spain 
10/19  1st Bariatric Endoscopy Sao Paulo. “Aspiration Therapy as a Tool to Treat Obesity”, Sao Paulo, 
Brazil 
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Workshops/seminars 
JHMI/Regional 
4/17 Division of Gastroenterology, Johns Hopkins University School of Medicine, Hopkins International 
Therapeutic Endoscopy Course (HITEC), Live endoscopy demonstration, Baltimore, MD  
5/18 Division of Gastroenterology, Johns Hopkins University School of Medicine, Hopkins International 
Therapeutic Endoscopy Course (HITEC), Live endoscopy demonstration, Baltimore, MD  
 
National 
10/13  American College of Gastroenterology “Hands on Sessions”. American College of Gastroenterology 
Annual Scientific Meeting, San Diego, USA 
4/17   Eastern Regional Postgraduate Course “Hands on Session”, American College of Gastroenterology 
Washington. DC 
6/17  Bariatric Endoscopy Today: From Theory to Practice, “Hands on Session” Chicago, IL 
6/17  ASGE Star Suturing Course: Fundamentals of Endoscopic Suturing, Chicago, IL 
12/17 Bariatric Endoscopy Hands on Session, New York Society of Gastrointestinal Endoscopy, New York, 
NY 
5/18  ASGE STAR Suturing Course, “Hands on Session” Chicago, IL 
6/18  American Society for Gastrointestinal Endoscopy, 2018 Digestive Disease Week, “Bariatric 
Therapies”, Washington, DC 
7/18  ASGE Endoscopic Bariatric Therapies: Position Your Practice for Success Course, “Hands On”  
Chicago, IL 
12/18  New York Society of Gastrointestinal Endoscopy, NYSGE Meeting, “Hands-On Training”, New 
York, NY 
1/19 American College of Gastroenterology, ACG 2nd Year Fellows Course, “Hands-On Endoscopy 
EMR”, Washington, DC 
8/19  13th Annual St Louis Live Therapeutic Endoscopy Course, Lecturer, “Hands-On Endoscopy”, St 
Louis MI 
8/19  6th Annual Orlando Live EUS 2019, Lecturer, “Hands on Lab”, Orlando, FL 
 
 
International 
5/17 Ecuatorian Institute of Digestive Diseases, VI Course of Live Endoscopy, Live endoscopy 
demonstration, Guayaquil, Ecuador 
9/17 Shaneed Beheshti University of Medical Sciences, 2nd Biannual International Endosonography 
Meeting, Live Endoscopy Demonstration, Tehran, Iran. 
7/18  Southern Medical University, Nanfang Hospital, The 2018 Southern Forum on GI Disease and 
Endoscopy, Live endoscopy demonstration, Guangzhou, China 
11/18  Turkish Gastrointestinal Society, Annual Meeting, Live Endoscopy Demonstration, “Endoscopic 
Suturing” Antalya, Turkey 
 
 
Mentoring 
Post-Doctoral Mentees 
 
2015- 2018   Abhishek Agnihotri MD, Medical Resident, Bayview Medical Center 
   Abdhishek has published 9 articles, under Dr. Kumbhari’s mentorship he has been appointed 
as a gastroenterology fellow at Beth Israel Deaconess Medical Center. 
2016 - 2017  Sindhu Barola MD. Post-doctoral fellow, Johns Hopkins Hospital. Sindhu published 15 
articles during her time with Dr Kumbhari, and she has been accepted into a residency 
program 
2016- Present   Christine Hill. Undergraduate Student Diversity Summer Studentship, School of Public 
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Health, Johns Hopkins University. Christine published 8 articles during her time with Dr 
Kumbhari. With his support, she was able to obtain appointment at the Division of Intramural 
Population Health Research, National Institute of Child Health and Human Development in 
Bethesda MD. Christine has now commenced medical school at Georgetown. 
2017-Present  Lea Fayad MD. Post-doctoral fellow, Johns Hopkins Hospital. Lea has published 9 articles in 
the short time she has been under Dr Kumbhari’s tutelage. She is responsible for coordinating 
his clinical trials. She has now been accepted into the Osler Medical Residency for 2019. 
2017-Present   Dilhana Sumaiya Badurdeen MD,. Assistant Professor of Medicine, Division of 
Gastroenterology, Johns Hopkins University School of Medicine. Since joining the staff she 
has published 4 articles with Dr Kumbhari, and is currently being trained to become an 
obesity physician and bariatric endoscopist. 
 
Thesis Committees  
None 
Educational Program Building/Leadership 
None 
Educational Demonstration Activities to external audience 
None 
 
RESEARCH ACTIVITIES 
 
Research Focus 
Dr Kumbhari’s research focus has spanned the breadth of basic science, translational research 
and clinical research. His basic science focus is two-fold: a) eliciting the underlying 
mechanisms of metabolic change observed post bariatric surgery and b) methods of liver 
directed gene delivery. This research has translated to studies using commercially available 
tools used clinically to perform feasibility, efficacy and safety in human sized porcine 
models. Dr Kumbhari’s clinical reseach has foccessed on novel endoscopic techniques to 
treat patients with obesity as well as treat complications of bariatric surgery. He has also 
contributed to dozens of publications in the fields of interventional EUS and submucosal 
endoscopy. 
    
Research Program Building/Leadership 
7/15 – Present   Bariatric Endoscopy Program 
Director of the Bariatric Endoscopy Program in the Division of Gastroenterology. This 
program is one of the first of its kind in North America. Dr. Kumbhari is a leader in the 
bariatric endoscopy field, his techniques are nationally and internationally recognized, and 
proven to be effective therapies for weight loss. The program’s success has resulted in the 
funding for a number of clinical studies. Dr. Kumbhari will be the principal investigator on a 
prospective, multicenter, open-label, post-approval study of the safety and effectiveness of 
ORBERA™ as an adjunct to weight reduction for obese adults (22 years of age and older) 
with a Body Mass Index (BMI) of ≥ 30 kg/m2. The program has also been awarded funding 
for the MERIT-Trial where Dr. Kumbhari will serve as the principal investigator in a multi-
center endoscopic sleeve gastroplasty (ESG) randomized interventional trail. Dr. Kumbhari’s 
innovative thinking in using C2 Therapeutics ablation therapy as a method to treating weight 
regain after Roux-en-y gastric bypass has earned him funding for the multi-center 
Cryoballoon ablation trial, where Dr. Kumbhari will also be the principal investigator. 
Dr. Kumbhari has spearheaded preclinical work into assessing the critical elements that result 
in metabolic improvements as a result of bariatric surgery. Of particular interest, Dr. 
Kumbhari was awarded a patent, which was subsequently licensed for Endoscopic Gastric 
Mucosal Ablation, Resection, and Exclusion, which he will be using in the Gastric Mucosal 
Devitalization as a Primary Obesity Therapy clinical trial as the principal investigator.  
Dr. Kumbhari’s success has garnered over 20 publications for the endoscopic weight loss 
program, many of which were collaborated with the department of surgery.  
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Research Demonstration Activities 
None 
 
Inventions, Patents, Copyrights  
12/28/2017 United States Patent Application Publication US 2017/0367723 A1 
   Endoscopic Gastric Mucosal Ablation/Resection/Exclusion (A/R/E) as a Minimally Invasive Weight 
Loss Approach 
   Kumbhari V, Khashab MA, Oberbach A, Kalloo AN 
 
Technology Transfer Activities  
11/15/2017 US 2017/0367723 A1 Licensed to ERBE Elektromedizin GmbH 
 
SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES 
None 
 
 ORGANIZATIONAL ACTIVITIES 
Institutional Administrative Appointments  
2010   Network Governance Committee, St George Hospital 
2010 – 2012  Clinical Examiner, Sydney University, Bachelor of Medicine Bachelor of Surgery 
2015 – 2018   Endoscopy-EPIC Steering Committee 
2015 – 2018  Endoscopy reporting Steering Committee 
2015 – 2018  Endoscopy Operations meeting 
2015 – 2018   Endoscopy Integration Committee 
 
Editorial Activities 
Editorial Board Appointments 
None 
 
Journal Reviewer 
2013 – Present  Reviewer for New England Journal of Medicine 
2013 – Present  Reviewer for Endoscopy 
2013 – Present  Reviewer for Gastrointestinal Endoscopy 
2013 – Present  Reviewer for American Journal of Gastroenterology 
2015 – Present  Reviewer for Video GIE 
2015 – Present   Reviewer for Clinical Gastroenterology and Hepatology 
 
Advisory Committees, Review Groups/Study Sections  
2015 – 2018  F1000Prime: http://f1000.com/prime/thefaculty/member/499999771097571186 
 2015 – Present   Board Member for Association for Bariatric Endoscopy 
 2019 – Present  Advisory Borard Member for Obalon 
 
Professional Societies  
2010 – 2015   Member of Gastroenterological Society of Australia 
2010 – Present   Member of American Society for Gastrointestinal Endoscopy 
2010 – Present   Member of American College of Gastroenterology 
2010 – Present   Member of American Gastroenterology Association 
2018 – 2019   The New York Academy of Sciences 
 
Conference Organizer 
JHMI/Regional 
5/18 Division of Gastroenterology, Johns Hopkins University School of Medicine, 2nd Annual Hopkins 
International Therapeutic Endoscopy Course (HITEC), Course Co-Director, Baltimore, MD 
4/19 Division of Gastroenterology, Johns Hopkins University School of Medicine, 3rd Annual Hopkins 
International Therapeutic Endoscopy Course (HITEC), Course Co-Director, Baltimore, MD 
National 
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7/18  American Society for Gastrointestinal Endoscopy, ASGE ABE Course: Endoscopic Bariatric 
Therapies Position Your Practice for Success, Course Co-Director, Chicago, IL 
5/19  American Society for Gastrointestinal Endoscopy, 4th Annual ABE Meeting: Global Experiences in 
Endobariatric Therapies: Optimizing or Technique, Course Co-Director, San Diego, CA 
 
International 
9/18  International Federation Society of Obesity,  23rd IFSO World Congress 2018, Course Co-Director, 
“Bariatric Endoscopy for Weight Loss, Weight Regain and Management of Complications”. Dubai, 
United Arab Emirates 
9/18 International Federation Society of Obesity,  23rd IFSO World Congress 2018, Course Co-Director, 
“IFSO Hands-on Simulation Center”, Dubai, United Arab Emirates 
 
Session Chair 
JHMI/Regional 
11/17  Division of Gastroenterology, Johns Hopkins University School of Medicine, 43rd Annual Johns 
Hopkins Topics in Gastroenterology and Hepato-Biliary Update Conference, “Future of Endoscopy”, 
Baltimore, MD 
3/18  Division of Gastroenterology, Johns Hopkins University School of Medicine, 18th Annual 
Gastroenterology and Hepatology: “Viva La Vida” course, “Bariatric Weight Loss”, Cancun, Mexico 
3/19  Division of Gastroenterology, Johns Hopkins University School of Medicine, 5th Annual Update on 
Advances in Endoscopy, Gastroenterology and Hepatology, “Session II”, Washington, DC 
10/19  Division of Gastroenterology, Johns Hopkins University School of Medicine, 45th Annual Johns 
Hopkins Topics in Gastroenterology and Hepato-Biliary Update Conference, “Obesity”, Baltimore, 
MD 
 
 
National 
5/17  “Endoscopic Management of Obesity”; Digestive Diseases Week, Moderator, Chicago, IL  
6/18  American Society for Gastrointestinal Endoscopy, 2018 Digestive Disease Week, Session Chair, 
“Bariatric endoscopy”, Washington, DC 
 
International  
10/14  Australian Gastroenterology Week, Chair, Neurogastroenterology Session, Queensland, Australia 
10/14  Australian Gastroenterology Week, Chair, Upper GI and Pancreatobiliary Session, Queensland, 
Australia 
4/19  4th Masterclass in Gastroenterology, Hepatology and Related Diseases Conference, Innovations in 
Therapeutic Endoscopy, Abu Dhabi, United Arab Emirates 
 
 
 
 
 
Consultantship 
2015  Consultant, Apollo Endosurgery, USA 
2015  Consultant, Medtronic, USA 
2016  Consultant, Boston Scientific, USA 
2017  Consultant, Pentax Medical, USA 
2017  Consultant, ReShape Lifesciences, USA 
2019  Consultant, Obalon, USA 
2019  Consultant, FujiFilm, USA 
 
 
RECOGNITION 
Awards, Honors  
1. Third in the School. Newington College, Yr 12, 1999 
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2. Endoscopy Quiz: First Prize. Gastrointestinal Skills Training Course, CTEC Australia, 2010 
3. Young Investigator Award. St George and Sutherland Hospital Medical Research Symposium, 2010 
4. Young Investigator Award. St George and Sutherland Hospital Medical Research Symposium, 2011 
5. United European Gastroenterology Travel Grant for top Basic Science Abstract at UEGW, 2015 
6. Best Research Proposal. First Prize. Fall C2 Network Research Meeting, 2017 
 
 
Invited Talks  
JHMI/Regional 
3/16  Department of Endocrinology, Johns Hopkins University School of Medicine, Endocrinology Grand 
Rounds, Lecturer, “Endoscopic Approaches to Treating Obesity”, Baltimore, MD 
8/16  Division of Gastroenterology, Johns Hopkins University School of Medicine, Gastroenterology 
Grand Rounds, “Management of Acute pancreatitis”, Baltimore, MD 
10/16   Paoli Hospital, Internal Medicine Grand Rounds, Lecturer, “Next generation cholangioscopy”, Paoli, 
PA 
11/16 Mercy Hospital, Internal Medicine Grand Rounds, Lecturer, “Bariatric Endoscopy”, Baltimore, MD 
2/17 Union Memorial Hospital, Internal Medicine Grand Rounds, Lecturer, “Endoscopic Bariatric 
Therapies”, Baltimore, MD 
10/18 Johns Hopkins Department of Medicine Grand Rounds, Lecturer ,“What’s Hot in in Medicine: Key 
Updates from General Internal Medicine, Hospitalist Medicine, Infectious Diseases and 
Gastroenterology”, Baltimore, MD 
 
National  As mentioned under CME Instruction and Workshop/seminars 
 
International As above under CME Instruction and Workshop/seminars 
 
Visiting Professorships 
9/19  Visiting Professor at Mayo Clinic Scottsdale, Arizona on Sept 24th 2019 
10/19  Visiting Professor at Beth Israel Deaconess, Massachusetts, October 23rd 2019  
